```
PUBLIC HEARING TO REVIEW )
```

REQUESTS TO ADD )
DEBILITATING CONDITIONS TO )
THE MEDICAL CANNABIS )
REGISTRY PROGRAM )
)
)
)
ILLINOIS DEPARTMENT OF PUBLIC HEALTH
PUBLIC HEARING
Springfield, Illinois
May 2nd, 2016
WHEREUPON, THE HEARING was held pursuant
to notice at 9:00 a.m., at the Illinois
Department of Natural Resources, One Natural
Resources Way, Springfield, IL, 62702.
MIDWEST LITIGATION SERVICES, by
Kathy L. Johnson
Court Reporter

1 APPEARANCES OF ADVISORY BOARD:

2

3

4

SPEAKERS:

FARAH ZALA

FELIZA CASTRO
I N D E X

FELIZA CASTRO

JARED TAYLOR
ANGELA BASOLO-BOND
TINA HIGENS108

AMANDA DICKERSON 114
DANA HALL
118

CHARLES BUSH-JOSEPH, M.D.
124

DAVID WALEGA, M.D.
144

JARED TAYLOR
165

JARED TAYLOR
169

(Hearing start time: 9:00 a.m.)
MS. TEMPLE: Thank you, everyone, for coming to this meeting. We welcome the public in hearing these petitions that were received during the January 2016 open petition period to request the addition of debilitating conditions to the qualifying conditions for our existing Medical Cannabis Registry Program.

A total of 15 debilitating conditions will be heard today, and we request that you silence or put on vibrate your cell phones so we can hear the proceedings, so our court reporter can ensure an accurate transcript.

So I wanted to start with some welcoming remarks. We will introduce the Board and we'll, hopefully, Dr. Christoff will be here by that time.

I do want to acknowledge the presence of our House Minority Leader, Lou Lange, who is the author of this Bill, for which we would not have this program if it were not for him. So I thank you very much.
(Applause.)
We are happy to have your here. I know

| 1 | you have to leave early, so everyone knows. I |
| :---: | :---: |
| 2 | wanted to give some updates on the Cannabis, |
| 3 | Compassionate Cannabis Pilot Program from a |
| 4 | clinician's point of view, as well as a member of |
| 5 | the Advisory Board. Should I stand up? Okay. |
| 6 | So I wanted to go through what I have |
| 7 | seen so far as a physician who's been certifying |
| 8 | patients, and hands down $I$ have seen nothing but |
| 9 | good come from this Pilot Program so, from the |
| 10 | existing conditions so far. |
| 11 | I wanted to stress to everyone here that |
| 12 | medicine is an art and a science. It's about art |
| 13 | just as much as science, and so we are going to |
| 14 | be discussing what is out there in the medical |
| 15 | evidence. But this is a Compassionate Pilot Act. |
| 16 | We are looking at more than just hard |
| 17 | core evidence seen in black and white. We need |
| 18 | to keep that in mind. At the same time, we must |
| 19 | respect the science. |
| 20 | Hello, Dr. Christoff. Thank you for |
| 21 | coming. And that this is a very, it's a tricky |
| 22 | business to weigh out what I feel is passable for |
| 23 | our scientific evidence, as well as using the |
| 24 | skills I have as a clinician for the patient in |

23 already policies and procedures in place that
24 guide physicians towards whether, or how to

24 right of this room for light snacks and sodas, or

24 something that hopefully expands with time. So

1 anyways, thank you.

23 John Knaus. I'm a gynecologic oncologist. I've
24 done mostly ovarian cancer and breast cancer

```
care, and I work primarily at St. Francis
Hospital in Evanston, Illinois. I'm Program
Director of an Obstetrics and Gynecology
Residency there.
    MS. MILLER: And I'm Theresa Miller. I
am an Associate Professor at a nursing college
and I'm here representing Nursing.
    MR. CHRISTOFF: Doctor Christoff, General
Internal Medicine and HIV at Northwestern. And
good morning, everyone.
    MS. TEMPLE: I'm Leslie Mendoza Temple.
I'm the Medical Director of the NorthShore
Integrative Medicine Program. I'm also a
Clinical Assistant Professor at the University of
Chicago-Pritzker School of Medicine.
    MR. FINE: I am a patient advocate. My
name is Michael Fine. I'm a recovering attorney
and have no medical background whatsoever, except
I see lots of doctors for a living.
    MR. MCCURDY: I'm David McCurdy, retired
from a long time work in healthcare as a health
care anesthetist in the last 20 years, and also
adjunct faculty at Elmhurst College.
    MS. MOODY: Good morning. I'm Connie
```

Moody, and I'm with the Illinois Department of
Public Health. I'm here with the Medical
Cannabis Program today.

MS. WEATHERS: Good morning. I'm Allison
Weathers. I am an Associate Professor in the
Department of Neurological Sciences at Rush
University Medical Center in Chicago where I'm a
neurologist, and also the Associate Chief Medical
Information Officer for Rush.
MR. CHAMPION: Good morning. I'm Jim
Champion. I'm the Veterans' representative on
the Advisory Board. I'm a 100\% Service connected
disabled veteran, and $I$ was diagnosed with
Multiple Sclerosis in 1988.
MS. TEMPLE: Thank you, everyone. I also
wanted to add one last comment that I know that
those who are not here in the room, who are not
here to witness what's going on with this Pilot
Act, I hope that they pay strong attention that
this Board will continue to do the work that we
were charged to do despite the outcome, and we
will continue to do that.
(Applause.)
MS. TEMPLE: So we need to actually make

24 Aureus, or MRSA, autism, Chronic pain due to
trauma, chronic pain syndrome, chronic
postoperative pain, intractable pain, Irritable
Bowel Syndrome, and migraine, neuropathy,
osteoarthritis, and post-traumatic stress
syndrome.
So we will hear those, hear everything in
those, in that order, and good to go. We have
now the next item, which is to review and approve
the October 7th, 2015 petition hearing Minutes,
and it requires a motion by the Board to approve
those Minutes, and we need a second.
MR. KNAUS: Motion to approve.
MS. WEATHERS: Second.
MS. TEMPLE: Comments from Jim?
MR. CHAMPION: I would like to make a
motion to table those Minutes until such time as
we can have ample time to review and approve
them.
MS. TEMPLE: Okay. So is that a motion?
MR. CHAMPION: That is a motion.
MR. RAMIREZ: That is an order. It needs
a second but it's an order. I second it.
MS. TEMPLE: Okay.
MS. MOODY: You have a second.

MS. TEMPLE: Either --
MR. RAMIREZ: You've got one on the table

```
    still.
```

MS. MOODY: So you've now made it a
friendly amendment, so you may take a vote on
the amended motion.

MS. TEMPLE: Okay. So take a vote on the amended motion to table the Minutes for a proper
review, and perhaps the next petition meeting
we'll go through those, or as a separate
conference call.

MR. FINE: I second.

MS. TEMPLE: Those who approve?
(Board responded aye.)
MS. TEMPLE: Those who oppose?
(No response.)
MS. TEMPLE: Okay. So we will table the approval of the October 7th, 2015 petition
hearing Minutes for a separate conference call or
at the next petition meeting. Okay. So the next
item here is to discuss petitions for the
addition of debilitating conditions and to
present technical evidence.
And following that, those presentations,

```
the Board will deliberate. The voting approach
that we have followed in the past two meetings is
once the deliberation has occurred and where
everyone's ready to vote, we have paper ballots
so that our votes are confidential, and then they
are tallied and announced at the end.
    So we will find out immediately after
these petitions if they were approved or not
approved. Another motion I'd like to have
someone propose is that we approved the
conditions that we have approved at either the
May 2015 or October 2015 meetings past.
    So when there are several conditions that
have been repeated on here that the Board has
already deliberated on, we've already voted upon,
and for the sake of time and energy and the fact
that all of this is public record, we will hear
the Petitioners, but we as a Board don't need to
vote anymore. That is --
    MR. FINE: So I hereby motion to not
require a vote on the conditions that we've
already previously passed.
    MR. RAMIREZ: Second.
    MR. KNAUS: Second.
```

MS. TEMPLE: All those in favor say aye. (Board responded aye.)

MS. TEMPLE: Those opposed?
(No response.)
MR. MCCURDY: I just want to say, my only
concern is $I$ hope that the petitioners won't fly
the coop, you know, now that they know that
they've got the request. I move, I would still
like to hear from them.
MR. CHAMPION: It becomes a part of
public record, and it's always good for review, and when Dr. Shah receives it he receives everyone's testimony. So it's always the more testimony, the better. And I know I appreciate it, and I'm sure everyone on the Board appreciates you coming out today. Thank you.
(Applause.)
MS. TEMPLE: Thank you, James. So we, I remind the speakers that they have three minutes to present their technical evidence. Please speak clearly and slowly for our court reporter. Introduce yourself by your full name and your, if you have an affiliation, an organization, or if you're representing yourself as a patient or as a

```
caregiver or an advocate. Please spell your
first and last name for the record, and you will
actually be timed. So when it's time, when your
time is up, you have 30 seconds left. We are
going to be very strict about this. There's the
sign. Okay. Heed the sign, please.
    Okay. Everyone ready? All right. We're
going to start with Diabetes Mellitus Type I, and
for that we have two speakers. We have Feliza
Castro from The Healing Clinic. And if she
would, is she present? Feliza Castro?
    AUDIENCE MEMBER: She's not here.
    MS. TEMPLE: Okay. Then we'll move on to
the next one, which is Farah Zala.
    MS. ZALA: Yes.
    MS. TEMPLE: Okay. Please. And please
state your full name, spell, and your
affiliation.
    MS. ZALA: I have a ton of technical
evidence, so --
    MS. MOODY: Do you wish to use the
microphone?
    MS. TEMPLE: We have to use the
microphone.
```

MS. ZALA: Yes. Yes.
MS. TEMPLE: I turned mine off.
MS. MOODY: If you will turn the power

```
on, there's a power button at the top. Turn that
```

on. And then if you'll speak close to the
microphone and clearly for our court reporter to
hear.

MS. ZALA: Check, check. Can you hear
me? My name is Farah Zala Morales, and this is
daughter Meera Zala. And let me just get my
notes out. We are here today to present
technical evidence to support --
MS. WEATHERS: Spell, would you first
spell your name?
MS. ZALA: It's spelled $F-a-r-a-h . ~ M y$
last name is Zala. Z for zebra, a-l-a. Morales,
M-o-r-a-l-e-s. And my daughter's name is Meera.
M-e-e-r-a. Last name is Zala. Z for zebra,
$a-1-a$.
We are here today to present technical
evidence to support medical cannabis as a
treatment alternative and a complement to
conventional medicine for Type I diabetes. My
daughter Meera was diagnosed a Type I diabetic

1 November 24, 2014, with a blood sugar reading of 2616 and an A1C that was off the charts. Today I 3 would like the opportunity to present Meera's

23100 percent, because of the dramatic lows and
school blood sugar logs since using CBD tinctures
six months ago that is legal and available under
the Hemp Act.
I believe starting at the lowest possible
recommended dosage by the medical cannabis
industry standard of one milligram, one squirt
once a day, six months ago to present day of 30
to 36 milligrams, 10 to 12 squirts three to four
times a day, that not only has Meera's blood
sugars changed and are stabilizing, but we are
also seeing numerous other positive differences,
with the understanding from her endocrinologist,
and insulin therapy to help regulate Meera's
blood sugars and countless negative symptoms and
experiences that come along with Type $I$ diabetic
at such a volatile, fragile and young age of 12.
With CBD supplementing, Meera's insulin
need and intake has consistently lowered and her
general well-being has improved, although not
100 percent, because of the dramatic lows and
detrimental spikes that come three to five hours

1 later from the excessive amounts of food she has
2 to take at school to be allowed to return to
3 class, which is a blood sugar reading of 80.
4 Getting back to 80 blood sugar takes a few hours
5 of time to quality healthy food choices that
6 don't spike her into 300 's, and CBD to gradually
7 stabilize her to a normal or comfortable blood
8 sugar number and disposition, which usually
9 occurs within 15 minutes.
continuous long lulls for hours, despite healthy
food choices, between 60 and 115 grams of
carbohydrates in increments of 10 to 20 minutes
with testing and pricking of her bruised fingers
every time.

Pricking your finger 10 to 20 times a day, and she's the only female bass player in our district, and an athlete and a basketball player and a straight A student, she still manages to keep it all together and be an amazing person as well as all this discomfort that she feels on a daily basis.

She feels icky. She feels uncomfortable. She feels yucky. She feels pain, burning

```
sensations all over her body when she's taking
injection sites. All I can say, and I have a
whole speech, and I don't have enough time to
even say it, but CBD has helped us so much.
    I would like the opportunity to present
her blood sugar logs that state and show how much
her blood sugar has decreased over the last six
months with CBD and insulin. However, insulin
now seems to be less and less and less because of
the CBD.
```

    MS. MOODY: Thank you very much for your
    testimony today.
MS. ZALA: Thank you very much.
MS. TEMPLE: Can you turn the microphone
off so I can turn mine on?
MS. ZALA: Off?
MS. TEMPLE: Thank you very much for that
testimony. That must have been very hard, and
you must be so proud.
MS. ZALA: So proud. Can I give you the
testimony? Can I give you her medicine that she
hasn't used as wasted medicine?
MS. MOODY: If you have written testimony
that you would like to share with the Board,

```
please feel free to provide that to our Chairs.
    MS. ZALA: Should I do it now or do you
want me to stick around and do that?
    MS. MOODY: You can do that now.
    MS. TEMPLE: Thank you very much.
    MS. ZALA: These are her recent blood
sugar logs from just this past week that probably
show a year and a half worth of blood sugar highs
and lows but that CBD has helped her so
tremendously.
    MR. CHRISTOFF: Could I just ask a
question?
    MS. ZALA: Yes, sir.
    MR. CHRISTOFF: Are you having any side
effects, do you notice, from taking this tincture
at all? Because that wasn't mentioned. Or if
you mentioned it, I didn't catch it.
    MS. ZALA: No. In fact, her blood sugar,
and if I may answer for her, her blood sugar, you
know, causes so many, --
    MR. CHRISTOFF: Right.
    MS. ZALA: -- increases headaches, these
kinds of things. Pain, discomfort. With the CBD
tincture she doesn't feel all the things. In
```

23 then the sequence of events that occur with
24 insulin, receiving insulin to come back up from

```
those lows to then have to take insulin, food, to
bring her back up, to then have to take insulin
again to bring her lows down again, her highs
down again, it's a vicious cycle.
    But with CBD before a meal or after a
meal it tends to lower out her blood sugar so her
insulin intake is not as dramatic.
    MS. TEMPLE: Thank you so much for your
testimony.
    MR. MCCURDY: Thank you. It's always
good to hear from the patient, so thank you.
    MS. TEMPLE: Yes, thank you.
    MS. ZALA: Thank you so much.
    MS. TEMPLE: Okay. Comments from the
Board?
    MS. ZALA: This is her bag of the wasted
insulin.
    MS. TEMPLE: Thank you. Unfortunately,
we can't take meds.
    MS. ZALA: Oh, Sorry. But just to let
you know, this is, this is one of seven bags of
wasted insulin.
    MR. CHAMPION: I've been there.
    MS. ZALA: It's an awful, terrible
```

23 condition, including MS. I think we need to
24 trust our doctors to only prescribe to their
patients who would benefit. And I think --
MS. TEMPLE: Certifying.
MR. CHAMPION: Certifying. But I think
this petition did a much better job than the last
time.
MS. TEMPLE: Doctor Weathers?
MS. WEATHERS: I think you all did an
amazing job and it was so impressive at your age
to get up, and people like to participate in
this. And I've been involved with diabetes here
since I was a medical student and participated at
camp programs where we were helping students.
So even though it's not my area of
specialty, $I$ do have a long history of
involvement. And I'm not minimizing at all what
the Petitioner's going through. The needle
sticks are horrible, but $I$ have a couple of
significant concerns.
One is, I think we need to be cautious
that there's not a causal relationship. By
providing CBD you still need very strict blood
pressure.
There is absolutely no evidence that this
would be curative and would not take away that

```
requirement for very close blood sugar
monitoring. And I think our, I know there's a,
we have very compassionate people on the Board,
as well as parents.
    I would never want that for my child, but
I think we need to not link the two, that by
proving this it's not going to spare people that
strict monitoring of their blood sugars.
    I know we've debated extensively in the
previous meetings the lack of evidence and how
strong we can use that for our decision making.
And there are certainly conditions where I feel,
as Leslie, you pointed out early, it is
compassionate use, and that means a lot that
we're not going to always have that level of
evidence because the history of this drug,
because of it being, the way it was classified.
    However, when you look at PubMed, which
is our, in the medical field kind of, the
articles that are put on PubMed have a certain
cache about them. They have to be from a
reputable journal, they're peer reviewed.
And when you look at this topic on PubMed
the articles that do come up, there are a few and
```

there are some that the Petitioner did submit, but the one that was submitted as evidence actually concludes that the evidence right now is too weak for casual inference and that we need a more stable evidence base.

And this just provides new lines for
translational research. The articles that are
there discuss the risk of aspergillosis. There
are few case reports. And also, very, very
conservatively, there are a number of articles
and there are case reports, but they're still
there about how the use of $C B D$, or cannabis, in
diabetes can mask DKA, and of course the fatality
with that.

And there's some also in PubMed articles that it can increase insulin insensitivity. So while $I$ certainly am, and the Board's heard me before, people who have been in the audience multiple times before know I'm the first to say when $I$ think that the adverse effects are not significant, that the benefit, potential benefit outweighs the risk. In this case, I just don't feel comfortable making that conclusion.

MS. TEMPLE: May I go next, or do you
have, so I, because it's not related to Dr. Weathers. So I did an extensive literature review on my own which included the Petitioner's presentation, plus, plus. And what $I$ found were pros and cons.

In Weiss, W-e-i-s-s, et al., 2006, they
looked at cannabidiol, which is CBD, lowering the
incidence of diabetes in non-obese diabetic mice.
So the researchers took mice and injected
Streptolysin into their peritoneal cavities and
made them diabetic, and then tested this group of
mice with CBD and with placebo, and they found
that those treated with $C B D$ had less diabetes.
They were not obese to begin with, so they were
baseline.

We have to keep in mind what we know about animal research and going straight and
leaping into humans, that's really not how it's
done. But this is, cannabis is one of those
situations where we're already doing that.
Another pro article was from Rieder,
R-i-e-d-e-r, et al., which looked at bench
research. This is a difference where you look at
petri dishes and cell cultures, and they found

1 that $C B D$ helped the death of immune cells and
2 helped with, as a pathway to immunosuppression. And they looked at it that way to help quell the inflammatory response you get from autoimmune diseases like rheumatoid arthritis, MS, and Lupus.

So now we have mice. We have bench data. Clinician's, okay. We want to see trials in humans. Another great rat model was in 2010 by Toth, $T-o-t-h$, et al., and they found that in the spinal cord there was less, sorry, CB2 receptors, CBD main players in chronic diabetic peripheral neuropathy states. And that we as a Board approved neuropathy as an additional condition.

The most interesting study was on
Diabetes Type II by Penner, et al., and it
actually showed that marijuana use on glucose
insulin and insulin resistance in U.S. adults
showed, and this blew my mind, it actually showed
an improvement in hemoglobin A1C's and fasting
insulin.

And this goes directly against what $I$ said at the first meeting. I thought you would get the munchies and your sugars would go out of

24 you can get more CBD in the cannabis that's

24 like there is anything, we already see data that

1 it's working. And so when you open up the
2 ability for patients to get full blown, full

24 to take out inflammation, we can't get to the

```
cell level to take out pain or to control blood
sugars. So there are options and I have seen, I
have seen it with my own eyes. Every single day.
I see testimony every single day in our
dispensary.
    MS. TEMPLE: Thank you.
    MS. ZALA: Thank you.
    MS. TEMPLE: And so just out of fairness
for the rest of those who only get three minutes,
I really, we have to draw the line there. So
thank you. And that should be, with that, we
have Feliza Castro who actually is here to give
her testimony, and then we'll resume our
conference agenda.
    MS. CASTRO: Yes. Hi. Thank you so
much.
    MS. TEMPLE: And if you would like to
come up to the podium, please state your full
name and spell it for the court reporter.
    MS. CASTRO: Hi. My full name is
Feliza --
    MS. MOODY: Feliza, you'll need to turn
the power on switch, please.
    MS. CASTRO: Okay.
```

24 read the testimony on behalf of this patient. It

```
says: My daughter and I have been suffering
together for far too long. I'm a little nervous.
    MS. TEMPLE: You might get a little cue
too when you're out of time, so you get --
    MS. CASTRO: I got it. My daughter and I
have been suffering together for far too long. I
have crippling neuropathy caused by my diabetes,
which until recently was entirely uncontrolled.
On a normal day I could not keep my blood sugar
above 50 and had absolutely no appetite.
    It's a vicious and dangerous cycle to
fall into. At one point I lost five pounds in
two days. My daily life is a constant struggle.
Just last Friday I got sugar up to 225 for the
first time in weeks, and then immediately it
started to downfall.
    Every part of my body started to hurt and
my muscles felt like they were deteriorating.
When this happens my extremities go numb and I
can't hold things or walk. It feels as though my
palms are on fire, and every moment, every
movement causes shooting pains.
    Amber, my 18-year old daughter, is far
too young to have to put up with the amount of
```

pain she has every day. Also a diabetic, I see this illness getting worse for her, just like it did for me at her age. Not only is she beginning to suffer with diabetes neuropathy, but she has crippling PTSD, which prevents her from leading a normal, teen-aged life.

And her flashbacks are getting more and more frequent during they day, and her night terrors have prevented her from getting regular sleep on day's end. Amber, too, cannot work or go to school.

With both of us being so mentally and physically unwell, we are always financially strapped and at risk of losing the roof over our heads. We cannot afford to suffer like this any longer.

A friend suggested that we both try using medical cannabis to ease our pains, and I started to regain hope. The difference was night and day for both me and Amber. Our appetites finally returned, and we were cooking together for the first time.

The numbness and tingling in my hands and feet disappeared, and I finally get around the

1 house on my own. I could actually walk. I felt
2 truly happy for the first time in years. Amber was also incredibly relaxed and didn't have any flashbacks for days, which brought tears to a mother who hasn't seen her baby (inaudible) for far too long.

It would mean the world to us to be able
to have safe and regulated cannabis at our
disposal. I cannot stress enough how much my
outlook improved when $I$ use marijuana medically.
I do not want to put me and my daughter at legal
risk to get this relief any longer. Please
expand access so that people like us who try
cannabis ease our suffering. Is that really so
criminal?

MS. MOODY: Thank you very much for your
testimony.

MS. WEATHERS: I have a question for you.
I'm sorry, to clarify, and I don't know if you'll
know the answer. The patient and her daughter,
were they, do they have Type I or Type II
diabetes?

MS. CASTRO: She did not specify. In her testimony she did not specify. And this is all
she has authorized me to share.
MS. TEMPLE: Thank you very much.
MS. CASTRO: You're very welcome.
MS. TEMPLE: Comments from the Board?
MS. CASTRO: Thank you for having me.
MS. WEATHERS: Will you turn off your

```
mic?
```

MS. CASTRO: Sure.
MS. TEMPLE: Yes, Theresa.
MS. MILLER: One of my concerns, I have
two. The first concerns the use of cannabis in
developing brains. Young people. There's lots
of evidence out there that indicates the impact
on adolescents and developing and brain function
in young children. That would be my first
concern.

The second concern $I$ have is with the petition. The support letter was written by a
Certified Nursing Assistant, and that is actually
out of their scope of practice. So I'm not
really sure what treatments that this Certified
Nursing Assistant is providing, but it is out of
their scope of practice when you look at the
Illinois Nursing Practice Act.

```
    MS. WEATHERS: And the point, oh, I'm
sorry. Is that sufficient as a
provider-supported letter?
    MS. MOODY: So we did, the Department
did, the Department did consider that because we
do request in our resumes a letter of support
from a certifying physician if the person
submitting the petition is a patient. A
qualifying patient or a registered patient.
    In this case we decided to be sympathetic
and allow the petition to proceed to the Board
for consideration because we had no indication
whether the individual was a registered patient
or not.
    MS. WEATHERS: Got it. Thank you.
    MR. MCCURDY: Can I make a comment? I
guess this would be a question to Theresa about,
and really to anybody who would be knowledgeable
about this. The effects of cannabis on the
developing brain I think are typically what we
hear about with regard to recreational use.
    My question is, would doses of cannabis
at the legal limit allowed under the current law
have the same effect, or is that actually at a
```

1 lower level than you might expect than people who 2 are using it recreationally?

23 there's about 111 other phytocannabinoids present
24 in cannabis, and 80 of the substances that are

1 there are only present in cannabis. So cannabis
2 is a huge variety of things, and you can do like
3 you do with corn and do like you do with peas, you can cultivate it and genetically alter it so it only produces certain kinds of substances. In Colorado this has become a science.

There are people that study this and can produce strains of cannabis that have almost no THC. There are others that have very high THCD, which is an appetite suppressant and has very much use. But this, with high THC it would not be good in cancer or AIDS because you want to stimulate the appetite.

So they want the part that stimulates the appetite. So we cannot generalize the word cannabis to all kinds of things. And I agree with Theresa that the ones that have the most THC are the ones that are more psychoactive, and the ones that produce more problems for brain development.

But right now there are botanists devoting their full lifetime to creating strains that have very specific actions. And that's where medical research is going to come in. The

1 advantage of all this is that on April 21 st the
2 DA turned its face around and said that yes, they

3 were going to allow research on smoking marijuana as legitimate medical use. So then we're standing in front of four or five years of
tremendous findings, tremendous evidence, and tremendous proof of some of the things people say.
(Applause.)
MS. TEMPLE: Actually, Nestor, as a pediatric, you know, I wonder, I'd love to hear your comments too, Dr. Christoff. That there is, like, as I said, I really went through the evidence base and found that there's a plausible mechanism of action, not from a pain management perspective but from an altering of the immune system.

But then we're charged as a Board to decide if we're going to open up the whole thing, the whole, and $I$ know Michael brings up a great point. Kids aren't going to be getting marijuana they smoke, they can only get oils. It will be strictly under the supervision. You need two physicians to sign off on this.

MR. FINE: Until they're 18.
MS. TEMPLE: Until they're about, until
they're 18 and they're able. But we also have to speak to, well, first of all, the evidence base, there's one that was not included in the petition where it really was lifetime and is 12 months' use of cannabis, and I'm quoting this, were associated with poorer glycemic control, which is hemoglobin A1C. Those numbers going over 8\%.

And adolescents with diabetes Type I
reported using illicit drugs, and they did
specify cannabis to a lesser extent. So the
folks who were using, who had Diabetes Type I in
this Polish study, did not use recreational drugs
as much as their peers.

But those who did use it, the use of cannabis was associated with poorer metabolic control in teens with diabetes Type I. And this is clearly not the case in Miss Zala. But we are also opening this up to the rest of the world. Okay?

This is what's tricky about the compassionate use is when we say okay, we are now allowing it for all, we have to understand what
the public health impact of that would be when we have a study that really flies in the face of it. This was a study of not 10 kids. This is 209 adolescents with diabetes Type I, which again I emphasize is very different from II.

These were age 15 to 18 years old
compared to 12,000 of their non-diabetic peers.
So when I read that, that gave me a lot of pause.
I would hate to potentially cause more problems
without a really, really solid evidence base I
want to see in this particular condition because
I want to see it.
Because there are no other states that
have Diabetes Mellitus Type I or II in any of
their Pilot Acts. In any of their Compassionate
Use Acts. So we're asking to be a front runner
in that, and that is going to take a lot more
evidence base than we have here to be the first
state to pass it.
So I just want you to keep in mind, there
aren't like five other places that are doing
this. This is a new thing. Yes.
MR. KNAUS: Can I just ask you a quick
question? Maybe clarification. It seems like if

1 we're charged with compassionate use, it seems
2 like we're burdening any of those decisions by

3 this need for this evidence-based medicine which
4 just doesn't exist. If we were charged with medical or evidence-based approval of these medical conditions with use of CBD or THC, that's one thing.

But it seems like we're charged with compassionate use, yet we're basing all our decisions on medical evidence that can go either way or vice versa. I think it's going to impair our decision making if we're structuring our compassionate approval based on medical evidence.

MS. TEMPLE: And this was discussed in our first two meetings.

MS. WEATHERS: Can I, yeah, I'd like to respond to that. I feel that's something that I've certainly struggled with. And I think we've done a really good job here is balance that. So, and I, you know, a little self-congratulatory, but I feel as a committee we have to very, very carefully consider that for each petition before us, over a year and a half now $I$ guess that we've been doing this. And I feel that there's, I

MR. KNAUS: Do you prescribe

```
medications _-
```

MS. WEATHERS: Yes.
MR. KNAUS: -- with the awful side effects?

MR. CHAMPION: I was going to say one of the, one of the other medications that you no longer take, what are the side effects of those?

MS. WEATHERS: But see --
MR. CHAMPION: And by decreasing those and, you know, I mean, we're left with a, you know, it is cannabis. It does less harm than that bag of medicine that she presented in front

23 different. There are strains of, with high THC.
24 For example, there's one called Doug's Varin

1 which has a THC/THCV ratio of six to seven. So 2 it's actually more THC than THCV. So, you know, I think that we've got to realize that we're not dealing with pot is pot is pot. No. We've got to think that some of the research has been done indiscriminately is like saying okay, we're going to give you carbonated soft drinks. What the hell does that mean?

We're going to give you Diet Coke, Diet Pepsi, Dr. Pepper, what are we going to give you? So we can't just say pot is pot is pot. I think we've got to start demanding of our medical community when they start doing research now to really clarify what strain, what concentrations of products they have, and what the effects of each of those products are. Otherwise, we're going to be --

MR. FINE: In that regard to all of the physicians on this Board, is this something that you would feel comfortable with based on the personal relationship that you've established with your patients to monitor?

I mean, obviously in the context with children under the age of 18 , the only thing that

```
they have access to, you know, are the oils and
some of the other products as well. Is it
something as doctors that you feel comfortable
monitoring? I know you don't have the control of
what they can buy in the dispensary after they're
18, but up until that point is it a monitoring,
you know, capacity that you feel comfortable, you
know, undertaking?
    MR. CHRISTOFF: Well, I'm not a
pediatrician, but I manage adults with Type I
diabetes, so I would answer yes to your question.
Allison, were there actually deaths from DKA, or
just ICU admissions where this was covered up?
    MS. WEATHERS: It was, it looked like ICU
admissions but, I mean, it can --
    MR. CHRISTOFF: Like how many of these
were, it looks like a case report?
    MS. WEATHERS: Yeah. I mean, that's what
I'm saying. There's not many --
    MR. CHRISTOFF: There were --
    MS. WEATHERS: But there's growing
evidence that --
    MR. CHRISTOFF: -- a few reports?
    MS. WEATHERS: Yeah.
```

MR. CHRISTOFF: Like they didn't notice
because this was covering up their, --
MS. WEATHERS: Yeah. Because --
MR. CHRISTOFF: -- you know --
MS. WEATHERS: -- change, yeah. With
respect to acid base, so it impacted the acid
base balance. When they presented the usual
markers to diagnose it, it altered it. It's not
like that because of the drug they didn't present
in time. It's that once at presentation it
masked the usual labs that led to a delay in diagnosis.

MR. CHRISTOFF: So what is her hemoglobin A1C?

MS. ZALA: Her A1C as of April 29th, which was this Friday that passed, was 8.8 .

MR. CHRISTOFF: And what was it the time before?

MS. ZALA: 17.
MR. CHRISTOFF: Oh.
MS. ZALA: Off the charts.
MS. TEMPLE: Connie, did you have
something you wanted to say?
MS. MOODY: Yes. I just, I just wanted

1

23 to answer the questions that have been raised
24 about what should be considered as part of this

```
23 I got like no ways, no way.
So the burden on this group is to provide
decision made by the Board.
    MR. MCCURDY: Well, clearly we've been
talking about both, that's for sure.
    MS. TEMPLE: Just on another note since
we are talking about diabetes, there's data on
diabetes Type II in Penner, P-e-n-n-e-r, et al.,
that talked about, which I thought had the most
teeth with respect to diabetes in favor of.
    And remember, I do get it that we're
talking about physician/patient relationship. I
get that. At the same time when we, when we pass
the recommendations at the end our letter goes
to, and all of the proceedings, goes to Dr. Nirav
Shah, who is the Medical Director of IDPH, and he
goes through and he actually does his own
literature review of all of this.
    So I want you to know that without
attending here, without the added human element,
that the people who are not in this room are the
physicians who would never even hear about this.
I actually, you know, I hate to say, but I read
some conditions out to some of my colleagues and
    I got like no ways, no way.
    So the burden on this group is to provide
```

1
2

24 conventional medicine, but that's for another

```
day, that today we need to consider what the
impact of this will be, and that there are, there
is evidence for it, but there's also evidence
against. This is what's going to be one of the
most challenging votes for this Board because of
that. So are there any other comments before
from the Board before we --
    MR. MCCURDY: Move to approve.
    MS. TEMPLE: Okay. Approved. Those in
favor?
    (Board responded aye.)
    MS. TEMPLE: So if the Board would get
out their paper ballots.
    MS. MOODY: In your blue packet you have
green paper ballots, one for each of the
conditions that you'll be considering today. You
may mark either yay or nay, and I will collect
those and tally those.
    MR. RAMIREZ: Now, when we're voting on
this we're voting on --
    MS. TEMPLE: Wait. We have a question on
the floor.
    MR. RAMIREZ: When we're voting on this
we're voting on conditions for patients that are
```

over 18 years of age?
MS. TEMPLE: No, this is for everybody.
MR. RAMIREZ: For everybody.
MS. MOODY: No, for everyone.
MR. RAMIREZ: The law says that we only
do it for people over 18.
MS. TEMPLE: No, it's for everyone.
MR. RAMIREZ: It had over 18 for one
specific condition but not generalized?
MS. MOODY: We have, the way that our
rules read at this point in time is that any of
the list of debilitating conditions that are
currently approved for the program are open for
both, for individuals of all ages.

MR. RAMIREZ: On the current list?
MS. MOODY: On the current list, yes.
MR. RAMIREZ: But otherwise?
MS. MOODY: The way that our, again, our
rules read, is that any action, any
recommendations the Board takes would allow that
condition to be open to any person of any age.

MR. FINE: They're regulated the same
way. Two physicians and, --

MS. MOODY: Yes.

MR. FINE: -- you know.
MS. TEMPLE: This is for Diabetes
Mellitus Type I, so it doesn't say that on the ballot but it's diabetes Type I. This might be a nice time if people need to take a break because
it takes a few minutes to tally.
(Break taken at this time.)

MS. TEMPLE: Okay. I wanted to announce
that the condition of Diabetes Mellitus Type I
passed with a vote of five yay, four nay. All
right. We're still waiting for Nestor who's also
on his break, and panic disorders is next.

We can maybe queue up the next speaker.
When Mr. Ramirez comes back in the room we'll
have Feliza Castro speak again. So just give him
a little moment here.
We're going to go ahead and get started
now. Shifting gears to panic disorder. Okay.
And we have petitioner Feliza Castro who will
come to the podium for her three-minute
discussion.
MS. CASTRO: Hi. Thanks again. I'm
going to read testimony on behalf of a patient
who wanted to speak anonymously. Hi. I, myself,

1 also suffered from anxiety disorder, and I can
2 say that medical cannabis helps me a lot
3 personally. But I'll read this testimony. I'm a
428 year old woman from Chicago, and before

23 Valium or tranquilizers just to be at social
24 gatherings. I was able to leave the house.

```
Cannabis alone has brought a whole new lease on
my existence. I haven't had a panic attack in
almost six months. I haven't hyperventilated or
cried at a single public function since I started
this regimen.
```

    I haven't had to miss out on one of the
    most precious parts of life because of crippling
anxiety. Medicinal marijuana has improved my
ability to be a good friend, partner, caregiver,
and overall has made me a healthier person.
In all honesty, I hate that $I$ require
anything to do what a normal person sans anxiety
and panic does on a daily basis, but this is the
first alternative I've ever tried that has given
me hope.
Every day is a little bit better because
of this medicine. Thank you. I'd also like to
point out that cannabis is much less addictive
than Benzodiazepines, which are often prescribed
for panic disorders and anxiety.
There are also studies on this by a Dr.
Irit Akirav, who is published in 39 different
studies. She's an expert in biological
psychology, and she published one study entitled

Cannabinoids Prevent the Development of Behavioral and Endocrine Alterations in a Rat Model of Intense Stress. That's it. Thank you.

MS. TEMPLE: Thank you. Comments from the Board regarding panic disorders?

MS. WEATHERS: So I know in the past that we have not approved anxiety. I personally am more comfortable with this one because of the
specificity of the nature of the condition. As I
was saying, from a medical standpoint I'm more
comfortable because of the specificity of this
condition and the difficult nature to treat
conventionally.
So to me, getting down to this kind of
level of granularity, it makes more sense I think
to approve it.
MR. CHAMPION: I don't need a mic.
MR. FINE: Oh, I'm sorry.
MS. WEATHERS: Jim.
MR. CHAMPION: Go ahead, you go first.
MR. FINE: I agree from the --
MS. WEATHERS: No, go ahead.
MR. FINE: I tend to agree from the
standpoint of specificity as we do not approve 24 it.

```
23 like the relaxing feeling that they achieve from
general anxiety as a, I think the degree of pain
threshold that we had looked at to qualify
things. This, you know, panic disorders I would,
you know, lump in the same category as PTSD
because it's chronic and specific and much more
intense than a general anxiety disorder.
    MS. TEMPLE: Go ahead.
    MR. CHAMPION: I was just going to say
due to the nature of this condition and the
medications that are prescribed to control this,
I can certainly see how cannabis would be
helpful.
    Most, most strains of cannabis give the
user a relaxed and euphoric state, which would
certainly be beneficial for this diagnosis. I
know that when I'm stressed out and wound up,
cannabis provides me with instant and
unparalleled relief.
    It's an instant relaxer, mood stabilizer.
So I believe that's why some people get the
false, the false sense that they're addicted to
it. They're not really addicted to it, they just
like the relaxing feeling that they achieve from
    it.
```

23 higher the THC is, the greater the anxiety can

24 be. A panic attack is classically present with

```
spontaneous, discreet episodes of intense fear
that begins abruptly and lasts for several
minutes to an hour. In panic disorder, patients
experience recurrent panic attacks, at least some
of which are not triggered or expected, and
there's about a month or more of either worry
about future attacks or consequences or a
significant maladaptive change in behavior
related to the attacks to avoid future panic
attacks.
    So there's a lot of avoidance of
potential triggering circumstances, and these
folks tend to just lock up. Panic disorder, we
have to keep in mind that the disturbance must
also not be from a physical condition from using
a medication.
    And it can't be from a condition like
hypothyroidism, and that the disturbance can't be
better explained by another mental disorder like
social anxiety disorder, specific phobias,
obsessive-compulsive disorder, or PTSD, or
separation anxiety disorder.
    So I just described for you a whole realm
of sub types of anxiety that we as physicians,
```

when we write our, and evaluate people for, we have to really categorize those things. So what the petition asks for is panic disorder. And when I looked at the evidence base I thought to myself well, okay, am I going to pull that, the strict scientific card, or do we make a little bit of a leap.

And panic attacks to me are a more severe case of anxiety. Even though social anxiety
Disorder, which is by definition a marked
persistent fear of social circumstances, of
unfamiliar people or possible scrutiny by others,
which sometimes $I$ have at this meeting.
But the exposure typically promotes
anxiety. The patient usually recognizes their
anxiety or fear as excessive, and a patient tends
to avoid peer situations or public speaking.
So that's social anxiety, and that was
studied by Bergamaschi and Crippa. I'll spell
it. $B-e-r-g-a-m-a-s-c-h-i$. And Crippa,
C-r-i-p-p-a. And they talked exclusively about
cannabidiol in these studies. They used it in
humans.
600 grams of $C B D$ seemed to work best in

23 had with some other things. There's enough
24 evidence in the neighborhood that I would support

1 this.

23 is why I said I want to hear what the rest of the
24 Board has to say. And that's Lev-Ran, et al,

```
meaning et cetera, they found that quality of
life in surveys given to people who are using
cannabis who had anxiety disorders actually
expressed poorer self reported mental health
outcomes, which I found interesting.
    I found that they discovered this in the
patients they surveyed with depression or
dysthymia, which will also be discussed today,
that those who used it more heavily, meaning more
than once a week, so that's heavy. The
occasional users were once in awhile, and then
there's the never users.
    So if we had to categorize, again,
another educational pearl, those who use it more
frequently didn't do as well. And this is then
where the chicken and the egg discussion comes.
Was it because of the cannabis use that made them
worse, or is it because they already had came in
with a higher baseline of anxiety that required
more, more medication, and so they were going to
be, they tended to report poorer mental health
outcomes.
And when we talk about quality of life
data, this is a huge area in the research
```

1

MS. WEATHERS: Was that, were you asking about the study?

MR. MCCURDY: I was going to ask --
MS. WEATHERS: Okay.

MR. MCCURDY: -- about it. So the use, level of use that you found, that they found in the study, how, you know, is there any way that you could compare that to what we would expect with people who are able to receive only the certified amount --

MS. TEMPLE: No.
MR. MCCURDY: -- through medical cannabis? I mean, that sort of recreational use

```
sounds like it's sort of cooked into it, that
it's going to be more --
    MS. WEATHERS: Well, was it a
recreational study or was it --
    MS. TEMPLE: Well, everyone in here is
going to be recreational because they're all
self-reported. I'm assuming these are, it did
not specify this is a medical marijuana study.
    MS. WEATHERS: Okay. Yeah. That's why I
didn't know where the study originated or what.
    MS. TEMPLE: Which also speaks to Dr.
Ramirez's point about this is cannabis from the
street, it's different, and so you're going to
get different responses. Yet this is what we've
got. We have to work with what we have,
recognizing the differences.
    So that's the one thing that gave me
pause, and that's why I wanted to hear from the
Board, that we have to recognize that cannabis
does have its risks, and acknowledge that.
    But I think in the properly vetted
patient/physician relationship that can be
determined. I'm not a big fan of
benzodiazepines. I'm not a big fan of certain
```

24 side effects in the original medications,

23 So I guess the, that's, that's really the first
24 comment I would have.

MS. WEATHERS: I was going to say initially, $I$ think in reading through $I$ did have some concerns because, again, worrying are we
losing that appropriate level of specificity.
But I think going to Michael's point, that given
the duration and the difficulty in treatment,
that because of the nature of the disorder that
some people are very intractable to the
medication that we have, that $I$ do think that
this is a reasonable one to approve.
MR. CHAMPION: I just want to say at the
beginning it says dysthymic disorder, and then at
the end they said please approve my petition for
panic disorder at the end, so I think --
MS. TEMPLE: You think they petitioned
twice? We don't have names. We don't get to see
the names of these petitioners, so it might have
been the same one.

MR. CHAMPION: And as I previously
stated, cannabis when you're stressed out and
wound up, provides excellent, instant relief, the
euphoria, all of that, which would be beneficial.

MR. MCCURDY: I don't want to hog the
mic, but does somebody else want to make a
comment?
MS. MILLER: I would prefer, one of the notes $I$ had written down was that in the petition the petitioner cited that they stopped taking their SSRI, and it was hard to determine whether or not the cognitive strategies were actually working or if they were doing the cognitive strategies, which evidence shows do work for depressive disorders.

And that he's still struggling with anxiety. And so, I mean, we've already approved anxiety so with the panic, it was panic, so.

MS. WEATHERS: Interestingly, we haven't approved major depressive disorder.

MR. MCCURDY: That's what I wanted to --
MS. WEATHERS: Yeah. Sure.
MS. TEMPLE: I kind of don't know about this one. It's, when I looked at depression, so I'm being a stickler with the research and the literature base to stay balanced as a Board, and we went back to ask okay, this is a hard one to say, A-s-p-s-i, et als.' Work, the title of the article was Cannabis Use and Mental Health Related Quality of Life Among Individuals With

```
Depressive Disorders, and they pointed out mixed
contradictory data about whether the quality of
life was better or worse for people with
depression and anxiety. So I had mentioned this
in the previous commentary about panic disorder.
    And all the quality of life studies
looked at questionnaires regarding, one,
self-perceived mental and physical health, pain,
vitality, social functioning, and role
functioning.
    And those who used cannabis and had
depression, so not anxiety and not panic, but
depression, reported poorer mental quality of
life if they used it every week or were
considered heavy users.
    The occasional users of cannabis, which
is less than that obviously, was not associated
with lower quality of life when compared to
non-users.
    So we can't say that the use of cannabis
caused, you know, the chicken versus the egg
story, the people who are using it more heavily,
are those folks having more severe issues with
their depression, or is cannabis causing it to
```

| 1 | get worse? We have no data to show cause or |
| :---: | :---: |
| 2 | effect. Just know there's a relationship and |
| 3 | that's important. Especially from like, I think, |
| 4 | from a patient/dispensary point of view, because |
| 5 | its the dispensaries that are giving the advice |
| 6 | to our patients, and they should know this. |
| 7 | So I thought that was interesting. Now, |
| 8 | us as a Board, we can't say well, you can only |
| 9 | use, you can only mandate patients use it once a |
| 10 | week or less. You know, we can't do that. When |
| 11 | we pass something or we recommended to pass |
| 12 | something, it's for everyone. |
| 13 | And that's, the fact that I didn't see |
| 14 | specific depression oriented human trials leads |
| 15 | my inclination to be less favorable compared to |
| 16 | panic disorder where we did see some evidence |
| 17 | base for social anxiety, and I did make that |
| 18 | leap. |
| 19 | So there, I also want to call to mind |
| 20 | there was one article on depression, which was on |
| 21 | animal experiments, based by Saito, $S$-a-i-t-o, et |
| 22 | al., that was in favor of using cannabis in |
| 23 | depression. But it was, again, an early study. |
| 24 | I'd like to see more evidence developed |

1

23 if $I$ read it right. So it's hard to gather any
24 real support from that angle from the --

23 PubMed and I looked at some of the other evidence

24 based search engines for cannabis use, there

```
were, there was no literature that I found
related to this particular disease process.
    MS. WEATHERS: I agree. And I think the
point the Petitioner was trying to make was that
the existing treatments aren't efficacious, and I
certainly recognize that. I think, I had a, I
had a number of concerns. I think carefully
going through the petition, many of the symptoms
that they were raised could be classified as
their own conditions I think.
    Chronic pain was mentioned. Fatigue,
PTSD I believe was there as well. And I think
that this is, so my concerns are one, I think
we're better fulfilling our duties as a Board and
helping patients, again, you've all heard me say
it multiple times, to get to the level of
specificity those individual conditions need to
be approved, and I think we evaluate those.
    I think this is such a controversial
disease overall, chronic Lyme disease, I think
that there's substantial evidence that really
raises concern about this diagnosis itself in the
first place, and then the absolute lack of
evidence at all, so nobody's even tried it, and
```

1 as well as the fact that we have recommended for

23 about anti-bacterial, anti-viral properties that
24 seemed intriguing was by, was by Russo,

```
    1 R-u-s-s-o. It was called Taming THC: Potential
    2 Cannabis Synergy and Phytocannabinoid Terpenoid
Entourage Effects. And they talk about the
entourage effect of cannabis with all of the
other cannabinoids.
    Because we talk about THC and CBD all
day, but there's so many more we're not talking
about that exist in other substances like lemons,
pine, lavender, hops, pepper, lemon balm, orange,
and green tea, that have been shown to have maybe
some anti-bacterial effects.
    So I thought that was interesting, and
it's important to note that we can take advantage
of these effects in hemp oil, which is another
form of cannabis sativa, except without the
higher amounts of THC in it. So I want to call
out that potential, and that's over the counter
so hey, why not look at that.
    The articles that were presented in the
Lyme petition were not specific for Lyme so I'm
reiterating what others have said, but rather for
the potential symptoms of Lyme.
    And the articles presented took a look at
anti-bacterial activity of cannabis sativa
```

```
    1 itself, but not of the spirochete called Borrelia
    2 that causes the Lyme disease. So we just don't
have enough at all to vote upon, I think to even
consider this as a disease. But my inclination
is a strong no against this condition until we
have more research.
    MS. WEATHERS: Move to vote.
    MS. TEMPLE: Okay. So we will vote. And
on your ballots, switch it. It's, Lyme is
underneath MRSA.
    MR. RAMIREZ: So to me cannabis is
something like aspirin. We've had aspirin for a
couple of hundred years and we still don't know
exactly how it works on some things. So
cannabis, we've had it for several thousand years
and we still don't know how it works in certain
things. We know that it has anti-bacterial
properties, but not which bacteria specifically
to.
    We know that sometimes it's been used
topically and it cures certain infections. We
know it's being used to smoke, it's being used
inhaled, it's being used orally in cookies and
brownies. But, in general, we do not have enough
```

24 situation, that looked at MRSA versus, well, and

```
cannabis. There was another study called the
Lone Study, L-o-n-e, that looked at cannabis at
Vibrio cholera. V-i-b-r-i-o, c-h-o-l-e-r-a, and
it looked at pseudomonas aeruginosa.
    Spell that? All right, I'll help you
out. P-s-e-u, pseudo, p-s-e-u-d-o-m-o-n-a-s.
And then aeruginosa is a-e-r-u-g-i-n-o-s-a.
    And Candida Albicans. Okay. Cannabis
was effective in all of the mentioned, all of the
studies mentioned above, in a test tube
situation. There was another article, this is
all in the petition and what I also looked at.
    There was an article by Das, D-a-s, that
was very, it was pretty poorly done, but it did
show that cannabis in individually obtained
samples of urine, ear swab and mouth swab had
activity in vitro activity against a very vague
group of organisms called mouth, skin and ear
microflora, which could be just anything.
    And they did find that it was effective
against E. Coli from a person who had a urinary
tract infection in that study. So basically the
researchers just took swabs of like various body
parts. They didn't describe the health of these
```

1

23 this group.
From the University of Mississippi, which

6 looking for anything about MRSA.
But two of those cannabinoids showed mild

```
activity against MRSA. So I think we're really
```

at just the very infantile neonatal level of --
MR. RAMIREZ: Well, wait, wait, wait.
MS. TEMPLE: Hold on a second. Okay.
Sorry. Very, how about just really early?
MR. RAMIREZ: There you go.
MS. TEMPLE: Very early stage of
understanding that there are potential benefits
in the infectious disease world. And my
inclination is to vote against MRSA. Did you
have anything else?
MR. RAMIREZ: No.
MS. TEMPLE: He's correcting my neonatal
comment.

MR. MCCURDY: I did have a, I suppose a comment and a question at least. So if $I$ understood the petition correctly, it sounds as

24 our purview, or in the, you know, one's, I

24 which, again, the petition, the Board has

23 doesn't say well, you can only buy antibacterial
24 to another person if they're over 18 , they would

1 be opening it up to the full array, so we can't 2 differentiate that, so.

MR. CHRISTOFF: I think that this presents an interesting research question but I'm not sure it's, I think because if it's dermatologic or it's very superficial, you can use it, in comparison, and a triple antibiotic ointment and things like that could not only be used to treat what is probably MRSA and it's very superficial and not, you know, too deep of an infection, and it's a deep subcutaneous infection it has to be drained and antibiotics won't work of any sort and then, you know, you have all the hospitalized types of context which MRSA
represents in an in-patient setting.

But, but $I$ think that's how I'm seeing this one, is that it's something interesting to look at for the research in general, but I'm not sure why we would not find our current, there are actually, besides the comparison, I think one or two other topicals that have been approved in the last three years to treat this.

MS. MILLER: This was another one I had some concerns with. One, because, again, going

23 a great point that, again, due to the public
24 nature of this I think we should take the

```
opportunity to formally put into the Minutes and
convey to the public how much we really very
carefully read the petitions and look for things
like this. It's a type of inconsistency, it's
flat out plagiarism when people aren't carefully
reading the application and providing us with the
personalized information that we as a Board
really look for and need to understand the, --
    MS. MILLER: Exactly.
    MS. WEATHERS: -- the rationale.
    MS. MILLER: Yeah. I think it's a good
teaching opportunity because the beginning of the
petition asks you for a brief description of the
disorder and how it's applying to you, and so I
didn't see that. I saw how, I learned to see how
Mayo Clinic defined MRSA, and so, yeah.
    MS. TEMPLE: Nestor.
    MR. RAMIREZ: Well, the other thing is
that I'm not a real doctor but I play one on TV,
so I don't see MRSA cases in adults when they're
very sick. But in the babies that I treat what
we have 99 percent of the time is MRSA
colonization.
```

    And like Eric said, we use Search Results
    ```
Mupirocin all the time, we don't treat them
systemically with antibiotics. We just isolate
them and give them, treat them for their
colonization. So if we consider MRSA as a
specific infection by a bacteria that is
resistant to methicillin and the group of
medications of methicillin, then it's something
that you either treat with antibiotics that will
work, Vancomycin, and all the other that are
specific, or you consider that it's an
intractable disease and the patient's going to
die from that infection anyways.
    It's not a chronic, debilitating
condition. You either die from it or you get
better from it. So it's not something that we
think should be the purview of when we talk about
chronic, debilitating conditions to be submitted
to, for approval to treatment by cannabis.
    MS. WEATHERS: Motion to vote.
    MS. TEMPLE: Motion. Oh, by the time
it's an acute condition, by the time a person
gets a card, you know, it's --
    MR. RAMIREZ: They die very quickly.
    MS. TEMPLE: Okay.
```

MS. MILLER: I'll second.
MS. TEMPLE: Okay. So let's vote. And
following the announcement of the results, we're
going to move to autism for which we have
multiple speakers. We have six speakers. We'll
not be acting on the condition, we've already
voted to approve autism, but we do welcome
comments to further educate the Board and the
public.
MR. RAMIREZ: If at first you don't
succeed, try, try again.

MR. MCCURDY: Can I make a comment while
we're counting? I want to read a couple of
sentences from one of the petitions we received.
This was for, I think, dysthymic disorders.

There's a sentence describing proposed
benefits that said that as a result of the relief
that I get from cannabis I'm able to spend more
time with my family and friends, and I'm able to
go to and enjoy sporting events, concerts and
festivals, and more of a normal life.

We have seen that sentence in any number of petitions over the years and others like it. So I think petitioners should be advised that

1 this sort of boilerplate stuff does not serve you
2 well. We really are asking you to give a personal account, not just borrow from somewhere else, pull from borrowing things from the website.

MR. RAMIREZ: All lives matter.

MS. TEMPLE: So the vote is, for MRSA, methicillin staphylococcus aureus infection is zero yay, nine nay. The condition fails. Okay. So we'll have to wait for Dr. Weathers to come back, but our first, I'll talk about the order of the speakers for autism.

We have Mr. Jared Taylor, Miss Feliza Castro, Angela Basolo-Bond, Tina Higens, or Higens, sorry. Amanda Dickerson, and Dana Hall. So we'll do it in that order, and you each get three minutes.

Our first speaker is Mr. Jared Taylor. Oh. I want to, I want to preface this by the next, from this point forward all of the petitions that we're going to be discussing have already been approved by the Board, and we're not going to vote on them.

We may have some deliberations, some
discussion, but we don't need to vote anymore.
They've already been approved.
MR. TAYLOR: All right.
MS. WEATHERS: And I'm sorry, Jared.
Just to clarify a point, and I know, Connie, you
said that, $I$ thought we had to vote as a group
but we don't have to reenter, because I thought
once the Director says no it kind of invalidates
everything that we did.
MR. MCCURDY: We voted earlier this
morning.
MS. MOODY: There was a motion made
earlier, and we can check that --
MS. WEATHERS: Okay.
MS. MOODY: -- motion, that the Board was
going to approve the entire list of petitions.
So we can, we can check that on the transcript if
you'd like to. Are we able to read that back?
MS. WEATHERS: Okay. I'm sorry.
MR. FINE: I made a motion before that
everything that we had approved, approved
previous, at previous hearings, --
MS. WEATHERS: Okay.
MR. FINE: -- this would the last one, if

```
we approved it before that there's no need to
approve, --
    MS. WEATHERS: Okay.
    MR. FINE: -- even though the Director of
Public Health denied them all.
    MS. WEATHERS: Okay. I mean, that's --
    MR. FINE: We still go down there.
    MS. WEATHERS: I think maybe we should
just wildly all vote just to have that on the
transcript.
    MS. TEMPLE: Should we do it again?
    MS. WEATHERS: Yes.
    MS. TEMPLE: Okay. Let's hear a motion.
    MS. WEATHERS: We'll do it again.
    MR. FINE: I hereby motion to approve all
the prior conditions that we have previously
approved up until this meeting if they come up
again in today's hearing.
    MR. CHAMPION: Second.
    MS. TEMPLE: All those in favor?
    (Board responded aye.)
    MS. TEMPLE: Nestor?
    MR. RAMIREZ: Aye.
    MS. TEMPLE: Okay.
```

MS. WEATHERS: Do you know what you're voting for? I just want to make sure.

MS. WEATHERS: Okay. Thank you for doing
that. I just wanted to --
MS. TEMPLE: No, that's very organized.
Okay. So we're good to go. Everything we're
going to talk about now has already been
approved, but we want to at least thank you.
And, please, proceed, Mr. Taylor.
MR. TAYLOR: Please, Jared. All right.
So my name is Jared Taylor. J-a-r-e-d,
T-a-y-l-o-r. And $I$ come before you to urge the recommendation of autism as a qualifying condition for the Medical Cannabis Pilot Program.

According to the Mayo Clinic, autism spectrum disorder is a serious neurodevelopmental disorder that impairs a child's ability to communicate and interact with others.

It also restricted repetitive behaviors, interests and activities. Now, these issues do cause significant impairment in social, occupational, and other areas of function.

Because autism is a spectrum, there are a variety of symptoms, including poor eye contact,

24 last year, October, was the first, first state, I

```
or lacking facial expressions. A child that may
repeat words or phrases verbatim without knowing
their meaning, constantly moving, or more
specific routines/rituals, and basically becoming
disturbed at the slightest change of these
routines or rituals.
    So I actually did some research and found
that cannabinoids within cannabis interact with
the body's endocannabinoid system and help to
regulate emotion and focus for individuals that
have autism.
```

    According to a father who administered
    medical cannabis to his autistic child; my son
was having another horrible day. After 30
minutes we could see that the medical cannabis
was taking effect.
His behavior was relaxed and less
anxious. Less anxious. My son started laughing
for the first time in weeks, and his anxiety,
rage and hostility melted away. He slept that
night with no problems and slept all through the
night.
So I realize that Illinois in its time
last year, October, was the first, first state, I
don't believe that any other state has currently
approved --
MS. TEMPLE: Pennsylvania.
MR. TAYLOR: Pennsylvania. Okay, so
great. So Pennsylvania's on board. So, you
know, we read in the newspaper about how Illinois
is slipping on this or that issue, and I realize
that there is some trepidation on adding a
condition that no other state has added before,
but $I$ really think that we shouldn't be so
concerned about, you know, opening the flood
gates, if you will.
I think that a doctor previously had said
opening the flood gates on a different condition,
but $I$ really don't think that should be a concern
here. So we've already approved this but, you
know, myself, I don't have any children.
I don't have a child who has autism, but
my heart goes out to the people, the parents, the
families, the actual patients themselves who do
have autism. And $I$ can really only imagine the
day-to-day challenges that both the parents and
the child face.
There is no cure for autism. But if

```
cannabis can be of benefit to children with
autism and their parents, cannabis should be an
option for Illinois families. Thank you for your
time.
    MS. TEMPLE: Thank you. Okay. Miss
Feliza Castro.
    MS. CASTRO: Thank you. And, again, I
would like to thank you, the Board, for allowing
me to submit testimony on behalf of other
patients. So this is an anonymous testimony from
a patient, oh, from the, I'm sorry, from the
father of a patient.
    He says I have never really considered
marijuana until my son was diagnosed with autism.
It all started when he was around two, and he
would throw violent fits in reaction to small
changes to his routine.
    Things only got worse as he started
pre-school and was formally diagnosed. It was
exhausting for me to manage his rage while trying
to give him a happy childhood.
    After trying a couple of mood
stabilizers, I decided I no longer wanted him to
be a guinea pig while they figured out the right
```

1 cocktail of pharmaceuticals to sedate him. He
2 wasn't responding well, if at all, and I couldn't
3 watch my four-year old baby boy taking all of
4 these toxic substances while he was still

5

23 there are some pretty compelling studies out
24 there around the benefits of cannabinoids for

1 autism. MAMMA is a great organization. It's
2 Mother's Advocating Medical Marijuana For Autism.

3 They have a really great selection of resources
4 and studies. Thank you for your time.

23 January 5th of this year he was able to get his
24 first dose of the candy form of the marijuana.

1 Prior to all this, we have been everywhere. He 2 developed normally. He was perfect. About 322 months old we started having the loss of eye 4 contact. He stopped talking, he started using Maryland, St. Louis. He goes to Riley Children's Hospital and sees the autism team there. He started having grand mal seizures. With the

```
grand mal seizures the anxiety, the flapping, the
barking, not able to communicate, getting out of
our house at night. And it was basically we'd
take him to the doctor and they'd give him this
pill to give him this pill to give him this pill.
    So we gave him all these pills. His
liver's shutting down. His kidneys are shutting
down. He can't take a crap. I mean, he's on, at
one time, probably 15 to 20 different fricking
meds. I was allowing him to die. I was watching
him die. And, you know, I didn't know what else
to do.
    I mean, we just didn't know what to do.
We didn't know what we could do to help him. Our
neurologist suggested about two and a half years
ago that we try the medical marijuana. She's in
Indianapolis and we're in Illinois. And I'm like
well, you know, I'll try anything. But how are
we going to get it, what are we going to do.
    Finally it became available, and you can
see from the pictures what it's doing. He's
wonderful contact, eye contact, talking. He
fixed eggs the other day. Join me on Facebook,
follow his story. We do weekly Wednesday photos
```

```
of him. It's unreal. He's in school. He's got
one, he's got two teacher's aides, self-contained
classroom. He's reading, he's writing. We went
and bought shoes yesterday. He wanted to go to a
store and he wanted shoes. It's unreal in five
months the change in my kid.
    MS. MOODY: Thank you.
    MS. BASOLO-BOND: And I do thank you guys
for passing this.
    MS. TEMPLE: I have a question for you
before you go. So did he get the card based on
seizures?
    MS. BASOLO-BOND: On seizures. We had to
get it on seizures.
    MS. TEMPLE: So that's how you were able
to see how --
    MS. BASOLO-BOND: That's how we got it.
        MS. TEMPLE: And what are you using for
him? What is your --
    MS. BASOLO-BOND: The sea salt dark
chocolate, we use that one. The gummies didn't
work. They tried to, they told us to try the
gummies at night. They did not work for Dalton.
    MR. KNAUS: In the sativa in a dark
```

23 the evening. And sometimes at school they have
24 to give him one. It just depends.

24 with him, so, you know.

MS. TEMPLE: Please send us feedback and your stories for our policy makers.

MS. BASOLO-BOND: Oh, I will. I will.
MS. TEMPLE: That was nice to hear.
Thank you.
(Applause.)
MS. TEMPLE: Next we have Tina Higens, or
Higens.
MS. HIGENS: My name is Tina Higens. The last name is spelled $H-i-g-e-n-s . ~ I ' m$ representing Autism As Medical, and it's a group that promotes the treatment of all the comorbid disorders of autism to help bring a person with autism to their best level. So thank you for allowing me this opportunity to speak.

As a mother of two boys diagnosed with autism and a medical cannabis patient myself, I have new perspective regarding the use of cannabis in autism.

Currently, the only FDA approved medication to treat autism is Risperdal, which is used to treat behaviors associated with autism. These behaviors include aggression, self injury and temper tantrums. This medication has

```
    horrific side effects, including development of
    2 breasts in males, neuroleptic malignant syndrome,
which causes confusion, irregular heartbeat,
fever, stiffness. Other side effects include
dizziness, fainting and seizures. My sons also
have mitochondrial disease, which is often seen
in autism.
    If you read studies by Dr. Frey, et al.,
they think mitochondrial dysfunction or disease
is indicated in about 30 percent of all people
with autism. Giving this medication to somebody
with mitochondrial disease and/or other metabolic
disorders can be fatal.
    I have many friends that gave this
medication and other psychiatric medications to
their children with horrific side effects with
their children being in-patient in places like
Lorace (phonetic) for 90 days and having them on
all types of meds, and their symptoms becoming
worse and worse.
    April was just Autism Awareness Month and
we see cute pictures with autism children
displaying musical and artistic talents on
television. What the public does not see is
```

1 children and adults with autism jumping through
2 and shattering sliding glass doors, ripping the
3 interior of a vehicle to shreds, mothers with
examples of the dark side of autism that myself
and/or friends have experienced.

People with autism also have, often have autonomic nervous symptom differences. They have a broken fright and flight system, which can lead
to very aggressive behaviors. And to try to
control that type of behavior, especially as
these children grow older and become adults is
very, very hard.
We need help with our children's
behaviors and their pain. Cannabis is already
helping people with autism and depression and
comorbid medical disorders for people that
already are qualified under conditions like
seizures.

People with autism have so many different
comorbid disorders, including severe bowel
disease, seizures, muscle pain and weakness from
mitochondrial disease, anxiety. A lot of parents
have said that the use of cannabis has led to the

```
production of more speech, better mood regulation
and states a more qualifying condition for the
person who qualifies one of the other comorbid
disorders.
    MS. MOODY: You have 30 seconds.
    MS. HIGENS: There's lot of research
showing that there is neuro information in the
brain. There's this famous story that showed
postmortem there was a high level of neuro
information. My younger son, we had done a study
with Dr. Gupta at UC Irvine where his
inflammatory cytokines were off the charts.
    If your brain is completely inflamed and
on fire you're not going to be able to regulate
your mood, you're not going to be able to have
proper behaviors. So, so for further reading I
suggest Dr. Sadir Gupta, et al's., literature,
Fran Kendall, et al., Richard Frey, et al., and
Jill James, et al.
    Thank you for the time.
    (Applause.)
    MS. TEMPLE: I have a question for you
actually.
    MS. HIGENS: Uh-huh.
``` MS. TEMPLE: Have you tried hemp oil? MS. HIGENS: I personally have not, but I
have a lot of friends that have. I think it
really depends on the particular child and their
comorbid disorders. A lot of, you know, there
was just a recent study that showed that persons
with autism actually died 30 years younger than
your typical people.
    So there is a lot of immunological
disease. My sons have CBID, so they're on IVIG
for that. They have mitochondrial disease, so
there's a whole cocktail of different types of
vitamins and supplements. But all of these
things are kind of band-aids.
    And when you get into the
neuropsychiatric medicines, a lot of them just
have such horrific side effects, you take a
problem and you're making it worse and worse, and
sometimes these kids are on just a cocktail of
SSRI's and all kinds of antidepressants, and
things like Risperdal, which I don't think should
ever be given to children.
    So I think that this is a much safer
alternative for children.

24 drugs, a lot of times they have liver failure and
```

it's just, it's just a hot mess. I don't know
how else to say it, you know.
MS. TEMPLE: Okay. Our last speaker is,
thank you very much for your testimony. Dana
Hall is our last speaker. She's present?
MS. DICKERSON: I got skipped.
MS. TEMPLE: Pardon?
MR. RAMIREZ: She said she got skipped.
MS. TEMPLE: Oh, there is another person.
Amanda, I'm sorry. I checked it and then I,
sorry. Amanda Dickerson. Then Dana. Sorry.
MS. TEMPLE: And please spell your first
and last name.
MS. DICKERSON: Okay. My name is Amanda
Dickerson. A-m-a-n-d-a, D-i-c-k-e-r-s-o-n. I'm
here to support adding autism to the list of
qualifying conditions approved for treatment by
medical marijuana.
MS. MOODY: Could you hold the mic closer
to you?
MS. DICKERSON: Is this working?
MS. MOODY: Yes.
MS. TEMPLE: Much better.
MS. DICKERSON: Okay. I'll start over.

```
```

I'm here to support adding autism to the list of
qualifying conditions approved for treatment by
medical marijuana. I'm here to improve my son's
quality of life. My son Cameron was diagnosed
with autism at two and a half years old.
Today at six years old he has nearly
recovered, and his success is due to none other
than alternative intervention. After seeing very
limited success with traditional therapy, we
implemented a number of alternative treatments
which have been proven to be safe and incredibly
effective.
But an eating disorder remains my son's
final and toughest challenge. We work with a
team of practitioners in Colorado to treat
comorbid conditions that autism encompasses.
Those same professionals whose expertise brought
Cameron to his current level of recovery -- I'm
sorry.
AUDIENCE MEMBER: Do you mind if I read
for her?
(Audience member proceeded to read.)
Those same professionals whose expertise
brought Cameron to his current level of recovery

```

1 have recommended trying medical marijuana to get
2 him over the final hurdle. They have documented

3 great success using cannabis as it is proven to
4 decrease anxiety sensory issues, all of which are
5 likely to be a contributing cause of my son's
eating disorder.
A quick Google search by thousands of parents who are effectively treating their autistic children with cannabis, many of whom are reporting success in the area of eating disorders.

A mom of two previously very severely
affected boys described their experience with
their youngest son whose diet was extremely
limited just like my son's. She described his improvement using cannabis as follows: My other son is also autistic. He was already talking, but now he's talking better.

He's asking for more food, different items. We would, he would self restrict his diet. This morning he asked for scrambled eggs. This is new. Joshua has been taking CBD and THC only a few weeks.

I believe that \(I\) should have the right to

23 far outweighs the risk. The underlying
24 conditions of autism make life for our son and
```

Our family very difficult. Our goal is to
alleviate symptoms, not create additional
symptoms. Furthermore, pharmaceuticals don't
always work. When they do ease symptoms they
tend to lose effectiveness over time.
MS. MOODY: Thank you for your time.
MS. DICKERSON: Oh, I'm sorry.
MR. MCCURDY: Thank you.
(Applause.)
MS. TEMPLE: Thank you, Miss Dickerson.
And lastly, Dana Hall, please.
MS. HALL: Hi. My name is Dana Hall.
D-a-n-a, H-a-l-l. My son Keller is seven years
old, and he was also diagnosed with autism when
he was two and a half. I am also here advocating
as a representative from the group MAMMA, Mothers
Advocating For Medical Marijuana For Autism, a
grass roots organization with no benefactors or
outside source of income, whose mission is to
educate parents and legislators about the healing
powers of medical marijuana for our kids.
Given that autism now affects
approximately one percent of the population
worldwide, we can conservatively assume that

```
```

    1 there are over 100,000 people in Illinois on the
    2 spectrum. There is no globally effective
    medical, dietary or therapeutic protocol that
helps them all.
Keller's pediatrician also suggested the
FDA approved pharmaceutical Risperdal. The drug
has terrifying common side effects. I've done
hours of research, spoke with dozens of families,
and declined his offer.
Government patent number 6630.507 states
that no signs of toxicity or serious side effects
have been observed following chronic
administration of cannabidiol to healthy
volunteers, even in large acute doses of 700
milligrams per day.
It should be my right to treat my son
with a natural plant that has no known deaths or
side effects. By 2013 Johnson \& Johnson and its
Janssen unit were facing over 500 class action
lawsuits for harmful side effects of Risperdal.
With only an autism diagnosis, patients
also commonly suffer from several underlying
conditions, as we've mentioned, that have already
been approved for qualifying conditions in the

```
```

1 State of Illinois or elsewhere. Allowing access
2 to medical marijuana for autism would give
parents a safe alternative and a better quality
of life. If my goal was to get my son stoned so
I didn't have to deal with him, I already have
that option, through pharmaceuticals and a
pediatrician that's willing to prescribe them.
That's not what I want for my son.
I want to give him a future. I want to
see him be the best person he can possibly be.
Excuse me. Isn't that what every mother wants?
Keller can get there with access to the plant
with which I have watched families across the
country have groundbreaking success.
The power of social media has given me a
glimpse into the lives of autistic children going
from non verbal to reciting the pledge of
allegiance. Children that were once aggressively
violent, as my son is, calm and engaging
appropriately with others using medical
marijuana. Excuse me.
My husband, Keller, his brother Grady,
and I have built a life surrounded by family and
friends, but we want this medicine for Keller.

```

1 Should we move out of the State to obtain it?
2 According to the Illinois Policy Institute, more
3 than 850,000 people have moved out of Illinois
4
gather all of these stories together and sort of look at them and say so what do they all have in common that could be put together in a, more of a proposal kind of thing? My naive question.

MS. DICKERSON: Well, we, there are several grass roots organizations like MAMMA that are trying to gather the evidence in one cohesive place. The website itself is mammausa.org is a great resource where a lot of the anecdotal evidence can be seen. The so far supporting scientific evidence can also be found.

AUDIENCE MEMBER: There's linked studies on that page.

MS. DICKERSON: Yes. And as far as
administration, the anecdotal evidence shows
children with edibles, with oils, smoking the
flower. There's several different accounts of
the story. I view myself as, for my son we have
attempted the CBD oil. We've seen very little of
success.

So that's, you know, why we have exposed ourselves to the anecdotal evidence that THC may be the missing piece that my son needs. Thank you.

MR. MCCURDY: Thank you.
MS. TEMPLE: Are there comments? Well, I very much applaud the bravery that these mothers came up and their helpers to assist in delivering

23 postoperative pain and intractable pain. We'll
24 see how it goes. So without further ado, we have

24 like to speak on, that would be, because we're
```

only allowing three minutes.
MR. FINE: Can we give him a little bit
more time?
MS. TEMPLE: But then you might not speak
at the other --
DR. BUSH-JOSEPH: That would be fine.
MS. TEMPLE: Okay.
DR. BUSH-JOSEPH: Yeah. My comments are
relatively generic for pain.
MS. TEMPLE: You think like five to six
minutes would be doable if you're going to be
covering --
MS. WEATHERS: What are you requesting?
What time are you requesting?
DR. BUSH-JOSEPH: Five to six minutes
would be fine.
MS. TEMPLE: Okay.
DR. BUSH-JOSEPH: And, certainly, if I
may read into the record, I'm an orthopedic
surgeon working at a tertiary Medical Center in
downtown Chicago. And generally about 30 to
3 5 percent of the patients I see are patients,
unfortunately, that failed care.
They've had prior injuries, prior

```
opiates, which unfortunately makes the
practitioner's ability to manage patients with
chronic un-resolvable conditions much more
difficult. Josephine Briggs, who is the Director
of the National Center for Complementary and Integrative Health Center of the NIH, reports in the United States over 23 million people suffer from chronic pain, in which 14.4 million are considered to have severe pain.

As I said, reconciling these conditions, or these two concerns, physicians and patients need alternative strategies to manage these difficult problems. And as an orthopedic surgeon in a tertiary medical center, many of these patients I have unfortunately come to me with unresolved and uncurable conditions and are forced to leave, to live with them in a very difficult circumstance.

The uncontrolled pain of failed treatment and progressive deterioration lead many patients into opiate dependency for simple activities of daily living. As we've noted, and you've heard testimony today, medical cannabis provides a very acceptable treatment option for many patients as long as it's provided in a safe and regular manner, like it is here in Illinois.

The evolving body of knowledge in the medical literature supports the efficacy of
```

1 treating a variety of non-cancer pain. Peer
2 reviewed studies, which we'll present today, and
I think many of you are well aware of the
literature, suggests that it's very effective in
the relief of pain leading to a significant
decrease in opiate use.
But the NIH for 2015 has funded over
\$49 million dollars in grants for the medical
treatment of cannabis for a variety of these
types of conditions, and according to the
Director they anticipate that number to go north
from there considerably.
The Foundation for Peripheral Neuropathy
will hold their annual 2016 Research Symposium
here in Chicago. They have over four hours of
scientific presentations devoted strictly to the
use of medical cannabis in the treatment of
neuropathic pain.
Again, these facts all testify to the
efficacy and the scientific validity of these
types of treatments. Certainly, any therapy that
involves medication compounds that have
psychoactive effects warrants some concern.
And, certainly, these concerns must be

```

1 addressed with regulation to allow the intended
2 benefits to minimize the side effects for leading
3 to uncontrolled, uncontrolled use. And it's my
4 belief that the Medical Cannabis Pilot Program of
5 Illinois is one of the most tightly regulated in

6 the United States, and is well crafted to
minimize and prevent, minimize its use and prevent abuse of what \(I\) believe is a beneficial therapy.

I believe the physician oversight and dispensing regulations allow safe use of medical cannabis for patients suffering with chronic pain due to chronic trauma, chronic pain due to postoperative pain, intractable pain, and neuropathy.

You know, \(I\) was just going off the cuff. You know, I take care of a lot of patients, unfortunately, that really do have difficult, unresolved problems. And I have to tell you, in many of these patients we do think that there are conditions that we can benefit with further basic treatment, the surgeons, but the patients are on such high doses of opiates that we deem their condition totally unmanageable postoperatively,

1 and we've had horrible consequences of trying to 2 operate on these patients and end up with very 3 serious, because of the serious level of opiate failures. And years ago, and sort of what drew me into this, I had several patients who, I said listen, I'm not operating on you until you're off our Vicodins or you're off your Fentanyl, you're
off all these, you know, all the analgesics
you're taking, and so we can manage them
postoperatively, take one more whack at their
non-union fracture or their shoulder or their
back problem.
    And many patients said listen, yeah, I'm
just using a lot of cannabis, and that helped
them. And to me, that helped open my eyes to see
that these are things that really help patients
move the needle on their care and treatment.
    Now, there's still lots of patients that
unfortunately we can't help, and many of these
patients are referred to David Walega and some of
my other colleagues in the Chicagoland area where
we do have to manage their problem on \(a\)
palliative basis.
    But I think this is one option, the way

1 it's crafted in Illinois, should be adopted on a 2 wider use, and \(I\) think has greater benefit, and \(I\) would encourage this Board to certainly attempt to move the Illinois Department of Public Health in that direction. I can answer any questions. MS. WEATHERS: Have you certified any of your patients?

DR. BUSH-JOSEPH: I have not. As a representative, I'm a consultant with Cresco. The Act defines that \(I\) cannot, so any relationship with a medical cultivator, which I've developed a consulting relationship with them in the last six months, prevents me from doing that.

But I have several partners who are involved, you know, in the treatment of cancer patients and in the non-cancer related patients with chronic pain or unresolved therapeutic patients who have.

MS. WEATHERS: So, that was a question.
I know our policy and our institution is
relatively new, so that's, the medical cannabis
policy at Rush is relatively recent. It was only
recently passed by the medical staff. So my

24 various modes of treatment. And I found this to
```

be an effective mode, and so I see my role as to
try to help, help practitioners understand the
pros and cons of this type of therapy.
MR. MCCURDY: Another question. So post,
so the reason you can't do, or think it's unwise
to do surgery on some of your patients who are
already on a high dose of opiates, so what
actually, what more specifically would happen if
you did the surgery and they were on the high
dose of opiates? What is the aftermath that you
would expect?
DR. BUSH-JOSEPH: You know, these
patients, unfortunately, they require such high
does of opiates --
MR. MCCURDY: To begin with.
DR. BUSH-JOSEPH: -- to begin with, for
activities of daily living, you impart a
significant surgical trauma and all the morbidity
that goes with that. I hate to say the analogy
would be, I know the simple one would be having a
root canal without anesthesia.
And so, in essence, that's what many of
these patients go through. If we do a third or a
fourth operation on their shoulder or re-plate a

```
```

non-union or a fracture, or attempt to fuse a
spine where they've had, where they're on chronic
levels, you cannot manage their pain
postoperatively. And unfortunately --
MR. MCCURDY: Because you can't increase
the dose anymore so you --
DR. BUSH-JOSEPH: You get to the level of
opiates where basically, I'm sure many of the
panel knows as well, but, you know, the
endocannabinoid system, which is nerve receptors
throughout the body, do not exist in the
hypothalamus where opiate receptors do occur.
And so when you get super high doses of
opiates and they get into the hypothalamus, you
get respiratory suppression and cardiac
suppression, and that's ultimately what kills
patients. That doesn't happen with the
cannabinoids.
So, you know, we like if we can take
patients down to an acceptable level of function
with activities of daily living using
cannabinoids, then we've still got the opiate as
a means of managing postoperative or intermittent
use of serious pain. To me, you know, we use

```
patients, you know, patients with, and this is certainly not on the, you know, not on the discussion here, but, you know, patients with end state osteoarthritis. And certainly I'm not speaking to that as an indication, but we typically use, when patients have end stage osteoarthritis and they're taking narcotics on a regular basis for activities of daily living, i say go get your damn knee replaced, you know. I mean, despite what, quote, medical fears of my non --

MR. CHRISTOFF: We approved that too. MS. TEMPLE: We approved that. DR. BUSH-JOSEPH: I'm sorry. I apologize.

MS. TEMPLE: This is more for the Board, and since you're a physician, if you can please, you know, comment if you find an opportunity is, I've been having in my own institution and others whole physician groups just saying we don't write letters, like the pain specialist who prescribed opioids, because it violates their pain contracts.

So these patients who are on those
```

prescribing programs that they want to be in the
practice, they have to get drug tested
periodically and they can't have any cannabinoids
or any other illicit Schedule I substances, or
else they lose their ability to go to that doctor
and get Norco, Fentanyl, etc.
So I don't know if others have had that
experience, but it, then it has created, I know
Dr. Christoff and I have talked about it too, a
huge glut, a huge demand of, for a physician that
will certify a patient, because your prime
audience in terms of these categories are
intractable pain, pain due to trauma, et cetera,
their, their current physicians, in my
experience, are not certifying because these are
policies within a group internally.
DR. BUSH-JOSEPH: Well, you know, I would
answer that to say, again, that's part of the
role of the educators to, essentially what I
believe, is demystify the recommendation of
medical cannabis to the general physician
population.
You know, I would certainly agree that we
are all fearful, in every doctor that I talk to,

```

23 supervisory function to its use.
whether it be with any new therapy, the last thing I want to do is see my name in the Chicago Tribune associated with a controversial therapy. So, you know, again, that's part of the process. The administrative process is to essentially put rules and regulations behind it and sort of
ensure safety and efficacy into how these things
are done.

I think that what \(I\) see and what many physicians, I've got a lot of patients who are using it and they're underground, they're doing it in the dark, and we want to bring them above surface where we can sort of regulate it and provide more appropriate use.
yeah, let them tax it. I mean, let there be some
benefit to its use. I mean, the State of, you
know, the hundreds of million dollars that the
State of Colorado has garnered from the medical
marijuana industry, obviously it's totally
discordant to Illinois but, you know, that has
beneficial use to allow a supervision or
supervisory function to its use.

And certainly for the State of Illinois,
    So, again, this is, these are all issues
```

that I think that this Board is charged with to
help, at least I think bring out into the open,
to demystify to patients, as well as to demystify
to physicians, to really find what I think is a
reasonable treatment option.
This is not curing cancer, at least in my
mind. I mean, we're not, we're not, you know,
this is, I know, you know, Dr. Ramirez talked
about aspirin. Aspirin's a great drug, and it
does a lot of things, but it still works in
defined areas. And we're trying to attempt to
put boundaries, but we think there are some very
good areas that this has benefit, so.
I have, I can submit into the record a
series of medical literature of recent articles
that are peer reviewed journals. Many of them
are double blinded and randomized controlled
studies that you may be aware of and I think, and
to aid my testimony.
MR. MCCURDY: That would be great.
MS. TEMPLE: Thank you very much.
(Applause.)
MS. TEMPLE: I assume then since we let
you go longer, when it's time to talk about the

```
```

other conditions, then you'll pass, right?
DR. BUSH-JOSEPH: I've spoken my piece.
MS. TEMPLE: Okay. Doctor Ramirez.
MR. RAMIREZ: Well, just to amplify Dr.
Bush's comments about this is not something new,
et cetera, the U.S. Pharmacopoeia had marijuana
officially as listed as one of the pharmacology
products approved in the United States until
1942, so this is not something new. This is not
something weird.
And to me it seems ironic that in order
to get people off Class II and Class III drugs we
have to try to prescribe a Schedule I drug. So
we need to reschedule a Class II or a Class III.
And the FDA in the rules says that anybody can
apply for rescheduling of a drug.
You just have to have the adequate
resources and the adequate evidence. So national
groups can petition in the FDA to reschedule.
Now, the Director of the DEA said that they were
going to try to apply for rescheduling in June.
But you know how government works.
So in the meantime the public, the users,
should try to put enough force together before a

```
```

petition to reschedule to at least a Class II. A
Schedule II, I'm sorry.
MS. WEATHERS: I have a motion, but I
want to make sure everybody's had their comment.
MS. TEMPLE: There's a motion in front of
you.
MS. MILLER: Second.
MR. RAMIREZ: Enthusiastic.
MS. TEMPLE: Okay. There's a second.
And then after this we will reconvene and talk
about chronic pain syndrome starting with Dr.
Walega. Wait a minute.
MS. WEATHERS: I think we need to take a
vote on my motion.
MS. TEMPLE: Oh.
MR. RAMIREZ: I said enthusiastically.
MS. TEMPLE: I know, but that was just
you. I was internally saying yes. Internally
saying yes.
MR. RAMIREZ: Approved by acclimation.
MS. TEMPLE: Then a second question
was --
MS. WEATHERS: No.
MS. TEMPLE: He declined. Okay. So Mr.

```

23 will stay here and eat our lunches, and so enjoy
24 your break. We'll see you here at 12:45 to talk

1 about chronic pain.

24 a better place to determine that.

MS. TEMPLE: So let's revisit that when we get to the end, which is after we discuss Post
Traumatic Stress Syndrome, ending with Miss
Feliza Castro. Then we can re-evaluate how our
time is going.

Okay. On another note, Mr. Joel Erickson
has had to leave, so he will not be speaking on
migraine nor on PTSD, so that will shorten up our
conversations a little here.
    Okay. Any other business before we
begin? And the other request, again, is for our
court reporter to hear everything as clearly and
slowly as possible, especially when we're
talking, speaking with medical terms to give her
a chance to catch up.
    Okay. So the next condition is chronic
pain syndrome, which the Board did approve. And
our first speaker is Dr. David Walega.
    And, Dr. Walega, I had heard earlier, did
you want to speak to the multiple conditions and
then save your testimony, save from not
testifying?
    DR. WALEGA: Yes. If I could just
combine everything --

23 I sit on some other community boards.
I'm the President of the Midwest Pain

23 There's actually a pretty significant incidence

24 of chronic pain following what we would assume to
\begin{tabular}{|c|c|}
\hline & be simple straightforward surgeries. Six months \\
\hline 2 & after a total knee replacement, 50 percent of \\
\hline 3 & patients still had pain at the site of their knee \\
\hline 4 & replacement. After a simple inguinal hernia \\
\hline 5 & repair, about 20 percent of patients have chronic \\
\hline 6 & pain in the groin of the surgical site six months \\
\hline 7 & after surgery. \\
\hline 8 & And I can go on and on. Neuropathic pain \\
\hline 9 & affects about 10 percent of the United States \\
\hline 10 & population. Probably the most common cause is \\
\hline 11 & diabetes. What is neuropathic pain? Imagine \\
\hline 12 & your hands in an ice bucket, not just for a few \\
\hline 13 & seconds but for every minute of every day. \\
\hline 14 & Imagine your feet being stung with \\
\hline 15 & hundreds of bumble bees or walking on pins or hot \\
\hline 16 & coals. How do we treat this in pain medicine? \\
\hline 17 & We use a multi-modal technique, or multiple \\
\hline 18 & treatments in order to get as much efficacy in \\
\hline 19 & pain treatment as possible. \\
\hline 20 & This would include medications. What are \\
\hline 21 & those medications? Opiates, anti-depressants, \\
\hline 22 & topicals, compounded medications, intravenous \\
\hline 23 & Ketamine, anti-inflammatories, muscle relaxants. \\
\hline 24 & In addition, we do a variety of \\
\hline
\end{tabular}

1

23 about 400 patients with neuropathic pain.
```

injections, nerve ablations, spinal cord
stimulator implants, and intrathecal opiate
delivery system implants where we're actually
delivering opiates to the spinal sack. And this
is obviously in patients with severe refractory
neuropathic pain or other types of chronic pain.
That said, about a third of patients who
are on all of these cocktails of medicines
getting the best medical care possible, still
suffer with their pain and don't have any
response to these medications or therapies.
Medical cannabis and cannabinoids do
offer a new way to manage these types of chronic
pain syndromes, and the medical literature has
shown repeatedly, specifically for chronic
neuropathic pain, that this is an effective and
safe treatment modality.
Last year in the New England, excuse me,
not the New England Journal, the other great
journal, JAMA, Journal of the American Medical
Association, Kevin Hill published a systematic
review of six clinical trials, which included
about 400 patients with neuropathic pain.
Medical cannabis was used in this group,

```
\(23 C-o-m-p-a-s-s\), that did support the safety of
24 medical cannabis.

Long term efficacy has also been shown in a prospective open labeled cohort study by Haroutounian, \(H-a-r-o-u-t-o-u-n-i-a-n\), in the Clinical Journal of Pain this year. This was a study out of Israel but was watching patients in their program who were getting medical cannabis for chronic pain for over a year, and found it to be a safe and effective method.

And I've extended my time. Thank you. MS. MOODY: Thank you.

MS. TEMPLE: Thank you.
DR. WALEGA: Any questions from the Board?

MR. MCCURDY: Not too long ago I was involved in some correspondence, part of which came from a pain physician elsewhere, and this person was reporting on attending a conference at Harvard recently where a number of pain experts he said were there. The sense the person said they got at the conference is that first there were too many strains of cannabis to know what specifically your patients will be getting.

And, secondly, there's not enough data to support the concomitant use of both cannabis and
```

opiates, which to me is a, would be a, you know,
maybe a real life, or potentially a real life
question. And then there, some people were aware
of that trial in France where they were testing
something having to do with cannabis and opiates
and one person died and several were critically
ill after the trial. Now, I don't know if
you're --
DR. WALEGA: I don't know of the details
of that particular trial.
MS. TEMPLE: I can speak to that.
MR. MCCURDY: But in any case, I think
the cannabis and opiates question, I mean, what's
your sense of, part of it is what you hear from
colleagues but how you would see that as well?
DR. WALEGA: So everyone on this Board
knows that we are living through an opiate
epidemic. Opiates are not the answer to every
single pain problem. I feel that the CDC
guidelines that were released in March, just a
couple of months, it's a little too little, a
little too late.
We already have a really huge problem.
We have a patient population and a public

```

24 patients are on a CBD type drug they decrease, if

23 to improve their quality of life, level of
24 functioning, ability to interact with their

1 families, with their community, and go back to 2 work, et cetera. Doctor Temple, you asked an 3 interesting question that I hadn't thought about 4 too much, and that was the distinction between 5 chronic pain patients who are being treated in a 6 pain center on an opiate contract, or what we prefer to call a narcotic agreement, and the presence of a cannabinoid, or cannabinoid metabolite in their urine tox screen test. MS. TEMPLE: I was about to ask you if you --

DR. WALEGA: Good. I anticipated your needs. So what do we do with that? I feel as a practitioner, so \(I\) have certified three patients thus far this year. I see 15 to 20 patients a day. I have certified just a handful, and I have turned away a few people.

That said, patients who are being, I would say, I'm not going to speak on behalf of every pain specialist in the State of Illinois, but \(I\) would say that my peers, most of my peers, are frustrated by the fact that some of these pain disorders are so challenging to treat effectively, that the tools that we have in our

1 tool box, you said weapons in your armamentarium,
2 I like tools in the tool box, the tools in our tool box are not effective. They're not helping every patient. If you had a bug strain or an antibiotic regimen that only helped 60 percent of the patients who were being treated for an infection, you'd say wow, infectious disease as a specialty is really not doing a very good job. We need other tools, right?

But with a pain condition, something that we can't always see with our eyes, where we can see bacteria growing in a petri dish, we seem to have a separate set of ideals. So I would say that most physicians who do what \(I\) do on a daily basis would welcome the use of their patients using a cannabinoid product if it was concomitantly showing an improvement in quality of life. Perhaps a decrease in medication use.

And as long as, and we screen our patients for misuse, abuse and diversion every time they come in. We use different outcome measures. There's one called the SOAPP, S-O-A-P-P, that helps stratify no, mild, moderate and severe risk of medication misuse, abuse and
```

    1 diversion. So I think that if we use the same
    2 standards in, or some of the same standards in
    qualifying cannabinoid use as we do with opiates,
then we'll be in a good place. We'll have
another effective tool in our tool box.
MS. TEMPLE: What I think needs to happen
on those, these policies I believe are generated
internally within a medical group, right? I
would say.
DR. WALEGA: Yes.
MS. TEMPLE: It's not a State mandated --
DR. WALEGA: No.
MS. TEMPLE: -- contract?
DR. WALEGA: No.
MS. TEMPLE: I don't even know how
enforceable it is. But these contracts allow
patients to stay on a physician's panel. So if
you break the rules you don't get to see that
doctor anymore and then you don't get your Norco
prescription.
And that's where my tension has been as a
clinician, since I'm not a pain specialist I will
get patients referred to me and they want to go
on cannabinoids. I think it's a good idea. I

```
```

certify them. But then they have their Norco
scrips they still need. I can't just take them
off Norco and get them on cannabi, you know,
cannabis. First of all, it's going to take a few
weeks to get their card.
So there's been a tension between well,
the pain doctor can no longer write the scrips,
so we've had to transfer that activity to their
primary care physician, if I can get them to do
it, since I don't want to do both. I would
rather them work with their primary.
DR. WALEGA: Yeah.
MS. TEMPLE: And I think that's where
we're hitting some road blocks. Because if these
groups have the policy that if cannabinoids are
found in the urine or any other testing, you
can't get it, then you can't do concomitant
cannabinoid opioid dosing, and you can't see that
response like in terms of decreasing opioids.
I have seen clinically when I have put
patients on medical cannabis we've been able to
successfully reduce their opioids by a lot. It's
been astounding. And it's just hard when you're
the only one in your institution who is doing it

```
and they send you all the referrals because
nobody else in the institution wants to do it.
And that's where the education comes. And I'm
really heartened that we have a pain physician up
here talking about this. This is the first time
ever. So you can come to all our meetings.
    DR. WALEGA: Okay.
    MR. KNAUS: Could I ask two unfair basic
science questions --
    DR. WALEGA: Sure.
    MR. KNAUS: -- that I don't remember from
medical school?
    DR. WALEGA: Okay.
    MR. KNAUS: Are pain receptors generic,
and is it true that there's more cannabinoid
receptors in our body than any other receptor?
    DR. WALEGA: So did you mean generic or
genetic?
    MR. KNAUS: Generic.
    DR. RAMIREZ: Generic.
    DR. WALEGA: So there are multiple pain
pathways, too numerous to mention, and I don't
want to bore you with the neurochemistry and the
biochemistry. But there are, every individual

23 to your point about education.
I have inadvertently become the voice of
medical cannabis at Northwestern, like it or not. And I think that the physician education is really important. Several physicians are now sending their patients to me to certify them. And, you know, I'll evaluate the patient and stratify their risk for you, but \(I\) don't have a relationship with this person.

I think communication is really key when you are certifying that patient in your practice and you know they are getting treatment by another pain specialist. And maybe having that dialogue of hey, you may not want to certify every patient in your practice and go down that road, but I'm doing it.

I find that it's effective. My personal experience is that opiate use decreases. Patients are happier, they're more satisfied with their care. And what else can I teach you about this.

MR. FINE: I use weapon, you use tool because, I use weapon because I'm fighting. It's an interesting distinction, and \(I\) applaud your efforts. I suffer from all the conditions that you talked about. I suffer from chronic residual

1 limb pain syndrome. So all the drugs that you
2 talked about, The Gabapentin, the Lyrica, the

3 Cymbalta, the side effects were just awful. And
doctor. My last two surgeries were at
Northwestern with Josh Rosenow for the Boston
Scientific.

DR. WALEGA: I know Josh very well.
MR. FINE: You know, the pain device that I have, the spinal stimulator that \(I\) have, it's, but it is, it's one more weapon, one more tool in our arsenal to deal with it. And if it's one less Vicodin that \(I\) have to take a day or one less Norco or Methadone or Oxycontin or a Fentanyl patch or any of that stuff, then why not? And without any side effects. So, so thank you for being here to legitimize that point of view.

DR. WALEGA: My pleasure.

MS. TEMPLE: Are you familiar with the
```

National Pain Strategy --

```

DR. WALEGA: Yes.
MS. TEMPLE: -- and stuff that they're, and I, so the National Pain Strategy was started
after a huge call to recognize this terrible pain
epidemic we have and what a crappy job we're
doing at managing it. The opioid epidemic, et
cetera.
    So the Institute of Medicine, NIH, and
another couple of governing bodies got together
to put together this National Pain Strategy again
in groups of people looking at various areas of
how to manage pain.
    But when \(I\) read the document \(I\) saw
nothing about cannabis, because obviously this is
a Federal initiative, which \(I\) think is very
interesting. So \(I\) wonder if, you know, there's
any talk amongst your Society about medical
cannabis. I know it's jumping way ahead, but
about medical cannabis as a potential factor in
the National Pain Strategy.
    DR. WALEGA: I would say that physicians
as a group are conservative. I would say that
pain specialists who almost feel like a scapegoat for the opiate epidemic are a little bit gun shy and may not be as informed as they should be about the efficacy of medical cannabis in the treatment of multiple pain disorders.

And, again, that goes back to education.
Even people in my own field, there are some
people that don't know this data. And, you know,
we prescribe things like Gabapentin and Fentanyl
with an absence of almost any randomized
controlled data. And here we have five trials
that all showed efficacy in multiple domains.
    Unfortunately, you know, dealing with the
Federal Government, you know, I'm also trying to
initiate some research in this specific realm. I
have four clinical trials right now. None of
them have anything to do with medical cannabis.
    And I feel like I'm an experienced
researcher. I have over 20 publications in the
peer reviewed literature. But \(I\) am finding
multiple obstacles getting this operationalized
in a tertiary top ten Medical Center in the
United States.
    And that's primarily due to a lot of
```

Federal obstacles, Federally imposed obstacles.
So I hope that my voice is heard as a physician
who deals with this in the trenches dealing with
chronic pain patients every day so that we can
potentiate positive change and help our patients.
MS. TEMPLE: I think Jim Champion has --
MR. CHAMPION: Oh. I was just going to
say along the lines of what you were saying about
neuropathic pain. I suffer from severe
neuropathic pain in my right knee. And I
testified until I'm green about how narcotics
have little to no effect.
Gabapentin was causing me extreme weight
gain. I've been narcotic free since November
2 0 1 4 ~ a n d ~ a l s o ~ a f t e r ~ 2 8 ~ y e a r s ~ o f ~ M S ~ a n d ~ a l l ~ t h e
pain that goes along with it. I'm also bowel
blockage free and all the other things that go
along with all those narcotics. So, yes, I'm
living proof of what you're talking about.
DR. WALEGA: That's excellent.
MS. TEMPLE: Any other comments or
questions for Dr. Walega?
MR. MCCURDY: Thank you so much.
MS. TEMPLE: Thank you very much for your

```
testimony.
    (All Board members thanked Dr. Walega.)
    DR. WALEGA: Thank you all for listening
to me.
    (Applause.)
    MS. TEMPLE: And so, Dr. Walega, we're
going to mention your testimony when the
conditions come up regarding neuropathies since
you've already spoken to that, as well as Dr.
Charles Bush-Joseph's testimony for the other
conditions.
    So I want to make sure that it's in the
record that they have spoken about the conditions
that we're going to be setting forth. Okay. So
next on the list for chronic pain syndrome is
Jared Taylor.
    Jared, do you want to, so just like with
the physicians, they had multiple conditions they
wanted to talk to? Or do you want to go one at a
time?
            MR. TAYLOR: I have a speech prepared for
each. Whichever is more convenient for the
Board.
    MS. TEMPLE: It doesn't matter. It might

24 more than six months as a qualifying criteria.

1 Other medical professionals have used three
    2 months of chronic pain as the minimum criteria.

24 loss of employment, and it may cause adverse
```

medical reactions and long-term treatments. I
myself have experienced chronic pain for the past
three years. While I now know that my chronic
pain is caused exactly by my osteoarthritis, many
patients with CPS don't know what the underlying
cause is.
As I can personally attest, chronic pain
makes daily life much more difficult. It's hard
sometimes to see the proverbial silver lining in
dark clouds when one has chronic pain, as chronic
pain causes sufferers to have gray skies for many
days.
Mundane activities such as going to work,
household chores, caring for dependants and other
day-to-day activities are difficult with chronic
pain. Cannabis is a proven medicine that
effectively inhibits pain signals from being
transferred from the brain to the point of
origin.
Pain is subjective, and what's painful to
me might not be painful to you. I do realize
that the Advisory Board is proceeding carefully
with blanket conditions such as chronic pain, but
I do admit that chronic pain is a very broad

```
```

condition. However, like I said, I did suffer
with chronic pain for nearly three years without
having a diagnosis. Other individual patients
that have chronic pain are not so lucky to be
afforded diagnosis. Because chronic pain
syndrome is a disease that affects every facet of
a patient's life, it's truly a debilitating
condition. Thanks for your time.
(Applause.)
MS. TEMPLE: Our next speaker is Jesse
Fosdick. Is Jesse present? Okay. Then we'll
move on to, let's see. To enter for the record
that Dr. Charles Bush-Joseph has spoken on
chronic pain syndrome in his previous testimony.
And then we can move on to Timothy --
MS. MOODY: Could you also enter into the
record that Melanie Dillon also submitted a
request to present technical evidence. So
Melanie Dillon, D-i-l-l-o-n, also submitted
information for the intent to present technical
evidence, and that is in the Board packets also
for you.
MS. WEATHERS: So she was unable to
attend?

```

MS. MOODY: That she was unable to attend, yes.

MS. WEATHERS: Do we need to review that?
MS. TEMPLE: No.
MS. WEATHERS: Okay.
MS. TEMPLE: So our next speaker is
Timothy Coughlin. Did I see that once? I don't
think, Timothy Coughlin not here?
MS. MOODY: No.
MS. TEMPLE: All right. So moving right
```

along, we, our next topic is chronic

```
postoperative pain, for which Mr. Taylor has
already provided his testimony. And also, Dr.
Charles Bush-Joseph has provided testimony
regarding chronic postoperative pain, a condition
that he passed last time.
    So the next condition to discuss is
intractable pain, and we have Jared Taylor also.
    MR. TAYLOR: It's like a frequent flier
or something. I thought about, you know,
    combining them all but \(I\) just couldn't do them
    with six of these. All right. You ready? Okay.
    My name is Jared Taylor.
    We've already approved this, but
```

intractable pain is actually defined by the
Minnesota Department of Public Health as a pain
state in which the cause of pain cannot be
removed or otherwise treated with the consent of
the patient, and which in generally course, an
accepted course of medical practice, no relief or
cure of the cause of pain is possible, or none
has been found after reasonable efforts.
To put it simply, intractable pain is
persistent and constant pain, and is happening
for an unknown reason. Intractable pain, IP, is
different from chronic pain. IP causes a patient
to become bedridden or housebound, and can even
cause early death.
IP actually causes adverse biological
effects on a patient's cardiovascular, hormone
and neurological systems. Patients experienced
changes in testosterone, estrogen, cortisol and
thyroid or pituitary hormones. There is no cure
for IP. The common treatments include opioid
medications, Methadone, a TENS unit, or an
intrathecal pain pump.
Other treatments include muscle
relaxants, stimulants, NSAIDs or physical

```

1 therapy. And similar to chronic pain treatment
2 for \(I P\) is merely throwing a treatment to the wall
and seeing what sticks. In December 2015, the State of Minnesota added intractable pain to its list of qualifying conditions.

Minnesota's medical cannabis program was passed in 2014, and Minnesota patients with IP will have access to medical cannabis in August of this year. As I'm sure you are all aware, Illinois has had our Medical Cannabis Pilot Program longer than the State of Minnesota. And for some, I don't know whatever reason, but things are getting done in Minnesota much faster here than in the State of Illinois.

I lived in the State of Minnesota for three years. It's a great state, but we really here in the State of Illinois are the powerhouse of the Midwest and we need to be making head gains rather than the North Star state.

Getting back to this, Minnesota Commissioner of Health, Dr. Ed Ehlinger, stated upon the passage of intractable pain that the relative scarcity from evidence to add IP made this a difficult decision. However, given the
```

strong medical focus of Minnesota's Medical
Cannabis Program, and the compelling testimony of
hundreds of Minnesotans, it became clear that the
right compassionate choice was to add intractable
pain to the Program's list of qualifying
conditions.
This gives new options for clinicians and
new hope for suffering patients. That's what he
said. Like I said to you, Minnesota's Medical
Cannabis Program is younger than Illinois, and
really Minnesota took the advice of its Advisory
Board and its Commissioner of Health and the
advice of its citizens.
MR. FINE: Wow, what a concept.
MR. TAYLOR: And they actually thought
about the compassion of people suffering with
intractable pain. We've already approved this,
but as I mentioned to you, as a person who
suffers from chronic pain caused by
osteoarthritis, I know what it's like to have
pain and not know the cause.
And it really sucks, to be honest with
you, to not know what's causing the pain. And
intractable pain is a lot worse than chronic

```
```

pain. Thanks for your time.
MS. TEMPLE: I have a question, Jared.
Who was the person that made that quote from
Minnesota?
MR. TAYLOR: Yeah. The Minnesota
Commissioner of Health, Dr. Ed Ehlinger.
MS. TEMPLE: Okay.
MR. TAYLOR: Very similar to the State of
Illinois, there's also an Advisory Board that
reports to this Director of Health that
apparently --
MR. FINE: So what do you think the
difference is, just out of curiosity.
MR. TAYLOR: From Minnesota to Illinois?
A couple hundred miles, but --
MR. FINE: Yeah.
MR. TAYLOR: To be honest, it's, in
theory there should be no difference. There is
an Advisory Board, there is a person that makes
that decision. And as Dr. Ehlinger from
Minnesota stated, he focused on the relatively
scarce evidence presented by technical evidence,
but took into account the compassion of this
program, of their program, and listened to the

```
```

patients --
MR. FINE: The what?
MR. TAYLOR: The compassion.
MR. FINE: Oh, okay. Thanks.
MR. TAYLOR: The compassion of the
program. So I hope that IDPH will also follow in
Minnesota's tracks of allowing compassionate
treatment of cannabis for those that suffer from
intractable pain. Thank you.
MR. FINE: Thank you.
(Applause.)
MS. WEATHERS: I certainly, I share the
frustration of the Board members, of our Board
members and many of the audience, and I know
we've discussed this to have our recommendations
kind of repeatedly not be approved. However, I
would like to be careful and again not deflate
the, kind of that decision with all the work the
IDPH does.
I think they've, I'm sitting next to
Connie so I will give you credit. I think
they've done kind of just an incredible amount of
work on behalf of this Act and the patients and
getting those that are approved moving through,

```

24 dispensaries and getting quality product is huge.
```

And so I hope that that, for the record, how it's
going down in my view as a clinician has been
excellent. So, yes, I definitely want to also
give credit to Connie Moody, who has worked
tirelessly. And it hasn't been perfect, it's not
going to be when you don't have a lot of help.
And so thank you very much.
MS. MOODY: Thank you.
(Applause.)
MR. KNAUS: Can I ask a question?
MS. TEMPLE: Yes.
MR. KNAUS: Is there a predictable
outcome of things that we've approved or
recommended and then have gotten to the point?
MS. TEMPLE: Predictable outcome, if we
go on the track record, is that the likelihood of
what we passed today getting passed again is
probably pretty slim if the same set of criteria
and decision makers are at the helm.
MR. KNAUS: Is it possible that the
people making those decisions should be here at
the hearing?
MS. TEMPLE: Okay. So --
MR. FINE: We have --

```

MS. TEMPLE: Yes. I would like to call attention to Mr. Wright here who is from the Governor's Office. Thank you for coming. So we do have representation there. We would have, you know, we would like to see more folks coming to hear this.

But in the meeting that Michael Fine, and Jim Champion and I had with Dr. Shah, the evidence base is what his hugest hang-up was about all of the conditions we've talked about. It's the evidence base, the black and white.

And we did stress that compassion is a very important part of this ruling, but he was quite focused on the evidence base, and nothing has really met the level of his criteria to move forward with these conditions.

MR. BACHTELL: It's subject to the clinical information that was brought forth by the physicians with the, right with the additional list of clinical studies.

MR. FINE: Just come up here and speak up.

MS. TEMPLE: I guess informally we're going to have a little chat.

MR. BACHTELL: I didn't mean to disrupt anything.

MS. TEMPLE: Then go ahead and state your name.

MR. BACHTELL: Sure. Charles Bachtell.
Last name is \(B-a-c-h-t-e-l-l\). I think one
distinguishing factor between previously approved
conditions and the ones that are going to be
approved today would be the additional clinical
information that was presented in written form by
the physicians that appeared. So I hope that's a
distinguishing factor.
    MS. TEMPLE: Every bit of extra
testimony, evidence, it all counts and it should
be reevaluated with fresh eyes. Nestor?
    MR. RAMIREZ: Just as a point of
curiosity, the original 39 , what kind of evidence
base did they have and who came up with that
list?
    MR. FINE: None. The Legislature passed
it.

MR. RAMIREZ: Oh.
    MS. TEMPLE: I actually did a little
literature review. I cherry picked one

24 we still have several testimonies to go through.

1 Let's, we're going to again reevaluate the 2 opportunity for members of the public to come up 3 and give their commentary at the end just based 4 on train schedules and travel schedules.
testimony, \(I\) just want to make very clear, I'm
very happy with Connie and all the people who are
part of her team. My frustration doesn't lie
with the Advisory Board or the people that really
have done the work.
    My frustration kind of lies where what
happens to these conditions after they're kind of
passed up the loop. So that's where my
frustrations lie. So my apologies for not making
that clear.
    According to the Mayo Clinic, Irritable
Bowel Syndrome, IBS, is a common disorder that
affects the large intestine. IBS commonly causes
cramping, abdominal pain, bloating, gas,
diarrhea, and constipation, and it affects

23 have the condition, those with a family history
24 of IBS, and those who have a mental health

24 Intestinal Motility - Welcome to CB2 Receptors.
```

This study found that cannabinoids, which are
found in cannabis, inhibit gastric and intestinal
motility through the activation of enteric CB1
receptors. In plain English, the use of cannabis
slows down the digestive process for those with
IBS by activating receptors in the intestine.
IBS, like I said, has no cure. Modern
medicine doesn't have an explanation for its
occurrence. The symptoms that this disease
causes are painful and inconvenient for those
affected with IBS.
Cannabis is a proven medicine that can
better help to regulate the digestive process for
those with IBS, and is effective to manage the
pain that IBS causes. Thank you for your time.
(Applause.)
MS. TEMPLE: I don't see Tina Higens here
anymore. Tina.
MS. HIGENS: I'm hiding back here.
MS. TEMPLE: Okay.
MS. HIGENS: Hi. My name is Tina Higens.
The last name is spelled H-i-g-e-n-s. First, I'm
just going to talk about my personal experience.
I'm a qualifying medical patient under the

```

1
2

23 test the potency and function of synthetic
24 cannabinoids. Research on a variety of rodents
powerfully to control GI motility and
inflammation, cannabinoid receptors compromise G
protein coupled receptors that are predominantly
in enteric central \(C B V 1 R\) and immune cells CB2R.
    These digestive tracts contain endogenous
cannabinoids and cannabinoid CB1 receptors can be
found in mucosal nerves. But basically it really
helps what \(I\) would call intestinal, like, it's
almost like a seizure.
    Your GI system just cannot stop having
these horrific contractions. You can get very
sick. You can be sweating. You feel like you're
going to pass out. And since using medical
cannabis for my qualifying conditions, I've
noticed that it has just had a dramatic decrease
of Irritable Bowel Syndrome, which I've been
suffering for for over half my life.
    So I really would like to see this as a
qualifying condition to be, you know, added.
Thank you for your time.

24 so many of the pills I am taking now. I have dry

23 the medicine prescribed would help calm my
24 stomach. I did some research online and found

1 that marijuana has been shown to help with IBS
2 and can calm the stomach. I finally gave it a
3 chance and never looked back. Almost instantly
started to subside. The most surprising thing
was that \(I\) no longer felt the urge to have to
consistently use the bathroom.

At my worst, I used to find myself on the toilet in pain between 10 to 15 times every
single day. Cannabis is the most effective
medicine \(I\) have used in relieving my IBS
symptoms. Since I have been using the natural
medicine \(I\) have never felt better.
    I am no longer having to look out for a
bathroom when I'm out doing errands, and I can
now be a much more efficient and effective
employee at my company. There have been some
published studies about the benefits of
cannabinoids for gastrointestinal problems.
    One was published by the British Journal
of Pharmacology in 2008. It says the body
produces its own cannabinoid molecules, called
endocannabinoids, which we have shown increase
the permeability during inflammation, the

1

23 fit basically, but \(I\) find it intriguing that the
24 research that we see out there is looking at the

24 a patient thinks about is finding a dark, quiet
```

place to lie down. Migraines might be caused by
changes in the brainstem and genetics, or
environmental factors may play a role. Triggers
for migraines include foods, food additives,
drinks such as alcohol, wine specifically,
stress, change of weather, and certain
medications.
Risk factors for migraines include family
history, age (the majority of the patients
experience migraines during adolescence), sex
(women are more than three times as likely to
have migraines than men), and hormonal changes.
Migraines have no cure, but medications
such as aspirin, NSAIDS, acetaminophen, also
known as Tylenol, ergons and triptans are also
used to treat migraines. While I did not
formally submit this study into evidence, a
January 2016 study tilted Effects of Medical
Marijuana on Migraine Headache Frequency in an
Adult Population, discovered that medical
cannabis helped with migraines.
From the }121\mathrm{ participants, researchers
saw a decrease of 10.4 migraines per month, to
roughly 4.6 migraines per month. 40 percent of

```
```

the }121\mathrm{ participants experienced positive
effects, and roughly }85\mathrm{ percent reported having
fewer migraines per month. Migraines may be
treated with cannabis by the activation of CB2
receptors.
That's also what the study had found, not
my personal opinion. I've seen friends and
people that I care about experience migraines,
and I know that migraines are not pleasant.
Even though medical cannabis is not a
cure for migraines, individuals should be able to
choose what medication works best to treat their
condition. Thank you for your time.

```
    (Applause.)
    MS. TEMPLE: Thank you. Tina Higens.
    MS. HIGENS: Tina Higens. Last name is
spelled \(H-i-g-e-n-s . ~ O n c e ~ a g a i n, ~ t h a n k ~ y o u ~ f o r ~\)
giving me this opportunity to speak. As I told
you before, I'm a qualifying patient for medical
cannabis for fibromyalgia and interstitial
cystitis.
    I have severe migraines of all different
types, but the ones that are most troublesome and
potentially life threatening for me are my

1 abdominal migraines. This is because \(I\) have a 2 metabolic disorder called mitochondrial disease.

3 I would vomit violently with the abdominal
4 migraines. I would often vomit 10 to 12 times in
5 an hour for up to 12 hours. The vomiting would
6 not subside even while \(I\) was retching up bile.
7 I would need to go to the ER to get
hydrous dextrose, Reglan, and sometimes all
different types of medications because I would become severely dehydrated, and with the mitochondrial disorder that can cause, you know, a metabolic crisis.

Most months I would need to go to the ER probably at least one time a month. I would often have to drag my children out of bed at 3:00 a.m. to go to the hospital. This process was very upsetting to my sons, and they would cry asking family if \(I\) was going to be okay.

Since becoming a medical cannabis patient in December \(I\) have not needed to go to the ER once. This has had a huge impact on my life, as I would live in fear that another episode would be coming soon.

The last episode I had was on Christmas
```

Eve. As soon as I feel an episode coming on, I
can medicate with cannabis and it aborts the
episode. I've used several different types of
medication for my abdominal migraines from
Benadryl to Xanax to Elavil to Imitrex to Reglan,
and nothing was even close to being as effective
as cannabis.
Please add migraine as a qualifying
condition as, if you have a migraine you really
can't function and there's really nothing else
you can do but ride it out and hopefully it ends
soon. But, you know, a lot of people that do
have migraines also have other metabolic
disorders that can really cause severe problems
for a patient. So thank you for your time.
MS. TEMPLE: Thank you.
(Applause.)
MS. TEMPLE: And then we have Feliza
Castro for migraines.
MS. CASTRO: Okay. Another testimony for
a patient that we collected. Steven Whitehurst
from Chicago. My name is Steven Whitehurst. I
am 49 years old. I'm an author and educator, and
have been permanently disabled since 1997. I

```

1 suffer from an illness called bile salt
2 malabsorption, which causes stomach pain,
3 vomiting, daily nausea, discomfort, severe
4 migraines, which at their worst have come eight and migraine relief.

He was right. Cannabis helps me eat and makes me have a brighter outlook on life. I can stop a migraine before it happens, prevent panic attacks, ease stomach pains and inflammation, and can finally enjoy my life.

Illinois is too restrictive when it comes
```

to this often life-saving treatment option. The
covered illnesses are inconsistent and exclusive,
and access to this medicine is limited to those
who can pass a background check. This is an
effective medicine and a huge resource of revenue
for other states, but cash strapped Illinois
still stands idly by while citizens needlessly
suffer. By Steven Whitehurst.
Okay. So I know that the study The
Effect of Medical Marijuana - Migraine Heachache
Frequency was mentioned, which is a really good
one. Also, the National Center For Biotechnology
Information published another really compelling
study.
More and more studies are emerging that
show how both migraine frequency and intensity
are significantly reduced by medical cannabis.
Patients in California have been sharing their
anecdotal success for many years. For some,
cannabis is the only treatment option that can
stop a migraine in its tracks or help deal with
the dizziness, pain and sometimes nausea that
comes along with the migraine.
Many of our patients with TBI and

```
```

postconcussion are reporting to us that medical
cannabis is actually relieving migraines that
they were dealing with often before. So I
definitely think that it needs to be added.
Thanks again.
MS. TEMPLE: Thank you.
(Applause.)
MS. TEMPLE: And TBI is traumatic brain
injury.
MS. CASTRO: Yeah.
MS. TEMPLE: We had Joel Erickson
scheduled to come, but he's not here or scheduled
to speak. He's not here. So the next condition
-- oh, Nestor. Sorry.
MR. RAMIREZ: Discussion on migraine?
MS. TEMPLE: Yes.
MR. RAMIREZ: I just want to mention a
little historical fact. Sir William Osler, who's
been called The Father of Modern Medicine, one of
the four founding doctors for John Hopkins
Hospital has said, or had said at one time
because he's dead, that marijuana was the best
treatment possible for migraines. And this was
in the late 1800's.

```

MS. TEMPLE: Okay. We have neuropathy, which, for which we have had speakers already. So I want to enter into the record that Dr. David Walega, am \(I\) saying that right?

DR. WALEGA: That's close enough.
MS. TEMPLE: Close enough? Okay. That he had spoken extensively on neuropathy as well as Dr. Bush-Joseph. So please refer to their testimony in the records.

Okay. Any comments about neuropathy?
MS. WEATHERS: Did, okay. I just want
```

to --

```

MS. TEMPLE: Or, are we done? Sorry. Did we finish migraine? Any comments on migraine other than we've heard?

MS. WEATHERS: Yeah. We have already past this, but \(I\) will say that this is something that \(I\) obviously in my role as a neurologist do see and treat frequently. And kind of going back to Dr. Walega's point that any other tool in the tool box for these patients is something that all, all treating neurologists would welcome.

It is something that we struggle with, and it's many lost days of work, you know, the
```

    1 impact of quality of life, the lack of
    2 productivity. The American Academy of Neurology
    has very clearly come out and said that opioids
should not be used for this, they are not
effective. It's not even chronic pain where they
might be effective early on and then you're just
weighing the side effects versus, the adverse
effects versus benefits.
There is no benefit. So we have even
less medications at our disposal than in other
chronic pain conditions, so. I again agree with
our previous group.
MS. TEMPLE: I have to throw a plug in
for acupuncture as well. Again, the work that I
do. Good evidence based on migraine data base
for tension headaches at least, but I know that's
Off the subject. It must be mentioned.
Osteoarthritis.
MR. CHAMPION: I was just going to say --
MS. TEMPLE: Oh, yes.
MR. CHAMPION: The last thing, a lot of
conditions, a lot of conditions really help the
migraines. By adding migraines to the group of
conditions approved it would cover other

```
```

conditions as well.
MS. TEMPLE: We covered the Lyme disease
rejection. Okay. Osteoarthritis. Jared Taylor.
MR. TAYLOR: Yep.
MS. TEMPLE: You get the frequent flyer.
MR. TAYLOR: This one's going to be a
little bit faster, just to warn you. All right.
Good afternoon. Again, thanks to the Advisory
Board and Connie and her staff for all that you
all have done. I'm really appreciative of that.
But since I spoke to you all before in
October there has not been a cure discovered for
osteoarthritis, OA. OA's the degradation of
cartilage in a joint. It's the most common form
of arthritis, and it can affect any joint in the
body.
Commonly affected areas include the
hands, the hips, the knees and the spine. My OA
is in the facet joints of my spine directly above
my --
MS. TEMPLE: Slow down.
MR. TAYLOR: Sure.
MR. FINE: You've got a little more time,
so you don't have to be the FedEx guy.

```

MS. TEMPLE: I ask you slow down.
MR. TAYLOR: Okay. All right. All
right. My OA is in the facet joints of my spine directly above my tailbone. And even with my super cool cushion, it's been a little bit painful here this morning and afternoon.

In 2005, the CDC estimated approximately eight percent of Americans had OA, and if these numbers held true today for the State of Illinois approximately 1.1 Illinoisans suffer from OA. That's just my non-academic estimate.

So even if 10 percent of these Illinois patients became registered patients, this program would be self-sustaining, which IDPH predicted 100 to 150,000 patients with 10 percent of OA patients in Illinois, 110,000 , we could make osteoarthritis the saving grace of this cannabis program.

OA causes bones to rub against each other after the cartilage is worn down. It's that friction. It's very painful, and OA patients like myself suffer from chronic pain on a daily basis.

> However, it's going to affect each
```

patient differently. For me, OA makes it painful
for me to do yard work, to do chores, painful to
sit. I wake up every single morning, this is a
hallmark of OA, with pain directly caused by this
disease. It affects me in almost every part of
my life.
Treatments for OA include taking Tylenol,
NSAIDS, chronic pain class, other pain management
based options. These therapies merely treat the
symptoms though of OA. There is no cure.
I am reintroducing a 2013 study by the
University of Nottingham titled Cannabinoids CB2
Receptors Regulate Central Sensitization and Pain
Responses Associated with OA of the Knee Joint.
In this study it was discovered that the
use of cannabis activate CB2 receptors in our
brain, and basically these signals are blocked
from transferring chronic pain from our brain to
the areas.
I'm also introducing a March 2016 study
titled Effectiveness of NSAIDS for the Treatment
of Pain in Knee and Hip Osteoarthritis, a Network
Meta Analysis. This study was conducted by Dr.
Sven Trelle, and through the study of 55,000+

```

2 effect on OA pain. It's a little bit better than
3 a sugar pill. So it really does nothing for us.
4 Rather, NSAIDS, according to the study, were

23 needed to make this program self-sustaining.
24 Thank you.
(Applause.)
MS. TEMPLE: Nestor.
MR. RAMIREZ: For the sake of the record, I think he said 1.1 Illinoisans, but \(I\) think he meant 1.1 million.

MR. TAYLOR: Yeah, 1.1 million
Illinoisans by estimates have OA.
MS. TEMPLE: This was a condition we debated early on at our first meeting and \(I\) had reservations because it's so common. I mean, I can't imagine, \(I\) don't know anyone who doesn't have some form of ache and pain.

And we had a good conversation at the first meeting that we need to remember this is
for debilitating conditions, that it's going to
be something that your physician,
patient/physician relationship will ferret out
whether other alternatives, other medications and
treatment programs have failed, or if this is a
better treatment option.
    Because my initial reaction to
osteoarthritis was way too common. But at the
same time, that's going to be between
doctor/patient, and that it has to be
```

debilitating. You have to remember that these
conditions must be at a level of debilitation.
There's a conversation that I brought up about
why don't we write severe osteoarthritis or put
moderate, severe, and start putting qualifiers on
it. And then we decided not to go that route.
And remember constantly that it's the,
all of these conditions have the requirement that
they must be debilitating enough to merit their
certification. Because I got a lot of flack for
the osteoarthritis one from my colleagues. I
just want you to know that.
Once you explain it that way it works and
they're like oh, okay. All right. So the last
condition, we're almost done. And we have two
speakers. We are at that point where we can
decide.
MS. WEATHERS: Yes. I would like to make
a, I will make a, given how we're doing on time,
I'll make a motion that we allow the additional
speakers who did not preregister to each have
three minutes.
MS. TEMPLE: Okay.
MR. RAMIREZ: Second.

```

23 We've already approved Post Traumatic Stress
24 Disorder, but years ago Post Traumatic Stress

```

    1 four out of every }100\mathrm{ men. So ladies
    2 unfortunately had about two and a half times
    worse occurrence risk of getting PTSD than men.
Also according to the VA, 11 out of 2100, out of
every 10 Veterans who served in Operations Iraqi
Freedom and Enduring Freedom, have Post Traumatic
Stress Disorder.
As well, approximately 12% of Gulf War
and 15% of Vietnam War Veterans experienced PTSD
during their lifetime. The VA currently reports
that 721,575 Veterans currently reside in the
State of Illinois out of a population of
12.8 million residents in the State. That's
approximately 5% of the population in the State
of Illinois.
Now, Dr. Rafael Mechoulam, he's an
Israeli scientist who first identified
Tetrahydrocannabinol, THC, as the psychoactive
compound in cannabis. Decades later, Dr.
Mechoulam discovered that the human brain's
endocannabinoid system in the endogenous
neurotransmitter anadamide --
MS. TEMPLE: Anadamide.
MR. TAYLOR: Okay. Thank you for that.

```
\begin{tabular}{|c|c|}
\hline & I appreciate that. Doctor Mechoulam believes \\
\hline 2 & that the cannabinoid system is integrally related \\
\hline 3 & to memory, including memory extinction, which is \\
\hline 4 & the normal, healthy process of removing \\
\hline 5 & associations from stimuli. \\
\hline 6 & Cannabis can therefore help to aid memory \\
\hline 7 & extinction by reducing association with an \\
\hline 8 & individual's association with stimuli such as \\
\hline 9 & loud noises or stress which are trigger things \\
\hline 10 & for Post Traumatic Stress Disorders. \\
\hline 11 & While PTSD can affect anyone who has \\
\hline 12 & experienced a traumatic event, PTSD \\
\hline 13 & disproportionately affects our Veterans. Because \\
\hline 14 & the debilitating symptoms that PTSD causes, we've \\
\hline 15 & already established that you guys are going to \\
\hline 16 & approve it, but basically I think the State and \\
\hline 17 & its Administration should recognize and respect \\
\hline 18 & and honor the service that Illinois Veterans have \\
\hline 19 & given to our nation without regards to their own \\
\hline 20 & personal safety, and also keep in mind that not \\
\hline 21 & only Veterans that have PTSD will benefit from \\
\hline 22 & this access to medical cannabis. \\
\hline 23 & Thank you for your time. \\
\hline 24 & MS. TEMPLE: Thank you. \\
\hline
\end{tabular}
(Applause.)
MS. TEMPLE: And we have our last scheduled speaker is Miss Feliza Castro.

MS. CASTRO: Thank you. Thanks again.
And this is a testimony from a patient, not a
Veteran but someone else who wanted me to share
her story to the Board and with the rest of you
here today.
    So this is Autumn of Champaign, Illinois.
And she says in 2009 I was diagnosed with PTSD
after my boyfriend committed suicide. I could
not help but blame myself, and I was convinced
everyone else knew that it was my fault.
    I could not eat at all, or \(I\) would eat so
much I would get sick. I could not sleep for
days, and then \(I\) would sleep for 18 hours each
night. My body was in constant flux, and I
couldn't talk to anyone about feeling their pity
or judgment.
    I dove into a deep, dark hole of
depression. I couldn't close my eyes without
imagining Will. I would have terrible dreams of
him dying in every way possible, or \(I\) would have
    dreams that it never happened and wake up

1 sobbing. My doctor diagnosed me with PTSD and
2 started to prescribe a lot of different

23 before my PTSD diagnosis. I still struggle every

24 day, but \(I\) no longer view death as my only exit

1

2

24 our last --
```

from this pain. I feel free and independent and
like I've regained so much of my life. This is
all thanks to cannabis, that at, currently in
Illinois, I'm not legally allowed to possess.
Cannabis saves so many lives of those with PTSD,
and if I hadn't given it a chance I'm certain I
would not be sharing this story with you today.
MS. TEMPLE: Thank you.
(Applause.)
MS. TEMPLE: Comments about PTSD?
MR. CHAMPION: As the Veterans rep I
guess I'm going to say a little bit of something.
My numbers are a little bit different than
Jared's, but the evidence in support of cannabis
as an effective treatment for PTSD is
overwhelming. Veteran suicide rates is as high
as 22 per day or 8,000 per year. That's more
than the people than we lost in the war itself.
PTSD affects over 30 percent of all
Vietnam, Iraq and Afganistan Veterans. PTSD in
all forms should be approved, but we especially
owe it to the Veterans of Illinois, so.
MS. TEMPLE: Any other comments? This is

```

MR. RAMIREZ: Well, we've got other -MS. TEMPLE: No, we don't have, it's not our last speaker.

MR. RAMIREZ: So we've got other
speakers?

MS. TEMPLE: Right. So if there's, and then the Board can jump in, but we've now opened it up to our spontaneous speakers. Mrs.
Champion?

MS. CHAMPION: Yeah. And I'll be really
quick. I'm Sandy Champaign, and I wanted to
address about the 39 conditions. One of the
things that we took into account was the idea of
palliative care, which is about quality of life,
because we don't have a lot of research out
there.
    And many of our representatives did not
want to take any research outside of the United
States, they wanted something from here. But
because we haven't rescheduled, we have this
problem.
    So palliative care was huge in
    determining what conditions were added. For
    example, Jim's MS, he was on 59 pills a day.
```

He's down to six. And that clearly makes a huge
statement as to why he uses cannabis. So I just
wanted to clear that up. I do have a quote from
our sponsor because I asked him what he would say
if he was asked that question. And he said he
listened to tons of people, took our best shot.
Some were negotiated.
The list is not perfect, but that's why
we created the Advisory Board. Thank you.
MS. TEMPLE: And your sponsor, you're
saying Mr. --
MS. CHAMPION: Representative Lou Lane.
MR. RAMIREZ: So I just want to say that
mine was more of a rhetorical question to say
that the excuse for not passing what we've done
in the past three meetings has been that it
doesn't have enough evidence. And the initial
ones didn't have enough evidence either, so it's
just like a protocol question.
MR. CHAMPION: I agree with you
100 percent.
MR. RAMIREZ: Yeah. It was not a, not a
critique of --
MS. CHAMPION: Oh, no, no. But I just

```
```

wanted to put that on public record that, you
know, because a lot of people have asked us that
question like what made us decide the 39, not me
personally, but we've negotiated a lot of people
in here, negotiated those conditions.
So a lot of times it was just personal
experience. So I just wanted to put that in the
record.
MR. MCCURDY: It's good to have a
historian in the room.
MS. CHAMPION: Thank you.
MS. TEMPLE: How about our second
speaker? The gentleman in the tie. Okay.
MR. KURFMAN: I'm trying to laugh on the
way up here, maybe I won't be so nervous. My
name's David Kurfman. K-u-r-f-m-a-n. I am an
approved patient in the Program and I take it for
seizures, epilepsy. And I, first off, I just
want to say that it's helped me. I've been on it
since the dispensary's opened in December last
year.
And I started out with 2000 milligrams of
Depakote. Now I'm down to 250, and I plan on
going off of that next week. So now that some of

```

1 the higher CBD medicine is out like Charles Webb,
2 in particular \(I\) take that, which actually they
3 changed the name but, called Sweet Relief. But anyways, I wanted to ask you guys to seriously consider migraines and chronic pain and depression and, basically because I've had all those things and I've been diagnosed with all those conditions.

And since this program's approved, or been approved, I've been taking cannabis, and I have to say that it's helped me in all of those areas. I've been on Xanax, I've been on, of course, my Depakote for epilepsy. That's almost gone.

I no longer take Xanax. I take Effexor for depression, and I've went way down on it. And I'm just down to 75 milligrams on that. Almost off. My point is that \(I\) think these conditions should be approved because they've, cannabis has helped me in those areas.

And I think there's overwhelming evidence out there that, from other states that's approved these conditions, why they should be approved, and that they've helped multitudes of people.

23 that \(I\) work with and that are showing specific
24 relief for specific symptoms are patient to
```

patient, individualized and customized to work
with each patient and their lifestyles. That
includes all the adversities that come along with
being ill. I start my initial consultation by
sitting with my patients discussing their needs,
their life, their concerns, their goals.
And before I dispense any type of
cannabis, medical cannabis, I talk about the
science and cannabis and how it would affect them
on an individual basis.
I also start with a high CBD and a low
THC or equal part strain. For example, White
Harmony, Canna Sue, Harley Sue, which are all CBD
and, CBD and THC and all of the other
cannabinoids all in one.
The White Harmony is an equal one to one
ratio, which is great for people who are
experiencing MS, for fibromyalgia, for cancer,
for HIV. The, for rheumatoid arthritis. I mean,
the list is, the symptoms are all the same. The
conditions are just different but the symptoms
are all there.
So what we start is we always start with
them with a really, really good CBD base to start

```
```

```
1 building up their system, and then everything
```

```
1 building up their system, and then everything
2 else is introduced, slowly, very slowly. To
2 else is introduced, slowly, very slowly. To
3 start with their building up of their system of
3 start with their building up of their system of
```

CBD, that is an anti-inflammatory, antioxidant,

```
CBD, that is an anti-inflammatory, antioxidant,
and antispasmodic effects. THC can then be
and antispasmodic effects. THC can then be
systematically induced, introduced, based on
systematically induced, introduced, based on
comfort level and tolerance.
comfort level and tolerance.
    The training I have received in cannabis
    The training I have received in cannabis
education ranges from thousands of hours
education ranges from thousands of hours
dedicated to education and in terpening, which is
dedicated to education and in terpening, which is
the science and art of studying terpenoid
the science and art of studying terpenoid
profiles of the cannabis plant, which means that
profiles of the cannabis plant, which means that
I'm able to help my patients distinguish which
I'm able to help my patients distinguish which
strain will affect them in a certain way based on
strain will affect them in a certain way based on
smell or essentially, aromatherapy, quality of
smell or essentially, aromatherapy, quality of
bud structure, land raise, and anecdotal
bud structure, land raise, and anecdotal
testimony globally.
testimony globally.
    So when we go into our patients, we are
    So when we go into our patients, we are
not just dispensing medical cannabis freely. We
not just dispensing medical cannabis freely. We
are talking to our patients and we are discussing
are talking to our patients and we are discussing
with them. We are understanding their needs and
with them. We are understanding their needs and
we're helping them succeed and successfully
we're helping them succeed and successfully
surpass the discomforts of their illness.
surpass the discomforts of their illness.
    Thank you very much once again for
```

    Thank you very much once again for
    ```
```

allowing us to speak.
MS. TEMPLE: Thank you.
(Applause.)
MS. TEMPLE: It's nice to have a
dispensary point of view, so that was very
helpful. Any other? Otherwise --
MR. FRIEDMAN: I wasn't planning on but
I, you know what, I think it's interesting. I
think it's --
MS. TEMPLE: They're making --
MR. FRIEDMAN: Whose idea to really --
MR. FINE: Talk into the --
MR. FRIEDMAN: Oh, I'm sorry. I'm sorry.
MS. TEMPLE: Yeah.
MR. FRIEDMAN: Joseph Friedman.
F-r-i-e-d-m-a-n. And I'm being forced to be up
here. But thank you, Michael. I appreciate the
opportunity. From the dispensary standpoint, and
I think this is where the rubber meets the road.
You know, we have patients coming in every day.
Some of them are familiar with cannabis.
Those kinds of patients have higher
tolerances, and so we consider the dosing
differently than those that come in that have

```
```

never touched it or haven't touched it since they
smoked a joint in the seventies. One of the
things that I'm very proud of is we have
healthcare professionals in our dispensary, and I
consider what we do very important from the
standpoint of communication, not only with the
patient but also many times with the physician.
The physician writes the certification
and then a lot of them don't know what happens at
that point. So I'm trying to take this a step
further where we're communicating with their
doctors and we're letting them know what we're
doing, and then we're also monitoring outcomes.
We're not expecting a whole lot to happen
with the first visit. We give them
recommendations. And then it's two weeks later
or a month later when they come back where we
talk about what they, what's helped them, what
hasn't helped them. And then we also, if
necessary, speak with the doctor, get on a
conference call when they have their doctor
visit.
So it's this triangle of care that I
think is very important. Something that I sort

```

23 unfortunately. When we look at the amount that
24 is being regulated in dispensaries, there is a

24 the standpoint of third party reimbursement. One

1

2 accreditation. We're hoping that accreditation, 3

23 have sales all the time, so we are always once
24 again trying very hard to make sure that our
patients get what they need.
AUDIENCE MEMBER: So it's about 360 to 440 an ounce. But it depends on the patient and what they need too.

MR. CHAMPION: It's cheaper if you buy an ounce too.

MS. ZALA: Absolutely.
MR. MCCURDY: Based on the State data, I want to say that the average patient spent about \(\$ 420.00\) in the month of March?

MS. ZALA: Correct.
AUDIENCE MEMBER: I was going to say, I spent, \(I\) spent personally as a normal patient without being a, getting any discounts, which not all of the dispensaries give.

MS. ZALA: Right.
AUDIENCE MEMBER: Mine doesn't. Mine only, mine does do a discount program where you can, for every \(\$ 50.00\) you spend you get a punch card and you fill out the punches and then you get free \(\$ 50.00\) off the next purchase or whatever. That takes time.

I generally spend between four and five hundred dollars.

MS. TEMPLE: In a month or?

AUDIENCE MEMBER: In a month.
MS. TEMPLE: Okay.
AUDIENCE MEMBER: So it's ungodly
expensive to me, but it's helping me and \(I\) want
to get off of all this medicine. The other thing
I would say is now that some of this newer
medicine's coming out, the oils and the
concentrates, which for somebody like me with epilepsy, \(I\) need higher \(C B D\) medicine that doesn't get you high, the THC.

And it's more expensive. I mean, you're talking \(\$ 80.00\) for a syringe of a little oil, what they have out so far. And that doesn't last very long for me. I mean, just to be honest with you, it might be five days. Four to five days.

MS. TEMPLE: Do we have figures from industry about how much, how much has been netted in sales so far?

MS. CHAMPION: There is, yeah, there is actually --

MS. ZALA: Actually, yeah. I think Joel Erickson would know, would be a really good person to ask.

23 succeed. And that's why we have this Board
24 because we need to add conditions to get more
patients and help more patients have a quality of
life. It's not even about quantity of life, it's
about quality of life many times. And just the
fact that we're paying out of pocket rather than
going to the insurance companies means a lot.
    Jim can get all the drugs he wants for
free through the VA, and they're more than
willing to give him methadone and morphine and
anything he would possibly want to get stoned,
but it's not about that for us, it's about his
quality of life. So we pay.
    MS. TEMPLE: So I'm just curious to know,
you know, is it financial data and safety data?
Are people diverting this? I mean, I would like
to know how is it being studied so that when it's
December 2017 when it's time to decide what
happens. That's the part where the process to me
is unclear.

And I'm sure it, you know, goes to the Governor's Office but, you know, I think we're
doing what we need to do as a Board.
    MS. MOODY: Right. It will take action
by the Legislature and then the Governor to sign
the Bill if the Legislature chooses to do that,
and appease or extend the pilot date, or, do away with the pilot and move it. So those are some of the options that the General Assembly have.

MS. CHAMPION: We will need the veto majority and the Governor's award to extend the program. We will need veto majority, which we're prepared to use.

MR. RAMIREZ: But other than the Department of Public Health, supposedly the Department of Agriculture and the Department of Tax Revenue are supposed to be picking up some of this information, is supposed to be generating some of this data. Because they're co, co-sponsors of the project, or whatever you want to call it.

MS. MOODY: So there are multiple agencies involved in the program. The Illinois Department of Public Health works with the Patient Registry Program. The Department of Financial and Professional Regulation, they are responsible for authorizing and licensing the medical cannabis dispensaries.

The Department of Agriculture is involved. They license the cultivation centers
where the medical cannabis is grown. The Secretary of State, they're responsible for collecting the tax revenue. The Illinois State Police is involved as a consultant.

We also work with the Secretary of
State's Office because when a medical cannabis
patient is approved to participate in the
Program, there's a notation on that patient's
driver's license record also.
    So there are multiple agencies that are
involved in the oversight. As you know, there's
an annual report that the Department of Public
Health is authorized to submit annually to the
General Assembly and the Office of the Governor.
And as the program continues to be implemented,
that annual report will include additional
information from each of those agencies.
    Our first two annual reports have been a
little bit sparse because, as you know, when that
report was written it's on a fiscal-year basis,
and at the end of June of 2015 we had not yet
approved, or issued a registration card for a
single medical cannabis patient, and dispensaries
were not yet open either. So that is some of the
thing though that, because \(I\) think that would
help. I guess it was last year or sometime I was
asked, and I'm sure a lot of people in this room
were asked, what can we do to make the program
better.
```

    And that was through the agencies and the
    Governor's Office and stuff. So that, I know I,
sometimes I sound negative, but I'm not always
negative. I'm actually an optimist.
And I don't think the program's going to
die. I don't think the Governor's going to kill
the program. I know a lot of people have, you
know, their opinions about that, including
myself, but I don't think the Program's going to
die.
But I do think it's going to take all of

```
```

us together because that, it takes a village,
it's going to take a huge village to make sure
that this is sustainable.
MR. KNAUS: Okay. Could I ask, was there
something about the 39 approved conditions that,
an element that gave them approval beyond what
this committee has looked at very carefully and
made recommendations as to other conditions?
MS. CHAMPION: Can you repeat that,
because I'm not sure I understand?
MR. KNAUS: It seems like if 39 things
were approved for this, that this committee has
looked at other things that they have looked at
very carefully, and some people said yes, some
people said no. It seems like somebody would
appreciate that effort and proceed on with
approval instead of non-approval.
MS. CHAMPION: Right. I completely agree
with you, and that's why we called it the
compassionate use of medical marijuana, medical
cannabis. Because when the program was passed it
was based on compassion.
It was based, again, on quality of life,
based on what research we could possibly find.

```

1

23 Dr. Shah the reason they were summarily rejected
24 is not for no reason, it's because the level of
```

scientific evidence did not pass muster.
MS. CHAMPION: Right. But, again, when
we --
MS. TEMPLE: On like blankets, which --
MS. CHAMPION: But, and that's --
MS. TEMPLE: -- of which --
MS. CHAMPION: -- was not supposed to be
happening because we're supposed to be using,
balancing --
MS. TEMPLE: Compassionate.
MS. CHAMPION: -- compassionate with the
scientific. And so we don't know why. But I
want to remain optimistic and positive that we
just keep doing what, we have patients keep
coming. I know it's a hardship, but we can't
give up. We can't let them think we're giving
up, because if we give up then we might as
well --
MS. TEMPLE: So are there other comments?
We're actually running ahead of time. This was
supposed to end at 3:00, it's 2:30.
MS. WEATHERS: A couple things. So my
question, comment and question, my understanding
too was that there was a statement made after our

```
```

initial meeting, the Advisory Board and
rejection. Not only the IDP Director's
statement, as well as the Governor's Office,
saying that part of the rationale was that
because this was a limited Pilot Program, the
decision was made to keep it as a kind of a
contained pilot and not expand that past that by
adding conditions that would be an expansion to
the Pilot Program.
MR. RAMIREZ: That was the first
rejection.
MS. TEMPLE: That was the very first
rejection.
MS. WEATHERS: That was the first
rejection.
MR. FINE: And time too.
MS. WEATHERS: And time that we haven't
even started, so how could we add before we've
even started? Now that we have, I don't know if
that will change, but I was wondering, I know
Mr. Wright is in the room.
Was there any comments that you can add
or understanding, shed light on, for the Board
and for the, kind of the questions that we

```
```

raised?
MR. WRIGHT: Sure. Yeah.
MR. WRIGHT: My name is Joseph Wright.
W-r-i-g-h-t. I'm the Director of the Illinois
Medical Cannabis Pilot Program. And would you
state your question one more time again just so I
can make sure I got it?
MS. WEATHERS: Sure. I was just, it was
kind of open ended, but given the questions that
have been raised, especially during this open
period, about the willingness of the Director and
the Governor to add more conditions, especially,
I know that some of the concern, let me take a
step back and rephrase.
I know that some of the concerns from the
rationale given for the rejections after our
initial meeting was that the program, nobody had
even got their cards yet and the program hadn't
even started, and how can we expand when we
haven't yet begun.
I wanted to know if that rationale, given
that we now do have data since November, if
there's a feeling that that rationale is still in
place, or if you feel that there was kind of any

```
```

    1 opportunity for further conditions to be added,
    2 and the viewpoint from your standpoint from the
    Governor's Office?
MR. WRIGHT: Sure. Well, the first thing
I do want to clarify though is that the
Governor's Office gave a statement at various
points along the way in terms of events that
happened. So there was a Bill that was passed to
extend it as well as add PTSD.
There was the first recommendation of the
Board. So some of the messaging, while the end
result may be the same, with some different
things and about different, you know, items. In
terms of whether or not additional time is still
needed, I would say that the position is probably
still the same.
But the Governor's Office has already
said as much, that they're willing to work with
the Legislature on an extension of the program.
That's already in the public domain.
In terms of when and how that happens and
how long that extension is, that will have to be
hammered out between the Legislature and the
Governor. In terms of additional conditions, you

```
```

know, I don't have a particular satisfying answer

```
know, I don't have a particular satisfying answer
for you how long. It's going to take a little
for you how long. It's going to take a little
bit more thought, and I don't have a crystal ball
bit more thought, and I don't have a crystal ball
to when or how conditions will be added.
to when or how conditions will be added.
    But, you know, there's two methods, as
    But, you know, there's two methods, as
you all know. One is this Board, another is
you all know. One is this Board, another is
through the Legislature. So we'll see what
through the Legislature. So we'll see what
happens with that. But, unfortunately, I don't
happens with that. But, unfortunately, I don't
have a definitive timeline for you on when that
have a definitive timeline for you on when that
can happen.
can happen.
    MS. TEMPLE: Okay. So on that note, I
    MS. TEMPLE: Okay. So on that note, I
would say we're going to just keep doing what the
would say we're going to just keep doing what the
Board was tasked to do, which is to provide a
Board was tasked to do, which is to provide a
balanced and fair look at the science and
balanced and fair look at the science and
patients and compassion, and really vet these
patients and compassion, and really vet these
conditions as thoughtfully as we have.
conditions as thoughtfully as we have.
    And I really appreciate how much work
    And I really appreciate how much work
you've all put in. This is a volunteer Board.
you've all put in. This is a volunteer Board.
You've taken Clinic off, you've taken time off of
You've taken Clinic off, you've taken time off of
your jobs. We've donated this time, including
your jobs. We've donated this time, including
the time that, just to prepare for this meeting.
the time that, just to prepare for this meeting.
    I want to thank you, IDPH, for all of
    I want to thank you, IDPH, for all of
their hard, hard work on making, in making this
their hard, hard work on making, in making this
Pilot Program a success as it is so far. And
```

Pilot Program a success as it is so far. And

```
```

that patience is key in all of this, and so we
keep trying. Our next meeting will be sometime
in the fall, and the venue is to be determined.
It will be announced on the State's website.
We may hear similar conditions again, I
believe the six-month period of time where our
recommendations from today, which we probably
should read for the record as to what was
approved and not approved, are going to be
decided upon by the Governor.
If you want to you can go ahead and sit
down. And then we will hear in six months
whether the conditions that we talked about today
would be approved or disapproved.
MR. MCCURDY: They get six months after
the time the petition period closes?
MR. FINE: Yes.
MS. TEMPLE: Is that right?
MR. FINE: Yes.
MS. MOODY: Right. So that would be
January 31st.
MR. MCCURDY: So January next year.
MS. MOODY: So 180 days after that.
MS. TEMPLE: Got it. So January 31st we

```
```

will hear the decision on today's --
MR. MCCURDY: No.
MS. MOODY: No.
MS. TEMPLE: No?
MR. MCCURDY: In July.
MS. MOODY: Yeah.
MR. MCCURDY: End of July.
MS. MOODY: So January 31st was the
closing date of the petition, open petition
period. And then from that date --
MS. TEMPLE: Okay.
MS. MOODY: -- the Board and the
Department have 180 days to render a final
recommendation.
MR. MCCURDY: So we're midway there.
We're midway there.
MS. TEMPLE: So two months from now?
MS. CHAMPION: Something like that.
MS. TEMPLE: Three months. Nestor.
MR. RAMIREZ: So I want to make a
personal comment. I want to thank personally
each and every person involved in this whole
project for their courage, their persistence,
their perseverance, their support of the

```
```

patients. Everything that you do for this
project is helping, and we've got to keep moving
forward. We don't even want to go backwards at
all at any time.
(Applause.)
MR. MCCURDY: I want to make one other
comment, and it's related I think maybe to
something Sandy said, and I may have
misunderstood you. But the legislation itself
actually did make a provision for the Advisory
Board. The Advisory Board was a result of the
Department's deciding on a process. And so we
actually owe the existence of the very Board
itself to the Department in the first place.
So --
MR. CHAMPION: Well, that was part of the
Bill as well, that it was, they put together the
rules for what would happen.
MR. MCCURDY: Right, right. But there
wasn't a Board in the legislation. The Board was
created because of (inaudible) the Department
made. Interestingly enough, yeah.
MS. TEMPLE: Let's not forget thanking
the patients and the advocates who really make

```
```

    1 this. So we're ahead of schedule. It's 2:37, so
    2 I think we did pretty well covering everything.
    3 Thank you, Board.
    4
    (Hearing end time: 2:37 p.m.)
    12
13
14
15
1 6
17
18
1 9
20
21

```
```

        MR. FINE: Motion to adjourn.
        MS. TEMPLE: Motion to adjourn.
        MR. RAMIREZ: Second.
        MS. WEATHERS: Second.
        MS. TEMPLE: All those in favor say aye.
        (Board responded aye.)
    ```
        CERTIFICATE OF REPORTER
        I, KATHY L. JOHNSON, a Certified
    Shorthand Reporter within and for the State of
    Illinois, do hereby certify that the hearing
    aforementioned was held on the time and in the
    place previously described.
    IN WITNESS WHEREOF, I have hereunto set
    my hand and seal.
            Kathy L. Johnson

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline A & 154:20,24 & 227:3,12 & adding 99:8 & 117:13 175:16 \\
\hline a-e-r-u-g-i-n-0... & academic 145:4 & acting 93:6 & 114:16 115:1 & 207:22 \\
\hline 83:7 & Academy 199:2 & 185:4 & 199:23 235:8 & advantage 43:1 \\
\hline a-l-a 18:16,19 & accept 82:2 & action 43:15 & addition 4:6 & 80:13 \\
\hline A-m-a-n-d-a & acceptable & 56:19 119:19 & 14:22 52:9 & adverse 28:20 \\
\hline 114:15 & 127:20 134:20 & 228:22 & 144:22 146:24 & 166:24 170:15 \\
\hline A-n-d-r-a-e & accepted 170:6 & actions 42:23 & 148:5 & 187:4 199:7 \\
\hline 148:6 & access 38:13 & activate 202:16 & additional 30:14 & adversities \\
\hline A-n-g-e & 41:6,10 50:1 & activating 183:6 & 70:23 71:3 & 218:3 \\
\hline 102:19 & 87:13 120:1,12 & activation 183:3 & 118:2 142:14 & advice 75:5 \\
\hline A-p-p-e-n-d-i-... & 171:8 196:3 & 192:4 & 177:20 178:9 & 172:11,13 \\
\hline 82:22 & 209:22 & active 41:22 & 205:20 230:16 & advised 93:24 \\
\hline A-s-p-s-i 73:22 & accident 184:11 & 84:20 & 237:14,24 & Advisory 1:1 2:1 \\
\hline a.m 1:14 4:1 & acclimatio & activities 97:20 & additives 191:4 & 5:5 11:12 \\
\hline 193:16 & 140:20 & 127:17 133:17 & address 76:21 & 52:11,18,20 \\
\hline A1C 19:2 44:9 & accommodate & 134:21 135:8 & 213:12 & 167:22 172:11 \\
\hline 51:14,15 & 223:6,14,20 & 167:13,15 & addressed 129:1 & 173:9,19 \\
\hline A1C's 30:20 & accompanied & activity 80:24 & adequate 139:17 & 180:13 200:8 \\
\hline abdominal & 190:19 & 83:17,17 84:17 & 139:18 152:10 & 214:9 233:1 \\
\hline 180:23 182:19 & accompanies & 85:8 156:8 & adjourn 242:4,5 & 235:1 241:10 \\
\hline 193:1,3 194:4 & 184:16 & Acts 45:15,16 & adjudicate & 241:11 \\
\hline ability \(33: 2,15\) & accomplis & act & 224:6 & advocacy 35:8 \\
\hline 59:9 97:17 & 175:10 & 86:17 99:20 & adjunct 10:23 & 35:15 123:12 \\
\hline 126:22 136:5 & account 94:3 & acupuncture & administered & advocate 10:16 \\
\hline 152:24 & 173:23 213:13 & 199:14 & 88:4 98:12 & 17:1 145:10 \\
\hline ablations 147:1 & accounts 121:15 & acute 92:21 & administration & advocates 175:4 \\
\hline able 8:8 23:17 & 122:13 & 119:14 & 119:13 121:17 & 175:4 179:4 \\
\hline 38:7 41:10 & accreditatio & adapted 203:9 & 122:11 209:17 & 241:24 \\
\hline 44:3 58:24 & 224:2,2 & adapting 6:19 & administrative & advocating \\
\hline 68:20 88:14 & accredited 224:4 & add 1:4 7:9 & 137:5 & 102:2 118:15 \\
\hline 93:18,19 95:18 & 224:5 & 11:16 32:9 & admissions & 118:17 \\
\hline 102:23 104:2 & accurate 4:13 & 66:13 70:16 & 50:13,15 & aeruginosa 83:4 \\
\hline 105:15 107:17 & 9:8 71:22 & 171:23 172:4 & admit 167:24 & 83:7 \\
\hline 107:18 111:14 & acetaminophen & 194:8 203:20 & ado 123:24 & Affairs 207:18 \\
\hline 111:15 156:21 & 191:14 & 227:24 233:2 & adolescence & affect 181:2 \\
\hline 187:17 189:3 & ache 204:12 & 233:22 235:18 & 191:10 & 200:15 201:24 \\
\hline 192:11 219:13 & achieve 61:23 & 235:22 236:12 & adolescents & 207:16 209:11 \\
\hline 224:6 & acid 51:6,6 & 237:9 & 39:14 44:10 & 218:9 219:14 \\
\hline aborts 194:2 & acknowledge & added 53:18 & 45:4 & affiliation 9:13 \\
\hline abruptly 63:2 & 4:18 69:20 & 71:7 99:9 & adopted 131 & 16:23 17:18 \\
\hline absence 162:10 & 175:19 & 171:4 185:23 & adult 181:5 & 144:8 \\
\hline absolute 78:23 & acknowledged & 197:4 213:23 & 191 & afford 37: \\
\hline absolutely 26:23 & 8:21 88:3 & 237:1 238:4 & adult-like & afforded 168:5 \\
\hline 36:10 79:3 & Act 5:15 11:19 & addicted 61:21 & 175:18 & Afganistan \\
\hline 225:7 & 19:6 39:24 & 61:22 & adults 30:18 & 212:20 \\
\hline abuse 129:8 & 131:10 132:7 & addictive 59:18 & 50:10 91:20 & aforementioned \\
\hline & 174:23 175:11 & 66:7 71:5 & 110:1,12 & 243:7 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline aftermath & AIDS 42:12 & 127:8 & 144:12 & antibiotics 89:12 \\
\hline 133:10 & Akirav 59:22 & alternativ & anesthetist & 90:16 92:2,8 \\
\hline afternoon & al 29:6,22 30:10 & 204:18 & 10:22 & anticipate \\
\hline 165:15 190:16 & 30:16 31:4 & Amanda 2:17 & Angela 2:15 & 128:11 \\
\hline 200:8 201:6 & 53:6 66:24 & 94:15 114:10 & 94:14 102:10 & anticipated \\
\hline 206:22 & 75:22 109:8 & 114:11,14 & 102:18 & 153:12 \\
\hline age 19:19 26:8 & 111:18,18,19 & 189:9 & Angelo 102:6 & antidepressants \\
\hline 37:3 41:5 45:6 & al's 111:17 & amazing 20:20 & angle 76:24 & 112:20 \\
\hline 49:24 56:1,21 & Albicans 83:8 & 26:8 & animal 29:17 & antioxidant \\
\hline 181:22 191:9 & alcohol 191:5 & Amber 36:23 & 75:21 & 33:12 219:4 \\
\hline 217:19 & aligned 160:6 & 37:10,20 38:2 & announce 57 & antipsychotic \\
\hline agencies 229:17 & allegiance & amended 14:6,8 & 82:12 & 117:17 \\
\hline 230:10,17 & 120:18 & amendment & announced 15:6 & antispasmodic \\
\hline 231:4,6,14 & alleviate 118:2 & 14:5 & 239:4 & 219:5 \\
\hline agenda 6:4 12:1 & alleviated 182:5 & Amentiza & announcement & antiviral 84:16 \\
\hline 34:14 77:9 & Allison 2:3 11:4 & 182:10,15 & 93:3 & anxiety 58:1 \\
\hline agent 33:8 & 50:12 & American & annual 126:11 & 59:8,12,20 \\
\hline ages 56:14 & allocated 124:19 & 147:20 199:2 & 128:14 230:12 & 60:7 61:1,6 \\
\hline aggression & allow 40:11 43:3 & Americans & 230:16,18 & 62:4,6,9,13,15 \\
\hline 108:23 & 56:20 107:1 & 148:19 166:10 & annually 230:13 & 62:23 63:20,22 \\
\hline aggressive & 129:1,11 & 166:12 181:1 & anonymous & 63:24 64:9,9 \\
\hline 110:10 & 137:22 142:14 & 201:8 & 100:10 & 64:15,16,18 \\
\hline aggressively & 155:16 189:5 & amount 36:24 & anonymously & 65:1,3,7,10 \\
\hline 120:18 & 205:20 206:6 & 68:21 174:22 & 57:24 & 66:16,19 67:3 \\
\hline ago 19:5,10 & allowed 20:2 & 179:19 222:23 & answer 22:19 & 67:19 70:20 \\
\hline 103:14 104:16 & 31:23 40:23 & amounts 20:1 & 33:6 38:20 & 73:11,12 74:4 \\
\hline 130:4 149:14 & 87:13 211:20 & 33:20 62:15 & 50:11 52:5,23 & 74:12 75:17 \\
\hline 187:12 206:24 & 212:4 & 80:16 & 82:4 131:5 & 98:19 104:1 \\
\hline agoraphobic & allowing 44:24 & ample 13:17 & 136:18 150:18 & 110:23 116:4 \\
\hline 58:6,10 & 100:8 104:10 & amplify 139:4 & 222:20 238:1 & 182:1 186:21 \\
\hline agree 42:16 & 108:15 120:1 & anadamide & answers 82:5,7 & 195:7,11 \\
\hline 60:21,23 78:3 & 125:1 174:7 & 208:22,23 & anti-bacterial & 207:12 \\
\hline 136:23 199:11 & 220:1 & analgesics 130:8 & 79:23 80:11,24 & anxious 98:18 \\
\hline 214:20 227:19 & allows 7:3 & analogy 133:19 & 81:17 & 98:18 \\
\hline 227:20 232:18 & 184:13 & analysis 148:6 & anti-depressa... & anybody 40:18 \\
\hline agreement 153:7 & alluring 66:6 & 202:23 & 146:21 & 139:15 \\
\hline Agriculture & Alosetron 182:9 & anchor 152:6 & anti-inflamma... & anymore 15:19 \\
\hline 229:10,23 & 182:10 & and/or 109:12 & 146:23 & 95:1 134:6 \\
\hline ahead 57:17 & als.' 73:22 & 110:6 & anti-inflamma... & 155:19 183:18 \\
\hline 60:20,22 61:7 & alter 42:4 & Andrae 148:6 & 33:11 86:3 & anyway 54:6 \\
\hline 82:19 161:20 & Alterations 60:2 & anecdotal & 219:4 & 107:14 \\
\hline 178:3 234:20 & altered 51:8 & 121:14 122:5 & anti-viral 79:23 & anyways 9:1 \\
\hline 239:11 242:1 & altering 43:16 & 122:11,18 & antibacterial & 92:12 216:4 \\
\hline aid 138:19 209:6 & alternative & 196:19 219:16 & 84:16 86:2,9 & apologies 180:18 \\
\hline 222:17 & 18:22 33:10 & anesthesia & 88:22,23 & apologize 135:15 \\
\hline aides 103:16 & 59:14 112:24 & 133:21 & antibiotic 89:7 & apoptosis 33:21 \\
\hline 105:2 & 115:8,10 120:3 & Anesthesiology & 154:5 & apparently 31:1 \\
\hline
\end{tabular}
\begin{tabular}{|c|c|c|c|c|}
\hline 173:11 & 25:18 & 118:23 166:10 & asks 64:3 91:13 & attention 11:19 \\
\hline appear 189:5 & approaches & 166:12 201:7 & aspect 7:14 & 177:2 \\
\hline APPEARAN... & 166:7 & 201:10 208:8 & 175:9 & attest 167:7 \\
\hline 2:1 & appropriate & 208:14 222:18 & aspergillosis & attorney 10:17 \\
\hline appeared & 72:4 137:14 & April 43:1 51:15 & 28:8 & audience 8:13 \\
\hline 178:11 & appropriately & 109:21 & aspirin 81:12,12 & 17:12 28:18 \\
\hline appears 71:11 & 120:20 & arbitrary 166:4 & 138:9 191:14 & 115:20,22 \\
\hline appease 229:1 & approval 14:18 & area 26:13 67:24 & Aspirin's 138:9 & 122:8 136:12 \\
\hline Appendino & 46:5,13 52:13 & 116:10 130:21 & Assembly 229:3 & 174:14 225:2 \\
\hline 82:22 & 79:2 92:18 & 184:9 190:18 & 230:14 231:2 & 225:12,17 \\
\hline appetite 36:10 & 232:6,17 & areas 97:22 & assessed 86:5 & 226:2,4 227:3 \\
\hline 42:10,13,15 & approve 13:8,10 & 124:17 138:11 & assist 122:24 & August 171:8 \\
\hline 48:2 195:17 & 13:12,17 14:13 & 138:13 161:13 & Assistant 10:14 & aureus 12:24 \\
\hline appetites 37:20 & 55:8 60:16,24 & 200:17 202:19 & 39:19,22 & 82:16 94:8 \\
\hline applaud 122:23 & 72:10,13 93:7 & 216:12,20 & Associate 10:6 & author 4:20 \\
\hline 159:22 & 95:16 96:2,15 & Arkansas & 11:5,8 144:12 & 152:6 194:23 \\
\hline Applause 4:23 & 143:17 209:16 & 113:11,18 & associated 44:8 & authorized 39:1 \\
\hline 11:23 16:17 & 217:8 & arm 186:16 & 44:17 74:17 & 230:13 \\
\hline 43:9 48:19 & approved 15:8,9 & armamentari... & 108:22 137:3 & authorizing \\
\hline 70:12 108:6 & 15:10,11 30:14 & 154:1 & 202:14 & 229:21 \\
\hline 111:21 118:9 & 55:9 56:13 & aromatherapy & association & autism 12:24 \\
\hline 121:8 123:2 & 58:17 60:7 & 219:15 & 145:3 147:21 & 93:4,7 94:12 \\
\hline 138:22 164:5 & 73:11,14 78:18 & array 89:1 & 209:7,8 & 97:13,15,23 \\
\hline 168:9 174:11 & 88:1 89:21 & arsenal 71:3,7 & associations & 98:11 99:18,21 \\
\hline 176:9 183:16 & 94:22 95:2,21 & 160:17 & 209:5 & 99:24 100:2,14 \\
\hline 186:2 192:14 & 95:21 96:1,17 & art 5:12,12 & assume 118:24 & 101:9 102:1,2 \\
\hline 194:17 197:7 & 97:8 99:2,16 & 32:20 219:11 & 138:23 145:2 & 103:23 108:11 \\
\hline 204:1 210:1 & 108:20 113:1,4 & arthritis 30:5 & 145:24 222:16 & 108:13,14,17 \\
\hline 212:9 217:12 & 114:17 115:2 & 58:18 200:15 & assuming 69:7 & 108:19,21,22 \\
\hline 220:3 222:14 & 119:6,24 & 218:19 & 71:22 & 109:7,11,21,22 \\
\hline 241:5 & 135:12,13 & article 29:21 & astounding & 110:1,5,7,16 \\
\hline apples 31:11,11 & 139:8 140:20 & 73:23 75:20 & 156:23 & 110:20 112:7 \\
\hline application & 169:24 172:17 & 83:11,13 84:11 & athlete 20:18 & 113:5 114:16 \\
\hline 86:19 90:4 & 174:16,24 & 84:18 & attached 77:15 & 115:1,5,16 \\
\hline 91:6 & 176:13 178:7,9 & articles 27:20,24 & attack 59:2 62:3 & 117:12,24 \\
\hline applied 87:2 & 182:9,13 & 28:7,10,15 & 62:24 & 118:14,17,22 \\
\hline apply 139:16,21 & 199:24 203:13 & 77:16,17 80:19 & attacks 63:4,7,9 & 119:21 120:2 \\
\hline applying 91:14 & 203:18 206:23 & 80:23 138:15 & 63:10 64:8 & autistic 98:13 \\
\hline appreciate & 212:21 215:17 & artistic 109:23 & 190:22 195:22 & 116:9,17 \\
\hline 16:14 165:13 & 216:9,10,19,22 & asked 31:18 62:6 & attempt 131:3 & 120:16 \\
\hline 209:1 220:17 & 216:23 230:7 & 116:21 153:2 & 134:1 138:11 & autoimmune \\
\hline 232:16 238:17 & 230:22 232:5 & 214:4,5 215:2 & attempted & 30:4 79:19 \\
\hline appreciates & 232:12 239:9,9 & 231:11,12 & 122:15 & autonomic \\
\hline 16:16 & 239:14 & asking 23:12,13 & attend 168:24 & 110:8 \\
\hline appreciative & approving 86:10 & 33:18,19 45:16 & 169:2 & Autumn 210:9 \\
\hline 200:10 & 88:21 & 68:12 94:2 & attending 53:18 & available 19:5 \\
\hline approach 15:1 & approximately & 116:19 193:18 & 149:17 & 32:1,3,23 66:5 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 104:20 203:19 & 141:22 153:1 & 52:17,21 75:21 & began 101:12 & 101:24 129:2 \\
\hline average 225:9 & 158:22 162:6 & 77:24 105:11 & 211:13 & 188:18 199:8 \\
\hline avoid 63:9 64:17 & 171:20 179:23 & 179:6 180:3 & beginning 32:19 & benzodiazepine \\
\hline 184:10 & 179:23 183:19 & 199:15 202:9 & 37:3 72:12 & 66:4 \\
\hline avoidance 63:11 & 188:3 198:19 & 219:6,14 225:8 & 91:12 & benzodiazepines \\
\hline avoiding 166:7 & 203:17 211:8 & 232:22,23,24 & begins 63:2 & 59:19 66:6 \\
\hline award 229:5 & 211:21 221:17 & baseline 29:15 & begun 236:20 & 69:24 \\
\hline aware 128:3 & 236:14 & 67:19 & behalf 35:21,24 & Bergamaschi \\
\hline 138:18 150:3 & background & basic 129:21 & 57:23 100:9 & 64:19 \\
\hline 171:9 & 10:18 158:2 & 157:8 & 145:7 153:19 & best 62:21 64:24 \\
\hline Awareness & 196:4 & basically 83:22 & 174:23 175:11 & 101:20 108:14 \\
\hline 109:21 & backwards & 98:4 103:10 & 217:16,18 & 120:10 121:18 \\
\hline Awesome & 241:3 & 104:3 134:8 & behavior 63:8 & 147:9 166:6 \\
\hline 190:14 & bacteria 81:18 & 185:11 189:23 & 98:17 110:11 & 190:12 192:12 \\
\hline awful 23:22 & 84:7 92:5 & 202:17 209:16 & 190:2 & 197:22 214:6 \\
\hline 24:24 47:15 & 154:12 & 216:6 & Behavioral 60:2 & 223:6,14,20 \\
\hline 117:16 160:3 & bad 166:7 & basing 46:9 & behaviors 97:19 & Bethesda 103:21 \\
\hline 184:16 & 187:22 & basis 20:22 & 108:22,23 & better 16:14 \\
\hline awhile 67:11 & bag 24:16 32:7 & 58:21 59:13 & 110:10,15 & 23:17,17,19 \\
\hline aye \(12: 13,14\) & 47:24 & 126:11 130:23 & 111:16 & 26:4 35:11 \\
\hline 14:14 16:1,2 & bags 24:21 & 135:8 145:16 & belief 129:4 & 59:16 63:19 \\
\hline 55:11 96:21,23 & balance 32:19 & 154:15 166:16 & believe 19:7 & 66:9 74:3 \\
\hline 142:11,12 & 46:19 51:7 & 201:23 218:10 & 61:20 78:12 & 78:14 84:22 \\
\hline 206:3 242:8,9 & balanced 73:20 & 230:20 & 99:1 116:24 & 92:15 111:1 \\
\hline & 166:9 238:14 & basketball 20:18 & 129:8,10 & 114:23 116:18 \\
\hline B & balancing 234:9 & Basolo 102:19 & 136:20 142:23 & 120:3 142:24 \\
\hline B 3:18 & ball 238:3 & Basolo-Bond & 155:7 223:17 & 183:13 188:13 \\
\hline B-a-c-h-t-e-l-I & ballot 57:4 & 2:15 94:14 & 239:6 & 203:2 204:20 \\
\hline 178:6 & ballots 15:4 & 102:6,7,11,14 & believes 209:1 & 231:13 \\
\hline B-a-s-0-1-0 & 55:13,15 70:9 & 102:18 105:8 & Ben 8:5 & beyond 232:6 \\
\hline 102:19 & 81:9 & 105:13,17,20 & Benadryl 194:5 & big 9:21 12:20 \\
\hline B-e-r-g-a-m-a... & balm 80:9 & 106:2,5,10,19 & bench 29:22 & 66:22 69:23,24 \\
\hline 64.20 & band-aids & 107:2,5 108:3 & 30:7 & 79:11 102:15 \\
\hline B-o-n-d 102:20 & 112:14 & bass 20:17 & benefactors & bigger 32:9 \\
\hline B-u-s-h 124:17 & barking 104:2 & bathing 211:10 & 118:18 & 54:10,11 84:7 \\
\hline babies 91:21 & barrier 189:7 & bathroom 103:5 & beneficial 33:16 & 227:1 \\
\hline baby 38:5 101:3 & base 6:13 28:5 & 184:8 188:7,15 & 61:15 72:22 & bile 193:6 195:1 \\
\hline Bachtell 3:2 & 43:14 44:4 & Bathrooms 8:1 & 129:8 137:22 & Bill 4:20 228:24 \\
\hline 177:17 178:1,5 & 45:10,18 51:6 & Bear 52:8 & benefit 25:21 & 233:2 237:8 \\
\hline 178:5 & 51:7 54:10,23 & beautiful 23:8 & 26:1 28:21,21 & 241:17 \\
\hline back 20:4 23:9 & 64:4 65:15 & becoming 98:4 & 35:18 100:1 & biochemistry \\
\hline 23:20,24 24:2 & 73:20 75:17 & 109:19 184:5 & 117:22 129:21 & 157:24 \\
\hline 57:14 62:14,18 & 177:9,11,14 & 193:19 & 131:2 137:17 & biological 59:23 \\
\hline 73:21 82:2 & 178:18 179:2 & bed 193:15 & 138:13 199:9 & 170:15 \\
\hline 90:1 94:11 & 199:15 218:24 & bedridden & 209:21 & biologically \\
\hline 95:18 130:12 & based 46:13 & 170:13 & benefits 33:16 & 84:19 \\
\hline 132:7 141:21 & 47:4 49:20 & bees 146:15 & 85:15 93:17 & Biotechnology \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 196:12 & 66:24 69:19 & bore 157:23 & bring 24:2,3 & button 18:4 \\
\hline bisect 123:16 & 70:8,16 73:20 & borne 79:5 & 106:6,9,12,17 & buy 50:5 88:23 \\
\hline bit 59:16 64:7 & 75:8 76:12 & Borrelia 81:1 & 108:13 137:12 & 225:5 \\
\hline 77:14 125:2 & 77:12 78:14 & borrow 94:3 & 138:2 & \\
\hline 162:2 178:13 & 82:18 87:21,24 & borrowing 94:4 & brings 43:20 & C \\
\hline 189:21 200:7 & 91:7 93:8 & Boston 160:11 & British 188:20 & C-a-s-t-r-o 35:8 \\
\hline 201:5 203:2 & 94:22 95:15 & botanists 42:21 & broad 62:7 & c-h-o-l-e-r-a \\
\hline 206:21 212:12 & 96:21 99:5 & bothered 90:4 & 167:24 & 83:3 \\
\hline 212:13 223:13 & 100:8 124:10 & 90:14 & broccoli 182:7 & C-I-a-u-w 152:7 \\
\hline 230:19 238:3 & 124:22 131:3 & bottleneck 85:3 & broke 123:5 & C-o-m-p-a-s-s \\
\hline black 5:17 110:4 & 135:16 138:1 & bought 105:4 & broken 110:4,9 & 148:23 \\
\hline 177:11 222:22 & 141:22 142:12 & boundaries & brother 120:22 & C-r-i-p-p-a \\
\hline blame 210:12 & 142:14 143:17 & 138:12 & brought 32:7 & 64:21 \\
\hline blanket 167:23 & 145:21 149:13 & bowel 13:3 & 38:4 59:1 & cabbage 182:7 \\
\hline blankets 234:4 & 150:16 164:2 & 110:21 163:16 & 102:7 115:17 & cache 27:21 \\
\hline blew 30:19 & 164:23 167:22 & 180:8,21 & 115:24 177:18 & cadence 206:21 \\
\hline blinded 138:17 & 168:21 172:12 & 185:20 186:5 & 179:17 205:3 & cafeteria 7:23 \\
\hline bloating 180:23 & 173:9,19 & 186:12 187:13 & brownies 81:24 & California \\
\hline 181:11 188:4 & 174:13,13 & 189:11 & bruised 20:14 & 196:18 \\
\hline blockage 163:17 & 179:20 180:13 & box 154:1, 2, 3 & bucket 146:12 & call 8:9 14:11,19 \\
\hline blocked 202:17 & 186:3 200:9 & 155:5 198:21 & bud 33:14 & 32:21 68:8 \\
\hline blocks 156:14 & 206:3 210:7 & boy 101:3 & 219:16 223:1,2 & 75:19 80:16 \\
\hline blood 19:1,4,12 & 213:7 214:9 & 102:20 & bug 154:4 & 153:7 161:6 \\
\hline 19:17 20:3,4,7 & 227:23 228:21 & boyfriend & building 106:9 & 177:1 179:14 \\
\hline 21:6,7 22:6,8 & 233:1 235:1,23 & 210:11 & 175:15 219:1,3 & 185:12 189:15 \\
\hline 22:18,19 24:6 & 237:11 238:6 & boys 108:16 & built 120:23 & 221:21 229:15 \\
\hline 25:19 26:21 & 238:13,18 & 116:13 & bumble 146:15 & called 48:24 \\
\hline 27:1,8 34:1 & 240:12 241:11 & brain 39:14 & bunch 217:1 & 80:1 81:1 83:1 \\
\hline 36:9 & 241:11,13,20 & 40:20 42:19 & burden 53:24 & 83:18 84:12 \\
\hline blown 33:2 & 241:20 242:3,9 & 111:8,13 & 54:16 & 148:22 154:22 \\
\hline blue 55:14 & Board's 28:17 & 167:18 181:15 & burdening 46:2 & 188:22 189:20 \\
\hline board 1:1 2:1 & boards 144:23 & 197:8 202:17 & burning 20:24 & 193:2 195:1 \\
\hline 4:15 5:5 9:12 & boat 87:5 & 202:18 & Bush's 139:5 & 197:19 216:3 \\
\hline 9:17 11:12,20 & bodies 161:11 & brain's 208:20 & Bush-Joseph & 232:19 \\
\hline 12:14 13:10 & body 21:1 \(23: 2\) & brains 39:12 & 2:19 124:2,7,9 & calm 101:15 \\
\hline 14:14 15:1,14 & 33:21 36:17 & brainstem 191:2 & 124:17 125:6,8 & 120:19 187:23 \\
\hline 15:18 16:2,15 & 83:23 103:17 & bravery 122:23 & 125:15,18 & 188:2 \\
\hline 21:24 24:15 & 127:23 134:11 & break 7:15 57:5 & 131:8 132:5 & Cameron 115:4 \\
\hline 25:8 27:3 & 157:16 181:15 & 57:7,12 106:21 & 133:12,16 & 115:18,24 \\
\hline 30:13 35:23 & 188:21 200:16 & 141:24 142:2 & 134:7 135:14 & camp 26:12 \\
\hline 39:4 40:11 & 210:17 & 155:18 & 136:17 139:2 & canal 133:21 \\
\hline 43:18 48:1 & body's 98:9 & breakfast 117:3 & 168:13 169:14 & cancer 9:24,24 \\
\hline 49:19 52:2,12 & boilerplate 94:1 & breast 9:24 & 198:8 & 42:12 131:16 \\
\hline 52:18,21 53:1 & Bond 102:19 & breasts 109:2 & Bush-Joseph's & 138:6 158:20 \\
\hline 54:6 55:5,7,11 & bonds 189:6 & brief 90:5 91:13 & 164:10 & 218:18 \\
\hline 55:12 56:20 & bones 201:19 & Briggs 126:24 & business 5:22 & Candida 83:8 \\
\hline 60:5 65:14 & booked 144:14 & brighter 195:20 & 143:10 165:16 & candy 102:24 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline Canna 218:13 & 74:11,16,20,24 & 211:16 212:3,5 & cartilage 200:14 & 70:22 74:21 \\
\hline cannabi 156:3 & 75:22 77:19,24 & 212:14 214:2 & 201:20 & 160:4 167:4 \\
\hline cannabidiol & 79:21 80:2,4 & 216:10,20 & case 28:9, 11,22 & 172:19 187:1 \\
\hline 29:7 62:14 & 80:15,24 81:11 & 217:2,19 218:8 & 31:1 40:10 & 191:1 202:4 \\
\hline 64:22 119:13 & 81:15 82:3 & 218:8,9 219:8 & 41:9 44:19 & causes 22:20 \\
\hline cannabinoid & 83:1,2,8,15 & 219:12,19 & 47:3,6,10 & 36:22 81:2 \\
\hline 151:21 152:11 & 84:14,20 85:2 & 220:21 224:6 & 50:17 64:9 & 109:3 165:20 \\
\hline 152:13 153:8,8 & 86:17 87:9,14 & 229:22 230:1,6 & 150:12 160:5 & 167:11 170:12 \\
\hline 154:16 155:3 & 92:18 93:18 & 230:23 232:21 & cases 91:20 & 170:15 180:22 \\
\hline 156:18 157:15 & 97:14 98:8,13 & 236:5 & cash 196:6 & 182:3 183:10 \\
\hline 158:11 185:6 & 98:15 100:1,2 & cannabis' 79:18 & cast 175:9 & 183:15 195:2 \\
\hline 185:10 188:22 & 101:6 108:17 & cannabis-trea... & Castro 2:12,13 & 201:19 209:14 \\
\hline 209:2 & 108:19 110:15 & 84:8 & 3:5,8,11 17:10 & causing 74:24 \\
\hline cannabinoids & 110:24 113:21 & capacity 50:7 & 17:11 34:12,15 & 88:19 163:13 \\
\hline 33:15 60:1 & 116:3,9,16 & carbohydrates & 34:20,24 35:2 & 172:23 181:11 \\
\hline 80:5 84:20 & 117:11,22 & 20:13 & 35:3,6,7,11,14 & 186:15 \\
\hline 85:4,7 98:8 & 127:19 128:9 & carbonated 49:7 & 36:5 38:23 & cautious 26:19 \\
\hline 101:24 134:18 & 128:17 129:4 & carbs 103:7,8 & 39:3,5,8 57:15 & cavities 29:10 \\
\hline 134:22 136:3 & 129:12 130:14 & card 58:17 64:6 & 57:19,22 58:8 & CB 84:4 \\
\hline 147:12 155:24 & 131:22 136:21 & 92:22 105:11 & 94:14 100:6,7 & CB1 183:3 \\
\hline 156:15 182:23 & 145:13 147:12 & 156:5 225:20 & 143:4 186:4,6 & 185:10 \\
\hline 183:1 184:17 & 147:24 148:3,7 & 230:22 & 194:19,20 & CB2 30:11 \\
\hline 184:20,24 & 148:21,24 & cardiac 134:15 & 197:10 210:3,4 & 182:24 192:4 \\
\hline 185:1,4,10 & 149:6,21,24 & cardiovascular & casual 28:4 & 202:12,16 \\
\hline 188:19 189:5 & 150:5,13 156:4 & 170:16 203:7 & catch 22:17 & CB2R 185:8 \\
\hline 202:12 218:15 & 156:21 159:1 & cards 175:23 & 143:15 & CBD 19:4,20 \\
\hline cannabis 1:1,5 & 160:4 161:16 & 236:18 & categories & 20:6 21:4,8,10 \\
\hline 4:8 5:2,3 6:8 & 161:20,21 & care 10:1,22 & 136:12 & 22:9,23 24:5 \\
\hline 6:14,19 7:1 & 162:4,17 & 125:23 126:19 & categorize 64:2 & 26:21 28:12 \\
\hline 11:3 18:21 & 167:16 171:6,8 & 129:17 130:17 & 67:13 & 29:7,12,13 \\
\hline 19:8 25:22 & 171:10 172:2 & 132:7,11,14 & category 61:4 & 30:1,12 31:19 \\
\hline 28:12 29:19 & 172:10 174:8 & 147:9 156:9 & 87:3 & 31:24 33:4,11 \\
\hline 31:16,19,24 & 175:23 179:7 & 159:18 160:9 & cauliflower & 41:8 46:6 \\
\hline 32:14 33:3,10 & 179:15 183:2,4 & 175:3 192:8 & 182:7 & 62:14,17 64:24 \\
\hline 33:13 35:9,18 & 183:12 184:3,5 & 211:9 213:14 & causal 26:20 & 80:6 106:3 \\
\hline 37:18 38:8,14 & 184:15 185:18 & 213:22 221:23 & cause 23:21 & 116:22 122:15 \\
\hline 39:11 40:19,22 & 186:18,22 & careful 76:2 & 32:12 45:9 & 151:11,24 \\
\hline 41:11,20,21,24 & 187:5,8 188:10 & 174:17 & 75:1 79:5 & 216:1 218:11 \\
\hline 42:1,1,8,16 & 191:21 192:4 & carefully 9:6 & 97:21 116:5 & 218:13,14,24 \\
\hline 44:7,12,17 & 192:10,20 & 46:22 70:6 & 117:16 146:10 & 219:4 226:10 \\
\hline 47:23 52:1 & 193:19 194:2,7 & 78:7 91:3,5 & 166:24 167:6 & CBG 33:15 \\
\hline 54:20 58:2,5,9 & 195:17,19 & 167:22 232:7 & 170:3,7,14 & CBID 112:10 \\
\hline 58:17 59:1,18 & 196:17,20 & 232:14 & 172:21 181:4 & CBN 33:15 \\
\hline 61:11,13,17 & 197:2 201:17 & caregiver 17:1 & 181:17 187:4 & CBV1R 185:8 \\
\hline 67:3,17 68:24 & 202:16 203:8 & 59:9 & 190:17,22 & CDC 126:7,13 \\
\hline 69:12,19 70:4 & 208:19 209:6 & caring 167:14 & 193:11 194:14 & 126:18 150:19 \\
\hline 72:20 73:23 & 209:22 211:13 & Carson 224:18 & caused 36:7 & 201:7 \\
\hline
\end{tabular}
\begin{tabular}{|c|c|c|c|c|}
\hline cell 4:11 29:24 & 161:9 & Charles 2:19 3:2 & 113:12,18 & 165:17 166:2,3 \\
\hline 33:21,22,23 & Chairs 22:1 & 124:2,17 & 117:12 & 166:11,13,14 \\
\hline 34:1 & challenge 115:14 & 164:10 168:13 & chocolate & 166:22 167:2,3 \\
\hline cells 30:1 185:8 & challenges 99:22 & 169:14 178:5 & 105:21 106:1 & 167:7,10,10,15 \\
\hline 189:6 & challenging 55:5 & 216:1 & choice 172:4 & 167:23,24 \\
\hline center 9:18 11:7 & 123:6 153:23 & charts 19:2 & choices 20:5,12 & 168:2,4,5,14 \\
\hline 35:8 113:11 & Champaign & 51:21 111:12 & cholera 83:3 & 169:11,15 \\
\hline 125:20 127:1,2 & 210:9 213:11 & chat 177:24 & choose 192:12 & 170:12 171:1 \\
\hline 127:10 144:19 & Champion 2:6 & cheaper 225:5 & chooses 228:24 & 172:19,24 \\
\hline 153:6 162:22 & 3:12 11:10,11 & check 8:8 18:8,8 & chores 167:14 & 181:3 199:5,11 \\
\hline 196:12 & 13:15,20 16:10 & 95:13,17 196:4 & 202:2 & 201:22 202:8 \\
\hline centers 35:15 & 23:10,13 24:23 & checked 8:5 & chosen 179:5 & 202:18 216:5 \\
\hline 229:24 & 25:10 26:3 & 114:10 & Christmas & circumstance \\
\hline central 151:18 & 47:17,21 60:17 & cherry 178:24 & 193:24 & 127:14 \\
\hline 185:8 202:13 & 60:20 61:8 & Chicago 11:7 & Christoff 2:4 & circumstances \\
\hline certain 7:15 & 72:11,19 76:10 & 35:16 58:4 & 4:16 5:20 10:8 & 63:12 64:11 \\
\hline 27:20 33:12 & 88:16 96:19 & 125:21 128:15 & 10:8 12:11 & cited 73:4 \\
\hline 42:5 69:24 & 107:12 163:6,7 & 137:2 144:13 & 22:11,14,21 & citizens 172:13 \\
\hline 81:16,21 191:6 & 177:8 179:16 & 186:10 187:11 & 23:3 43:12 & 196:7 \\
\hline 212:6 219:14 & 199:19,21 & 194:22 & 50:9,16,20,23 & claim 86:12 \\
\hline certainly 27:12 & 212:11 213:9 & Chicago-Pritz... & 51:1,4,13,17 & claiming 86:1,4 \\
\hline 28:17 46:18 & 213:10 214:12 & 10:15 & 51:20 66:2 & claims 224:6 \\
\hline 61:11,15 78:6 & 214:20,24 & Chicagoland & 89:3 113:1,6 & clarification \\
\hline 125:18 126:12 & 215:11 225:5 & 130:21 & 135:12 136:9 & 45:24 71:9,18 \\
\hline 126:13 128:21 & 226:20 227:6,8 & chicken 67:16 & Christopher & clarify 38:19 \\
\hline 128:24 131:3 & 227:16 229:4 & 74:21 & 107:7 & 49:14 62:1 \\
\hline 135:2,4 136:23 & 231:8 232:9,18 & Chief 11:8 & chronic 12:24 & 95:5 237:5 \\
\hline 137:15 174:12 & 233:6,11,14 & 144:16 & 13:1,1 30:12 & class 20:3 \\
\hline CERTIFICATE & 234:2,5,7,11 & child 23:9 27:5 & 58:21 61:5 & 119:19 139:12 \\
\hline 3:23 243:1 & 240:18 241:16 & 33:17 98:1,13 & 78:11,20 79:7 & 139:12,14,14 \\
\hline certification & chance 107:21 & 99:18,23 112:4 & 92:13,17 & 140:1 202:8 \\
\hline 6:19 205:10 & 143:15 188:3 & 211:10 & 119:12 123:17 & classes 203:10 \\
\hline 221:8 & 212:6 & child's 97:17 & 123:18,21,22 & classically 62:24 \\
\hline certified 39:19 & change 51:5 & childhood & 124:1,7,15,15 & classified 27:17 \\
\hline 39:21 68:21 & 63:8 98:5 & 100:21 101:10 & 126:5,23 127:4 & 78:9 \\
\hline 131:6 153:14 & 105:6 163:5 & children 39:15 & 129:12,13,13 & classroom \\
\hline 153:16 243:4 & 190:8 191:6 & 41:5 49:24 & 131:18 132:17 & 103:15 105:3 \\
\hline certify 7:1 & 233:18 235:20 & 99:17 100:1 & 134:2 140:11 & Clauw 152:5 \\
\hline 136:11 156:1 & changed 19:13 & 109:16,17,22 & 141:5,5,12,15 & clear 86:14 \\
\hline 159:4,12 243:6 & 58:19 103:6 & 110:1,12 & 142:1 143:16 & 172:3 180:10 \\
\hline certifying 5:7 & 187:15 216:3 & 112:22,24 & 145:10,11,16 & 180:19 182:2 \\
\hline 26:2,3 40:7 & changes 100:17 & 113:2,8,13 & 145:19,24 & 214:3 \\
\hline 132:4 136:15 & 170:18 181:16 & 116:9 120:16 & 146:5 147:6,13 & clear-cut 132:9 \\
\hline 159:9 & 182:4 191:2,12 & 120:18 122:12 & 147:15 148:8 & clearly 16:21 \\
\hline cetera 67:1 & charged 11:21 & 193:15 & 148:16 149:7 & 18:6 44:19 \\
\hline 136:13 139:6 & 43:18 46:1,4,8 & children's & 153:5 159:24 & 53:2 143:12 \\
\hline 145:20 153:2 & 138:1 & 103:22 110:14 & 163:4 164:15 & 199:3 214:1 \\
\hline
\end{tabular}
\begin{tabular}{|c|c|c|c|c|}
\hline clinic 17:10 35:3 & collect 55:17 & 16:16 101:7 & 97:18 104:2 & complement \\
\hline 91:16 97:15 & collected 194:21 & 123:14 177:3,5 & 132:13 & 18:22 \\
\hline 144:14 180:20 & collecting 230:3 & 193:23 194:1 & communicating & Complementary \\
\hline 186:9 190:17 & collective 52:18 & 220:20 226:8 & 221:11 & 127:1 \\
\hline 207:8 238:19 & college 10:6,23 & 234:15 & communication & completed \\
\hline Clinic's 90:9,12 & 207:3 211:4 & comment 11:16 & 33:22 159:8 & 142:22 \\
\hline clinical 10:14 & colon 182:10 & 40:16 71:24 & 221:6 222:2,10 & completely \\
\hline 65:20 147:22 & colonization & 73:1 85:21,23 & community 7:5 & 90:11 111:13 \\
\hline 149:4 162:16 & 91:23 92:4 & 93:12 135:18 & 49:13 68:7 & 117:12 160:6 \\
\hline 177:18,20 & colonized 88:18 & 140:4 223:23 & 144:23 153:1 & 232:18 \\
\hline 178:9 & colony 84:7 & 234:23 240:21 & comorbid & complex 54:21 \\
\hline clinically 156:20 & Colorado 42:6 & 241:7 & 108:12 110:17 & 165:19 \\
\hline clinician 5:24 & 101:11 115:15 & commentary & 110:21 111:3 & complicates \\
\hline 6:8 31:21 76:9 & 137:19 & 74:5 180:3 & 112:5 113:9,14 & 187:16 \\
\hline 155:22 176:2 & combat 184:15 & comments 13:14 & 115:16 & compound \\
\hline clinician's 5:4 & combine 124:20 & 24:14 25:8 & companies & 208:19 \\
\hline 30:8 & 143:24 & 33:5 39:4 & 228:5 & compounded \\
\hline clinicians 172:7 & combining & 41:18 43:12 & company 188:17 & 146:22 \\
\hline clock 227:9 & 166:6 169:21 & 55:6 60:4 76:9 & comparable & compounds \\
\hline close 18:5 27:1 & come 5:9 8:9 & 77:3 93:8 & 222:21 & 41:22 128:22 \\
\hline 102:13 194:6 & 19:18,24 23:24 & 122:22 125:8 & compare 68:19 & compromise \\
\hline 198:5,6 210:21 & 25:13 27:24 & 139:5 142:14 & 158:13 & 185:6 \\
\hline closed 7:22 33:5 & 34:18 42:24 & 142:16 163:21 & compared 45:7 & concentrates \\
\hline closer 114:19 & 57:20 94:10 & 180:6 186:3 & 74:18 75:15 & 226:9 \\
\hline closes 239:16 & 96:17 97:12 & 189:10 198:10 & comparing & concentrations \\
\hline closing 240:9 & 124:3,5 127:11 & 198:14 212:10 & 31:11 & 49:14 \\
\hline clouds 167:10 & 141:21,22 & 212:23 224:16 & comparison 89:7 & concept 172:14 \\
\hline CNA 90:1 & 154:21 157:6 & 234:19 235:22 & 89:20 207:24 & concern 16:6 \\
\hline co-sponsors & 164:8 177:21 & Commissioner & Compass 148:22 & 39:16,17 47:3 \\
\hline 229:14 & 179:4 180:2,7 & 171:21 172:12 & compassion & 78:22 99:15 \\
\hline coals 146:16 & 195:4 197:12 & 173:6 & 32:20 54:16 & 128:23 236:13 \\
\hline coattail 175:14 & 199:3 203:5,17 & commit 132:10 & 172:16 173:23 & concerned 77:13 \\
\hline cocktail 101:1 & 218:3 220:24 & committed & 174:3,5 177:12 & 99:11 148:18 \\
\hline 112:12,19 & 221:17 224:14 & 210:11 & 179:10 232:22 & concerns 26:18 \\
\hline cocktails 147:8 & comes 23:20 & committee 46:21 & 238:15 & 39:10,11 72:3 \\
\hline cognitive 41:16 & 32:2 57:14 & 232:7,12 & compassionate & 78:7,13 89:24 \\
\hline 73:6,7 & 67:16 121:4 & common 119:7 & 5:3,15 27:3,14 & 127:7 128:24 \\
\hline cohesive 122:3 & 123:16 157:3 & 121:23 146:10 & 44:23 45:15 & 218:6 236:15 \\
\hline cohesiveness & 195:24 196:23 & 165:18 170:20 & 46:1,9,13 & concerts 93:20 \\
\hline 88:12 & 222:5 224:13 & 180:21 200:14 & 101:22 172:4 & concluded 88:7 \\
\hline cohort 149:2 & comfort 219:7 & 204:10,22 & 174:7 175:4 & concludes 28:3 \\
\hline Coke 49:9 & comfortable 7:6 & commonly & 179:15 232:20 & conclusion \\
\hline Coli 83:21 & 20:7 23:1 & 119:22 148:15 & 234:10,11 & 28:23 52:21 \\
\hline colleague 152:6 & 28:23 49:20 & 151:14,14 & compelling & 148:2,10 \\
\hline colleagues 53:22 & 50:3,7 60:8,11 & 166:14 180:22 & 32:11 54:10 & conclusive 41:17 \\
\hline 130:21 145:8 & 184:13 & 190:19 200:17 & 76:15 101:23 & concomitant \\
\hline 150:15 205:11 & coming 4:3 5:21 & communicate & 172:2 196:13 & 149:24 151:10 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 156:17 & 167:23 171:5 & 28:10 118:24 & continues & \(\boldsymbol{\operatorname { c o o l }} 201: 5\) \\
\hline concomitantly & 172:6 177:10 & consider 40:5 & 230:15 & coop 16:7 \\
\hline 154:17 & 177:16 178:8 & 46:22 55:1 & continuous & coordinated \\
\hline condition 25:23 & 179:5,9,17 & 65:8 66:5 70:4 & 20:11 & 181:7,14 \\
\hline 30:14 45:11 & 180:16 185:18 & 81:4 92:4,10 & contract 153:6 & cord 30:11 147:1 \\
\hline 56:9,21 57:9 & 187:3 199:11 & 132:18 165:23 & 155:13 181:6 & core 5:17 \\
\hline 60:9,12 61:9 & 199:22,22,24 & 187:5 216:5 & contractions & corn 42:3 \\
\hline 63:15,17 70:9 & 200:1 204:15 & 220:23 221:5 & 181:10,12 & correct 41:4,12 \\
\hline 70:14 76:13 & 205:2,8 213:12 & 222:3 & 185:15 & 52:7 126:4 \\
\hline 77:7,8,11 & 213:23 215:5 & considerably & contracts 135:23 & 225:11 \\
\hline 79:21 81:5 & 216:8,19,23 & 128:12 & 155:16 & correcting 85:20 \\
\hline 82:12,13,15,19 & 217:9,21 & consideration & contradictory & Corrections \\
\hline 86:11 88:10 & 218:21 227:24 & 40:12 52:6 & 74:2 & 106:13 \\
\hline 92:14,21 93:6 & 232:5,8 233:2 & considered & contributing & correctly 85:24 \\
\hline 94:9 97:14 & 233:4 235:8 & 52:24 74:15 & 116:5 & 145:15 \\
\hline 99:9,14 111:2 & 236:12 237:1 & 87:15,17 & control 31:1,9 & correspondence \\
\hline 129:24 143:16 & 237:24 238:4 & 100:13 127:5 & 33:3 34:1 44:8 & 149:15 \\
\hline 154:10 168:1,8 & 238:16 239:5 & considering & 44:18 48:2 & cortisol 170:18 \\
\hline 169:15,17 & 239:13 & 55:16 & 50:4 61:10 & cost 222:18,22 \\
\hline 179:1 181:3,23 & conducted & consistency 8:18 & 107:16 110:11 & 223:1 \\
\hline 185:23 189:22 & 182:23 202:23 & consistent 79:14 & 152:10 179:23 & Coughlin 169:7 \\
\hline 192:13 194:9 & conference & consistently & 185:5 & 169:8 \\
\hline 197:13 204:8 & 14:11,19 34:14 & 19:21 188:7 & controlled & count 206:9 \\
\hline 205:15 207:9 & 149:17,20 & constant 36:13 & 138:17 162:11 & counter 8:11 \\
\hline 233:7 & 221:21 & 170:10 210:17 & controlling & 31:20 80:17 \\
\hline conditions 1:4 & confidentia & constantly 98:3 & 185:2 & counting 93:13 \\
\hline 4:6,7,9 5:10 & 15:5 & 205:7 211:11 & controversial & countless 19:17 \\
\hline 6:3,5 12:2,2 & confluence 65:8 & constipation & 78:19 79:17 & country 113:17 \\
\hline 14:22 15:11,13 & confusion 109:3 & 151:16 180:24 & 137:3 152:17 & 120:14 \\
\hline 15:21 27:12 & conglomeration & 181:18 186:14 & convenient & counts 178:14 \\
\hline 35:19 46:6 & 166:4 & consultant 131:9 & 164:22 & couple 26:17 \\
\hline 52:10 53:22 & connected 11:12 & 217:18 230:4 & conventional & 81:13 93:13 \\
\hline 54:17,19 55:16 & Connie 2:3 9:3 & consultation & 18:23 54:24 & 100:22 102:8 \\
\hline 55:24 56:12 & 10:24 12:20 & 217:5 218:4 & 79:13 & 150:21 161:11 \\
\hline 78:10,17 79:2 & 51:22 87:4 & consulting & conventionally & 173:15 234:22 \\
\hline 79:8,20 92:17 & 95:5 165:14 & 131:12 & 60:13 & coupled 185:7 \\
\hline 96:16 110:18 & 174:21 176:4 & contact 97:24 & conversation & 195:11 \\
\hline 114:17 115:2 & 180:11 200:9 & 103:4 104:22 & 62:19 77:11 & courage 240:23 \\
\hline 115:16 117:24 & cons 29:5 31:2 & 104:22 & 204:13 205:3 & course 28:13 \\
\hline 119:23,24 & 133:3 & contain 185:9 & conversations & 62:7 65:19 \\
\hline 124:6,11,23 & consent 170:4 & contained 235:7 & 143:9 & 170:5,6 216:13 \\
\hline 126:3,4,16,23 & consequences & context 49:23 & convey 91:2 & 217:3 \\
\hline 127:6,12 & 63:7 90:17,19 & 89:14 & convinced & court 1:24 4:12 \\
\hline 128:10 129:21 & 130:1 & continually & 210:12 & 9:6 16:21 18:6 \\
\hline 132:13 139:1 & conservative & 117:14 & cooked 69:1 & 34:19 143:12 \\
\hline 143:20 159:23 & 161:24 & continue 7:4 & cookies 81:23 & cover 76:1 \\
\hline 164:8,11,13,18 & conservatively & 11:20,22 & cooking 37:21 & 199:24 207:6 \\
\hline
\end{tabular}
\begin{tabular}{|c|c|c|c|c|}
\hline coverage 224:12 & cuff 129:16 & D-a-v-i-d 144:10 & 144:10 198:3 & debilitating 1:4 \\
\hline covered 50:13 & 165:5 & D-i-c-k-e-r-s-0... & 215:16 & 4:6,9 14:22 \\
\hline 196:2 200:2 & cultivate 42:4 & 114:15 & day 19:10, 10,12 & 52:10 56:12 \\
\hline 222:17 & cultivation & D-i-1-1-o-n & 20:17 34:3,4 & 62:8 92:13,17 \\
\hline covering 51:2 & 229:24 & 168:19 & 36:9 37:1,8,19 & 168:7 184:16 \\
\hline 125:12 242:2 & cultivator & DA 43:2 \(82: 1\) & 54:22 55:1 & 195:9 204:15 \\
\hline covers 62:7 68:2 & 131:11 223:4 & daily 20:22 & 59:16 66:11 & 205:1,9 209:14 \\
\hline CPS 165:17,22 & cultivators 86:8 & 36:13 58:21 & 80:7 98:14 & 211:3 \\
\hline 166:4,16 167:5 & cultures 29:24 & 59:13 127:18 & 104:23 106:21 & debilitation \\
\hline crafted 129:6 & curative 26:24 & 133:17 134:21 & 119:15 146:13 & 205:2 \\
\hline 131:1 & curb 126:20 & 135:8 154:14 & 148:19 151:8 & Decades 208:19 \\
\hline cramping & cure 99:24 170:7 & 166:16 167:8 & 153:16 160:18 & December 102:9 \\
\hline 180:23 184:16 & 170:19 183:7 & 195:3 201:22 & 163:4 187:22 & 171:3 193:20 \\
\hline 186:13 & 191:13 192:11 & Dalton 105:23 & 188:10 195:5 & 215:20 227:4,6 \\
\hline crap 104:8 & 200:12 202:10 & 106:15 107:11 & 211:24 212:17 & 228:16 \\
\hline crappy \(161: 7\) & 203:8 & damn 135:9 & 213:24 220:20 & decent 54:2 \\
\hline crass 222:15 & cures 81:2 & Dan 152:5 & 224:9 & decide 43:19 \\
\hline creams 88:9 & curing 138:6 & Dana 2:18 94:15 & day's 37:10 & 205:17 215:3 \\
\hline create 33:20 & curiosity 173:13 & 114:4,11 & day-to-day & 228:16 \\
\hline 79:6 118:2 & 178:17 & 118:11,12 & 99:22 145:16 & decided 40:10 \\
\hline created 65:3 & curious 228:12 & dangerous 36:11 & 167:15 & 100:23 101:10 \\
\hline 136:8 214:9 & current 40:23 & dark 105:20,24 & days 36:13 38:4 & 205:6 239:10 \\
\hline 241:21 & 56:15,16 89:19 & 110:5 137:12 & 109:18 167:12 & deciding 241:12 \\
\hline creating 42:22 & 115:18,24 & 167:10 190:24 & 190:23 198:24 & decision 27:11 \\
\hline 70:2 & 136:14 & 210:20 & 210:16 226:16 & 46:12 53:1 \\
\hline credit 174:21 & currently 56:13 & Das 83:13 & 226:16 239:23 & 76:12 171:24 \\
\hline 176:4 & 88:10,22 99:1 & data 30:7 32:5 & 240:13 & 173:20 174:18 \\
\hline Cresco 131:9 & 108:20 179:18 & 32:11,24 53:5 & DEA 139:20 & 176:19 235:6 \\
\hline 132:20 & 182:8,9 186:19 & 67:24 74:2 & dead 197:22 & 240:1 \\
\hline cried 59:4 & 208:10,11 & 75:1 117:20 & deadline 142:16 & decisions 46:2 \\
\hline criminal 38:15 & 212:3 & 126:7,9 149:23 & deal 32:9 54:11 & 46:10 176:21 \\
\hline cringe 58:11 & curricula 145:6 & 162:8,11 & 70:20 71:3 & declined 119:9 \\
\hline Crippa 64:19,20 & cushion 201:5 & 199:15 225: & 120:5 160:17 & 124:5 140:24 \\
\hline crippling 36:7 & customized & 227:10 228:13 & 196:21 & 141:3,4 \\
\hline 37:5 59:7 & 218:1 & 228:13 229:13 & dealing 49:4 & declining 141:18 \\
\hline crisis 193:12 & cute 109:22 & 236:22 & 162:13 163:3 & decrease 116:4 \\
\hline criteria 165:24 & cycle 24:4 36:11 & date 229:1 240:9 & 197:3 & 128:6 151:24 \\
\hline 166:2 176:18 & Cymbalta 160:3 & 240:10 & deals 163:3 & 152:3 154:18 \\
\hline 177:15 & cystitis 184:1 & daughter 18:10 & dealt 195:15 & 160:4 184:4 \\
\hline critical 175:7 & 189:18 192:21 & 18:24 36:1,5 & death 30:1 88:19 & 185:19 191:23 \\
\hline critically 150:6 & cytokines & 36:23 38:11,20 & 117:16 170:14 & decreased 21:7 \\
\hline critique 214:23 & 111:12 & daughter's & 211:24 & decreases \\
\hline crossing 141:14 & & 18:17 & deaths 50:12 & 159:16 \\
\hline crucial 185:2 & & Dave 87:8 & 117:18,21 & decreasing \\
\hline cry 193:17 & D 2:9 & David 2:5,20 & 119:17 126:8 & 47:21 156:19 \\
\hline crystal 238:3 & D-a-n-a 118:13 & 3:13 10:20 & debated 27:9 & dedicated \\
\hline cue 36:3 & D-a-s 83:13 & 130:20 143:18 & 204:9 & 219:10 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline deem 129:23 & 217:4 & desperately & diabetic 18:24 & 110:8 \\
\hline deep 89:10,11 & Department 1:9 & 187:9 & 19:18 29:8,11 & different 41:22 \\
\hline 210:20 & 1:15 11:1,6 & despite 11:21 & 30:12 31:5 & 45:5 48:23 \\
\hline deficiency & 40:4,5 52:4 & 20:11 135:10 & 37:1 & 59:22 65:7 \\
\hline 189:20 & 106:13 131:4 & details 150:9 & diagnose 51:8 & 69:13,14 70:21 \\
\hline define 88:20 & 170:2 207:17 & deteriorating & diagnosed 11:13 & 86:10 87:3,7 \\
\hline defined 91:16 & 229:9,10,10,18 & 36:18 & 18:24 87:23 & 99:14 104:9 \\
\hline 132:10 138:11 & 229:19,23 & deterioration & 100:14,19 & 110:20 112:12 \\
\hline 165:22 170:1 & 230:12 240:13 & 127:16 & 102:21 108:16 & 116:19 122:13 \\
\hline defines 131:10 & 241:14,21 & determination & 115:4 118:14 & 154:21 158:8 \\
\hline 132:8 207:8 & Department's & 52:11 & 187:14 210:10 & 170:12 192:22 \\
\hline definitely 176:3 & 241:12 & determine 73:5 & 211:1 216:7 & 193:9 194:3 \\
\hline 197:4 & dependants & 142:24 & diagnoses & 211:2 212:13 \\
\hline definition 64:10 & 167:14 & determined & 145:13 184:1 & 218:21 237:12 \\
\hline 70:17 87:9 & dependen & 69:23 239:3 & diagnosis 51:12 & 237:13 \\
\hline definitions 62:2 & 127:17 & determining & 61:15 65:12 & differentiate \\
\hline definitive 238:9 & depending & 213:23 & 78:22 119:21 & 89:2 \\
\hline deflate 174:17 & 123:21 & detrimental & 168:3,5 211:23 & differently 202:1 \\
\hline degradation & depends 106:24 & 19:24 47:5 & dialogue 159:12 & 220:24 \\
\hline 200:13 & 112:4 158:17 & 189:3 & diarrhea 180:24 & difficult 60:12 \\
\hline degree 61:1 & 223:11 225:3 & develop 207:23 & 181:12,18 & 76:12 87:20 \\
\hline degrees 88:17 & depressed & developed 75:24 & 182:19 186:14 & 118:1 123:1 \\
\hline dehydrated & 166:17 & 103:2 131:12 & Dickerson 2:17 & 126:3,24 127:9 \\
\hline 193:10 & depression 67:7 & developing & 94:15 114:6,11 & 127:14 129:18 \\
\hline delay 51:11 & 70:20 71:14 & 39:12,14 40:20 & 114:14,15,21 & 167:8,15 \\
\hline deliberate 15:1 & 73:18 74:4,12 & 101:5 & 114:24 117:8 & 171:24 \\
\hline deliberated & 74:13,24 75:14 & development & 118:7,10 & difficulty \(72: 6\) \\
\hline 15:15 & 75:20,23 79:8 & 42:20 60:1 & 121:12 122:1 & digestive 181:16 \\
\hline deliberation & 110:16 182:1 & 88:9 109:1 & 122:10 & 183:5,13 185:9 \\
\hline 15:3 & 186:21 195:6,6 & device 160:14 & dictates 222:22 & Dillon 168:17,19 \\
\hline deliberations & 195:11 210:21 & devoted 128:16 & Dicyclomine & dinner 117:3 \\
\hline 94:24 & 216:6,16 & devoting 42:22 & 187:19 & direction 131:5 \\
\hline delineate 52:19 & depressive 70:18 & dextrose 193:8 & die \(92: 12,14,23\) & directly 30:22 \\
\hline delivering & 71:11,13 73:9 & diabetes 12:19 & 104:10,11 & 200:19 201:4 \\
\hline 122:24 147:4 & 73:14 74:1 & 12:20 17:8 & 148:19 195:16 & 202:4 \\
\hline delivery 147:3 & depth 84:13 & 18:23 25:8 & 231:19,23 & Director 10:3,12 \\
\hline demand 136:10 & dermatologic & 26:10 28:13 & died 112:7 & 52:12 53:14 \\
\hline demanding & 89:6 & 29:8,13 30:16 & 148:21 150:6 & 95:8 96:4 \\
\hline 49:12 & describe 83:2 & 31:9,11 32:5,9 & diet 25:19 49:9,9 & 126:13,24 \\
\hline demarcation & described 63:23 & 32:14,15,21 & 116:14,21 & 128:11 139:20 \\
\hline 166:3 & 65:21 116:13 & 35:20 36:7 & dietary 119:3 & 144:18,20 \\
\hline demystify & 116:15 243:8 & 37:4 38:22 & 182:4 & 173:10 227:2 \\
\hline 136:20 138:3,3 & describing 93:16 & 44:10,13,18 & difference 12:21 & 236:4,11 \\
\hline denial 52:14 & description & 45:4,14 50:11 & 29:23 37:19 & Director's 235:2 \\
\hline denied 96:5 & 66:18 90:5 & 53:5,6,8 54:11 & 62:3 173:13,18 & Directors 145:4 \\
\hline Depakote & 91:13 & 54:21 57:2,4,9 & differences & 231:3 \\
\hline 215:23 216:13 & despair 54:7 & 146:11 & 19:14 69:16 & disability 166:20 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 223:15,18 & 109:12 110:22 & 225:15 229:22 & 104:4 136:5,24 & 129:23 134:13 \\
\hline disabled 11:13 & 110:23 112:10 & 230:23 & 139:3 144:11 & dosing 156:18 \\
\hline 166:12 194:24 & 112:11 154:7 & dispensary 8:13 & 153:2 155:19 & 220:23 \\
\hline disappeared & 168:6 183:9 & 33:7,8 34:5 & 156:7 160:10 & double 138:17 \\
\hline 37:24 & 193:2 200:2 & 50:5 62:20 & 187:18 195:15 & 144:14 \\
\hline disapproved & 202:5 203:7 & 217:19 220:5 & 209:1 211:1 & Doug's 48:24 \\
\hline 239:14 & diseases 30:5 & 220:18 221:4 & 217:6 221:20 & dove 210:20 \\
\hline disclaimer 65:18 & 79:16 & 223:3,4,5,17 & 221:21 & downfall 36:16 \\
\hline discomfort & dish 154:12 & 224:20 & doctor/patient & downtown \\
\hline 20:21 22:23 & dishes 29:24 & dispensary's & 204:24 & 125:21 \\
\hline 32:2 195:3 & 84:4,8,9 & 215:20 217:17 & doctors 10:19 & dozens 119:8 \\
\hline discomforts & disorder 12:22 & dispense 218:7 & 23:6 25:24 & Dr 4:16 5:20 \\
\hline 219:23 & 12:22 57:18 & dispensing & 48:3,5 50:3 & 9:11,14,21 \\
\hline discontinue & 58:1 61:6 62:4 & 129:11 219:19 & 117:13 132:6 & 16:12 29:1 \\
\hline 152:1 & 62:13 63:3,13 & displayed 20:10 & 179:7 182:12 & 43:12 49:10 \\
\hline discordant & 63:19,20,21,22 & displaying & 197:20 221:12 & 53:13 59:21 \\
\hline 137:21 & 64:3,10 65:7,7 & 109:23 & document & 69:11 71:8 \\
\hline discount 22 & 65:10,15 70:10 & disposal 38:9 & 161:15 & 94:10 109:8 \\
\hline discounts & 70:11,15,18 & 199:10 & documentation & 111:11,17 \\
\hline 225:14 & 71:11 72:7,12 & disposition 20:8 & 231:1 & 113:12,15,19 \\
\hline discovered 67:6 & 72:14 73:14 & disproportion... & documented & 124:2,7,9 \\
\hline 85:3 191:20 & 74:5 75:16 & 209:13 & 116:2 & 125:6,8,15,18 \\
\hline 200:12 202:15 & 76:21,22 77:7 & disregard 58:13 & doing 6:11 23:16 & 131:8 132:5 \\
\hline 203:1 208:20 & 91:14 97:16,17 & disrupt 178:1 & 29:20 32:14 & 133:12,16 \\
\hline discreet 63:1 & 115:13 116:6 & disruptive 165:1 & 45:21 46:24 & 134:7 135:14 \\
\hline discretion & 145:18 180:21 & distinct 181:20 & 49:13 66:14 & 136:9,17 138:8 \\
\hline 124:21 & 186:20 193:2 & distinction & 73:7 97:3 & 139:2,4 140:11 \\
\hline discuss 14:21 & 193:11 195:7 & 153:4 159:22 & 104:21 107:20 & 143:18,19,23 \\
\hline 28:8 124:12 & 206:24 207:1,5 & distinguish & 131:14 137:11 & 144:3,5,9 \\
\hline 143:2 169:17 & 208:7 & 219:13 & 154:8 156:24 & 149:12 150:9 \\
\hline discussed 46:14 & disorders 57:12 & distinguishing & 159:14 161:8 & 150:16 153:12 \\
\hline 67:8 79:9 & 59:20 60:5 & 178:7,12 & 188:15 205:19 & 155:10,12,14 \\
\hline 174:15 & 61:3 62:5,12 & district 20:18 & 221:13 222:3 & 156:12 157:7 \\
\hline discussing 5:14 & 67:3 73:9 74:1 & disturbance & 228:21 233:21 & 157:10,13,17 \\
\hline 94:21 218:5 & 93:15 108:13 & 63:14,18 & 234:14 238:12 & 157:20,21 \\
\hline 219:20 & 109:13 110:17 & disturbed 98:5 & dollars 128:8 & 158:12,17 \\
\hline discussion 57:21 & 110:21 111:4 & diversion 154:20 & 137:18 225:24 & 160:13,24 \\
\hline 67:16 70:16 & 112:5 113:9 & 155:1 & domain 237:20 & 161:3,23 \\
\hline 95:1 135:3 & 116:11 148:17 & diverting 228:14 & domains 162:12 & 163:20,22 \\
\hline 197:15 & 153:23 162:5 & Division 144:17 & donated 238:20 & 164:2,3,6,9 \\
\hline disease 12:23 & 182:2 184:17 & dizziness 109:5 & door 8:5 32:1 & 168:13 169:13 \\
\hline 25:1 76:2 & 194:14 209:10 & 196:22 & doors 110:2 & 171:21 173:6 \\
\hline 77:10,18,20 & disoriented & DKA 28:13 47:7 & dosage 19:8 & 173:20 177:8 \\
\hline 78:2,20,20 & 23:22 & 50:12 & dose 65:4 102:24 & 179:17 198:3,5 \\
\hline 79:4,5 81:2,4 & dispensaries & doable 125:11 & 133:7,10 134:6 & 198:8,20 \\
\hline 82:13 85:16 & 75:5 175:24 & doctor 10:8 26:6 & doses 40:22 65:3 & 202:23 208:16 \\
\hline 92:11 109:6,9 & 222:24 224:5 & 91:19 99:13 & 101:13 119:14 & 208:19 233:16 \\
\hline
\end{tabular}
\begin{tabular}{|c|c|c|c|c|}
\hline 233:23 & 70:17 & 86:3 88:18 & egg 67:16 74:21 & endocrinologist \\
\hline drag 193:15 & dysthymic 12:22 & 98:16 152:12 & eggs 104:23 & 19:15 23:6 \\
\hline drained 89:12 & 70:15 72:12 & 158:5,9 163:12 & 116:21 & endogenous \\
\hline dramatic 19:23 & 76:22 77:7 & 196:10 203:2 & Ehlinger 171:21 & 185:1,9 208:21 \\
\hline 24:7 160:4 & 93:15 & effective 83:9,20 & 173:6,20 & nds 194:11 \\
\hline 184:4 185:19 & & 115:12 119:2 & eight 195:4 & 227:3 \\
\hline dramatically & E & 128:4 133:1 & 201:8 207:18 & Enduring 208:6 \\
\hline 126:20 184:12 & E & 147:16 148:11 & 207:21 & energy 6:6 15:16 \\
\hline drastically & e-I-i-z-a 35:7 & 148:13 149:8 & eighth 223 & 68:1 \\
\hline 187:15 & ear 83:16,18 & 154:3 155:5 & 224:19 & enforceable \\
\hline draw 34:10 & earlier 95:10 & 159:15 183:14 & either 8:2 14: & 155:16 \\
\hline dreams 210:22 & 143:19 & 188:10,16 & 5:11 46:10 & engaging 120:19 \\
\hline 210:24 & early 5:1 27:13 & 194:6 196:5 & 52:13 55:17 & engines 77:24 \\
\hline dressed 103 & 32:16 75:23 & 199:5,6 203:5 & 63:6 86:5 92:8 & England 79:10 \\
\hline drew 130:4 & 85:12,14 & 212:15 & 92:14 106:12 & 147:18,19 \\
\hline drinks 49:7 & 170:14 199:6 & effectively 116:8 & 207:10 214:18 & English 183:4 \\
\hline 191:5 & 204: & 153:24 167:17 & 230:24 & enjoy 93:20 \\
\hline driver's 230 & ease 37:18 38:14 & effectiveness & Elavil 194: & 141:23 195:23 \\
\hline drop 211:5 & 118:4 195:22 & 118:5 182:14 & Elect 145:2 & 211:18 \\
\hline drug 27:16 51:9 & easier 58:13 & 182:18 202:21 & elective 145:22 & enjoyed 101:16 \\
\hline 119:6 126:9 & 187:6 & effects 22:15 & element 53:18 & enjoying 184:14 \\
\hline 136:2 138:9 & eat 103:7,8 & 28:20 40:19 & 166:11 232:6 & enrolled 182:12 \\
\hline 139:13,16 & 141:23 195: & 47:16,19 48:22 & eliminate 58:20 & ensure 4:13 \\
\hline 151:13,24 & 210:14,14 & 49:15 70:3,3 & eliminated & 137:7 \\
\hline drugs 44:11,14 & eating 115:13 & 70:24 71:1,2 & 182:6 & enter 168:12,16 \\
\hline 107:10 113:24 & 116:6,10 & 80:3,11,14 & Elmhurst 10:23 & 184:8 198:3 \\
\hline 117:14,18 & 195:14 & 109:1,4,16 & embarrassing & enteric 183:3 \\
\hline 139:12 160:1 & ed 103:14 & 112:17 117:16 & 58:15 184:11 & 185:8 \\
\hline 187:2 228:6 & 171:21 1 & 119:7,11,18,20 & emerging 196:15 & Enthusiastic \\
\hline dry 54:14 & edibles 122:12 & 128:23 129:2 & emotion 98:10 & 140:8 \\
\hline 186:24 187:1 & educate 93:8 & 151:16 160:3 & emotional 68:4 & enthusiastically \\
\hline due 12:24 61:9 & 118:20 & 160:21 170:16 & emphasize 45:5 & 140:16 \\
\hline 90:23 115:7 & educating & 182:15,19 & employee 188:17 & entire 95:16 \\
\hline 123:19 124:1,8 & 132:23 & 191:18 192:2 & employment & entirely 36:8 \\
\hline 124:15 129:13 & education & 199:7,8 219:5 & 166:24 & 121:9 \\
\hline 129:13 136:13 & 62:22 132:21 & Effexor 216:15 & enchilada 31:23 & entitled 59:24 \\
\hline 141:2,5 151:19 & 157:3 158:23 & efficacious 78:5 & encompasses & entity 189:19 \\
\hline 162:24 166:13 & 159:2 162:6 & efficacy 127:24 & 115:16 & entourage 80:3 \\
\hline 186:19 187:8 & 219:9,10 & 128:20 137:7 & encourage 131:3 & 80:4 \\
\hline 195:14 & educational 65:4 & 146:18 149:1 & ended 236:9 & environmental \\
\hline duper 41:22 & educator 194:23 & 162:4,12 & endocannabin... & 191:3 \\
\hline duration 72:6 & educator 194:23 & efficient 124:13 & 33:17 98:9 & epidemic 150:18 \\
\hline duties 78:14 & educators & 188:16 & 134:10 189:20 & 161:7,8 162:2 \\
\hline dying 210:23 & & effort 101:2 & 190:1 208:21 & epilepsy \(215: 18\) \\
\hline dysfunction & effect 32:12 & 232:16 & endocannabin... & 216:13 226:10 \\
\hline 109:9 & :24 71:5 & efforts 159:23 & 188:23 & episode 193:22 \\
\hline dysthymia 67:8 & 75:2 80:4 86:2 & 170:8 & Endocrine 60:2 & 193:24 194:1,3 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline episodes 63:1 & evening 106:23 & 211:3 & 8:20 33:9 63:4 & extra 178:13 \\
\hline 71:13 & event 207:10,13 & exactly 7:17 & 116:13 136:8 & extract 33:13 \\
\hline epithelial 189:6 & 209:12 & 32:15 81:14 & 136:15 159:16 & extreme 163:13 \\
\hline epithelium & events 23:23 & 91:9 167:4 & 166:20 183:23 & 190:20 \\
\hline 189:1 & 93:20 237:7 & 179:16 & 191:10 192:8 & extremely 33:19 \\
\hline equal 218:12,16 & eventually & examined & 215:7 & 33:19 116:14 \\
\hline ER 193:7,13, 20 & 103:13 107:22 & 132:10 & experienced & extremities \\
\hline ergons 191:15 & 195:16 & example 48:24 & 58:21 110:6 & 36:19 \\
\hline Eric 2:4 91:24 & everybody 7:11 & 213:24 218:12 & 132:23 162:18 & eye 97:24 103:3 \\
\hline Erickson 143:6 & 56:2,3 106:14 & examples 110:5 & 167:2 170:17 & 104:22 187:1 \\
\hline 197:11 226:23 & everybody's & excellence & 192:1 208:9 & eyes 34:3 110:4 \\
\hline errands 187:16 & 140:4 & 113:10,11 & 209:12 & 130:15 154:11 \\
\hline 188:15 & everyday 187:16 & excellent 72:21 & experiences 8:15 & 178:15 210:21 \\
\hline escalating 151:4 & everyone's 15:4 & 163:20 176:3 & 8:22 19:18 & \\
\hline especially 75:3 & 16:13 76:16 & excessive 20:1 & experiencing & F \\
\hline 76:16 110:11 & evidence 5:15,17 & 64:16 & 207:10 218:18 & F 35:6 \\
\hline 143:13 189:13 & 5:23 6:13 8:4 & excluded 35:19 & experiments & F-a-r-a-h 18:15 \\
\hline 212:21 236:10 & 14:23 16:20 & exclusive 196:2 & 75:21 & F-r-i-e-d-m-a-n \\
\hline 236:12 & 17:20 18:12,21 & exclusively & expert 59:23 & 220:16 \\
\hline essence 133:22 & 26:23 27:10,16 & 64:21 & expertise 52:18 & face 43:2 45:2 \\
\hline essentially & 28:2,3,5 32:17 & excuse 120:1 & 115:17,23 & 99:23 211:8 \\
\hline 136:19 137:5 & 39:13 43:6,14 & 120:21 147:18 & experts 149:18 & Facebook \\
\hline 219:15 & 44:4 45:10,18 & 214:15 & explain 205:13 & 104:23 106:20 \\
\hline established & 46:10,13 47:1 & executives 224:9 & explained 63:19 & facet 168:6 \\
\hline 49:21 184:20 & 47:4,9,10 & exercising 166:8 & explaining 25:18 & 200:19 201:3 \\
\hline 209:15 & 50:22 52:21 & exhausting & explanation & facial \\
\hline estimate 201:11 & 54:2,10,18,23 & 100:20 & 183:8 233:10 & facility 85:1 \\
\hline estimated 181:2 & 55:3,3 64:4 & exist 46:4 80:8 & exposed 122:17 & facing 119:19 \\
\hline 201:7 & 65:15,24 73:8 & 134:11 179:18 & exposure 64:14 & fact 15:16 22:18 \\
\hline estimates 204:7 & 75:16,24 77:15 & existence 59:2 & 207:16 & 23:1 52:20 \\
\hline estrogen 170:18 & 77:23 78:21,24 & 241:13 & expressed 67:4 & 54:12 75:13 \\
\hline et 29:6,22 30:10 & 88:12 122:3,6 & existing 4:7 5:10 & expressing 88:2 & 79:1 153:22 \\
\hline 30:16 31:4 & 122:7,11,18 & 78:5 & expressions 98:1 & 175:22 184:19 \\
\hline 53:6 66:24 & 139:18 148:4 & exit 211:24 & extend 229:1,5 & 197:18 224:7 \\
\hline 67:1 73:22 & 168:18,21 & expand 38:13 & 237:9 & 228:4 \\
\hline 75:21 109:8 & 171:23 173:22 & 235:7 236:19 & extended 117:4 & factor 161:21 \\
\hline 111:17,18,18 & 173:22 177:9 & expands 8:24 & 149:9 & 178:7,12 \\
\hline 111:19 136:13 & 177:11,14 & expansion 235:8 & extending & factors 191:3,8 \\
\hline 139:6 145:20 & 178:14,17 & expect 41:1 & 165:12 & facts 128:19 \\
\hline 153:2 161:8 & 179:2 191:17 & 68:19 117:20 & extension & faculty 10:23 \\
\hline ethnic 158:2 & 199:15 212:14 & 133:11 & 237:19,22 & fail 152:21 \\
\hline euphoria 72:22 & 214:17,18 & expected 63:5 & extensive 29:2 & failed 76:5 82:13 \\
\hline euphoric 61:14 & 216:21 234:1 & expecting 151:1 & extensively 27:9 & 125:23 126:2 \\
\hline evaluate 64:1 & evidence-based & 221:14 & 198:7 & 127:15 204:19 \\
\hline 78:18 159:5 & 46:3,5 & expensive 223:7 & extent 44:12 & fails 94:9 \\
\hline Evanston 10:2 & evolving 127:23 & 223:8 226:5,12 & extinction 209:3 & failure 113:24 \\
\hline Eve 194:1 227:7 & exacerbating & experience 8:19 & 209:7 & failures 130:4 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline fainting 109:5 & 70:11 75:22 & 210:3 & findings 43:6 & 204:14 208:17 \\
\hline fair 165:12 & 96:20 142:10 & fell 124:12 & 52:13,15,20 & 211:18 215:18 \\
\hline 238:14 & 206:2 242:8 & Fellowship & fine 2:5 7:10 & 221:15 230:18 \\
\hline fairness 34:8 & favorable 75:15 & 144:21 & 10:16,17 14:12 & 235:10,12,14 \\
\hline fall 36:12 86:23 & 152:13 & felt 36:18 38:1 & 15:20 41:3 & 237:4,10 \\
\hline 239:3 & FDA 108:20 & 179:7 188:6,13 & 44:1 49:18 & 241:14 \\
\hline falls 87:9 & 113:1,4 117:20 & female 20:17 & 56:22 57:1 & fiscal-year \\
\hline false 61:21,21 & 119:6 139:15 & females 181:22 & 60:18,21,23 & 230:20 \\
\hline familiar 161:1 & 139:19 & Fentanyl 130:7 & 70:19 77:4 & fit 101:17 \\
\hline 206:16 207:2 & fear 63:1 64:11 & 136:6 151:5 & 95:20,24 96:4 & 189:23 \\
\hline 217:22 220:21 & 64:16 193:22 & 160:20 162:9 & 96:7,15 125:2 & fits 100:16 \\
\hline families 99:20 & fearful 136:24 & ferret 204:17 & 125:6,16 142:7 & five 6:2 12:2 \\
\hline 100:3 101:7 & fears 135:10 & festivals 93:21 & 159:20 160:14 & 19:24 23:7 \\
\hline 119:8 120:13 & Federal 85:1 & fever 109:4 & 172:14 173:12 & 36:12 41:21 \\
\hline 153:1 & 161:17 162:14 & fewer 192:3 & 173:16 174:2,4 & 43:5 45:21 \\
\hline family 35:7 & 163:1 & fibromyalgia & 174:10 175:12 & 57:10 105:5 \\
\hline 93:19 101:18 & Federally 163:1 & 58:18 184:2 & 176:24 177:7 & 117:17 123:20 \\
\hline 118:1 120:23 & FedEx 200:24 & 189:18 192:20 & 177:21 178:20 & 125:10,15 \\
\hline 166:23 181:23 & feedback 108:1 & 218:18 & 190:8,14 & 148:7 162:11 \\
\hline 184:14 191:8 & feeding 117:1 & field 27:19 & 200:23 206:16 & 225:23 226:16 \\
\hline 193:18 & feel 5:22 22:1,24 & 158:20 162:7 & 220:12 222:12 & 226:16 \\
\hline famous 111:8 & 23:11,16,19,21 & fighting 159:21 & 233:5,9,12 & fixed 104:23 \\
\hline fan 69:23,24 & 27:12 28:23 & fights 25:13 & 235:16 239:17 & fixture 71:12 \\
\hline far 5:7,10 32:11 & 35:20 46:17,21 & figured 100:24 & 239:19 242:4 & flack 205:10 \\
\hline 36:2,6,23 38:6 & 46:24 48:4 & figures 226:17 & finger 20:16 & flapping 104:1 \\
\hline 117:23 122:6 & 49:20 50:3,7 & figuring 62:21 & 25:11,12,15 & flares 184:5 \\
\hline 122:10 153:15 & 88:13 150:19 & fill 70:9 225:20 & fingers 20:14 & flashbacks 37:7 \\
\hline 158:12 226:14 & 152:21 153:13 & filled 151:6 & finish 198:14 & 38:4 207:12 \\
\hline 226:19 233:4,5 & 162:1,18 & final 52:11 & fire 36:21 & 211:4 \\
\hline 238:24 & 185:16 194:1 & 115:14 116:2 & 111:14 & flat 91:5 \\
\hline Farah 2:11 3:14 & 211:16 212:1 & 240:13 & first 6:5 12:18 & flew 101:11 \\
\hline 17:14 18:9 & 236:24 & finally \(37: 20,24\) & 17:2 18:13 & flier 169:19 \\
\hline faster 171:13 & feeling 23:10 & 104:20 144:21 & 25:10 28:19 & flies 45:2 \\
\hline 200:7 206:19 & 61:23 210:18 & 188:2 195:23 & 30:23 36:15 & flight 110:9 \\
\hline fasting 30:20 & 236:23 & financial 228:13 & 37:22 38:2 & flood 99:11,14 \\
\hline fatal 109:13 & feels 20:21, 23,23 & 229:20 & 39:11,15 44:4 & floor 55:22 \\
\hline 113:23 126:16 & 20:24,24 23:1 & financially \(37: 13\) & 45:18 46:15 & flower 41:7,10 \\
\hline fatality \(28: 13\) & 36:20 & find 15:7 32:5 & 58:22 59:14 & 107:19 122:13 \\
\hline 47:8 & feet 37:24 & 52:7 62:12 & 60:20 62:5 & fluid 182:16 \\
\hline father 98:12 & 146:14 & 77:2 79:22 & 71:23 78:23 & flux 210:17 \\
\hline 100:12 197:19 & Feliza 2:12,13 & 83:20 89:19 & 79:20 93:10 & fly 16:6 \\
\hline fatigue 78:11 & 3:5,8,11 17:9 & 107:14 135:18 & 94:11,18 98:19 & flyer 200:5 \\
\hline 79:7 & 17:11 34:12,21 & 138:4 159:15 & 98:24,24 & focus 98:10 \\
\hline fatigued 166:19 & 34:22 35:2 & 188:8 189:23 & 102:24 114:12 & 106:3 172:1 \\
\hline fault 210:13 & 57:15,19 94:13 & 232:24 & 143:18 149:20 & 182:3 \\
\hline favor 12:13 16:1 & 100:6 143:4 & finding 162:20 & 156:4 157:5 & focused 66:15 \\
\hline 53:8 55:10 & 186:4 194:18 & 190:24 & 183:22 204:9 & 173:21 177:14 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline fogginess 151:17 & 98:7 122:7 & friction 201:21 & 221:11 237:1 & 158:3,8,21 \\
\hline folks 44:13 & 132:24 149:7 & Friday 23:6 & Furthermore & genetically 42:4 \\
\hline 54:14,15 63:13 & 156:16 170:8 & 36:14 51:16 & 118:3 & geneticist \\
\hline 74:23 121:15 & 179:6 183:1,2 & Friedman 3:15 & fuse 134:1 & 113:19 \\
\hline 177:5 & 185:11 187:24 & 8:14 126:14 & future 63:7,9 & genetics 191:2 \\
\hline follow 41:4 & 192:6 & 220:7,11,13,15 & 76:14 120:9 & gentleman \\
\hline 104:24 165:1 & Foundation & 220:15 223:22 & G & 215:13 \\
\hline 174:6 & 128:13 & friend \(37: 17\) & G & getting 20:4 \\
\hline followed 15:2 & foundational & 59:9 152:6 & G 185:6 & 33:4,4 37:2,7,9 \\
\hline following 12:18 & 217:22 & friendly \(14: 5\) & Gabapentin & 43:21 60:14 \\
\hline 14:24 93:3 & founding 197:20 & 222:6 & 148:14 160:2 & 104:2 147:9 \\
\hline 119:12 123:20 & four 19:11 23:7 & friends 93:19 & 162:9 163:13 & 149:6,22 \\
\hline 145:11,20,24 & 41:21 43:5 & 101:18 109:14 & gain 163:14 & 159:10 162:21 \\
\hline follows 116:16 & 57:10 66:11 & 110:6 112:3 & gains 171:19 & 171:13,20 \\
\hline food 20:1,5,12 & 103:16 124:10 & 120:24 184:15 & Galter 144:19 & 174:24 175:1 \\
\hline 24:1 116:19 & 124:16 128:15 & 192:7 211:18 & garnered 137:19 & 175:22,24 \\
\hline 181:7,13 191:4 & 162:16 181:20 & fright 110:9 & gas 180:23 & 176:17 208:3 \\
\hline foods 182:6 & 187:12 197:20 & front 6:1 43:5 & 181:11 182:6 & 225:14 \\
\hline 191:4 & 208:1 225:23 & 45:16 47:24 & gastric 183:2 & GI 184:17 185:5 \\
\hline force 139:24 & 226:16 & 76:4 140:5 & gastrointestinal & 185:14 \\
\hline forced 127:13 & four-year 101:3 & fruition 224:15 & 185:3 188:19 & give 5:2 8:14 \\
\hline 220:16 & fourth 133:24 & frustrated & gates 99:12,14 & 21:20,21 34:12 \\
\hline forget 241:23 & fracture 130:11 & 153:22 & gather 76:23 & 49:7,9,10 \\
\hline forgot 84:5 & 134:1 186:16 & frustration & 121:21 122:3 & 57:15 61:13 \\
\hline 106:7 & fragile 19:19 & 174:13 180:12 & gatherings & 90:13 92:3 \\
\hline form 33:14,14 & framed 86:6 & 180:15 & 58:24 & 94:2 100:21 \\
\hline 80:15 102:24 & Fran 111:18 & frustration & gears 57:18 & 104:4,5,5 \\
\hline 178:10 189:6 & France 150:4 & 180:18 & general 10:8 & 106:24 107:9 \\
\hline 200:14 204:12 & Francis 10:1 & fulfilling 78:14 & 19:22 61:1,6 & 107:21 113:23 \\
\hline formal 142:23 & free 22:1 163:14 & full 16:22 17:17 & 81:24 89:18 & 120:2,9 125:2 \\
\hline formally 91:1 & 163:17 212:1 & 31:15,18 33:2 & 136:21 145:9 & 143:14 152:22 \\
\hline 100:19 191:17 & 225:21 228:7 & 33:2,4 34:18 & 158:18 229:3 & 174:21 176:4 \\
\hline format 179:23 & Freedom 208:6 & 34:20 42:22 & 230:14 231:2 & 180:3 206:9 \\
\hline forms 212:21 & 208:6 & 84:5 89:1 & generalize 42:15 & 221:15 224:18 \\
\hline forth 164:14 & freely 219:19 & fun 71:21 & generalized 56:9 & 225:15 228:8 \\
\hline 177:18 179:7 & frequency & function 39:14 & generally 125:21 & 233:17 234:16 \\
\hline forward 8:9 & 191:19 196:11 & 59:4 68:1 & 126:1 170:5 & 234:17 \\
\hline 94:20 177:16 & 196:16 & 97:22 134:20 & 225:23 & given 47:10 \\
\hline 241:3 & frequent 37:8 & 137:23 184:23 & generated 155:7 & 59:14 67:2 \\
\hline Fosdick 168:11 & 169:19 200:5 & 194:10 & generating & 72:5 112:22 \\
\hline found 29:4,12 & frequently \(67: 15\) & functioning 23:2 & 229:12 & 113:2 118:22 \\
\hline 29:24 30:10 & 126:17 198:19 & 74:9,10 152:24 & generic 125:9 & 120:15 142:19 \\
\hline 31:4,8 43:14 & fresh 178:15 & 181:5 & 157:14,17,19 & 171:24 205:19 \\
\hline 62:12 65:2 & freshman 211:5 & funded 128:7 & 157:20 & 207:22 209:19 \\
\hline 66:15,21 67:1 & Frey 109:8 & further 93:8 & generically & 212:6 236:9,16 \\
\hline 67:5,6 68:17 & 111:18 113:12 & 111:16 123:24 & 41:21 & 236:21 \\
\hline 68:17 78:1 & fricking 104:9 & 129:21 206:7 & genetic 157:18 & gives 172:7 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 223:17 & 11:18 12:18 & 217:16,17 & grand 103:24 & 50:21 154:12 \\
\hline giving 75:5 & 17:5,8 25:10 & 224:3,11 & 104:1 & grown 58:1 \\
\hline 101:13 109:11 & 26:16 27:7,15 & 225:12 227:22 & grants 128:8 & 230:1 \\
\hline 192:18 234:16 & 29:17 42:24 & 228:5 231:6,18 & granular 65:11 & guaranteed \\
\hline glass 110:2 & 43:3,19,21 & 231:19,22,24 & granularity & 107:9 \\
\hline glimpse 120:16 & 44:9 45:17 & 232:2 233:6 & 60:15 & guard 103:18 \\
\hline globally 119:2 & 46:11 47:17 & 238:2,12 239:9 & grass 118:18 & guess 40:17 \\
\hline 219:17 & 48:22 49:6,9 & good 5:9 7:10 & 122:2 & 46:23 65:20 \\
\hline glucose 30:17 & 49:10,17 55:4 & 10:10,24 11:4 & gray 167:11 & 71:23 177:23 \\
\hline glut 136:10 & 57:17,23 58:12 & 11:10 13:7 & great 8:17,23 & 212:12 231:10 \\
\hline glycemic 44:8 & 61:8 64:5 & 16:11 24:11 & 30:9 43:20 & guide 6:24 \\
\hline go 5:6 13:7 & 67:20 68:14 & 42:12 46:19 & 54:23 70:20 & guidelines \\
\hline 14:10 28:24 & 69:2,6,13 72:1 & 54:2 59:9 & 90:23 99:5 & 126:19 150:20 \\
\hline 30:24 36:19 & 72:5 76:10 & 70:14 91:11 & 102:1,3 113:20 & guinea 100:24 \\
\hline 37:11 46:10 & 78:8 82:2,11 & 97:6 107:20 & 116:3 122:5 & 184:21 \\
\hline 54:9 57:17 & 85:5 88:16 & 138:13 153:12 & 138:9,20 & Gulf 208:8 \\
\hline 60:20,20,22 & 89:24 90:2 & 154:8 155:4,24 & 147:19 151:12 & gummies 105:21 \\
\hline 61:7 62:2 79:7 & 92:11 93:4 & 165:14,15 & 171:16 218:17 & 105:23 \\
\hline 82:19 85:13 & 94:21,23 95:16 & 166:8 190:15 & 222:10 223:22 & gun 162:2 \\
\hline 93:20 96:7 & 97:7 104:19,19 & 196:11 199:15 & greater 62:23 & Gupta 111:11 \\
\hline 97:6 105:4,11 & 106:6 107:11 & 200:8 204:13 & 131:2 & 111:17 113:15 \\
\hline 107:13,22 & 107:14,17,18 & 206:22 215:9 & greed 227:18 & gut 189:15 190:1 \\
\hline 113:10,13,17 & 107:20,23 & 218:24 226:23 & green 55:15 & guy 200:24 \\
\hline 128:11 133:23 & 111:14,15 & Google 116:7 & 80:10 163:11 & 206:17 \\
\hline 135:9 136:5 & 113:18,19 & gotten 176:14 & grew 222:1 & guys 102:8 \\
\hline 138:24 146:8 & 120:16 123:7 & governing & groin 146:6 & 105:8 107:20 \\
\hline 153:1 155:23 & 123:15,18 & 161:11 & ground 123:5 & 207:2 209:15 \\
\hline 159:13 163:17 & 124:7,11 & government & groundbreaking & 216:4 233:3 \\
\hline 164:19 176:16 & 125:11 129:16 & 106:9 119:10 & 120:14 & gynecologic 9:23 \\
\hline 178:3 179:24 & 132:15,16 & 139:22 162:14 & groundswell & Gynecology \\
\hline 193:7,13,16,20 & 139:21 141:8 & Governor & 224:10 & 10:3 \\
\hline 203:16,21 & 141:21 143:5 & 228:23 230:14 & group 6:18 & \\
\hline 205:6 219:18 & 153:19 156:4 & 231:5 236:12 & 29:11 31:7 & H \\
\hline 227:15 239:11 & 158:9 163:7 & 237:24 239:10 & 53:24 83:18 & H 3:18 \\
\hline 241:3 & 164:7,14 & Governor's & 84:23 92:6 & H-a-l-1 118:13 \\
\hline goal 118:1 120:4 & 167:13 175:23 & 177:3 228:20 & 95:6 101:6 & H-a-r-o-u-t-0-... \\
\hline goals 218:6 & 176:2,6 177:24 & 229:5 231:15 & 107:22 108:11 & 149:3 \\
\hline God 107:19 & 178:8 180:1 & 231:19 235:3 & 118:16 136:16 & H-i-g-e-n-s \\
\hline 152:20 & 183:23 184:14 & 237:3,6,17 & 145:4 147:24 & 108:10 183:22 \\
\hline goes 30:22 53:12 & 185:17 186:7 & grace 201:17 & 155:8 161:24 & 192:17 \\
\hline 53:13,15 99:19 & 193:18 195:16 & 203:22 & 179:8 199:12 & H-o-g-e-n-d-0... \\
\hline 103:22 123:22 & 198:19 199:19 & gradually 20:6 & 199:23 & 31:4 \\
\hline 123:24 133:19 & 200:6 201:24 & Grady 120:22 & groups 135:20 & habits 166:8 \\
\hline 162:6 163:16 & 203:8,11,16,17 & gram 223:2,2 & 139:19 156:15 & half \(22: 846: 23\) \\
\hline 175:21 228:19 & 203:21 204:15 & 224:21 & 161:13 181:20 & 102:21,22 \\
\hline going 5:13 6:2,4 & 204:23 209:15 & grams 20:12 & grow 110:12 & 104:15 106:22 \\
\hline 7:15 8:15 & 212:12 215:24 & 64:24 & growing 23:8 & 115:5 118:15 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 185:21 208:2 & harm 47:23 & 13:6,6 15:17 & 138:2 145:5 & 108:7,8,9,9 \\
\hline Hall 2:18 94:15 & harmful 119:20 & 16:9 18:7,8 & 163:5 176:6 & 111:6,24 112:2 \\
\hline 114:5 118:11 & 186:23 & 23:14 24:11 & 182:17 183:13 & 113:3,7 183:17 \\
\hline 118:12,12 & Harmony & 35:14,17 40:21 & 187:5,9,23 & 183:19,21,21 \\
\hline hallmark 202:4 & 218:13,16 & 43:11 53:20 & 188:1 196:21 & 189:17 192:15 \\
\hline hammered & Haroutounian & 65:14 66:23 & 199:22 209:6 & 192:16,16 \\
\hline 237:23 & 149:3 & 69:18 90:7 & 210:12 219:13 & high 23:22 42:9 \\
\hline hand 206:8 & Harvard 149:18 & 96:13 108:4 & 228:1 231:10 & 42:11 48:23 \\
\hline 243:11 & 152:15,19 & 123:6 143:12 & helped 21:4 22:9 & 54:14 84:20 \\
\hline handful 153:16 & hat 190:9 & 150:14 177:6 & 30:1,2 130:14 & 111:9 117:15 \\
\hline hands 5:8 37:23 & hate 45:9 53:21 & 239:5,12 240:1 & 130:15 154:5 & 126:12 129:23 \\
\hline 146:12 200:18 & 59:11 133:19 & heard 4:10 12:4 & 187:20 191:21 & 133:7,9,13 \\
\hline hang-up 177:9 & 222:15 & 12:5 28:17 & 211:14 215:19 & 134:13 148:4 \\
\hline happen 52:3 & hats 144:16 & 58:5,9 78:15 & 216:11,20,24 & 182:6 212:16 \\
\hline 133:8 134:17 & Heachache & 127:18 143:19 & 217:8 221:18 & 218:11 224:18 \\
\hline 155:6 221:14 & 196:10 & 163:2 198:15 & 221:19 & 226:11 \\
\hline 238:10 241:18 & head 171:18 & 203:15 & helpers 122:24 & higher 23:18 \\
\hline happened & 190:19 206: & hearing 1:3,9,13 & helpful 52:22 & 62:15,23 65:3 \\
\hline 210:24 237:8 & headache & 4:1,4 9:9 13:9 & 61:12 148:3 & 67:19 80:16 \\
\hline happening & 190:17 191:19 & 14:19 52:3 & 220:6 222:7 & 181:21 216:1 \\
\hline 170:10 223:23 & headaches 22:22 & 62:5 66:18 & helping 26:12 & 220:22 226:10 \\
\hline 234:8 & 199:16 & 96:18 176:22 & 78:15 110:16 & Highland 35:16 \\
\hline happens 8:13 & heads 37:15 & 242:11 243:6 & 154:3 184:3 & highly 66:7 \\
\hline 36:19 62:19 & headway 70:14 & hearings 95:22 & 219:22 226:5 & highs 22:8 24:3 \\
\hline 151:5 180:16 & healing 17:10 & heart 99:19 & 241:2 & Hill 147:21 \\
\hline 195:21 221:9 & 35:3 118:20 & heartbeat 109:3 & helps 25:19 58:2 & Hip 202:22 \\
\hline 228:17 237:21 & 186:9 & heartened 157:4 & 76:15,16 119:4 & hips 200:18 \\
\hline 238:8 & health 1:9 6:18 & heavily 67:9 & 154:23 184:15 & historian 215:10 \\
\hline happier 159:17 & 6:22 10:21 & 68:9 74:22 & 185:12 195:19 & historical 197:18 \\
\hline happiness 68:2 & 11:2 45:1 67:4 & heavy 67:10 & hemoglobin & history 26:14 \\
\hline happy 4:24 23:1 & 67:21 73:23 & 74:15 207:15 & 30:20 44:9 & 27:16 132:9 \\
\hline 38:2 100:21 & 74:8 83:24 & Heed 17:6 & 51:13 & 165:20 181:23 \\
\hline 180:11 & 86:13 96:5 & heels 23:8 & hemp 19:6 31:20 & 191:9 \\
\hline hard 5:16 21:18 & 127:2 131:4 & held 1:13 201:9 & 32:3,22 54:12 & hitting 156:14 \\
\hline 58:16 73:5,21 & 170:2 171:21 & 243:7 & 80:14 112:1 & HIV 10:9 218:19 \\
\hline 76:23 88:20 & 172:12 173:6 & hell 49:8 & hereunto 243:10 & \(\boldsymbol{\operatorname { h o g }} 72: 23\) \\
\hline 110:13 117:3 & 173:10 181:24 & Hello 5:20 & hernia 146:4 & Hogendorg 31:3 \\
\hline 156:23 167:8 & 195:14 207:9 & helm 176:19 & hey 80:18 & hold 7:13 35:10 \\
\hline 175:11,20 & 229:9,18 & helmet 103:16 & 107:13 159:12 & 36:20 47:2 \\
\hline 223:8,13 & 230:13 & help 19:16 30:3 & Hi 34:15, 20 35:2 & 85:11 114:19 \\
\hline 224:24 238:23 & healthcare 10:21 & 52:5 71:2 & 57:22,24 & 128:14 142:21 \\
\hline 238:23 & 165:19 221:4 & 76:11 83:5 & 118:12 183:21 & hole 210:20 \\
\hline hardship 223:15 & 222:3,4 224:8 & 87:18 98:9 & 186:6 & home 58:14 \\
\hline 234:15 & healthier 59:10 & 104:14 108:13 & hiding 183:19 & 101:9 107:22 \\
\hline hardships & healthy 20:5,11 & 110:14 130:16 & 211:11 & honest 172:22 \\
\hline 223:19 & 119:13 209:4 & 130:19 132:15 & Higens 2:16 3:4 & 173:17 226:15 \\
\hline Harley 218:13 & hear 4:12 12:18 & 132:17 133:2,2 & 3:7 94:14,15 & honesty 59:11 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline honor 209:18 & household & 183:7,11,14,15 & 196:6 201:9,12 & 175:16 177:13 \\
\hline hope 11:19 16:6 & 167:14 & 184:4,5 186:20 & 201:16 208:12 & 221:5,24 \\
\hline 37:19 59:15 & housekeeping & 187:14,15,22 & 208:15 209:18 & imposed 163:1 \\
\hline 123:9 145:15 & 9:3 & 188:1,11 & 210:9 212:4,22 & impression \\
\hline 163:2 172:8 & huge 32:7 42:2 & 189:18 190:4 & 229:17 230:3 & 86:18 \\
\hline 174:6 176:1 & 67:24 101:10 & ice 146:12 & 236:4 243:6 & impressive 26:8 \\
\hline 178:11 217:8 & 136:10,10 & icky 20:23 & Illinoisans & improve 115:3 \\
\hline 233:1,3 & 150:23 161:6 & ICU 50:13,14 & 201:10 204:4,7 & 152:23 233:20 \\
\hline hopefully 4:16 & 175:24 193:21 & idea 155:24 & illness 37:2 90:6 & improved 19:22 \\
\hline 8:24 82:1 & 196:5 213:22 & 213:13 220:11 & 195:1 219:23 & 38:10 59:8 \\
\hline 194:11 & 214:1 232:2 & ideals 154:13 & illnesses 196:2 & 101:8 148:12 \\
\hline hoping 124:14 & hugest 177:9 & identified & imagine 99:21 & 184:12 \\
\hline 224:2,5 & human 32:5 & 208:17 & 146:11,14 & improvement \\
\hline Hopkins 197:20 & 53:18 65:2 & idly 196:7 & 204:11 & 30:20 86:13,15 \\
\hline hops 80:9 & 75:14 208:20 & IDP 235:2 & imagining & 116:16 154:17 \\
\hline hormonal & humans 29:18 & IDPH 53:14 & 210:22 & improvements \\
\hline 191:12 & 30:9 64:23 & 174:6,19 175:3 & Imitrex 194:5 & 113:20 \\
\hline hormone 170:16 & hundred 81:13 & 175:20 201:14 & immediately & in-patient 89:15 \\
\hline hormones & 151:1 173:15 & 238:22 & 15:7 36:15 & 109:17 \\
\hline 170:19 & 225:24 & II 6:9 30:16 & 101:15 & inadvertently \\
\hline horrible 26:17 & hundreds & 38:21 45:5,14 & immune 30:1 & 158:24 \\
\hline 98:14 130:1 & 137:18 146:15 & 53:6 139:12,14 & 43:16 185:8 & inaudible 38:5 \\
\hline horrific 109:1 & 172:3 & 140:1,2 & immunodefici... & 241:21 \\
\hline 109:16 112:17 & hurdle 116:2 & III 139:12,14 & 113:15 & inch 195:10 \\
\hline 185:15 & hurt 36:17 & IL 1:16 & immunological & incidence 29:8 \\
\hline hospital 10:2 & husband 103:21 & ill 150:7 218:4 & 112:9 & 145:23 \\
\hline 88:5 103:23 & 120:22 & illegal 48:7,11 & immunosuppr... & inclination \\
\hline 113:12 144:17 & hydrous 193:8 & 48:13 & 30:2 & 75:15 81:4 \\
\hline 193:16 197:21 & hyperalgesia & Illegally 48:12 & impact 39:13 & 85:17 \\
\hline hospitalized & 151:17 & illicit 31:14 & 45:1 54:13 & include 52:16 \\
\hline 89:14 & hyperventilated & 44:11 136:4 & 55:2 193:21 & 108:23 109:4 \\
\hline host 203:6 & 59:3 & Illinois 1:9,11,14 & 199:1 & 146:20 170:20 \\
\hline hostility 98:20 & hyphen 124:18 & 9:17,18 10:2 & impacted 51:6 & 170:23 182:19 \\
\hline hot 114:1 146:15 & hypothalamus & 11:1 33:8 & 90:14,18 & 191:4,8 200:17 \\
\hline hour 63:3 193:5 & 134:12,14 & 39:24 98:23 & impair 46:11 & 202:7 207:11 \\
\hline 195:5 & hypothetical & 99:6 100:3 & impairment & 230:16 \\
\hline hours 19:24 20:4 & 86:7 & 101:19 104:17 & 41:16 97:21 & included 29:3 \\
\hline 20:11 119:8 & hypothyroidism & 107:7 119:1 & 166:21 & 44:5 84:14 \\
\hline 128:15 190:23 & 63:18 & 120:1 121:2,3 & impairs 97:17 & 145:12 147:22 \\
\hline 193:5 210:16 & & 127:22 129:5 & impart 133:17 & includes 218:3 \\
\hline 219:9 & I & 131:1,4 137:15 & implants 147:2,3 & including 25:23 \\
\hline house 4:19 38:1 & Ian 187:11 & 137:21 145:13 & implemented & 97:24 109:1 \\
\hline 58:16,24 104:3 & IBS 7:21 141:13 & 153:20 171:10 & 115:10 230:15 & 110:21 117:16 \\
\hline 117:4 186:15 & 180:21,22 & 171:14,17 & implying 189:2 & 166:7 209:3 \\
\hline 211:9 & 181:5,10,20,21 & 172:10 173:9 & important 7:14 & 231:21 238:20 \\
\hline housebound & 181:24 182:3,5 & 173:14 186:10 & 65:4 75:3 & inclusion 145:10 \\
\hline 170:13 & 182:9,20 183:6 & 187:11 195:24 & 80:13 159:3 & income 118:19 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline inconsistency & infantile 85:9 & injection 21:2 & 80:12 89:4,17 & 219:2,6 \\
\hline 91:4 & infection 83:22 & injections 147:1 & 153:3 159:22 & introducing \\
\hline inconsistent & 84:3 89:11,11 & injuries 125:24 & 161:18 189:14 & 202:20 \\
\hline 196:2 & 92:5,12 94:8 & injury 108:23 & 189:16 220:8 & introductions \\
\hline inconvenient & 154:7 & 197:9 & Interestingly & 9:4,11 \\
\hline 183:10 & infections 81:21 & insensitiv & 73:13 241:22 & intrusive 211:4 \\
\hline increase 28:16 & infectious 79:19 & 28:16 & interests 97:20 & invalidates 95:8 \\
\hline 134:5 188:23 & 79:21 82:18 & insomnia 186:21 & interior 110:3 & invitro 82:23 \\
\hline increases 22:22 & 85:16 154:7 & instance 126:4 & intermittent & involved 26:10 \\
\hline increasing & inference 28:4 & instances 58:13 & 134:23 & 131:16 149:15 \\
\hline 158:20 182:16 & 65:21 & 132:12 & Internal 10:9 & 175:3 229:17 \\
\hline incredible 8:16 & inflamed 111:13 & instant 61:17,19 & internally & 229:24 230:4 \\
\hline 174:22 & inflammation & 72:21 & 136:16 140:18 & 230:11 240:22 \\
\hline incredibly 38:3 & 33:24 185:6 & instantly 188:3 & 140:18 155:8 & involvement \\
\hline 115:11 & 188:24 189:2 & Institute 121:2 & interstitial 184:1 & 26:15 \\
\hline increments & 195:22 & 161:10 & 189:17 192:20 & involves 128:22 \\
\hline 20:13 & inflammatory & institution & intervention & IP 170:11, 12, 15 \\
\hline independent & 30:4 79:19 & 131:21 135:19 & 115:8 & 170:20 171:2,7 \\
\hline 212:1 & 111:12 & 156:24 157:2 & intestinal 181:8 & 171:23 \\
\hline Indianapolis & informally & insulin 19:16,20 & 182:24 183:2 & Iraq 212:20 \\
\hline 104:17 & 177:23 & 21:8,8 23:24 & 185:12 & Iraqi 208:5 \\
\hline indica 48:16,16 & information & 23:24 24:1,2,7 & intestine 180:22 & Irit 59:22 \\
\hline 48:21 & 11:9 91:7 & 24:17,22 28:16 & 182:17 183:6 & ironic 139:11 \\
\hline indicated 109:10 & 111:7,10 & 30:18,18,21 & intestines 181:6 & irregular 109:3 \\
\hline indicates 39:13 & 168:20 177:18 & insurance & 181:15 184:18 & irritable 13:2 \\
\hline indication 40:12 & 178:10 196:13 & 222:17 224:12 & 184:21 & 180:7,20 \\
\hline 135:5 & 224:11 229:12 & 228:5 & intractable 7:19 & 185:20 186:4 \\
\hline indiscriminately & 230:17 231:3,4 & intake 19:21 & 13:2 72:8 & 186:12 187:13 \\
\hline 49:6 & 231:7 & 24:7 & 92:11 123:23 & 189:11 \\
\hline individual 40:13 & informed 162:3 & integrally 209:2 & 124:16 129:14 & Irvine 111:11 \\
\hline 52:17 78:17 & infused 87:10,13 & Integrative & 136:13 141:9 & 113:15,18 \\
\hline 157:24 158:1 & 87:14,16,17 & 10:13 127:2 & 141:11,13 & isolate 92:2 \\
\hline 168:3 218:10 & ingested 86:22 & intended 76:21 & 169:18 170:1,9 & Israel 149:5 \\
\hline individual's & 87:2 & 129:1 & 170:11 171:4 & Israeli 152:2 \\
\hline 209:8 & inguinal 146:4 & intense 60:3 & 171:22 172:4 & 208:17 \\
\hline individualized & inhaled 81:23 & 61:6 63:1 & 172:17,24 & issue 76:22 99:7 \\
\hline 158:19 218:1 & 148:7 & 190:17 & 174:9 & issued 230:22 \\
\hline individually & inhibit 183:2 & intensity 148:12 & intrathecal & issues 74:23 \\
\hline 83:15 & inhibits 167:17 & 196:16 & 147:2 170:22 & 76:21 87:22 \\
\hline individuals & initial 204:21 & intent 168:20 & intravenous & 97:20 116:4 \\
\hline 56:14 73:24 & 214:17 218:4 & interact 97:18 & 88:6 146:22 & 137:24 \\
\hline 84:1 98:10 & 235:1 236:17 & 98:8 152:24 & intrigued 79:17 & item 13:8 14:21 \\
\hline 182:5 192:11 & initially 72:2 & interest 224:11 & intriguing 79:24 & items 9:3 116:20 \\
\hline induced 219:6 & initiate 162:15 & interested 65:13 & 189:23 & 237:13 \\
\hline industry 19:9 & initiated 126:19 & interesting & introduce 4:15 & IVIG 112:10 \\
\hline 137:20 226:18 & initiative 161:17 & 30:15 32:10 & 16:22 & \\
\hline 227:18,21,21 & injected 29:9 & 67:5 75:7 & introduced & J \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline J 186:11 & joints 200:19 & Kendall 111:18 & 202:14,22 & 136:7,8,17,23 \\
\hline J-a-r-e-d 97:11 & 201:3 & kept 85:5 & knees 200:18 & 137:4,18,21 \\
\hline J-o-s-e-p-h & joke 25:12 & Ketamine & knew 210:13 & 138:7,8,8 \\
\hline 124:18 & Joseph 3:15,16 & 146:23 & 211:22 & 139:22 140:17 \\
\hline JAMA 147:20 & 220:15 236:3 & Kevin 147:21 & know 4:24 7:8 & 149:21 150:1,7 \\
\hline James 2:6 16:18 & Josephine & key 159:8 239:1 & 7:17,18 9:7 & 150:9 151:5,9 \\
\hline 111:19 & 126:24 & Khadem 84:11 & 11:16 12:7 & 152:21 155:15 \\
\hline Janssen 119:19 & Josh 160:11,13 & kid 101:9 105:6 & 16:7,7,14 & 156:3 158:13 \\
\hline January 4:5 & Joshua 116:22 & kidneys 104:7 & 22:20 24:21 & 159:5,10 \\
\hline 102:23 179:13 & journal 27:22 & kids 31:10,13 & 27:2,9 28:19 & 160:13,14 \\
\hline 191:18 227:4 & 79:10,11 84:12 & 43:21 45:3 & 29:16 31:23 & 161:18,20 \\
\hline 239:21,22,24 & 84:21 147:19 & 107:10,21 & 32:6,8 33:5 & 162:8,8,13,14 \\
\hline 240:8 & 147:20,20 & 112:19 113:23 & 38:19,20 43:11 & 167:3,5 169:20 \\
\hline Jared 2:14,21,22 & 148:5 149:4 & 117:14 118:21 & 43:20 46:20 & 171:12 172:20 \\
\hline 3:3,6,9,10 & 188:20 & 121:18 & 47:4,6,22,23 & 172:21,23 \\
\hline 94:13,18 95:4 & journals 138:16 & kill 231:19 & 49:2 50:1,4,7,8 & 174:14 175:2 \\
\hline 97:10,11 141:1 & judgment & kills 126:16 & 51:4 52:22 & 177:5 185:23 \\
\hline 141:15 164:16 & 210:19 & 134:16 & 53:17,21 54:3 & 186:22 189:12 \\
\hline 164:17 165:15 & July 240:5,7 & kind 6:10 27:19 & 54:7,8,9,15 & 190:3,11 192:9 \\
\hline 169:18,23 & jump 213:7 & 60:14 73:17 & 57:1 60:6 61:3 & 193:11 194:12 \\
\hline 173:2 180:8 & jumping 110:1 & 86:10 87:7 & 61:4,16 62:18 & 196:9 198:24 \\
\hline 190:5 200:3 & 161:20 & 95:8 101:15 & 68:18 69:10 & 199:16 204:11 \\
\hline 206:13,22 & June 139:21 & 106:10 112:14 & 71:2,4,6 73:17 & 205:12 207:5 \\
\hline Jared's 212:14 & 179:13 230:21 & 121:24 123:14 & 74:21 75:2,6 & 215:2 220:8,20 \\
\hline Jesse 168:10,11 & justification & 174:16,18,22 & 75:10 76:7 & 221:9,12 222:5 \\
\hline Jill 111:19 & 52:16,19 & 178:17 180:15 & 79:13 81:13,16 & 222:6 223:3,11 \\
\hline Jim 11:10 13:14 & & 180:16 198:19 & 81:17,20,22 & 223:23 226:23 \\
\hline 60:19 163:6 & K & 222:2 223:12 & 82:6,7 86:4,9 & 227:13 228:12 \\
\hline 177:8 228:6 & K-h-a-d-e- & 227:10 231:7 & 86:24 88:19 & 228:13,15,19 \\
\hline Jim's 213:24 & 84:11 & 235:6,24 236:9 & 89:10,13 92:22 & 228:20 230:11 \\
\hline job 25:17 26:4,8 & K-u-r-f-m-a-n & 236:24 & 95:5 97:1 99:6 & 230:19 231:3 \\
\hline 46:19 101:18 & 215:16 & kindly 206:8 & 99:11,17 & 231:15,20,21 \\
\hline 154:8 161:7 & Kathy 1:23 & kinds 22:23 42:5 & 103:18 104:11 & 233:3,15,19,19 \\
\hline 211:20 & 243:4,17 & 42:16 112:20 & 104:11,13,14 & 233:20 234:12 \\
\hline jobs 238:20 & keep 5:18 6:1 & 121:15 220:22 & 104:18 106:7 & 234:15 235:19 \\
\hline Joe 8:14 222:12 & 20:20 29:16 & kitchen 117:6 & 107:11,13,15 & 235:20 236:13 \\
\hline Joel 143:6 & 36:9 45:20 & Knaus 2:7 9:21 & 107:19,23,24 & 236:15,21 \\
\hline 197:11 226:22 & 63:14 123:11 & 9:23 13:12 & 112:5 113:22 & 237:13 238:1,5 \\
\hline John 2:7 9:23 & 123:15 141:21 & 15:24 45:23 & 113:22 114:1,2 & 238:6 \\
\hline 197:20 & 165:2 179:22 & 47:12,15 & 122:17 126:14 & knowing 65:15 \\
\hline Johnson 1:23 & 209:20 234:14 & 105:24 142:9 & 129:16,17 & 98:2 184:9 \\
\hline 119:18,18 & 234:14 235:6 & 157:8,11,14,19 & 130:8 131:16 & knowledge 33:9 \\
\hline 243:4,17 & 238:12 239:2 & 158:11,15 & 131:21 132:2,5 & 82:9 127:23 \\
\hline Join 104:23 & 241:2 & 176:10,12,20 & 132:8,22 & 148:20 \\
\hline joint 79:5 & Keller 118:13 & 232:4,11 & 133:12,20 & knowledgeable \\
\hline 200:14,15 & 120:12,22,24 & knee 135:9 & 134:9,19,24 & 8:17 40:18 \\
\hline 202:14 221:2 & Keller's 119:5 & 146:2,3 163:10 & 135:1,2,3,9,18 & known 71:4 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 119:17 165:17 & leaky 189:15 & 40:6 53:12 & 213:14 218:6 & 76:18,20 78:1 \\
\hline 181:4 191:15 & leap 64:7 65:6 & 90:1 & 223:10 228:2,2 & 79:22 84:10 \\
\hline 207:1 & 65:21 66:17,18 & letters 135:21 & 228:3,11 & 111:17 127:24 \\
\hline knows 5:1 134:9 & 75:18 & letting 31:22 & 232:23 & 128:4 138:15 \\
\hline 150:17 & leaping 29:18 & 221:12 & life-saving 196:1 & 147:14 148:2 \\
\hline Kurfman 3:13 & 31:22 & Lev-Ran 66:24 & lifestyles 218:2 & 151:23 162:20 \\
\hline 215:14,16 & learn 222:8,9 & level 27:15 32:2 & lifetime 42:22 & 178:24 \\
\hline & learned 54:5 & 33:23 34:1 & 44:6 207:24 & LITIGATION \\
\hline L & 91:15 & 41:1 60:15 & 208:10 & 1:22 \\
\hline L 1:23 52:10 & lease 59:1 & 68:17 71:12 & lifted 90:12 & little 23:21 36:2 \\
\hline 243:4,17 & leave 5:1 58:16 & 72:4 78:16 & light 7:24 101:8 & 36:3 46:20 \\
\hline L-o-n-e 83:2 & 58:24 117:4 & 85:9 108:14 & 190:20 235:23 & 57:16 59:16 \\
\hline labeled 149:2 & 121:7 127:13 & 111:9 115:18 & likelihood & 64:6 66:21,21 \\
\hline labs 51:11 & 143:7 & 115:24 130:3 & 176:16 & 77:14 88:18 \\
\hline 132:20 & leaving 121:5 & 134:7,20 & limb 160:1 & 102:20 107:6 \\
\hline lack 27:10 47:8 & led 51:11 110:24 & 152:23 175:17 & limit 40:23 & 122:15 125:2 \\
\hline 78:23 88:11,12 & left 17:4 47:22 & 177:15 205:2 & 142:16 & 143:9 150:21 \\
\hline 117:1 166:19 & 54:14 126:2,5 & 219:7 223:12 & limitations & 150:21,22 \\
\hline 175:8 199:1 & legal 19:5 31:20 & 233:24 & 35:13 & 162:2 163:12 \\
\hline lacking 98:1 & 38:11 40:23 & levels 25:19 & limited 41:6 & 177:24 178:23 \\
\hline ladies 208:1 & 82:3 & 41:14 134:3 & 115:9 116:15 & 197:18 200:7 \\
\hline lady 41:9 & legally 212:4 & libido 166:19 & 175:21 196:3 & 200:23 201:5 \\
\hline land 219:16 & legislation 241:9 & license 229:24 & 207:14 235:5 & 203:1,2 206:21 \\
\hline Lane 214:12 & 241:20 & 230:9 & limits 117:2 & 212:12,13 \\
\hline Lange 4:19 & legislators & licensing 229:21 & line 34:10 160:6 & 223:13 226:13 \\
\hline large 6:18 33:18 & 118:20 & lie 180:12,18 & lines 28:6 163:8 & 230:19 238:2 \\
\hline 119:14 180:22 & Legislature & 191:1 & lining 167:9 & live 127:13 \\
\hline largest 6:12 & 178:20 228:23 & lies 180:15 & link 27:6 & 193:22 \\
\hline lasting 71:20 & 228:24 237:19 & life 23:9 36:13 & linked 122:8 & lived 171:15 \\
\hline lastly 84:18 & 237:23 238:7 & 37:6 58:18 & list 9:12 56:12 & liver 113:24 \\
\hline 118:11 & legitimate 43:4 & 59:7 67:2,23 & 56:15,16 95:16 & liver's 104:7 \\
\hline lasts 63:2 165:23 & legitimize & 68:3,6 70:22 & 114:16 115:1 & lives 94:6 120:16 \\
\hline late 150:22 & 160:22 & 73:24 74:3,6 & 164:15 171:5 & 212:5 \\
\hline 197:24 & lemon 80:9 & 74:14,18 93:21 & 172:5 177:20 & living 10:19 \\
\hline laugh 215:14 & lemons 80:8 & 101:22 115:4 & 178:19 179:9 & 127:18 133:17 \\
\hline laughing 98:18 & Leslie 2:2 8:12 & 117:2,24 120:4 & 214:8 218:20 & 134:21 135:8 \\
\hline lavender 80:9 & 8:21 10:11 & 120:23 148:13 & listed 139:7 & 150:17 163:19 \\
\hline law 40:23 56:5 & 27:13 65:21 & 150:2,2 152:23 & listen 106:16 & 195:12 \\
\hline 227:12 233:16 & 66:14 & 154:18 160:7 & 130:6,13 & locate 184:7 \\
\hline laws 121:6 & lessening 117:11 & 167:8 168:7 & 132:14 & lock 63:13 \\
\hline lawsuits 119:20 & lesser 44:12 & 184:13 185:21 & listened 173:24 & lockers 107:14 \\
\hline lead 110:9 & let's 93:2 96:13 & 186:19 187:6 & 214:6 & logs 19:4 21:6 \\
\hline 127:16 166:22 & 121:6 143:1 & 187:15 192:24 & listening 164:3 & 22:7 \\
\hline Leader 4:19 & 168:12 179:9 & 193:21 195:11 & literally 113:16 & Lone 83:2 \\
\hline leading 37:5 & 180:1 190:4 & 195:20,23 & literature 29:2 & long 10:21 20:11 \\
\hline 128:5 129:2 & 241:23 & 199:1 202:6 & 53:16 62:11 & 26:14 36:2,6 \\
\hline leads 75:14 & letter 39:18 40:3 & 207:20 212:2 & 68:1 73:20 & 38:6 127:21 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 149:1,14 & 195:13 198:24 & lunch 7:15,21,22 & 63:8 & 117:21 \\
\hline 154:19 226:15 & 212:18 & 8:1 12:4 117:3 & males 109:2 & marital 166:23 \\
\hline 237:22 238:2 & lot 6:16 27:14 & 123:14,15 & malignant 109:2 & mark 55:17 \\
\hline long-term 79:6 & 45:8,17 48:20 & 142:2 189:13 & MAMMA 102:1 & marked 3:20 \\
\hline 167:1 181:4 & 48:21 54:8 & lunches 141:23 & 118:16 122:2 & 64:10 \\
\hline longer 37:16 & 58:2 63:11 & Lupus 30:6 & mammausa.org & markers 51:8 \\
\hline 38:12 47:19 & 66:15 82:9,9 & Lyme 12:22 77:9 & 122:4 & market 222:22 \\
\hline 71:20 100:23 & 84:7,15 107:21 & 77:18,20 78:20 & manage 50:10 & Maryland \\
\hline 138:24 156:7 & 110:23 111:6 & 79:4,15 80:20 & 100:20 126:3 & 103:22 \\
\hline 171:11 181:10 & 112:3,5,9,16 & 80:20,22 81:2 & 126:22 127:8 & mask 28:13 \\
\hline 181:11 184:7 & 113:21,24 & 81:9 82:12 & 130:9,22 & masked 51:11 \\
\hline 188:6,14 211:7 & 122:5 129:17 & 200:2 & 132:17 134:3 & masking 47:7 \\
\hline 211:24 216:15 & 130:14 137:10 & Lyrica 160:2 & 147:13 161:14 & Masonic 9:17 \\
\hline 217:1 227:12 & 138:10 152:16 & & 183:14 & materialistic \\
\hline look 27:18,23 & 152:17 156:22 & M & managed 166:6 & 222:16 \\
\hline 29:23 39:23 & 162:24 172:24 & M-e-e-r-a 18:18 & management & matter 94:6 \\
\hline 66:16 79:20 & 175:2,21 176:6 & M-o-r-a-l-e-s & 43:15 126:6 & 164:24 179:21 \\
\hline 80:18,23 84:6 & 179:3,4,10 & 18:17 & 148:11 181:4 & Mayo 90:8,12 \\
\hline 88:8 89:18 & 189:13 194:12 & M.D 2:19, 20 & 186:18 202:8 & 91:16 97:15 \\
\hline 91:3,8 101:6 & 199:21,22 & main 30:12 & manages 20:19 & 180:20 190:16 \\
\hline 102:8 121:22 & 205:10 211:2 & 77:16 & managing & 207:8 \\
\hline 188:14 222:23 & 213:15 215:2,4 & maintain 66:8 & 134:23 161:8 & McCURDY 2:5 \\
\hline 238:14 & 215:6 221:9,14 & 175:17 & mandate 7:2 & 10:20,20 16:5 \\
\hline looked 29:7,22 & 224:10 227:17 & maintenance & 75:9 & 24:10 40:16 \\
\hline 30:3 50:14 & 228:5 231:11 & 25:20 & mandated & 53:2 55:8 \\
\hline 61:2 62:11 & 231:20 & major 70:17 & 155:11 & 65:18 68:14,16 \\
\hline 64:4 73:18 & lots 10:19 39:12 & 71:13 73:14 & manner 127:22 & 68:23 71:8,16 \\
\hline 74:7 77:1,2,22 & 130:18 227:13 & 86:13 165:18 & mannerisms & 71:19 72:23 \\
\hline 77:23 82:24 & Lou 4:19 214:12 & 195:6,6 & 175:18 & 73:15 76:17 \\
\hline 83:2,4,12 & loud 209:9 & majority 191 & March 150:20 & 85:22 86:21 \\
\hline 84:19 188:3 & louder 35:9 & 229:5,6 & 202:20 225:10 & 87:11,15 90:10 \\
\hline 232:7,13,13 & Louis 103:22 & makers 108:2 & marijuana & 93:12 95:10 \\
\hline looking 5:16 & love 6:8 43:11 & 176:19 & 30:17 38:10 & 118:8 121:9,13 \\
\hline 77:14 85:6 & low 23:20,21 & makeup 158:3,8 & 43:3,21 48:8 & 122:21 133:4 \\
\hline 158:18 161:13 & 48:18 218:11 & making 27:11 & 59:8 69:8 & 133:15 134:5 \\
\hline 189:24 231:6 & lower 24:6 41:1 & 28:23 46:12 & 100:14 101:8 & 138:20 149:14 \\
\hline looks 50:17 68:1 & 41:14,14,15 & 54:13 70:13 & 102:2,24 & 150:12 163:23 \\
\hline 206:16 & 65:4 71:12 & 112:18 142:16 & 104:16 107:11 & 175:13 215:9 \\
\hline loop 180:17 & 74:18 & 142:21 171:18 & 114:18 115:3 & 217:11 225:8 \\
\hline looped 79:3 & lowered 19:21 & 176:21 180:18 & 116:1 118:17 & 239:15,22 \\
\hline Lorace 109:18 & lowering 29:7 & 220:10 238:23 & 118:21 120:2 & 240:2,5,7,15 \\
\hline lose 118:5 136:5 & lowest 19:7 & 238:23 & 120:21 121:6 & 241:6,19 \\
\hline losing 37:14 & lows 19:23 22:9 & mal 103:24 & 137:20 139:6 & meal 24:5,6 \\
\hline 72:4 & 24:1,3 & 104:1 & 188:1 191:19 & meals 166:9 \\
\hline loss 103:3 & lucky 168:4 & malabsorption & 196:10 197:22 & mean 38:7 47:22 \\
\hline 166:24 & lulls 20:11 & 195:2 & 222:16 232:20 & 49:8,23 50:15 \\
\hline lost 36:12 165:6 & lump 61:4 & maladaptive & marijuana-rel... & 50:18 54:1,14 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 54:21 68:24 & 110:17 113:11 & 108:24 109:11 & 19:16,20 & mentioned \\
\hline 73:11 85:5 & 114:18 115:3 & 109:15 113:4 & 217:16 & 22:16,17 74:4 \\
\hline 86:6,12,18 & 116:1 117:22 & 126:15 128:22 & meeting 1:1 4:3 & 78:11 83:9,10 \\
\hline 87:4 96:6 & 118:17,21 & 148:15 151:6 & 14:9,20 30:23 & 119:23 152:2 \\
\hline 103:9 104:8,13 & 119:3 120:2,20 & 154:18,24 & 64:13 96:17 & 172:18 196:11 \\
\hline 107:21 132:21 & 121:6 125:20 & 158:5 182:21 & 142:5,8 177:7 & 199:17 \\
\hline 135:10 137:16 & 127:10,19,24 & 192:12 194:4 & 189:12 204:9 & merely 171:2 \\
\hline 137:17 138:7 & 128:8,17 129:4 & 217:2 & 204:14 235:1 & 202:9 \\
\hline 150:13 152:19 & 129:11 131:11 & medications & 236:17 238:21 & merit 205:9 \\
\hline 157:17 160:5 & 131:22,24 & 32:7 47:13,18 & 239:2 & mess 114:1 \\
\hline 178:1 204:10 & 132:9,20 & 61:10 70:21,23 & meetings 15:2 & messaging \\
\hline 218:19 226:12 & 135:10 136:21 & 70:24 71:1 & 15:12 27:10 & 237:11 \\
\hline 226:15 228:14 & 137:19 138:15 & 76:5 92:7 & 46:15 157:6 & met 177:15 \\
\hline meaning 67:1,9 & 143:14 144:11 & 109:15 146:20 & 214:16 & meta 148:6 \\
\hline 82:23 98:3 & 144:18 145:13 & 146:21,22 & meets 220:19 & 202:23 \\
\hline means 27:14 & 147:9,12,14,20 & 147:11 152:14 & Melanie 168:17 & metabolic 44:17 \\
\hline 121:17 134:23 & 147:24 148:3 & 170:21 182:8 & 168:19 & 109:12 113:9 \\
\hline 151:2,3 219:12 & 148:21,24 & 191:7,13 193:9 & Mellitus 12:19 & 193:2,12 \\
\hline 228:5 & 149:6 155:8 & 199:10 204:18 & 17:8 25:9 & 194:13 \\
\hline meant 204:5 & 156:21 157:12 & 211:3 223:10 & 45:14 57:3,9 & metabolite \\
\hline measures 154:22 & 159:1 161:19 & Medicinal 59:8 & melted 98:20 & 153:9 \\
\hline mechanism & 161:21 162:4 & medicine 5:12 & member 5:4 & methadone \\
\hline 43:15 & 162:17,22 & 10:9,13,15 & 17:12 115:20 & 160:19 170:21 \\
\hline Mechoulam & 165:22 166:1,5 & 18:23 21:21,22 & 115:22 122:8 & 228:8 \\
\hline 208:16,20 & 167:1 170:6 & 32:20 46:3 & 225:2,12,17 & methicillin 92:6 \\
\hline 209:1 & 171:6,8,10 & 47:24 54:24 & 226:2,4 & 92:7 94:8 \\
\hline media 120:15 & 172:1,1,9 & 59:17 79:11,13 & members 35:23 & Methicillin-R... \\
\hline 207:16 & 179:15 183:24 & 120:24 144:17 & 164:2 174:13 & 12:23 82:16 \\
\hline medical 1:1,5 & 184:3,5 185:17 & 144:19,21 & 174:14 180:2 & method 149:8 \\
\hline 4:7 5:14 6:19 & 186:17 191:18 & 145:6,8,9 & 207:14 & methods 238:5 \\
\hline 7:1,5 8:22 9:17 & 191:20 192:10 & 146:16 158:19 & membrane & mic 39:7 60:17 \\
\hline 9:19 10:12,18 & 192:19 193:19 & 161:10 167:16 & 148:14 151:14 & 72:24 102:13 \\
\hline 11:2,7,8 18:21 & 195:17 196:10 & 183:8,12 & 189:7 & 114:19 \\
\hline 19:8 26:11 & 196:17 197:1 & 187:23 188:11 & memory 209:3,3 & mice 29:8,9,12 \\
\hline 27:19 33:10 & 203:8 209:22 & 188:13 196:3,5 & 209:6 & 30:7 \\
\hline 35:9,18 37:18 & 217:19 218:8 & 197:19 216:1 & men 182:13,14 & Michael 2:5 7:9 \\
\hline 42:24 43:4 & 219:19 224:6 & 226:6,10 & 182:18 191:12 & 10:17 43:20 \\
\hline 46:5,6,10,13 & 229:22 230:1,6 & medicine's & 208:1,3 & 177:7 220:17 \\
\hline 49:12 52:1,10 & 230:23 232:20 & 226:8 & Mendoza 2:2 & 222:8,9 \\
\hline 52:16,19,22 & 232:20 236:5 & medicines & 10:11 71:9 & Michael's 72:5 \\
\hline 53:14 58:2,5,8 & medically 38:10 & 112:16 147:8 & mental 63:19 & 222:5 \\
\hline 58:17 60:10 & 87:13 & meds 24:19 & 67:4,21 68:4 & Michigan 152:5 \\
\hline 68:23 69:8 & medicate 194:2 & 104:10 109:19 & 73:23 74:8,13 & 152:9 \\
\hline 82:3 87:9,14 & medication & Meera 18:10,17 & 181:24 207:9 & microflora 83:19 \\
\hline 97:14 98:13,15 & 63:16 67:20 & 18:24 20:10 & mentally 37:12 & microphone \\
\hline 102:2 104:16 & 70:1 72:9 & 23:16 & mention 157:22 & 17:22,24 18:6 \\
\hline 108:11,17 & 107:6,8 108:21 & Meera's 19:3,12 & 164:7 197:17 & 21:14 25:3 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 35:10 144:6 & 207:21 208:13 & Mississippi & 239:15 240:17 & motion 12:1,6,8 \\
\hline middle 223:5 & mimic 70:3 & 84:24 & 240:19 & 13:10,12,16,19 \\
\hline midway 240:15 & mind 5:18 6:1 & misunderstood & months' 44:6 & 13:20 14:6,8 \\
\hline 240:16 & 29:16 30:19 & 241:9 & \(\operatorname{mood} 61: 19\) & 15:9,20 70:7 \\
\hline Midwest 1:22 & 45:20 63:14 & misuse 154:20 & 100:22 111:1 & 77:4 92:19,20 \\
\hline 132:2 144:24 & 68:8 75:19 & 154:24 & 111:15 166:18 & 95:12,15,20 \\
\hline 171:18 & 115:20 126:18 & mitochondrial & 195:17 & 96:13,15 140:3 \\
\hline migraine 13:3 & 138:7 209:20 & 109:6,9,12 & Moody 2:3 9:5 & 140:5,14 142:5 \\
\hline 141:13 143:8 & mindful 68:10 & 110:23 112:11 & 10:24 11:1 & 142:7,13,21 \\
\hline 190:5,17,22 & mine 18:2 21:15 & 193:2,11 & 13:24 14:4 & 205:20 242:4,5 \\
\hline 191:19 194:8,9 & 211:15 214:14 & mix 106:4 & 17:21 18:3 & motivation \\
\hline 195:18,21 & 225:17,17,18 & mixed 74:1 & 21:11,23 22:4 & 211:7 \\
\hline 196:10,16,21 & minimize 129:2 & 106:5,6 & 34:22 35:1,5 & mouth 9:22 \\
\hline 196:23 197:15 & 129:7,7 & mixing 87:22 & 35:10,12 38:16 & 83:16,18 \\
\hline 198:14,14 & minimizing & modality 147:17 & 40:4 51:24 & 102:15 187:1 \\
\hline 199:15 & 26:15 & mode 133:1 & 55:14 56:4,10 & move 16:8 17:13 \\
\hline migraines & minimum 166:2 & model 30:9 60:3 & 56:16,18,24 & 55:8 81:7 93:4 \\
\hline 186:21 191:1,4 & Minnesota & moderate & 58:7 87:8,12 & 101:19 121:1 \\
\hline 191:8,10,12,13 & 170:2 171:4,7 & 154:23 205:5 & 87:17 95:12,15 & 130:17 131:4 \\
\hline 191:16,21,23 & 171:11,13,15 & Modern 183:7 & 102:12 105:7 & 168:12,15 \\
\hline 191:24 192:3,3 & 171:20 172:11 & 197:19 & 111:5 114:19 & 177:15 186:4 \\
\hline 192:8,9,11,22 & 173:4,5,14,21 & modes 132:24 & 114:22 118:6 & 229:2 \\
\hline 193:1,4 194:4 & Minnesota's & modulating & 124:19 149:10 & moved 121:3 \\
\hline 194:13,19 & 171:6 172:1,9 & 158:1 & 168:16 169:1,9 & 181:7 211:8 \\
\hline 195:4,8 197:2 & 174:7 & molecules 84:12 & 176:4,8 228:22 & movement 36:22 \\
\hline 197:23 199:23 & Minnesotans & 188:22 & 229:16 239:20 & 175:9 182:11 \\
\hline 199:23 216:5 & 172:3 & mom 116:12 & 239:23 240:3,6 & moving 98:3 \\
\hline mild 85:7 154:23 & minor 33:1 & 211:9 & 240:8,12 & 123:6 158:18 \\
\hline mildly 187:19 & 145:22 & moment 36:21 & Morales 18:9,16 & 169:10 174:24 \\
\hline miles 173:15 & Minority 4:19 & 52:9 57:16 & morbidity & 195:10 241:2 \\
\hline Military 207:7 & minute 140:12 & money 227:18 & 133:18 & MRSA 12:24 \\
\hline 207:15 & 146:13 & monitor 49:22 & morning 7:10 & 81:10 82:15,18 \\
\hline Miller 2:4 10:5,5 & minutes 13:9,11 & monitoring 27:2 & 10:10,24 11:4 & 82:24 85:6,8 \\
\hline 39:10 41:13 & 13:16 14:8,19 & 27:8 31:15 & 11:10 12:3 & 85:17 87:23 \\
\hline 66:13 73:2 & 16:19 20:9,13 & 50:4,6 221:13 & 95:11 106:22 & 88:17 89:9,14 \\
\hline 77:5,13 89:23 & 34:9 57:6 63:3 & month 63:6 & 116:21 201:6 & 90:15 91:16,20 \\
\hline 90:11 91:9,11 & 91:1 94:17 & 109:21 191:23 & 202:3 & 91:22 92:4 \\
\hline 93:1 140:7 & 98:15 121:5 & 191:24 192:3 & morphine 228:8 & 94:7 \\
\hline 175:14 & 124:20,23 & 193:14 221:17 & mother 38:5 & Mt 217:19 \\
\hline milligram 19:9 & 125:1,11,15 & 225:10 226:1,2 & 101:5 108:16 & mucosal 185:11 \\
\hline milligrams & 142:17 144:2,3 & months 19:5,10 & 120:11 123:4 & MUELLER 2:3 \\
\hline 19:11 119:15 & 184:10 205:22 & 21:8 59:3 & Mother's 102:2 & multi-modal \\
\hline 215:22 216:17 & 206:10 & 103:3 105:6 & mothers 101:14 & 146:17 \\
\hline million 126:10 & missed 9:3 65:16 & 131:13 146:1,6 & 110:3 118:16 & multiple 11:14 \\
\hline 127:3,4 128:8 & missing 87:5 & 150:21 165:24 & 122:23 & 28:19 78:16 \\
\hline 137:18 166:12 & 122:19 & 166:2 193:13 & motility 182:24 & 93:5 124:4 \\
\hline 181:1 204:5,6 & mission 118:19 & 217:3 239:12 & 183:3 185:5 & 143:20 146:17 \\
\hline
\end{tabular}
\begin{tabular}{|c|c|c|c|c|}
\hline 157:21 162:5 & 163:11,18 & needed 107:3 & 104:15 198:18 & night 37:8,19 \\
\hline 162:12,21 & nation 209:19 & 193:20 203:23 & neurologists & 98:21,22 104:3 \\
\hline 164:18 187:19 & national 127:1 & 227:11 237:15 & 198:22 & 105:23 210:17 \\
\hline 229:16 230:10 & 139:18 161:2,5 & needle 26:16 & Neurology 199:2 & nightmares \\
\hline multitudes & 161:12,22 & 130:17 & neuromodulat... & 207:12 \\
\hline 216:24 & 196:12 & needles 227:14 & 185:2 & NIH 127:2 128:7 \\
\hline munchies 30:24 & natural 1:15,15 & needlessly 196:7 & neuropathic & 161:10 \\
\hline Mundane & 84:21 119:17 & needs 12:8 13:21 & 128:18 145:12 & nine 70:11 82:14 \\
\hline 167:13 & 185:4 186:23 & 23:9 52:3 & 145:18 146:8 & 85:4 94:9 \\
\hline Mupirocin 92:1 & 188:12 & 62:22 122:19 & 146:11 147:6 & Nirav 53:13 \\
\hline muscle 110:22 & nature 60:9, & 153:13 155:6 & 147:16,23 & Niyazov 113:19 \\
\hline 146:23 170:23 & 61:9 72:7 & 175:5 190:2 & 148:1,3,16 & nobody's 78:24 \\
\hline 184:18,19 & 90:24 101:16 & 197:4 218:5 & 151:12 163:9 & noises 209:9 \\
\hline muscles 36:18 & nausea 182:19 & 219:21 227:21 & 163:10 & nominated 9:19 \\
\hline musical 109:23 & 190:20 195:3 & negative 19:17 & neuropathies & non 120:17 \\
\hline muster 211:7 & 196:22 & 66:21 231:16 & 164:8 & 126:15 135:11 \\
\hline 234:1 & nay 55:17 57:10 & 231:17 & neuropathy \(13: 3\) & non-academic \\
\hline myriad 195:14 & 77:7 82:14 & negotiated 214:7 & 30:13,14 36:7 & 201:11 \\
\hline N & 94:9 & 215:4,5 & 37:4 79:6 & non-approval \\
\hline & & & 124:14 128:13 & \\
\hline 121 & 117:5 168:2 & 65:24 & 129:15 141:6 & non-cancer \\
\hline naive 121:9,24 & necessarily 88:3 & Neither 189:10 & 141:16 198:1,7 & 128:1 131:17 \\
\hline name 8:9 9:12 & 121:11 & neonatal 85:9,20 & 198:10 & non-diabetic \\
\hline 9:14,15 10:17 & necessary 151:2 & nerve 134:10 & neuropsychiat... & 45:7 \\
\hline 16:22 17:2,17 & 221:20 & 147:1 & 112:16 & non-obese 29:8 \\
\hline 18:9,14,16,17 & need 5:17 6:10 & nerves 185:11 & neurotransmit... & non-restorative \\
\hline 18:18 34:19,20 & 7:4 11:24 & nervous 36:2 & 208:22 & 166:18 \\
\hline 35:2,5,6,7 & 13:11 15:18 & 110:8 151:18 & never 27:5 53:20 & non-specific \\
\hline 97:11 102:10 & 19:21 25:23 & 215:15 & 67:12 100:13 & 84:13 \\
\hline 102:16 108:9 & 26:19,21 27:6 & Nestor 2:6 9:14 & 107:17,18 & non-treated \\
\hline 108:10 114:13 & 28:4 34:22 & 9:15 43:10 & 188:3,13 207:6 & 84:9 \\
\hline 114:14 118:12 & 43:23 46:3 & 48:1 57:11 & 210:24 221:1 & non-union \\
\hline 124:17 137:2 & 48:4,5 55:1 & 91:17 96:22 & new 6:3,5 12:2 & 130:11 134:1 \\
\hline 141:7 144:9,10 & 57:5 58:22 & 178:15 197:14 & 28:6 45:22 & non-users 74:19 \\
\hline 165:15 169:23 & 60:17 78:17 & 204:2 240:19 & 59:1 79:10 & noon 123:14 \\
\hline 178:4,6 183:21 & 91:8 95:1 96:1 & netted 226:18 & 85:4 101:22 & Norco 136:6 \\
\hline 183:22 186:11 & 110:14 123:7 & Network 202:22 & 108:18 116:22 & 151:4 155:19 \\
\hline 192:16 194:22 & 127:8 139:14 & neuro 111:7,9 & 126:19 131:22 & 156:1,3 160:19 \\
\hline 206:22 216:3 & 140:13 142:5 & neurochemistry & 137:1 139:5,9 & norepinephrine \\
\hline 236:3 & 144:5 154:9 & 157:23 & 147:13,18,19 & 158:14 \\
\hline name's 9:22 & 156:2 169:3 & neurodevelop & 172:7,8 217:18 & normal 20:7 \\
\hline 215:16 & 171:18 184:7 & 97:16 & 227:7 & 36:9 37:6 \\
\hline names 72:16,17 & 187:9 193:7,13 & neuroleptic & newborn 103:11 & 59:12 93:21 \\
\hline Naples 182:22 & 204:14 225:1,4 & 109:2 & newer 226:7 & 101:10 181:5 \\
\hline narcotic 153:7 & 226:10 227:20 & neurological & newspaper 99:6 & 181:16 209:4 \\
\hline 163:14 & 227:24 228:21 & 11:6 170:17 & nice 57:5 76:6 & 225:13 \\
\hline narcotics 135:7 & 229:4,6 & neurologist 11:8 & 108:4 220:4 & normally 103:2 \\
\hline
\end{tabular}
\begin{tabular}{|c|c|c|c|c|}
\hline north 128:11 & O & Officer 11:9 & 125:7,17 139:3 & online 101:5 \\
\hline 171:19 & OA 141:13 & officially 9:18 & 140:9,24 & 187:24 \\
\hline NorthShore & 200:13,18 & 139:7 142:4 & 141:14,20 & open 4:5 33:1 \\
\hline 6:22 10:12 & 201:3,8,10,15 & oh 12:7,10 24:20 & 142:10 143:6 & 43:19 56:13,21 \\
\hline Northwestern & 201:19,21 & 40:1 51:20 & 143:10,16 & 70:15 77:11 \\
\hline 6:21 10:9 & 202:1,4,7,10 & 60:18 92:20 & 144:1,4 157:7 & 82:17 130:15 \\
\hline 144:13,16 & 202:14 203:2 & 94:19 100:11 & 157:13 164:14 & 138:2 149:2 \\
\hline 159:1 160:11 & 203:17 204:7 & 108:3 114:9 & 165:3,14 & 230:24 236:9 \\
\hline notation 230:8 & OA's 200:13 & 118:7 140:15 & 168:11 169:5 & 236:10 240:9 \\
\hline note 25:16 53:4 & obese 29:14 & 163:7 174:4 & 169:22 173:7 & opened 213:7 \\
\hline 80:13 143:6 & observed 119:12 & 178:22 197:14 & 174:4 176:23 & 215:20 \\
\hline 238:11 & 148:9 & 199:20 205:14 & 183:20 190:4,4 & opening 44:20 \\
\hline noted 126:7 & obsessive-com... & 214:24 220:13 & 190:7 193:18 & 70:5 89:1 \\
\hline 127:18 & 63:21 & oil 31:20 32:3,22 & 194:20 196:9 & 99:11,14 \\
\hline notes 18:11 73:3 & obstacle 6:13 & 33:14 54:12 & 198:1,6,10,11 & opens 32:1,1 \\
\hline notice 1:14 & obstacles 162:21 & 80:14 101:6 & 200:3 201:2 & operate 130:2 \\
\hline 22:15 51:1 & 163:1,1 & 112:1 122:15 & 205:14,23 & operating 130:6 \\
\hline noticed 101:14 & Obstetrics 10 & 223:1,2 226:13 & 206:2,6,11,12 & operation \\
\hline 185:19 & obtain 121:1 & oils 41:6,8,8,11 & 206:20 208:24 & 133:24 185:3 \\
\hline Nottingham & obtained 83:15 & 43:22 50:1 & 215:13 217:9 & operationalized \\
\hline 202:12 & obviously 49:23 & 122:12 226:8 & 226:3 227:10 & 162:21 \\
\hline November 19:1 & 74:17 137:20 & ointment 89:8 & 227:11,12 & Operations \\
\hline 145:2 163:14 & 147:5 161:16 & okay 5:5 12:12 & 232:4 238:11 & 208:5 \\
\hline 236:22 & 198:18 & 13:19,23 14:7 & 240:11 & opiate 126:9 \\
\hline NSAIDs 170:24 & occasional 67:11 & 14:17,20 17:6 & old 36:23 45:6 & 127:17 128:6 \\
\hline 191:14 202:8 & 74:16 & 17:7,13,16 & 58:4 101:3 & 130:3 134:12 \\
\hline 202:21 203:4,5 & occupational & 24:14 25:2,7 & 103:3 115:5,6 & 134:22 147:2 \\
\hline numb 36:19 & 97:22 & 30:8 31:6 & 118:14 194:23 & 148:20 150:17 \\
\hline number 20:8 & occur 23:23 & 32:12 34:24 & older 35:13 & 152:3 153:6 \\
\hline 28:10 78:7 & 134:12 & 35:11,14 44:21 & 110:12 & 158:14,22 \\
\hline 93:22 115:10 & occurred 15:3 & 44:23 49:6 & once 15:3 19:10 & 159:16 162:2 \\
\hline 119:10 128:11 & occurrence & 55:9 57:8,18 & 51:10 67:10,11 & opiate-induced \\
\hline 132:8 149:18 & 183:9 208:3 & 64:5 68:15 & 75:9 95:8 & 151:17 \\
\hline 158:12,13 & occurs 20:9 & 69:9 70:8,13 & 120:18 142:22 & opiates 126:11 \\
\hline 203:22 224:18 & Ochsner 113:19 & 73:21 77:3,9 & 151:8 169:7 & 126:17,21 \\
\hline numbers 23:21 & October 13:9 & 81:8 82:2,11 & 192:17 193:21 & 129:23 132:17 \\
\hline 23:22 44:9 & 14:18 15:12 & 82:15,21 83:8 & 205:13 219:24 & 133:7,10,14 \\
\hline 126:12 201:9 & 98:24 200:12 & 85:11 87:11 & 224:23 & 134:8,14 \\
\hline 212:13 & 203:16 & 92:24 93:2 & oncologist 9:23 & 146:21 147:4 \\
\hline numbness 37:23 & offer 8:11 119:9 & 94:9 95:14,19 & oncology 158:20 & 150:1,5,13,18 \\
\hline numerous 19:14 & 147:13 165:12 & 95:23 96:3,6 & one's 86:24 & 151:11,12,20 \\
\hline 157:22 & Office 177:3 & 96:13,24 97:3 & 200:6 206:20 & 152:1,9 155:3 \\
\hline nurse 186:19 & 228:20 230:6 & 97:6 99:4 & ones 42:17,18,19 & opinion 192:7 \\
\hline nurses 25:13 & 230:14 231:5 & 100:5 102:18 & 178:8 179:20 & opinions 231:21 \\
\hline nursing 10:6,7 & 231:15 235:3 & 106:8 114:3,14 & 192:23 214:18 & opioid 156:18 \\
\hline 39:19,22,24 & 237:3,6,17 & 114:24 123:10 & ongoing 79:18 & 161:8 170:20 \\
\hline & & 123:13 124:10 & 132:10 165:23 & opioids 135:22 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 156:19,22 & original 70:24 & 181:16 & 141:2,5,6,9,11 & 190:2,23 195:2 \\
\hline 199:3 & 178:17 & overreaction & 141:12,13,15 & 195:11 196:22 \\
\hline opportunity & originated 69:10 & 181:17 & 142:1 143:17 & 199:5,11 \\
\hline 19:3 21:5 66:3 & orthopedic & oversight 129:10 & 144:17,19,20 & 201:22 202:4,8 \\
\hline 91:1,12 108:15 & 124:18 125:19 & 230:11 & 144:24 145:3,6 & 202:8,13,18,22 \\
\hline 135:18 142:4 & 127:9 132:21 & overwhelming & 145:8,9,10,11 & 203:2,10 \\
\hline 152:22 180:2 & 132:22 & 212:16 216:21 & 145:12,16,18 & 204:12 212:1 \\
\hline 192:18 220:18 & orthopedics & overwhelmingly & 145:19,24 & 216:5 \\
\hline 237:1 & 132:1,2 & 54:1,1 & 146:3,6,8,11 & painful 167:20 \\
\hline oppose 14:15 & Osler 197:18 & owe 212:22 & 146:16,19 & 167:21 183:10 \\
\hline opposed 12:15 & osteoarthritis & 241:13 & 147:6,6,10,14 & 184:15 201:6 \\
\hline 16:3 48:17 & 13:4 135:4,7 & owner 8:12 35:3 & 147:16,23 & 201:21 202:1,2 \\
\hline 152:13 206:4 & 167:4 172:20 & Oxycontin & 148:1,4,6,8,11 & pains 36:22 \\
\hline opt 7:4 & 186:20 199:18 & 160:19 & 148:12,12,16 & 37:18 195:22 \\
\hline optimist 231:17 & 200:3,13 & & 148:16 149:4,7 & palliative 130:23 \\
\hline optimistic & 201:17 202:22 & P & 149:16,18 & 213:14,22 \\
\hline 234:13 & 203:9,20 & P-e-n-n-e-r & 150:19 151:2 & palms 36:21 \\
\hline option 7:6 66:4 & 204:22 205:4 & P-s-e-u 83:6 & 151:12,19 & Pamela 186:9,11 \\
\hline 66:10 70:5 & 205:11 & p-s-e-u-d-o-m... & 152:10,10 & panel 134:9 \\
\hline 76:6 100:3 & ounce 225:3,6 & 8 6 & 153:5,6,20,23 & 155:17 \\
\hline 120:6 127:20 & outcome 11:21 & p.m 242 & 154:10 155:22 & panic 12:22 \\
\hline 130:24 138:5 & 154:21 176:13 & packet 55:14 & 156:7 157:4,14 & 57:12,18 58:10 \\
\hline 186:23 196:1 & 176:15 & packets 168:21 & 157:21 158:1 & 59:2,13,20 \\
\hline 196:20 204:20 & outcomes 67:5 & padded 103:15 & 159:11 160:1,9 & 60:5 61:3 62:3 \\
\hline options 32:22 & 67:22 221:13 & page 2:10 3:1 & 160:14 161:2,5 & 62:3,11,24 \\
\hline 34:2 54:20 & outgoing 211:22 & 122:9 & 161:6,12,14,22 & 63:3,4,9,13 \\
\hline 117:1 172:7 & outlook 38:10 & pain 7:19 12:24 & 162:1,5 163:4 & 64:3,8 65:7,14 \\
\hline 182:3 202:9 & 195:20 & 13:1,2,2 20:24 & 163:9,10,16 & 66:19 70:10,10 \\
\hline 229:3 & outpatient & 22:23 25:20 & 164:15 165:17 & 72:14 73:12,12 \\
\hline orally \(81: 23\) & 145:22 & 34:1 37:1 & 165:23 166:2,3 & 74:5,12 75:16 \\
\hline orange 80:9 & outside 8:6 77:2 & 43:15 58:21 & 166:11,13,14 & 76:20 186:20 \\
\hline Oraveck 187:11 & 90:2 118:19 & 61:1 68:2 74: & 166:22 167:2,4 & 195:21 \\
\hline order 6:4 12:19 & 213:18 & 78:11 79:5 & 167:7,10,11,16 & pants 103:5 \\
\hline 13:7,21,22 & outweighs 28:22 & 110:15,22 & 167:17,20,23 & paper 15:4 \\
\hline 94:11,16 & 117:23 & 123:17,19,21 & 167:24 168:2,4 & 55:13,15 \\
\hline 139:11 144:14 & ovarian 9:24 & 123:23,23 & 168:5,14 & paraphrase \\
\hline 144:15 146:18 & oven 117:7 & 124:1,8,11,15 & 169:12,15,18 & 224:17 \\
\hline 203:20 & over-the-coun... & 124:16,16 & 170:1,2,3,7,9 & Pardon 114:7 \\
\hline organisms 83:18 & 32:23 & 125:9 126:6 & 170:10,11,12 & parents 27:4 \\
\hline organization & overall 25:20 & 127:4,5,15 & 170:22 171:1,4 & 99:19,22 100:2 \\
\hline 16:23 102:1 & 59:10 78:20 & 128:1,5,18 & 171:22 172:5 & 110:23 116:8 \\
\hline 118:18 & 88:14 & 129:12,13,14 & 172:17,19,21 & 117:11 118:20 \\
\hline organizations & overdose 148:20 & 129:14 131:18 & 172:23,24 & 120:3 \\
\hline 122:2 & 148:21 & 132:17 134:3 & 173:1 174:9 & parents' 211:8 \\
\hline organized 97:5 & overproduction & 134:24 135:21 & 180:23 181:17 & Park 35:16 \\
\hline oriented 75:14 & 189:2 & 135:22 136:13 & 182:20 183:15 & part 16:10 31:21 \\
\hline origin 167:19 & overreact & 136:13 140:11 & 186:18 188:4,9 & 36:17 42:14 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 52:24 65:10 & 214:15 & 78:15 99:20 & pay 11:19 223:9 & 180:13 181:2 \\
\hline 136:18 137:4 & passion 175:21 & 100:10 119:21 & 228:11 & 181:19,20 \\
\hline 149:15 150:14 & patch 151:5 & 125:22,22 & paying 228:4 & 187:6,7 192:8 \\
\hline 175:7,8 177:13 & 160:20 & 126:5,16,22 & PDI 8:15 & 194:12 207:6 \\
\hline 180:12 202:5 & patent 119:10 & 127:7,11,16,20 & pearl 65:5 67:14 & 207:19 212:18 \\
\hline 218:12 228:17 & pathway 30:2 & 129:12,17,20 & peas 42:3 & 214:6 215:2,4 \\
\hline 235:4 241:16 & pathways & 129:22 130:2,5 & pediatric 9:16 & 216:24 218:17 \\
\hline partially 166:13 & 157:22 & 130:13,16,18 & 43:11 & 227:13,17 \\
\hline participants & patience 239:1 & 130:20 131:7 & pediatrician & 228:14 231:11 \\
\hline 65:2 191:22 & patient 5:24 & 131:17,17,19 & 50:10 119:5 & 231:20 232:14 \\
\hline 192:1 & 8:12,23 10:16 & 132:4,6,12 & 120:7 & 232:15 \\
\hline participate 26:9 & 16:24 24:11 & 133:6,13,23 & Pediatrics 9:15 & people's 142:19 \\
\hline 230:7 & 35:22,24 38:20 & 134:17,20 & peer 27:22 31:7 & pepper 49:10 \\
\hline participated & 40:8,9,9,13 & 135:1,1,3,6,24 & 47:9 64:17 & 80:9 \\
\hline 26:11 & 57:23 62:20 & 137:10 138:3 & 128:1 138:16 & Pepsi 49:10 \\
\hline particular 45:11 & 64:15,16 70:2 & 145:9,16,17,19 & 151:23 162:20 & percent 19:23 \\
\hline 70:1 78:2 & 76:4 100:11,12 & 146:3,5 147:5 & peers 44:15 45:7 & 91:22 109:10 \\
\hline 90:21 112:4 & 108:17 132:8 & 147:7,23 148:8 & 153:21,21 & 118:23 125:22 \\
\hline 150:10 158:4 & 132:15 136:11 & 148:9 149:5,22 & Penner 30:16 & 145:17,18 \\
\hline 175:20 216:2 & 150:24 151:6 & 151:24 152:8 & 53:6 & 146:2,5,9 \\
\hline 238:1 & 154:4 158:22 & 152:22 153:5 & Pennsylvania & 151:1 152:3 \\
\hline particularly & 159:5,9,13 & 153:14,15,18 & 99:3,4 & 154:5 166:10 \\
\hline 189:17 & 170:5,12 & 154:6,15,20 & Pennsylvania's & 191:24 192:2 \\
\hline partner 59:9 & 183:24 184:6 & 155:17,23 & 99:5 & 201:8,12,15 \\
\hline partners 131:15 & 190:24 192:19 & 156:21 159:4 & people 26:9 27:3 & 212:19 214:21 \\
\hline parts 59:7 83:24 & 193:19 194:15 & 159:17 163:4,5 & 27:7 28:18 & 223:17,18 \\
\hline party 223:24 & 194:21 202:1 & 167:5 168:3 & 38:13 39:12 & perfect 103:2 \\
\hline pass 32:17 45:19 & 210:5 215:17 & 170:17 171:7 & 41:1 42:7 43:7 & 176:5 189:13 \\
\hline 53:11 54:11 & 217:18,24 & 172:8 174:1,23 & 53:19 56:6 & 190:13 214:8 \\
\hline 62:6 65:9 & 218:1,2 221:7 & 175:5,22 186:8 & 57:5 58:12 & perform 187:17 \\
\hline 75:11,11 77:8 & 225:3,9,13 & 189:16 191:9 & 61:20 62:14 & period 4:5 \\
\hline 139:1 179:9 & 229:19 230:7 & 196:18,24 & 64:1,12 66:8 & 236:11 239:6 \\
\hline 185:17 186:14 & 230:23 & 198:21 201:13 & 67:2 68:20 & 239:16 240:10 \\
\hline 196:4 234:1 & patient's 92:11 & 201:13,15,16 & 72:8 74:3,22 & periodically \\
\hline passable 5:22 & 168:7 170:16 & 201:21 203:1 & 85:2 91:5 & 136:3 \\
\hline passage 171:22 & 230:8 & 203:22 218:5 & 99:19 107:4 & periods 117:4 \\
\hline 181:13 182:17 & patient/dispen... & 219:13,18,20 & 109:10 110:7 & peripheral 30:12 \\
\hline passed 6:3 15:22 & 75:4 & 220:20,22 & 110:16,17,20 & 128:13 \\
\hline 51:16 54:17 & patient/physic... & 222:8,9 223:7 & 112:8 119:1 & peritoneal 29:10 \\
\hline 57:10 123:4 & 69:22 204:17 & 223:14,21 & 121:3,13 127:3 & permanently \\
\hline 131:24 144:22 & patients 5:87:1 & 225:1 227:20 & 139:12 148:19 & 194:24 \\
\hline 169:16 171:7 & 25:21 26:1 & 227:21 228:1,1 & 150:3 152:17 & permeability \\
\hline 176:17,17 & 33:2 35:9,15 & 234:14 238:15 & 153:17 161:13 & 188:24 189:1 \\
\hline 178:20 180:17 & 35:17 47:5 & 241:1,24 & 162:7,8 172:16 & permission \\
\hline 189:11 190:3 & 49:22 55:24 & pause 45:8 & 175:2,11 & 107:4 \\
\hline 232:21 237:8 & 63:3 67:7 70:6 & 47:11 66:22 & 176:21 179:4 & perseverance \\
\hline passing 105:9 & 75:6,9 76:11 & 69:18 & 179:10 180:11 & 240:24 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline persistence & 80:20 83:12 & photos 104:24 & pills 104:6 & 58:7 65:17 \\
\hline 240:23 & 84:14 85:24 & phrases 98:2 & 186:24 213:24 & 72:13 97:9,10 \\
\hline persistent 64:11 & 86:1,4 87:24 & physical 63:15 & pilot 5:3,9,15 & 102:16 108:1 \\
\hline 71:11 170:10 & 88:13 90:15,21 & 74:8 166:23 & 11:18 45:15 & 114:12 118:11 \\
\hline person 20:20 & 91:13 123:5 & 170:24 & 97:14 129:4 & 135:17 141:22 \\
\hline 40:7 56:21 & 139:19 140:1 & physically 37:13 & 145:13 171:10 & 187:5 194:8 \\
\hline 59:10,12 83:21 & 189:12 239:16 & physician 5:7 & 227:3,12 229:1 & 198:8 \\
\hline 86:6,12 88:18 & 240:9,9 & 7:3 40:7 65:19 & 229:2 235:5,7 & pleasurable 8:19 \\
\hline 88:24 90:3,8 & petitioned 72:15 & 129:10 135:17 & 235:9 236:5 & pleasure 160:24 \\
\hline 92:21 108:13 & petitioner 25:17 & 135:20 136:10 & 238:24 & pledge 120:17 \\
\hline 111:3 113:16 & 28:1 31:17 & 136:21 145:8 & pine 80:9 & plug 199:13 \\
\hline 114:9 120:10 & 57:19 73:4 & 149:16 156:9 & pins 146:15 & plus 29:4,4 62:4 \\
\hline 149:17,19 & 78:4 87:21 & 157:4 159:2 & 227:14 & pocket 228:4 \\
\hline 150:6 158:8 & petitioner's & 160:9 163:2 & pituitary 170:19 & podium 34:18 \\
\hline 159:7 172:18 & 26:16 29:3 & 195:16 204:16 & pity 210:18 & 57:20 \\
\hline 173:3,19 & 52:14 86:12 & 221:7,8 & place 6:23 66:9 & podunk 107:6 \\
\hline 226:24 240:22 & petitioners & physician's & 78:23 113:10 & point 5:4 6:7 \\
\hline person's 181:6 & 15:18 16:6 & 155:17 & 122:4 142:24 & 7:16 36:12 \\
\hline personal 49:21 & 72:17 77:10 & physician/pati... & 155:4 191:1 & 40:1 43:21 \\
\hline 76:14 94:3 & 93:24 & 53:10 & 236:24 241:14 & 50:6 56:11 \\
\hline 159:15 179:10 & petitions 4:4 & physicians 6:24 & 243:8 & 9:18 69:12 \\
\hline 183:23 192:7 & 12:4 14:21 & 7:2 43:24 & placebo 29:12 & 71:9 72:5 75:4 \\
\hline 209:20 215:6 & 15:8 90:7 91:3 & 49:19 53:20 & 84:4 & 78:4 82:5 \\
\hline 240:21 & 93:14,23 94:21 & 56:23 63:24 & places 45:21 & 90:23 94:20 \\
\hline personality & 95:16 & 126:20 127:7 & 109:17 & 95:5 117:8 \\
\hline 182:2 211:22 & petri 29:24 84:4 & 132:6,14,23 & plagiarism 91:5 & 158:23 160 \\
\hline personalized & 84:8,9 154:12 & 136:14 137:10 & plain 183:4 & 160:22 167:18 \\
\hline 91:7 & pharmaceutical & 138:4 145:5 & plan 215:23 & 176:14 178:16 \\
\hline personally 58:3 & 70:1 119:6 & 151:3 154:14 & planning 220:7 & 198:20 205:16 \\
\hline 60:7 112:2 & pharmaceutic... & 159:3 161:23 & plant 33:10 & 207:19 216:18 \\
\hline 167:7 215:4 & 101:1 118:3 & 164:18 177:19 & 41:11 84:15 & 220:5 221:10 \\
\hline 225:13 240:21 & 120:6 & 178:11 & 119:17 120:12 & pointed 27:13 \\
\hline persons 87:12 & pharmacist & Phytocannabi... & 187:3 219:12 & 74:1 \\
\hline 112:6 & 222:1 & 80:2 & plant-derived & points 237:7 \\
\hline perspective 8:11 & pharmacogen... & phytocannabi... & 189:4 & poke 25:15 \\
\hline 43:16 71:19 & 158:15 & 41:23 & plated 84:3 & pokes 25:11,12 \\
\hline 108:18 160:7 & pharmacology & pick 79:17 & plausible 43:14 & Poland 31:5 \\
\hline petition 4:5 13:9 & 139:7 188:21 & picked 178:24 & play 91:19 185:1 & Police 230:4 \\
\hline 14:9,18,20 & Pharmacopoeia & picking 229:11 & 191:3 & policies 6:20,23 \\
\hline 26:4 31:18 & 139:6 & pictures 102:8 & player 20:17,18 & 136:16 155:7 \\
\hline 32:17 39:18 & phobia 65:1 & 104:21 109:22 & players 30:12 & policy 108:2 \\
\hline 40:8,11 44:5 & phobias 63:20 & piece 122:19 & pleasant 192:9 & 121:2 131:21 \\
\hline 46:22 47:2 & phone 106:20 & 139:2 & please 8:4,7 9:12 & 131:23 156:15 \\
\hline 62:5 64:3 & phones 4:11 & pig 100:24 & 16:20 17:1,6 & Polish 44: \\
\hline 71:10,10 72:13 & 35:13 & 184:21 & 17:16,16 22:1 & poor 97:24 \\
\hline 73:3 76:19 & phonetic 109:18 & pill 104:5,5,5 & 34:18,23 35:5 & 165:20 166:18 \\
\hline 77:14 78:8 & photo 106:17,19 & 203:3 & 38:12 41:12 & 187:7 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline poorer 31:9 44:8 & 129:24 130:10 & preparation & 173:22 178:10 & 71:879:16 \\
\hline 44:17 67:4,21 & 134:4 & 117:6 & 179:20 & 84:22 89:9 \\
\hline 74:13 & posture 166:8 & preparations & presenting & 104:9 123:16 \\
\hline poorly 83:14 & pot 49:4,4,4,11 & 184:21 & 187:12 & 146:10 176:18 \\
\hline 165:22 181:14 & 49:11,11 & prepare 238:21 & presents 89:4 & 193:14 224:3 \\
\hline population & potency 84:20 & prepared 164:21 & 165:18 & 237:15 239:7 \\
\hline 118:23 136:22 & 184:23 & 165:5 203:18 & President & probiotics \\
\hline 146:10 150:24 & potential 28:21 & 229:7 & 144:24 145:1,3 & 187:19 \\
\hline 151:1 191:20 & 63:12 68:9,11 & preregiste & pressure 26:22 & problem 41:19 \\
\hline 208:12,14 & 80:1,17,22 & 205:21 & pretty 6:2 66:22 & 66:7 112:18 \\
\hline portion 152:8 & 85:15 117:22 & prescribe 25:24 & 76:1 83:14 & 130:12,22 \\
\hline poses 68:9 & 161:21 & 47:12 48:3 & 101:23 145:23 & 145:20 150:19 \\
\hline position 237:15 & potentially 45:9 & 117:14 120:7 & 176:18 242:2 & 150:23 165:18 \\
\hline positive 19:14 & 150:2 192:24 & 139:13 162:9 & prevalent 76:2 & 165:18 182:1 \\
\hline 158:9 163:5 & potentiate 163:5 & 211:2 & prevent 60:1 & 213:21 \\
\hline 192:1 231:8 & pounds 23:7 & prescribed & 129:7,8 182:21 & problems 42:19 \\
\hline 234:13 & 36:12 195:13 & 59:19 61:10 & 187:20 195:21 & 45:9 98:21 \\
\hline possess 87:1 & power 18:3,4 & 70:23 107:6,8 & prevented 37:9 & 127:9 129:19 \\
\hline 212:4 & 34:23 120:15 & 107:15 126:11 & preventing & 166:23 188:19 \\
\hline possibilities & powerfully & 135:21 182:11 & 195:9 & 194:14 195:14 \\
\hline 224:14 & 185:5 & 187:18,23 & prevents 37:5 & procedures 6:23 \\
\hline possible 19:7 & powerhouse & prescribing & 131:13 187:17 & proceed 9:4 \\
\hline 58:19 64:12 & 171:17 & 136:1 & previous 27:10 & 40:11 97:9 \\
\hline 88:8 121:20 & powers 118:21 & prescription & 74:5 95:22,22 & 232:16 \\
\hline 143:13 146:19 & practice 39:20 & 126:8 151:4 & 168:14 199:12 & proceeded \\
\hline 147:9 170:7 & 39:23,24 90:3 & 155:20 187:2 & previously 12:4 & 115:22 \\
\hline 176:20 181:12 & 132:3 136:2 & prescriptions & 15:22 72:19 & proceeding \\
\hline 197:23 210:23 & 145:19 159:9 & 126:10 & 96:16 99:13 & 167:22 \\
\hline possibly 120:10 & 159:13 170:6 & presence 4:18 & 116:12 178:7 & proceedings \\
\hline 228:9 232:24 & practitioner & 7:8 151:19 & 243:8 & 4:12 53:13 \\
\hline post 133:4 143:2 & 65:20 153:14 & 153:8 & prices 223:12 & 84:22 142:6 \\
\hline 206:12,23,24 & practitioner's & present 8:4,9 & 224:19 & process 78:2 \\
\hline 207:5 208:6 & 126:22 & 14:23 16:20 & pricking 20:14 & 137:4,5 181:17 \\
\hline 209:10 & practitioners & 17:11 18:11,20 & 20:16 & 183:5,13 189:4 \\
\hline post-traumatic & 115:15 133:2 & 19:3,10 21:5 & primarily 10:1 & 193:16 209:4 \\
\hline 13:4 & pre-school & 41:23 42:1 & 106:3 162:24 & 228:17 241:12 \\
\hline postconcussion & 100:19 103:13 & 51:9 62:24 & primary 126:19 & produce 42:8,19 \\
\hline 197:1 & precious 59:7 & 102:6 114:5 & 132:7,14 156:9 & produces 42:5 \\
\hline postmortem & predictable & 128:2 168:11 & 156:11 160:9 & 188:22 \\
\hline 111:9 & 176:12,15 & 168:18,20 & prime 136:11 & product 8:17 \\
\hline postop 141:15 & predicted & presentation & prior 96:16 & 87:8,10 154:16 \\
\hline postoperative & 201:14 & 29:4 51:10 & 103:1 125:24 & 175:24 \\
\hline 13:2 123:23 & predominantly & presentations & 125:24 126:1 & production \\
\hline 124:15 129:14 & 185:7 & 14:24 128:16 & 180:9 & 111:1 \\
\hline 134:23 141:6 & preface 94:19 & presented 12:3 & pro 29:21 & productivity \\
\hline 169:12,15 & prefer 73:2 & 47:24 51:7 & probably 6:12 & 199:2 \\
\hline postoperatively & 153:7 & 80:19,23 & 7:18,19 22:7 & products 41:7 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 49:15,16 50:2 & 127:16 & 61:17 72:21 & 188:20 196:13 & 23:9 67:1,23 \\
\hline 87:14 139:8 & project 229:14 & 127:19 & PubMed 27:18 & 68:3,6 73:24 \\
\hline professional & 240:23 241:2 & providing 26:21 & 27:20,23 28:15 & 74:2,6,13,18 \\
\hline 8:20,22 222:7 & prolonged & 39:22 91:6 & 47:9 77:23 & 115:4 120:3 \\
\hline 229:20 & 166:22 & proving 27:7 & pull 64:5 94:4 & 148:4,12 \\
\hline professionalism & promise 206:14 & provision & pulsing 190:18 & 152:23 154:17 \\
\hline 175:17 & promotes 64:14 & 241:10 & pump 170:22 & 166:18 175:24 \\
\hline professionals & 108:12 & pseudo 83:6 & punch 225:19 & 184:12 199:1 \\
\hline 115:17,23 & proof 43:7 88:6 & pseudomonas & punches 225:20 & 213:14 219:15 \\
\hline 165:23 166:1 & 163:19 & 83:4 & purchase 225:21 & 228:1,3,11 \\
\hline 221:4 & proper 14:8 & psychiatric & purely 132:20 & 232:23 \\
\hline professor 10:6 & 25:19 111:16 & 109:15 & purported 79:6 & quantified 68:5 \\
\hline 10:14 11:5 & properly 69:21 & psychoactive & pursuant 1:13 & quantities 33:18 \\
\hline 132:21 144:12 & properties 79:23 & 42:18 128:23 & pursue 203:18 & quantity 228:2 \\
\hline 152:16 & 81:18 88:22 & 208:18 & purview 86:24 & quell 30:3 \\
\hline profile 152:12 & 184:20 & psychology & 92:16 & question 22:12 \\
\hline profiles 219:12 & proportion & 59:24 & put 4:11 27:20 & 33:7 38:18 \\
\hline program 1:5 4:8 & 166:20 & PTSD 37:5 61:4 & 36:24 38:11 & 40:17,22 41:3 \\
\hline 4:21 5:3,9 10:2 & proposal 121:24 & 63:21 65:9,11 & 48:3 86:17 & 45:24 48:6 \\
\hline 10:13 11:3 & propose 15:10 & 78:12 87:23 & 91:1 103:13,14 & 50:11 55:21 \\
\hline 35:19 52:2 & proposed 93:16 & 143:8 207:8,11 & 117:15 121:23 & 85:23 86:16 \\
\hline 56:13 66:8 & pros 29:5 133:3 & 207:14,16,19 & 137:5 138:12 & 89:4 105:10 \\
\hline 88:22 97:14 & Prospect 217:19 & 207:22,23 & 139:24 156:20 & 111:22 121:10 \\
\hline 129:4 144:20 & prospective & 208:3,9 209:11 & 161:12 170:9 & 121:11,16,19 \\
\hline 145:4,14 149:6 & 149:2 & 209:12,14,21 & 190:9 205:4 & 121:24 131:20 \\
\hline 171:6,11 172:2 & protect 103:19 & 210:10 211:1 & 215:1,7 233:1 & 132:1 133:4 \\
\hline 172:10 173:24 & protein 185:7 & 211:14,23 & 233:16 238:18 & 140:21 150:3 \\
\hline 173:24 174:6 & protocol 119:3 & 212:5,10,15,19 & 241:17 & 150:13 153:3 \\
\hline 175:1 179:15 & 214:19 & 212:20 237:9 & putting 66:11 & 158:10 173:2 \\
\hline 179:18 182:12 & proud 21:19,20 & public 1:3,9,9 & 205:5 & 176:10 214:5 \\
\hline 187:9 201:13 & 221:3 & 4:3 11:2 15:17 & & 214:14,19 \\
\hline 201:18 203:20 & proven 115:11 & 16:11 45:1 & Q & 215:3 227:1 \\
\hline 203:23 215:17 & 116:3 167:16 & 59:4 64:17 & QOL 68:6 & 234:23,23 \\
\hline 225:18 227:14 & 182:14,18 & 65:1 90:23 & qualified 110:18 & 236:6 \\
\hline 229:6,17,19 & 183:12 203:5 & 91:2 93:9 96:5 & qualifiers 205:5 & questionnaires \\
\hline 230:8,15 & proverbial 167:9 & 109:24 131:4 & qualifies 111:3 & 74:7 \\
\hline 231:12,20 & provide 22:1 & 139:23 142:16 & qualify 61:2 & questions 52:5 \\
\hline 232:21 235:5,9 & 31:18 52:12 & 150:24 170:2 & qualifying 4:7 & 52:23 77:9 \\
\hline 236:5,17,18 & 53:24 137:14 & 180:2 184:9 & 40:9 97:13 & 82:4,7 131:5 \\
\hline 237:19 238:24 & 238:13 & 215:1 222:17 & 111:2 114:17 & 149:12 157:9 \\
\hline program's 172:5 & provided 127:21 & 229:9,18 & 115:2 119:24 & 163:22 235:24 \\
\hline 216:9 231:18 & 169:13,14 & 230:12 237:20 & 145:12 155:3 & 236:9 \\
\hline 231:22 & provider-supp... & publications & 165:24 171:5 & queue 57:13 \\
\hline programs 26:12 & 40:3 & 162:19 & 172:5 183:24 & quick 45:23 \\
\hline 136:1 204:19 & providers 132:3 & published 59:22 & 185:18,23 & 116:7 213:11 \\
\hline 223:15,15,16 & 165:19 & 59:24 79:12 & 192:19 194:8 & quickly 92:23 \\
\hline progressive & provides 28:6 & 147:21 188:18 & quality 20:5 & quiet 190:24 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline quite 23:1 & randomized & 34:10 38:14 & receives 16:12 & 164:13 168:12 \\
\hline 126:12 177:14 & 138:17 148:7 & 39:21 40:18 & 16:12 & 168:17 176:1 \\
\hline quote 135:10 & 162:10 & 43:13 44:6 & receiving 23:24 & 176:16 198:3 \\
\hline 173:3 214:3 & ranges 219:9 & 45:2,10,10 & receptor 157:16 & 204:3 215:1,8 \\
\hline quoted 126:14 & 223:2,3 & 46:19 49:14 & 158:4,6 & 230:9 239:8 \\
\hline quoting 44:7 & rat 30:9 60 & 61:22 64:2 & receptors 30:11 & records 198:9 \\
\hline R & rate 121:4 & 66:19 71:23 & 134:10,12 & ecovered 115:7 \\
\hline R & rates 212:1 & 77:18,21 78:2 & 157:14,16 & recovering \\
\hline R-a-d-w- & ratio 49:1 & 79:22 85:8,12 & 158:11,14,14 & 10:17 \\
\hline 84:19 & 218:17 & 90:13,18,20 & 182:24 183:4,6 & recovery 115:18 \\
\hline R-i-e-d-e & rationale 91:10 & 91:2,8 94:2 & 185:6,7,10 & 115:24 \\
\hline 29:22 & 235:4 236:16 & 99:10,15,21 & 190:2 192:5 & recreational \\
\hline R-u-s-s-o 80:1 & 236:21,23 & 100:13 102:3 & 202:13,16 & 40:21 44:14 \\
\hline Radwan 84:19 & re-evaluate & 112:4 129:18 & reciting 120:17 & 68:24 69:4,6 \\
\hline Rafael 208:16 & 143:4 & 130:16 132:20 & recognize 47:1 & recreationally \\
\hline rage 98:20 & re-plate 133:24 & 138:4 150:23 & 69:19 78:6 & 41:2 48:10 \\
\hline 100:20 & reaction 100:16 & 151:12 154:8 & 161:6 209:17 & rectum 181:9 \\
\hline raise 206:8 & 204:21 & 157:4 158:1 & recognized & recur 195:6 \\
\hline 219:16 & reactions 167:1 & 159:3,8 171:16 & 175:6 & recurrent 63:4 \\
\hline raised 52:23 & 187:4 & 172:11,22 & recognizes 64:15 & 195:7 \\
\hline 78:9 236:1,10 & read 7:12,13 & 175:2,3 177:15 & recognizing & reduce 156:22 \\
\hline raises 78:22 & 31:2 35:24 & 180:13 185:11 & 69:16 & reduced 196:17 \\
\hline Ramirez 2:6 & 41:15 45:8 & 185:22 194:9 & recommendati... & reducing 209:7 \\
\hline 9:11,14,14,16 & 48:7 52:1 & 194:10,14 & 52:4,17 86:10 & reduction \\
\hline 12:6,9 13:21 & 53:21 56:11,19 & 196:11,13 & 97:13 136:20 & 166:19 \\
\hline 14:2 15:23 & 57:23 58:3 & 199:22 200:10 & 203:15 237:10 & reenter 95:7 \\
\hline 41:19 48:6,11 & 71:16 76:23 & 203:3,11,14 & 240:14 & reevaluate 180:1 \\
\hline 48:13,15 55:19 & 91:3 93:13 & 211:20 213:10 & recommendati... & reevaluated \\
\hline 55:23 56:3,5,8 & 95:18 99:6 & 217:7,7 218:24 & 53:12 54:9 & 178:15 \\
\hline 56:15,17 57:14 & 109:8 115:20 & 218:24 220:11 & 56:20 123:9 & refer 198:8 \\
\hline 81:11 82:20 & 115:22 125:19 & 222:10 223:13 & 174:15 221:16 & reference 52:8 \\
\hline 85:10,13,19 & 161:15 186:7 & 226:23 238:15 & 232:8 239:7 & 76:14 \\
\hline 91:18 92:23 & 211:13 239:8 & 238:17 241:24 & recommended & referrals 157:1 \\
\hline 93:10 94:6 & reading 19:1 & realm 63:23 & 19:8 75:11 & referred 130:20 \\
\hline 96:23 114:8 & 20:3 71:10 & 162:15 & 79:1 101:14 & 132:6 155:23 \\
\hline 138:8 139:3,4 & 72:2 91:6 & reason 65:13 & 116:1 176:14 & refractory 147:5 \\
\hline 140:8,16,20 & 105:3 111:16 & 121:7 133:5 & 203:14 & regain 37:19 \\
\hline 157:20 178:16 & 117:9 & 170:11 171:12 & recommending & regained 212:2 \\
\hline 178:22 179:12 & ready 15:4 17:7 & 233:15,17,23 & 52:13 & regaining \\
\hline 197:15,17 & 165:14 169:22 & 233:24 & reconciling & 211:21 \\
\hline 204:3 205:24 & real 8:19 76:24 & reasonable & 127:6 & regard 7:11 \\
\hline 213:1,4 214:13 & 91:19 150:2,2 & 72:10 138:5 & reconvene & 40:21 49:18 \\
\hline 214:22 222:15 & realistic 203:14 & 170:8 & 140:10 & 158:21 \\
\hline 224:16 229:8 & realize 49:3 & receive 68:20 & record 12:17 & regarding 25:8 \\
\hline 235:10 240:20 & 98:23 99:7 & 151:20 & 15:17 16:11 & 60:5 62:11 \\
\hline 242:6 & 167:21 & received 4:4 & 17:2 123:3 & 74:7 108:18 \\
\hline Ramirez's 69:12 & really \(29: 18\) & 93:14 219:8 & 125:19 138:14 & 164:8 169:15 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 180:6 & 131:17 209:2 & removing & 16:24 108:11 & researcher \\
\hline regards 209:19 & 241:7 & 117:12 209:4 & 132:1 & 162:19 \\
\hline regeneration & relationship & render 240:13 & represents 89:15 & researchers 29:9 \\
\hline 33:22 & 26:20 32:13 & reopen 142:4 & reputable 27:22 & 83:23 191:22 \\
\hline regimen 59:5 & 49:21 53:10 & reorder 12:1,1 & request 4:5,10 & reservations \\
\hline 154:5 & 69:22 75:2 & \(\boldsymbol{r e p} 212: 11\) & 8:3 16:8 40:6 & 204:10 \\
\hline registered 40:9 & 131:11,12 & repair 146:5 & 52:14 143:11 & reside 208:11 \\
\hline 40:13 201:13 & 159:7 204:17 & repeat 98:2 & 168:18 & Residency 10:4 \\
\hline registration & relative 171:23 & 232:9 & requesting & resident 121:4 \\
\hline 230:22 & relatively 124:13 & repeated 15:14 & 125:13,14 & residents 208:13 \\
\hline Registry 1:5 4:8 & 125:9 131:22 & repeatedly & REQUESTS 1:4 & residual 159:24 \\
\hline 52:1 152:9 & 131:23 173:21 & 147:15 174:16 & require 15:21 & resistance 30:18 \\
\hline 229:19 & relax 181:6 & repetitive \(97: 19\) & 59:11 133:13 & resistant 92:6 \\
\hline Reglan 193:8 & 182:10 184:17 & rephrase 236:14 & 181:3 & resource 122:5 \\
\hline 194:5 & relaxants 146:23 & replaced 135:9 & required 67:19 & 196:5 \\
\hline regressed & 170:24 & replacement & 187:18 & resources 1:15 \\
\hline 103:11 & relaxed 38:3 & 146:2,4 & requirement & 1:16 102:3 \\
\hline regular 37:9 & 61:14 98:17 & report 31:10 & 27:1 205:8 & 139:18 175:21 \\
\hline 127:21 135:8 & relaxer 61:19 & 50:17 52:12,15 & requirements & respect 5:19 \\
\hline 211:17 & relaxing 61:23 & 67:21 230:12 & 142:20 & 51:6 53:8 \\
\hline regulate 19:16 & 184:19 & 230:16,20 & requires 13:10 & 209:17 \\
\hline 98:10 111:14 & release 6:15 & reported 44:11 & 117:6 & respiratory \\
\hline 137:13 183:13 & released 150:20 & 67:4 74:13 & reschedule & 134:15 \\
\hline 202:13 & reliable 158:16 & 166:14 192:2 & 139:14,19 & respond 46:17 \\
\hline regulated 38:8 & reliance 48:3 & reporter 1:24 & 140:1 & 158:22 166:5 \\
\hline 56:22 129:5 & relief 38:12 & 3:23 4:129:7 & rescheduled 6:9 & responded 12:14 \\
\hline 222:24 & 61:18 72:21 & 16:21 18:6 & 213:20 & 14:14 16:2 \\
\hline regulation 111:1 & 93:17 128:5 & 34:19 143:12 & rescheduling & 55:11 62:13 \\
\hline 129:1 229:20 & 151:2 152:11 & 243:1,5 & 139:16,21 & 96:21 142:12 \\
\hline regulations & 170:6 179:6 & reporting & research 6:10,16 & 206:3 242:9 \\
\hline 129:11 137:6 & 182:4 195:18 & 116:10 149:17 & 28:7 29:17,23 & responding \\
\hline reimbursement & 216:3 217:24 & 197:1 & 32:4 41:16 & 90:16 101:2 \\
\hline 223:24 & relieving 188:11 & reports 28:9,11 & 42:24 43:3 & response 12:16 \\
\hline reintroducing & 197:2 & 47:6 50:23 & 48:6 49:5,13 & 14:16 16:4 \\
\hline 202:11 & reluctant 32:16 & 127:2 173:10 & 52:22 66:14,15 & 30:4 147:11 \\
\hline reiterate 90:2 & remain 175:17 & 208:10 230:18 & 67:24 68:6 & 156:19 206:5 \\
\hline reiterating & 234:13 & represent 9:18 & 73:19 79:18 & responses 69:14 \\
\hline 80:21 & remains 115:13 & representation & 81:6 82:3,4 & 148:10 165:20 \\
\hline rejected 233:4,8 & remarks 4:15 & 177:4 & 85:2 88:2 89:4 & 202:14 \\
\hline 233:9,23 & remedies 203:19 & representative & 89:18 98:7 & responsible \\
\hline rejection 200:3 & remember 32:18 & 9:16 11:11 & 111:6 119:8 & 117:18 229:21 \\
\hline 235:2,11,13,15 & 53:9 106:4,10 & 118:16 131:9 & 128:14 162:15 & 230:2 \\
\hline rejections & 157:11 204:14 & 214:12 224:8 & 179:19 184:24 & rest 34:9 44:20 \\
\hline 236:16 & 205:1,7 & representatives & 186:17 187:24 & 65:14 66:23 \\
\hline related 29:1 & remind 16:19 & 213:17 & 189:14,24 & 187:7 210:7 \\
\hline 63:9 73:24 & 52:2 & representing & 213:15,18 & restore 189:7 \\
\hline 77:17 78:2 & removed 170:4 & 9:15 10:7 & 232:24 & restrict 116:20 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline restricted 97:19 & 32:17 35:23 & 136:19 145:2 & safer 112:23 & scary 113:8 \\
\hline restriction 6:15 & 42:21 57:11 & 191:3 198:18 & safety 137:7 & schedule 6:9 \\
\hline restrictive 187:8 & 71:16 76:23 & roles 185:2 & 148:18,19,22 & 136:4 139:13 \\
\hline 195:24 & 82:6,6,19 83:5 & roof \(37: 14\) & 148:23 209:20 & 140:2 211:18 \\
\hline result 47:7 93:17 & 95:3 97:10 & room 7:22,24 & 228:13 & 224:13 242:1 \\
\hline 237:12 241:11 & 100:24 116:24 & 8:2 11:17 & Saito 75:21 & scheduled \\
\hline results 91:24 & 119:16 139:1 & 53:19 57:14 & sake 15:16 204:3 & 142:18 197:12 \\
\hline 93:3 & 154:9 155:8 & 141:22 215:10 & sales 224:23 & 197:12 210:3 \\
\hline resume 34:13 & 162:16 163:10 & 231:11 235:21 & 226:19 & schedules \\
\hline 142:6,7 & 165:9,10,15 & root 133:21 & salt 105:20 & 142:20 180:4,4 \\
\hline resumed 117:8 & 169:10,10,22 & roots 118:18 & 195:1 & school 10:15 \\
\hline resumes 40:6 & 172:4 177:19 & 122:2 & samples 83:16 & 19:4 20:2 \\
\hline retching 193:6 & 180:9 190:7,15 & Rosenow 160:11 & sanctioned 85:1 & 37:11 103:12 \\
\hline retired 10:20 & 195:19 198:4 & roughly 191:24 & Sandy 3:12 & 105:1 106:23 \\
\hline retract 222:21 & 200:7 201:2,3 & 192:2 207:24 & 213:11 241:8 & 107:1,6 157:12 \\
\hline retrospective & 205:14 206:14 & route 205:6 & sans 59:12 & 211:6 \\
\hline 152:4 & 206:22 211:11 & routine 100:17 & Santos 186:10 & science 5:12,13 \\
\hline return 20:2 & 213:6 225:16 & routinely 126:15 & 186:11 & 5:19 32:19 \\
\hline returned 37:21 & 227:2,4 228:22 & 184:22 & satisfied 159:17 & 42:6 157:9 \\
\hline revenue 196:5 & 232:18 233:11 & routines 98:6 & satisfying 238:1 & 218:9 219:11 \\
\hline 229:11 230:3 & 233:14,14 & routines/rituals & sativa 48:17 & 238:14 \\
\hline reverse 189:4 & 234:2 239:18 & 98:4 & 80:15,24 84:21 & Sciences 11:6 \\
\hline review 1:3 13:8 & 239:20 241:19 & rub 201:19 & 105:24 106:2 & scientific 5:23 \\
\hline 13:17 14:9 & 241:19 & rubber 220:19 & save 143:21,21 & 52:21 64:6 \\
\hline 16:11 29:3 & Riley 103:22 & rules 52:2,7 & saves 106:15,15 & 122:7 128:16 \\
\hline 53:16 117:20 & ring 84:6 & 56:11,19 137:6 & 212:5 & 128:20 160:12 \\
\hline 147:22 169:3 & ripping 110:2 & 139:15 155:18 & saving 106:14 & 234:1,12 \\
\hline 178:24 & risk 28:8,22 & 241:18 & 201:17 203:22 & scientist 208:17 \\
\hline reviewed 27:22 & 37:14 38:12 & ruling 177:13 & saw 12:19 91:15 & Sclerosis 11:14 \\
\hline 47:9 128:2 & 41:14,15 68:10 & run 184:10 & 161:15 191:23 & scope 39:20,23 \\
\hline 138:16 151:23 & 101:10 117:23 & runner 45:16 & saying 49:6 & 90:3 \\
\hline 162:20 & 154:24 159:6 & running 234:20 & 50:19 60:10 & scores 148:12 \\
\hline revisit 143:1 & 181:21 191:8 & Rush 11:6,9 & 113:2 126:14 & scrambled \\
\hline rhetorical & 208:3 & 131:23 & 135:20 140:18 & 116:21 \\
\hline 214:14 & risks 69:20 & Russo 79:24 & 140:19 160:7 & screen 153:9 \\
\hline rheumatoid & 203:6 & & 163:8 198:4 & 154:19 \\
\hline 30:5 58:18 & Risperdal & S & 214:11 235:4 & screening \\
\hline 218:19 & 108:21 112:21 & S 3:18 & says 9:21 36:1 & 184:22 \\
\hline rheumatologist & 113:3 117:17 & S-a-i-t-o 75:21 & 56:5 65:14 & scrips 156:2,7 \\
\hline 203:11 & 119:6,20 & S-O-A-P-P & 71:10 72:12 & scrutiny 64:12 \\
\hline rhythm 181:7 & rituals 98:6 & 154:23 & 95:8 100:13 & sea 105:20 \\
\hline Richard 111:18 & road 156:14 & sack 147:4 & 139:15 186:11 & seal 243:11 \\
\hline ride 194:11 & 159:14 220:19 & Sadir 111:17 & 187:12 188:21 & search 77:24 \\
\hline Rieder 29:21 & 224:4 & safe 38:8 115:11 & 210:10 227:11 & 91:24 116:7 \\
\hline right 7:23,24 8:2 & rodents 184:24 & 120:3 127:21 & scapegoat 162:1 & second 7:12 \\
\hline 12:3 17:7 & role 74:9 132:19 & 129:11 147:17 & scarce 173:22 & 12:11,12 13:11 \\
\hline 22:21 28:3 & 132:20 133:1 & 149:8 & scarcity 171:23 & 13:13,22,22,24 \\
\hline
\end{tabular}
\begin{tabular}{|c|c|c|c|c|}
\hline 14:12 15:23,24 & 34:2,3 38:5 & separate 14:10 & shake 107:13 & 71:5 109:1,4 \\
\hline 39:17 77:5 & 58:5,9 93:22 & 14:19 154:13 & share 21:24 39:1 & 109:16 110:5 \\
\hline 85:11 93:1 & 109:6 122:6,15 & 165:8 186:8 & 101:8 174:12 & 112:17 117:16 \\
\hline 96:19 140:7,9 & 156:20 184:4 & separation & 210:6 231:6 & 119:7,11,18,20 \\
\hline 140:21 142:5,9 & 192:7 207:4 & 63:22 & shared 231:1 & 129:2 151:16 \\
\hline 158:10 187:10 & sees 103:23 & sequence 23:23 & sharing 196:18 & 152:12 160:3 \\
\hline 205:24 206:1 & seizure 185:13 & series 138:15 & 212:7 & 160:21 182:15 \\
\hline 215:12 242:6,7 & seizures 103:24 & serious 25:16 & shattering 110:2 & 182:18 199:7 \\
\hline secondly 149:23 & 104:1 105:12 & 97:16 119:11 & shed 235:23 & \(\boldsymbol{\operatorname { s i g n }} 17: 6,6\) \\
\hline seconds 17:4 & 105:13,14 & 130:3,3 134:24 & shell 207:1,3 & 43:24 141:17 \\
\hline 111:5 146:13 & 109:5 110:19 & seriously 106:21 & Shifting 57:18 & 228:23 \\
\hline Secretary 230:2 & 110:22 215:18 & 216:4 & 90:8 & signals 167:17 \\
\hline 230:5 & selected 70:6 & serve 94:1 & shock 207:1,3 & 181:14 202:17 \\
\hline secretion 182:16 & selection 102:3 & served 32:8 & shoes 105:4,5 & signed 142:15 \\
\hline section 52:8,9,10 & self 31:9 67:4 & 207:6 208:5 & shooting 36:22 & 206:7 \\
\hline sedate 101:1 & 108:23 116:20 & service 11:12 & shorten 143:8 & significant 26:18 \\
\hline see 6:8 7:13 & self-congratul... & 209:18 & Shorthand & 28:21 63:8 \\
\hline 10:19 30:8 & 46:20 & SERVICES & 243:5 & 97:21 128:5 \\
\hline 32:3,10,24 & self-contained & 1:22 & shortly 187:14 & 133:18 145:23 \\
\hline 34:4 37:1 & 103:15 105:2 & serving 31:10 & shot 214:6 & 152:8 190:22 \\
\hline 41:19 45:11,12 & self-perceived & set 142:17 145:5 & shoulder 130 & significantly \\
\hline 47:20 61:11 & 74:8 & 154:13 176:18 & 133:24 & 196:17 \\
\hline 72:16 75:13,16 & self-rep & 243:10 & shout-out 8:14 & signs 119:11 \\
\hline 75:24 84:10 & 69:7 & setting 88:5 & show 21:6 22:8 & 181:19 \\
\hline 91:15,15,20 & self-sustaining & 89:15 164:1 & 75:1 83:15 & silence 4:11 \\
\hline 98:15 104:21 & 201:14 203:23 & settled 188:4 & 106:14,20 & silver 167:9 \\
\hline 105:16 109:22 & sell 8:18 & seven 24:21 49:1 & 196:16 224:17 & similar 171:1 \\
\hline 109:24 113:20 & send 108:1 & 118:13 207:18 & showed 30:17,19 & 173:8 239:5 \\
\hline 120:10 123:24 & 157:1 & seventies 221:2 & 30:19 85:7 & simple 127:17 \\
\hline 125:22 130:15 & sending 159:4 & severe 64:8 & 111:8 112:6 & 133:20 146:1,4 \\
\hline 133:1 137:2,9 & sensation 190:18 & 71:20 74:23 & 152:2,7 162:12 & 187:16 \\
\hline 141:24 142:22 & sensations 21:1 & 90:17,19 & showing 111:7 & simply 170:9 \\
\hline 145:15,17 & sense 60:15 & 110:21 127: & 154:17 217:23 & single 34:3,4 \\
\hline 150:15 153:15 & 61:21 86:14,23 & 147:5 154:24 & shown 80:10 & 59:4 101:17 \\
\hline 154:11,12 & 87:4 90:13 & 163:9 186:13 & 147:15 149:1 & 150:19 188:10 \\
\hline 155:18 156:18 & 149:19 150:14 & 186:20 190:23 & 151:22 185:1 & 202:3 230:23 \\
\hline 158:9,19 167:9 & sensitivity & 192:22 194:14 & 188:1,23 & 233:7 \\
\hline 168:12 169:7 & 190:20 & 195:3 205:4,5 & shows 32:4 73:8 & sir 22:13 197:18 \\
\hline 177:5 183:17 & Sensitization & 207:12 211:15 & 122:11 & sit 23:19 58:14 \\
\hline 185:22 189:18 & 202:13 & severely 116:12 & shreds 110:3 & 144:23 202:3 \\
\hline 189:24 190:5 & sensitized & 117:2 193:10 & shutting 104:7,7 & 239:11 \\
\hline 198:19 238:7 & 151:19 & sex 191:10 & shy 162:2 & site 146:3,6 \\
\hline seeing 19:14 & sensory 116:4 & shadow 175:10 & sick 91:21 179:4 & sites 21:2 \\
\hline 58:12 89:16 & sent 152:20 & Shah 16:12 & 185:16 210:15 & sitting 174:20 \\
\hline 115:8 171:3 & sentence 93:16 & 53:14 177:8 & side 8:2 22:14 & 218:5 \\
\hline 203:10 & 93:22 & 179:17 233:17 & 47:15,19 70:2 & situation 82:24 \\
\hline seen 5:7,8,17 8:7 & sentences 93:14 & 233:23 & 70:3,24 71:1,1 & 83:11 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline situations 29:20 & smoking 43:3 & 100:11 114:10 & 198:2 205:16 & 114:12 \\
\hline 64:17 & 122:12 & 114:11,11 & 205:21 213:5,8 & spelled 18:15 \\
\hline six 19:5,10 21:7 & smooth 184:18 & 115:19 118:7 & speaking 64:17 & 35:6 108:10 \\
\hline 49:1 59:3 77:8 & 184:19 & 121:10 135:14 & 65:1 135:5 & 183:22 192:17 \\
\hline 93:5 115:6 & snacks 7:24 & 140:2 197:14 & 143:7,14 & spelling 31:3 \\
\hline 125:10,15 & SOAPP 154:22 & 198:13 220:13 & speaks 69:11 & spend 93:18 \\
\hline 131:13 144:1,3 & sobbing 211:1 & 220:13 & special 103:13 & 225:19,23 \\
\hline 146:1,6 147:22 & social 58:23 & sort 65:8 68:24 & 182:12 & spent 225:9,13 \\
\hline 165:24 169:22 & 62:13 63:20 & 69:171:12 & specialist 135:21 & 225:13 \\
\hline 214:1 239:12 & 64:9,11,18 & 89:13 94:1 & 153:20 155:22 & spike 20:6 \\
\hline 239:15 & 65:1,6 66:16 & 121:21 130:4 & 159:11 203:10 & spikes 19:24 \\
\hline six-month 239:6 & 66:19 74:9 & 132:7,23 137:6 & specialists 162:1 & spinal 30:11 \\
\hline skies 167:11 & 75:17 97:21 & 137:13 221:24 & specialty 26:14 & 147:1,4 160:15 \\
\hline skills 5:24 & 120:15 & sound 190:21 & 154:8 & spine 134:2 \\
\hline skin 83:18 87:3 & socialize 211:21 & 231:16 & specific 41:9 & 200:18,19 \\
\hline skipped 114:6,8 & Society 9:19 & sounds 69:1 & 42:23 56:9 & 201:3 \\
\hline 141:7 & 145:1 161:19 & 85:24 & 61:5 63:20 & spirochete 81:1 \\
\hline sleep 37:10 68:1 & sodas 7:24 & source 118:19 & 65:11 75:14 & spoke 119:8 \\
\hline 103:6,9 166:18 & soft 49:7 & south 107:7 & 76:22 77:16,17 & 195:16 200:11 \\
\hline 210:15,16 & solid 45:10 & spare 27:7 & 80:20 84:6 & spoken 121:14 \\
\hline 211:17 & somebody 66:11 & sparse 230:19 & 90:6 92:5,10 & 139:2 152:15 \\
\hline sleeping 166:8 & 70:19 72:24 & speak 9:6 16:21 & 98:4 162:15 & 164:9,13 \\
\hline sleeplessness & 84:2 88:8 & 18:5 35:9,21 & 217:23,24 & 168:13 198:7 \\
\hline 103:9 & 109:11 179:8 & 44:4 57:15,24 & 223:1 & 217:21 \\
\hline slept 98:20,21 & 222:18 226:9 & 87:20 108:15 & specifically & sponsor 214:4 \\
\hline sliding 110:2 & 232:15 & 124:6,10,14,24 & 81:18 133:8 & 214:10 \\
\hline slightest 98:5 & son 98:13,18 & 125:4 141:4,17 & 147:15 148:1 & spontaneous \\
\hline slim 176:18 & 100:14 101:20 & 141:18 143:20 & 149:22 151:11 & 63:1 213:8 \\
\hline slipping 99:7 & 111:10 115:4 & 150:11 151:10 & 190:1 191:5 & sporting 93:20 \\
\hline slow 58:7 181:13 & 116:14,17 & 153:19 165:5 & specificity 60:9 & Springfield 1:11 \\
\hline 182:10 200:21 & 117:1,24 & 177:21 184:2 & 60:11,24 72:4 & 1:16 \\
\hline 201:1 & 118:13 119:16 & 192:18 197:13 & 78:17 & square 106:21 \\
\hline slower 206:21 & 120:4,8,19 & 206:18 217:16 & specifics 62:10 & squirt 19:9 \\
\hline slowly 9:6 16:21 & 122:14,19 & 217:17 220:1 & specify 38:23,24 & squirts 19:11 \\
\hline 143:13 219:2,2 & son's 115:3,13 & 221:20 & 44:12 69:8 & SSD 186:19 \\
\hline slows 183:5 & 116:5,15 & speaker 57:13 & spectrum 31:15 & SSRI 73:5 \\
\hline small 7:23 33:20 & sons 109:5 & 82:17 94:18 & 31:18 33:3 & SSRI's 112:20 \\
\hline 100:16 101:13 & 112:10 193:17 & 102:5 114:3,5 & 62:4 65:10 & St 10:1 103:22 \\
\hline 175:8 182:16 & soon 25:14 & 124:1,4 143:18 & 97:16,23 119:2 & stabilize 20:7 \\
\hline smaller 65:22 & 184:8 193:23 & 168:10 169:6 & 123:17 & stabilizer 61:19 \\
\hline smart 152:16 & 194:1,12 & 189:9 210:3 & speech 21:3 & 148:14 \\
\hline smell 219:15 & 224:13 & 213:3 215:13 & 111:1 164:21 & stabilizers \\
\hline smoke 43:22 & sorry 24:20 25:3 & 217:14 & 165:1 & 100:23 151:15 \\
\hline 81:22 211:16 & 30:11 35:12 & speakers 2:10 & spell 17:1,17 & stabilizing 19:13 \\
\hline smokeable & 38:19 40:2 & 3:1 16:19 17:9 & 18:13,14 34:19 & stable 23:4 28:5 \\
\hline 107:17 & 60:18 85:12 & 93:5,5 94:12 & 35:5 64:19 & staff 6:20 8:17 \\
\hline smoked 221:2 & 94:15 95:4,19 & 123:18,20 & 83:5 102:16 & 62:20 131:24 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 200:9 & 135:4 137:15 & stimuli 209:5,8 & 191:6 206:12 & 152:1,2,4 \\
\hline stage 85:14 & 137:17,19 & stomach 181:8 & 206:23,24 & 182:23 183:1 \\
\hline 135:6 & 144:7 151:18 & 187:24 188:2,4 & 207:5 208:7 & 191:17,18 \\
\hline stages 88:3 & 153:20 155:11 & 195:2,22 203:6 & 209:9,10 & 192:6 196:9,14 \\
\hline staircase 8:3 & 170:3 171:4,11 & stoned 120:4 & stressed 61:16 & 202:11,15,20 \\
\hline stand 5:5 7:11 & 171:14,15,16 & 228:9 & 72:20 & 202:23,24 \\
\hline 33:9 & 171:17,19 & stool 182:17 & strict 17:5 26:21 & 203:4 207:3 \\
\hline standard 19:9 & 173:8 178:3 & stop 185:14 & 27:8 64:6 & studying 219:11 \\
\hline standards 155:2 & 187:8 201:9 & 195:21 196:21 & strictly 43:23 & stuff 23:18 71:4 \\
\hline 155:2 & 208:12,13,14 & stopped 73:4 & 128:16 & 94:1 160:20 \\
\hline standing 43:5 & 209:16 225:8 & 103:4 152:9 & strikes 87:6 & 161:4 231:15 \\
\hline standpoint & 230:2,3 236:6 & store 105:5 & striking 227:9 & stung 146:14 \\
\hline 60:10,24 70:17 & 243:5 & 184:8 & strong 11:19 & sub 63:24 \\
\hline 160:8 220:18 & State's 230:6 & stories 108:2 & 27:11 81:5 & subcutaneous \\
\hline 221:6 223:24 & 239:4 & 121:21 & 172:1 & 89:11 \\
\hline 224:12 237:2 & stated 72:20 & story 74:22 & struck 76:17 & subject 177:17 \\
\hline stands 196:7 & 171:21 173:21 & 104:24 111:8 & structure 219:16 & 199:17 \\
\hline staphylococcus & statement 214:2 & 122:14 123:1 & structuring & subjective \\
\hline 12:23 82:16 & 234:24 235:3 & 210:7 212:7 & 46:12 & 167:20 \\
\hline 94:8 & 237:6 & stove 117:6 & struggle 36:13 & submit 28:1 \\
\hline Star 171:19 & states 30:13 & straight 20:19 & 76:8 198:23 & 100:9 138:14 \\
\hline start 4:1,14 9:10 & 45:13 52:11 & 29:17 & 211:23 & 191:17 230:13 \\
\hline 17:8 49:12,13 & 111:2 119:10 & straightfor & struggled 46:18 & submitted 8:3 \\
\hline 101:21 114:24 & 127:3 129:6 & 146:1 & struggling 73:10 & 28:2 76:19,20 \\
\hline 205:5 218:4,11 & 139:8 146:9 & strain 49:14 & student 20:19 & 92:17 168:17 \\
\hline 218:23,23,24 & 162:23 196:6 & 62:16,21 154:4 & 26:11 & 168:19 \\
\hline 219:3 & 213:19 216:22 & 218:12 219:14 & students & submitting 40:8 \\
\hline started 36:16,17 & stay 73:20 & strains 42:8,22 & studied 64:19 & subside 188:5 \\
\hline 37:18 57:17 & 101:21 141:23 & 48:2,16,16,17 & 228:15 & 193:6 \\
\hline 59:4 87:22 & 155:17 & 48:17,20,23 & studies 59:21,23 & substance 87:1 \\
\hline 98:18 100:15 & stayed 101:12 & 61:13 86:9 & 64:22 74:6 & substances \\
\hline 100:18 102:9 & step 221:10 & 149:21 217:22 & 82:1 83:10 & 41:24 42:5 \\
\hline 103:3,4,12,24 & 236:14 & strapped 37:14 & 101:23 102:4 & 80:8 84:16 \\
\hline 161:5 175:1 & Steven 194:21 & 196:6 & 109:8 122:8 & 101:4 136:4 \\
\hline 187:12 188:5 & 194:22 196:8 & strategies 73:6,8 & 128:2 138:18 & substantial \\
\hline 211:2,16,16 & stick 22:3 & 127:8 & 151:22 177:20 & 78:21 \\
\hline 215:22 235:18 & 123:10 & Strategy 161:2,5 & 179:19 188:18 & suburbs 190:11 \\
\hline 235:19 236:19 & stickler 73:19 & 161:12,22 & 196:15 & succeed 93:11 \\
\hline starting 19:7 & sticks 26:17 & stratify 154:23 & study 30:15 42:7 & 219:22 227:23 \\
\hline 140:11 145:1 & 171:3 & 159:6 & 44:14 45:2,3 & success 115:7,9 \\
\hline 223:12 & stiffness 109:4 & street 48:13,15 & 59:24 66:21 & 116:3,10 \\
\hline state 9:19 17:17 & stimulants & 48:20 69:13 & 68:8,13,18 & 120:14 122:16 \\
\hline 21:6 34:18 & 170:24 & Streptolysin & 69:4,8,10 & 196:19 238:24 \\
\hline 45:19 61:14 & stimulate 42:13 & 29:10 & 75:23 82:22,22 & successfully \\
\hline 98:24 99:1,9 & stimulates 42:14 & stress 5:11 13:4 & 83:1,2,22 & 156:22 219:22 \\
\hline 101:22 117:15 & stimulator 147:2 & 38:9 60:3 & 84:22 111:10 & sucks 172:22 \\
\hline 120:1 121:1 & 160:15 & 143:3 177:12 & 112:6 149:2,5 & Sue 218:13,13 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline suffer 37:4,15 & supplementing & surface 137:13 & 182:20 183:9 & 97:12 \\
\hline 119:22 127:3 & 19:20 & surgeon 125:20 & 185:3 187:13 & T-o-t-h 30:10 \\
\hline 147:10 159:23 & supplements & 127:9 132:22 & 187:20 188:12 & table 13:16 14:2 \\
\hline 159:24 163:9 & 112:13 & surgeons 129:22 & 202:10 203:12 & 14:8,17 \\
\hline 168:1 174:8 & supply 151:8 & surgeries 126:1 & 207:11 209:14 & tailbone 201:4 \\
\hline 195:1 196:8 & support 18:12 & 146:1 160:10 & 211:15 217:22 & take 14:5,7 20:2 \\
\hline 201:10,22 & 18:21 39:18 & surgery 132:22 & 217:24 218:20 & 24:1,2,19 \\
\hline suffered 58:1 & 40:6 65:24 & 133:6,9 145:11 & 218:21 & 26:24 33:24 \\
\hline 70:19 & 76:24 79:3 & 145:20,22,22 & syndrome 13:1,3 & 34:1 45:17 \\
\hline sufferers 166:16 & 88:14 90:1 & 146:7 & 13:5 109:2 & 47:19 57:5 \\
\hline 166:17 167:11 & 101:5 114:16 & surgical 133:18 & 123:17,21 & 58:22 80:13 \\
\hline suffering 6:1 & 115:1 145:5 & 146:6 & 140:11 141:12 & 90:24 101:10 \\
\hline 36:1,6 38:14 & 148:23 149:24 & surpass 219:23 & 143:3,17 & 102:12,13 \\
\hline 129:12 166:23 & 212:14 240:24 & surprising 188:5 & 145:11 160:1 & 104:4,8 112:17 \\
\hline 172:8,16 & supported 148:2 & surrounded & 164:15 165:17 & 129:17 130:10 \\
\hline 185:21 186:12 & supporting & 120:23 & 168:6,14 180:8 & 134:19 140:13 \\
\hline 187:7 & 90:21 122:6 & surrounding & 180:21 185:20 & 156:2,4 160:18 \\
\hline suffers 172:19 & supports 127:24 & 211:12 & 186:5,13 187:1 & 187:2 211:9 \\
\hline sufficient 40:2 & suppose 85:22 & surveillance & 187:13 189:11 & 213:18 215:17 \\
\hline 47:1 & 87:1 121:16,19 & 31:14 & 189:20 206:13 & 216:2,15,15 \\
\hline sugar 19:1,4 & supposed 7:3 & survey 68:3 & syndromes 65:9 & 217:1 221:10 \\
\hline 20:3,4,8 21:6,7 & 62:8 87:1 90:5 & surveyed 31:6 & 147:14 166:5 & 224:3 228:22 \\
\hline 22:7,8,18,19 & 229:11,12 & 67:7 & 189:19 & 231:24 232:2 \\
\hline 24:625:19 & 234:7,8,21 & surveys 67:2 & Synergy 80:2 & 236:13 238:2 \\
\hline 27:1 36:9,14 & supposedly & sustainable & synthetic 184:23 & taken 57:7 \\
\hline 203:3 & 229:9 & 232:3 & 185:4 & 132:19 142:2 \\
\hline sugars 19:13,17 & suppressa & Sven 202:24 & syringe 226:13 & 217:2 238:19 \\
\hline 27:8 30:24 & 42:10 & swab 83:16,16 & system 6:22 & 238:19 \\
\hline 34:2 & suppression & swabs 83:23 & 33:17 43:17 & takes 20:4 56:20 \\
\hline suggest 111:17 & 134:15,16 & sway 77:21 & 98:9 110:9 & 57:6 225:22 \\
\hline suggested 37:17 & sure 7:10 8:4,7 & sweating 185:16 & 134:10 144:18 & 232:1 \\
\hline 101:6 104:15 & 9:8 16:15 & Sweet 216:3 & 147:3 151:18 & talents 109:23 \\
\hline 119:5 195:17 & 23:15 39:8,21 & switch 34:23 & 158:6 185:14 & talk 6:5 7:20 \\
\hline suggests 128:4 & 53:3 58:8 & 81:9 & 190:1 208:21 & 41:20,20 54:22 \\
\hline suicide 71:6 & 73:16 89:5,19 & swoop 124:12 & 209:2 219:1,3 & 67:23 80:3,6 \\
\hline 210:11 212:16 & 97:2 107:4 & sympathetic & systematic & 82:20 90:18 \\
\hline summarily & 121:12 134:8 & 40:10 & 147:21 & 92:16 94:11 \\
\hline 233:9,23 & 140:4 144:9,9 & Symposium & systematically & 97:7 136:24 \\
\hline sunglasses 190:9 & 157:10 164:12 & 128:14 & 219:6 & 138:24 140:10 \\
\hline super 41:22 & 165:11,13 & symptom 110:8 & systemically & 141:8,24 \\
\hline 134:13 201:5 & 171:9 178:5 & 195:9 & 92:2 & 161:19 164:19 \\
\hline superficial 89:6 & 180:6 200:22 & symptoms 19:17 & systems 6:18 & 183:23 189:12 \\
\hline 89:10 & 224:24 227:13 & 71:13 78:8 & 117:13 170:17 & 210:18 218:8 \\
\hline supervision & 228:19 231:1,5 & 79:9 80:22 & & 220:12 221:18 \\
\hline 43:23 137:22 & 231:11 232:2 & 97:24 109:19 & T & 227:17 \\
\hline supervisory & 232:10 236:2,7 & 118:2,3,4 & T3:18 & talked 53:7 \\
\hline 137:23 & 236:8 237:4 & 181:19 182:4,5 & T-a-y-l-o-r & 64:21 84:15 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 90:15 136:9 & teaching 91:12 & 71:17 72:15 & 199:13,20 & test 82:23 83:10 \\
\hline 138:8 159:24 & team 103:23 & 73:17 77:1,6 & 200:2,5,21 & 153:9 184:23 \\
\hline 160:2 177:10 & 115:15 180:12 & 79:4 81:8 & 201:1 204:2,8 & tested 29:11 \\
\hline 239:13 & tears 38:4 & 82:11,21 85:11 & 205:23 206:1,6 & 136:2 \\
\hline talking 6:2 53:3 & technical 8:4 & 85:14,20 91:17 & 206:18 208:23 & testified 163:11 \\
\hline 53:5,10 80:7 & 14:23 16:20 & 92:20,24 93:2 & 209:24 210:2 & testify 76:13 \\
\hline 87:22 103:4 & 17:19 18:12,20 & 94:7 96:11,13 & 212:8,10,23 & 128:19 \\
\hline 104:22 116:17 & 168:18,20 & 96:20,22,24 & 213:2,6 214:10 & testifying 117:9 \\
\hline 116:18 123:16 & 173:22 & 97:5 99:3 & 215:12 217:10 & 143:22 \\
\hline 124:7 143:14 & technique & 100:5 102:5 & 217:13 220:2,4 & testimonials \\
\hline 157:5 163:19 & 146:17 & 105:10,15,18 & 220:10,14 & 117:10 \\
\hline 219:20 224:7,9 & teen-aged 37:6 & 106:3,8,17 & 222:13 226:1,3 & testimonies \\
\hline 226:13 & teenagers \(31: 5\) & 107:1,3,13 & 226:17 227:1,7 & 142:18 179:24 \\
\hline taller 23:7 & teens 44:18 48:7 & 108:1,4,7 & 227:10 228:12 & 186:7,8 \\
\hline tallied 15:6 & teeth 53:8 110:4 & 111:22 112:1 & 233:22 234:4,6 & testimony \(8: 10\) \\
\hline tally 55:18 57:6 & television & 114:3,7,9,12 & 234:10,19 & 16:13,14 21:12 \\
\hline Taming 80:1 & 109:24 & 114:23 118:10 & 235:12 238:11 & 21:18,21,23 \\
\hline tangents 85:5 & tell 32:14 70:22 & 122:22 123:3 & 239:18,24 & 24:9 34:4,13 \\
\hline tantrums 108:24 & 129:19 224:22 & 125:4,7,10,17 & 240:4,11,17,19 & 35:22,24 38:17 \\
\hline tasked 238:13 & tells 123:15 & 135:13,16 & 241:23 242:5,8 & 38:24 57:23 \\
\hline tasks 187:18 & temper 108:24 & 138:21,23 & ten 162:22 & 58:3 76:15 \\
\hline tastes 103:6 & Temple 2:2 4:2 & 139:3 140:5,9 & tend 60:23 63:13 & 100:9,10 114:4 \\
\hline \(\boldsymbol{\operatorname { t a x }} 137: 16\) & 9:2,10 10:11 & 140:15,17,21 & 66:6 118:5 & 124:3 127:19 \\
\hline 229:11 230:3 & 10:11 11:15,24 & 140:24 141:4 & tended 67:21 & 138:19 142:23 \\
\hline Taylor 2:14,21 & 12:7,10,12,15 & 141:11,14 & tends 24:6 64:16 & 143:21 164:1,7 \\
\hline 2:22 3:3,6,9,10 & 12:17 13:14,19 & 142:3,10,13 & TENS 170:21 & 164:10 168:14 \\
\hline 94:13,18 95:3 & 13:23 14:1,7 & 143:1 144:1,4 & tension 155:21 & 169:13,14 \\
\hline 97:9,10,11 & 14:13,15,17 & 144:7 149:11 & 156:6 199:16 & 172:2 178:14 \\
\hline 99:4 141:1,2 & 16:1,3,18 & 150:11 153:2 & term 149:1 & 180:10 187:10 \\
\hline 141:10,12,15 & 17:13,16,23 & 153:10 155:6 & 189:22 & 194:20 198:9 \\
\hline 164:16,21 & 18:2 21:14,17 & 155:11,13,15 & termed 126:10 & 206:7,9 210:5 \\
\hline 165:3,7,13,16 & 22:5 24:8,12 & 156:13 161:1,4 & terms 31:23 52:5 & 219:17 \\
\hline 169:12,18,19 & 24:14,18 25:2 & 163:6,21,24 & 136:12 143:14 & testing 20:14 \\
\hline 169:23 172:15 & 25:5,7 26:2,6 & 164:6,24 165:4 & 156:19 237:7 & 150:4 156:16 \\
\hline 173:5,8,14,17 & 28:24 34:6,8 & 165:10 168:10 & 237:14,21,24 & 158:16,21 \\
\hline 174:3,5 180:8 & 34:17 36:3 & 169:4,6,10 & terpening & testosterone \\
\hline 180:9 190:6,7 & 39:2,4,9 41:18 & 173:2,7 175:19 & 219:10 & 170:18 \\
\hline 190:10,15 & 43:10 44:2 & 176:11,15,23 & terpenoid 80:2 & Tetrahydroca... \\
\hline 200:3,4,6,22 & 46:14 48:9,12 & 177:1,23 178:3 & 219:11 & 208:18 \\
\hline 201:2 204:6 & 48:14 51:22 & 178:13,23 & terrible 24:24 & thank 4:2,21 \\
\hline 206:13,14,20 & 53:4 55:9,12 & 179:22 183:17 & 161:6 210:22 & 5:20 7:7 9:1 \\
\hline 206:22 208:24 & 55:21 56:2,7 & 183:20 186:1,3 & 227:15 & 11:15 16:16,18 \\
\hline TBI 196:24 & 57:2,8 60:4 & 189:9 190:13 & terrifying 119:7 & 21:11,13,17 \\
\hline 197:8 & 61:7 62:1 & 192:15 194:16 & 207:10 & 22:5 24:8,10 \\
\hline tea 80:10 & 66:20 68:22 & 194:18 197:6,8 & terrors 37:9 & 24:11,12,13,18 \\
\hline teach 159:18 & 69:5,11 70:8 & 197:11,16 & tertiary 125:20 & 34:6,7,11,15 \\
\hline teacher's 105:2 & 70:13 71:9,15 & 198:1,6,13 & 127:10 162:22 & 35:1 38:16 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 39:2,5 40:15 & 208:18 218:12 & 103:19 112:14 & 174:21 175:1,5 & three-minute \\
\hline 59:17 60:3,4 & 218:14 219:5 & 112:21 113:14 & 175:7,8,15 & 57:20 124:3 \\
\hline 71:17 76:9 & 226:11 & 130:16 137:7 & 178:6 180:5 & three-pronged \\
\hline 97:3,8 100:3,5 & THC/THCV & 138:10 152:18 & 189:15 197:4 & 25:18 \\
\hline 100:7,8 102:4 & 49:1 & 162:9 163:17 & 204:4,4 209:16 & threshold 61:2 \\
\hline 102:5 105:7,8 & THCD 42:9 & 171:13 176:13 & 216:18,21 & throbbing \\
\hline 108:5,14 & THCV 48:22 & 209:9 213:13 & 220:8,9,19 & 190:18 \\
\hline 111:20 114:4 & 49:2 & 216:7 217:5 & 221:24 224:14 & throw 66:20 \\
\hline 118:6,8,10 & theme 180:6 & 221:3 224:1 & 226:22 228:20 & 100:16 199:13 \\
\hline 121:7 122:19 & theory 173:18 & 227:16 232:11 & 231:9,18,19,22 & throwing 171:2 \\
\hline 122:21 124:9 & therapeutic & 232:13 234:22 & 231:24 234:16 & thyroid 170:19 \\
\hline 138:21 142:3 & 33:16 119:3 & 237:13 & 241:7 242:2 & tic 79:4 \\
\hline 149:9,10,11 & 131:18 & think 25:16,23 & thinks 190:24 & tie 215:13 \\
\hline 160:21 163:23 & therapies 147:11 & 26:1,3,7,19 & third 123:10 & tighter 189:6 \\
\hline 163:24 164:3 & 202:9 & 27:2,6 28:20 & 133:23 147:7 & tightly 129:5 \\
\hline 174:9,10 176:7 & therapy 19:16 & 40:20 46:11,18 & 190:4 223:24 & tilted 191:18 \\
\hline 176:8 177:3 & 32:22 115:9 & 47:3 49:3,5,11 & Thomas 126:14 & time 4:1,17 5:18 \\
\hline 183:15 185:24 & 128:21 129:9 & 60:15 61:1 & thorough 25:17 & 7:13 8:20,24 \\
\hline 186:1 189:7 & 133:3 137:1,3 & 62:19 66:17 & thought 30:23 & 10:21 13:16,17 \\
\hline 192:13,15,17 & 165:21 171:1 & 68:3 69:21 & 32:10 53:7 & 15:16 17:3,4 \\
\hline 194:15,16 & 223:11 & 70:4,13 72:2,5 & 58:12,14 64:4 & 20:5,15 21:3 \\
\hline 197:6 203:24 & thereof 79:9 & 72:9,14,15 & 75:7 80:12 & 23:4 26:5 \\
\hline 208:24 209:23 & Theresa 2:4 10:5 & 75:3 78:3,6,7 & 95:6,7 153:3 & 35:17 36:4,15 \\
\hline 209:24 210:4 & 39:9 40:17 & 78:10,12,13,18 & 169:20 172:15 & 37:22 38:2 \\
\hline 212:8 214:9 & 42:17 90:22 & 78:19,20 79:16 & 238:3 & 51:10,17 53:11 \\
\hline 215:11 217:9 & they'd 25:13 & 81:3 82:8 85:8 & thoughtfully & 54:3 56:11 \\
\hline 217:10,11,15 & 104:4 & 87:19 89:3,5 & 238:16 & 57:5,7 58:22 \\
\hline 219:24 220:2 & thing 6:17 25:11 & 89:16,20 90:22 & thoughts 207:13 & 70:22 76:8 \\
\hline 220:17 222:11 & 31:2 43:19 & 90:24 91:11 & 211:4 & 88:15 91:22 \\
\hline 238:22 240:21 & 45:22 46:7 & 92:16 93:15,24 & thousand 81:15 & 92:1,20,21 \\
\hline 242:3 & 49:24 68:2 & 96:8 99:10,13 & thousands 116:7 & 93:19 98:19,23 \\
\hline thanked 164:2 & 69:17 76:17 & 99:15 102:22 & 117:10 219:9 & 100:4 102:4 \\
\hline thanking 241:23 & 86:7 87:7 & 109:9 112:3,21 & threatening & 103:17 104:9 \\
\hline thanks 57:22 & 91:18 107:20 & 112:23 123:13 & 192:24 & 111:20 117:4 \\
\hline 168:8 173:1 & 113:7,22 & 125:10 126:13 & three 16:19 & 118:5,6 123:10 \\
\hline 174:4 186:6 & 121:24 137:2 & 128:3 129:20 & 19:11,24 34:9 & 123:22 124:13 \\
\hline 197:5 200:8 & 158:7 188:5 & 130:24 131:2 & 77:7 82:8 & 125:3,14 \\
\hline 210:4 212:3 & 199:21 226:6 & 133:5 137:9 & 89:22 94:17 & 138:24 142:2 \\
\hline 222:12 & 231:9 237:4 & 138:1,2,4,12 & 103:12,14 & 142:22 143:5 \\
\hline THC 33:4,20 & things 22:23,24 & 138:18 140:13 & 124:19,22 & 149:9 154:21 \\
\hline 41:13 42:9,11 & 33:12 36:20 & 142:19 144:5 & 125:1 142:17 & 157:5 164:20 \\
\hline 42:17 46:6 & 42:2,16 43:7 & 150:12 152:5 & 153:14 166:1 & 166:3 168:8 \\
\hline 48:18,21,23 & 61:3 64:2 & 155:1,6,24 & 167:3 168:2 & 169:16 173:1 \\
\hline 49:2 62:15,16 & 65:23 79:7 & 156:13 158:15 & 171:16 191:11 & 183:15 184:9 \\
\hline 62:23 65:3,4 & 81:14,17 84:3 & 159:2,8 161:17 & 205:22 206:10 & 184:14 185:24 \\
\hline 80:1,6,16 & 89:8 91:3 94:4 & 163:6 169:8 & 206:10,11 & 190:12 192:13 \\
\hline 116:22 122:18 & 100:18 103:18 & 173:12 174:20 & 214:16 240:19 & 193:14 194:15 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 195:6,13 & 145:7 176:17 & toxicity 119:11 & 115:15 119:16 & 162:11,16 \\
\hline 197:21 200:23 & 178:9 179:12 & track 176:16 & 146:16 153:23 & triangle 221:23 \\
\hline 203:17 204:23 & 184:2 201:9 & tracks 174:7 & 191:16 192:12 & Tribune 137:3 \\
\hline 205:19 209:23 & 210:8 212:7 & 196:21 & 198:19 202:9 & tricky 5:21 \\
\hline 211:5,18 & 239:7,13 & tract 83:22 84:3 & 203:12 & 44:22 \\
\hline 224:23 225:22 & today's 96:18 & 181:8 & treated 29:13 & tried 59:14 \\
\hline 228:16 233:13 & 117:20 240:1 & tracts 185:9 & 153:5 154:6 & 78:24 105:22 \\
\hline 234:20 235:16 & toilet 188:9 & tradeoff 71:21 & 170:4 192:4 & 112:1 \\
\hline 235:17 236:6 & told 105:22 & traditional & treating 116:8 & trigger 209:9 \\
\hline 237:14 238:19 & 192:18 195:15 & 115:9 & 128:1 198:22 & triggered 63:5 \\
\hline 238:20,21 & tolerance 219:7 & train 142:20 & treatment 18:22 & 207:9 \\
\hline 239:6,16 241:4 & tolerances & 180:4 & 54:20 70:5 & triggering 63:12 \\
\hline 242:11 243:7 & 220:23 & trainees 145:6 & 72:6 77:20 & 211:12 \\
\hline timed 17:3 & tolerate 117 & training 219:8 & 92:18 108:12 & Triggers 191:3 \\
\hline timeline 238:9 & tomorrow & tranquilizers & 113:5 114:17 & triple 89:7 \\
\hline timely 187:17 & 144:15 & 58:23 & 115:2 127:15 & triptans 191:15 \\
\hline times 19:12 & ton 17:19 & transcript 4:13 & 127:20 128:9 & trouble 31:22 \\
\hline 20:16 28:19 & Tonight 224:17 & 95:17 96:10 & 128:17 129:22 & 90:20 \\
\hline 54:6 66:11 & tons 214:6 & transcription & 130:17 131:16 & troublesome \\
\hline 78:16 113:24 & tool 148:11 & 9:9 & 132:24 138:5 & 192:23 \\
\hline 124:5 186:15 & 154:1,2,3 & transfer 156:8 & 146:19 147:17 & true 117:13 \\
\hline 188:9 191:11 & 155:5,5 159:20 & transferred & 148:15 158:5 & 157:15 175:13 \\
\hline 193:4 195:5 & 160:16 184:22 & 167:18 & 159:10 162:5 & 201:9 \\
\hline 208:2 215:6 & 198:20,21 & transferring & 171:1,2 174:8 & truly 38:2 87:22 \\
\hline 221:7 228:3 & tools 153:24 & 202:18 & 182:3 196:1,20 & 168:7 \\
\hline Timothy 168:15 & 154:2,2,9 & transition & 197:23 202:21 & trust 25:24 \\
\hline 169:7,8 & top 18:4 162:22 & 211:21 & 204:19,20 & truth 107:12 \\
\hline Tina 2:16 3:4,7 & topic 27:23 & translational & 212:15 222:19 & try 37:17 38:13 \\
\hline 94:14 108:7,9 & 169:11 180:7 & 28:7 & treatments 32:6 & 47:2 93:11,11 \\
\hline 183:17,18,21 & 207:15 & trauma 13:1 & 39:21 78:5 & 104:16,18 \\
\hline 192:15,16 & topical 86:18 & 123:19 124:1,8 & 90:16 113:21 & 105:22 110:10 \\
\hline tincture 22:15 & 87:8 & 124:15 129:13 & 115:10 126:1 & 117:1 133:2 \\
\hline 22:24 & topically 81:21 & 133:18 136:13 & 128:21 146:18 & 139:13,21,24 \\
\hline tinctures 19:4 & 86:23 & 141:2,5 145:20 & 166:6 167:1 & trying 78:4 \\
\hline tingling 37:23 & topicals 89:21 & traumatic 143:3 & 170:20,23 & 100:20,22 \\
\hline tireless 175:4 & 146:22 & 197:8 206:12 & 202:7 & 102:22 116:1 \\
\hline tirelessly 176:5 & topics 141:17 & 206:23,24 & Trelle 202:24 & 122:3 130:1 \\
\hline title 73:22 & total 4:9 117:21 & 207:5 208:6 & tremendous & 138:11 162:14 \\
\hline titled 182:23 & 146:2 & 209:10,12 & 43:6,6,7 & 182:21 215:14 \\
\hline 202:12,21 & totally 48:22 & travel 142:20 & tremendously & 221:10 223:6 \\
\hline today 4:10 11:3 & 129:24 137:20 & 180:4 & 22:10 & 223:13,20 \\
\hline 16:16 18:11,20 & 166:13 & traveling 113:17 & trenches 163:3 & 224:24 239:2 \\
\hline 19:2 21:12 & Toth 30:10 & treat 60:12 & trepidation 99:8 & tube 82:23 83:10 \\
\hline 54:3 55:1,16 & touched 221:1,1 & 79:13 88:10 & trial 148:22,22 & turn 18:3,4 \\
\hline 67:8 115:6 & toughest 115:14 & 89:9,22 91:21 & 150:4,7,10 & 21:14,15 25:2 \\
\hline 127:19 128:2 & tox 153:9 & 92:1,3,8 & trials 30:8 75:14 & 34:22 39:6 \\
\hline 144:14,15 & toxic 101:4 & 108:21,22 & 147:22 148:7 & turned 18:2 25:4 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 35:22 43:2 & 166:5 & 24:18 107:16 & 17:23 27:11,14 & 208:4,10 228:7 \\
\hline 82:1 153:17 & & 125:23 126:2,5 & 28:12 30:17 & vague 83:17 \\
\hline 186:8 & U & 126:21 127:11 & 33:15 38:10 & valid 82:3 \\
\hline TV 91:19 & U.S 30:18 139:6 & 129:18 130:19 & 39:11 40:21 & validity \(82: 10\) \\
\hline twice 72:16 & UC 111:11 & 132:15 133:13 & 42:11 43:4 & 128:20 \\
\hline 181:22 189:12 & 113:15,17 & 134:4 162:13 & 44:7,14,16,16 & Valium 58:23 \\
\hline two 15:2 17:9 & Uh-huh 111:24 & 208:2 222:23 & 44:23 45:16 & Vancomycin \\
\hline 27:6 36:13 & ultimately & 238:8 & 46:1,6,9 54:16 & 92:9 \\
\hline 39:11 43:23 & 134:16 & ungodly 226 & 54:17 66:3 & variety 42:2 \\
\hline 46:15 48:5 & un-resolvab & unit 119:19 & 67:14,17 68:16 & 97:24 128:1,9 \\
\hline 56:23 82:8 & 126:23 & 170:21 & 68:17,24 73:23 & 146:24 166:7 \\
\hline 85:7 89:21 & unable 168:23 & United 127:3 & 74:20 75:9,9 & 184:24 \\
\hline 90:3 100:15 & 169:1 & 129:6 139:8 & 77:19,24 79:18 & Varin 48:24 \\
\hline 101:12 102:21 & unclear 228:18 & 146:9 162:23 & 86:17 89:7 & various 79:2 \\
\hline 104:15 105:2 & uncomfortable & 213:18 224:8 & 91:24 105:21 & 83:23 132:24 \\
\hline 108:16 115:5 & 20:23 & University 6:21 & 108:18 110:24 & 161:13 237:6 \\
\hline 116:12 118:15 & uncontrollab & 6:22 10:14 & 124:22 126:9 & varying 88:17 \\
\hline 123:18 127:7 & 207:13 & 11:7 84:24 & 126:20 128:6 & vehicle 110:3 \\
\hline 141:16 157:8 & uncontrolled & 144:13 152:4 & 128:17 129:3,7 & venue 239:3 \\
\hline 160:10 182:8 & 36:8 127:15 & 182:22 202:12 & 129:11 131:2 & verbal 120:17 \\
\hline 186:7,7 205:15 & 129:3,3 & unknown & 134:24,24 & verbatim 98:2 \\
\hline 206:10 208:2 & uncurable & 165:20 170:11 & 135:6 137:14 & versa 46:11 \\
\hline 211:19 221:16 & 127:12 & unmanageable & 137:17,22,23 & versus 74:21 \\
\hline 230:18 238:5 & undergroun & 129:24 & 146:17 149:24 & 82:24 84:8 \\
\hline 240:17 & 137:11 & unparalleled & 151:11,13,21 & 199:7,8 223:1 \\
\hline Tylenol 191:15 & underlying & 61:18 & 152:3 154:15 & 223:2 \\
\hline 202:7 203:1 & 117:23 119:22 & unreal 103: & 154:18,21 & vet \(238: 15\) \\
\hline type 12:20 17:8 & 167:5 & 105:1,5 & 155:1,3 159:16 & veteran 11:13 \\
\hline 18:23,24 19:18 & underneat & unresolved & 159:20,20,21 & 210:6 212:16 \\
\hline 25:9 30:16 & 81:10 & 127:12 129:19 & 160:4 182:13 & 223:15 \\
\hline 31:5,10 38:21 & understand & 131:18 132:13 & 183:4 188:7 & Veterans 207:4 \\
\hline 38:21 44:10,13 & 44:24 62:8 & unwell 37:13 & 190:12 202:16 & 207:17 208:5,9 \\
\hline 44:18 45:4,14 & 76:3 91:8 & unwise 133:5 & 229:7 232:20 & 208:11 209:13 \\
\hline 50:10 53:6 & 133:2 224:16 & upcoming & useful 66:12 & 209:18,21 \\
\hline 57:3,4,9 71:4 & 232:10 & 141:16 & user 61:14 & 211:14 212:11 \\
\hline 91:4 110:11 & understanding & update 6:17 & users 67:11,12 & 212:20,22 \\
\hline 133:3 151:24 & 19:15 85:15 & updates 5:2 & 74:15,16 & 223:18 \\
\hline 218:7 222:2 & 219:21 234:23 & upset 203:6 & 139:23 & Veterans' 11:11 \\
\hline types 63:24 & 235:23 & upsetting 193:17 & uses 214:2 & veto 229:4,6 \\
\hline 89:14 109:19 & understood & urge 9:5 97:12 & usual 51:7,11 & vetted 69:21 \\
\hline 112:12 128:10 & 85:24 & 123:11 188:6 & 65:18 & vibrate 4:11 \\
\hline 128:21 147:6 & undertaking & urinary 83:21 & usually 20:8 & Vibrio 83:3 \\
\hline 147:13 192:23 & 50:8 & 84:2 & 64:15 90:6 & vice 46:11 \\
\hline 193:9 194:3 & unfair & urine 83:16 84:1 & & vicious 24:4 \\
\hline typical 112:8 & unfamilia & 153:9 156:16 & & 36:11 \\
\hline typically 40:20 & 64:12 & USA 117:19 & V-i-b-r-i-o 83:3 & Vicodin 160:18 \\
\hline 64:14 135:6 & unfortunately & use 9:22 17:21 & VA 207:21 & Vicodins 130:7 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline Vietnam 208:9 & 144:11 & 141:21 143:20 & watched 120:13 & 124:24 132:14 \\
\hline 212:20 & W-e-i-s-s 29:6 & 151:10 155:23 & watching 104:10 & 132:16 138:7,7 \\
\hline view 5:4 75:4 & W-r-i-g-h-t & 156:10 157:23 & 149:5 231:4 & 138:11 141:14 \\
\hline 122:14 160:23 & 236:4 & 159:12 164:12 & way \(1: 1627: 17\) & 143:13 147:3 \\
\hline 176:2 211:24 & wait 55:21 82:8 & 164:17,19 & 30:3 31:14 & 148:18 156:14 \\
\hline 220:5 & 85:10,10,10 & 175:15 176:3 & 46:11 53:23 & 158:9 161:7 \\
\hline viewpoint 237:2 & 94:10 140:12 & 180:10 184:2 & 56:10,18,23 & 164:6,14 \\
\hline village 232:1,2 & waiting 57:11 & 197:17 198:3 & 58:19 62:6 & 175:16 177:23 \\
\hline violates 135:22 & wake 202:3 & 198:11 205:12 & 68:18 71:21 & 180:1 203:21 \\
\hline violent 100:16 & 210:24 & 206:8 213:18 & 77:22 79:14 & 205:15,19 \\
\hline 120:19 & Walega 2:20 & 214:13 215:19 & 88:14 107:7 & 219:22 221:11 \\
\hline violently 193:3 & 130:20 140:12 & 225:9 226:5 & 121:16 130:24 & 221:12,12,13 \\
\hline visit 221:15,22 & 143:18,19,23 & 228:9 229:14 & 132:16 147:13 & 221:14 222:3 \\
\hline visiting 152:16 & 144:3,5,9,10 & 233:18,19 & 158:1 161:20 & 223:13 224:1,2 \\
\hline vitality 74:9 & 149:12 150:9 & 234:13 237:5 & 165:2,8,8 & 224:5 227:22 \\
\hline vitamins 112:13 & 150:16 153:12 & 238:22 239:11 & 190:10 204:22 & 228:4,20 229:6 \\
\hline vitro 83:17 & 155:10,12,14 & 240:20,21 & 205:13 210:23 & 233:6,20 234:8 \\
\hline 184:22 & 156:12 157:7 & 241:3,6 & 215:15 216:16 & 234:16,20 \\
\hline voice 158:24 & 157:10,13,17 & wanted 4:14 5:2 & 219:14 237:7 & 238:12 240:15 \\
\hline 163:2 & 157:21 158:12 & 5:6,11 6:7,17 & ways 53:23 & 240:16 242:1 \\
\hline volatile 19: & 158:17 160:13 & 11:16 51:23,24 & we'll 4:15 7:18 & we've 9:3 15:15 \\
\hline volunteer & 160:24 161:3 & 57:8,24 62:1 & 7:20 8:8 9:4,11 & 15:21 27:9 \\
\hline 238:18 & 161:23 163:20 & 69:18 73:15 & 14:10 17:13 & 46:18,23 49:3 \\
\hline volunteers & 163:22 164:2,3 & 97:4 100:23 & 34:13 57:14 & 49:4,12 53:2 \\
\hline 119:14 & 164:6 198:4,5 & 105:4,5 106:13 & 70:15 82:8,9 & 54:4 69:14 \\
\hline vomit 193:3,4 & Walega's 198:20 & 132:2 142:13 & 82:17 93:5 & 73:11 79:8 \\
\hline vomiting 190:20 & walk 36:20 38:1 & 164:19 165:11 & 94:10,16 96:14 & 81:12,15 84:11 \\
\hline 193:5 195:3 & walking 146:15 & 190:11 210:6 & 123:23 128:2 & 93:6 99:16 \\
\hline vote 14:5,7 15:4 & walks 101:16 & 213:11,19 & 141:24 142:23 & 119:23 122:15 \\
\hline 15:19,21 57:10 & wall 171:2 & 214:3 215:1,7 & 155:4,4 165:16 & 124:19 127:18 \\
\hline 70:7,9,10 & want 4:18 7:7 & 216:4 236:21 & 168:11 238:7 & 130:1 134:22 \\
\hline 76:16,16 77:4 & 9:8 16:5 22:3 & wants 120:11 & we're 6:4,10 & 141:7 142:22 \\
\hline 77:6 81:3,7,8 & 23:14 27:5 & 157:2 228:6 & 7:15 12:18 & 156:8,21 165:5 \\
\hline 82:13 85:17 & 30:8 32:3 & war 208:8,9 & 17:7 27:15 & 169:24 172:17 \\
\hline 92:19 93:2 & 38:11 42:12,14 & 212:18 & 29:20 31:11 & 174:15 176:13 \\
\hline 94:7,23 95:1,6 & 45:11,12,20 & warn 200:7 & 43:4,18,19 & 177:10 190:3,5 \\
\hline 96:9 140:14 & 53:17 54:4,5 & warrants 128:23 & 45:16 46:1,2,8 & 198:15 203:13 \\
\hline voted 15:15 93:7 & 54:15 66:20,23 & washes 58:11 & 46:9,12 47:22 & 203:13 206:23 \\
\hline 95:10 & 72:11,23,24 & wasn't 22:16 & 49:3,6,9,16 & 209:14 213:1,4 \\
\hline votes 15:5 55:5 & 75:19 80:16 & 101:2 179:8 & 53:9 55:19,20 & 213:7 214:15 \\
\hline 82:12 & 87:20 93:13 & 220:7 241:20 & 55:23,24 57:11 & 215:4 217:21 \\
\hline voting 15:1 & 94:19,19 97:2 & waste 182:11 & 57:17 62:18 & 233:7 235:18 \\
\hline 55:19,20,23,24 & 97:8 101:19 & wastebasket & 70:2,13 78:14 & 238:20 241:2 \\
\hline 77:3 97:2 & 102:8 120:8,9 & 189:21 & 80:7 82:11 & weak 28:4 \\
\hline & 120:9,24 & wasted 21:22 & 85:8 93:3,13 & weaker 181:13 \\
\hline W & 124:20 136:1 & 24:16,22 & 94:21,22 97:6 & weakness 110:22 \\
\hline W-a-l-e-g-a & 137:2,12 140:4 & watch 101:3 & 97:6 104:17 & weaning 217:3 \\
\hline
\end{tabular}

MIDWEST LITIGATION SERVICES

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline weapon \(71: 3,7\) & 98:19 101:12 & wise 222:4 & 81:14,16 & 230:20 \\
\hline 159:20,21 & 116:23 156:5 & wish 17:21 33:6 & 138:10 139:22 & wrong 41:5,12 \\
\hline 160:16 & 221:16 & withdrawn & 182:16 192:12 & wrote 90:1 \\
\hline weapons 154:1 & weigh 5:22 & 103:8 & 205:13 229:18 & X \\
\hline wear 103:16 & weighing 199:7 & withdrew 7:20 & world 38:7 & X \\
\hline 144:16 & weight 23:3 & witness 11:18 & 44:20 85:16 & X 2:9 3:18 \\
\hline weather 191:6 & 163:13 & 243:10 & 103:10 211:8 & Xanax 66:11 \\
\hline Weathers 2:3 & weird 139:10 & witnessing & 211:12 & 194:5 216:12 \\
\hline 11:4,5 13:13 & Weiss 29:6 & 207:11 & worldwide & 216:15 \\
\hline 18:13 26:6,7 & welcome 4:3 & woman 58:4,15 & 118:24 181:2 & Y \\
\hline 29:2 38:18 & 39:3 66:4 71:6 & women 166:15 & worn 201:20 & Y \\
\hline 39:6 40:1,15 & 71:6 93:7 & 191:11 207:23 & worry 63:6 & yard 202:2 \\
\hline 46:16 47:14,20 & 154:15 182:24 & wonder 43:11 & worrying 72:3 & yay 55:17 57:10 \\
\hline 50:14,18,21,24 & 198:22 & 86:22 161:18 & worse 31:12 & 7 94:9 \\
\hline 51:3,5 60:6,19 & welcoming 4:14 & wonderful 31:14 & 37:2 67:18 & \[
\text { yays } 82: 14
\] \\
\hline 60:22 68:12,15 & well-being 19:22 & 104:22 & 74:3 75:1 & yeah 7:20 23:16 \\
\hline 69:3,9 70:7 & went \(23: 543: 13\) & wondering & 100:18 107:10 & 48.9 50:18 \\
\hline 72:173:13,16 & 73:21 88:1 & 235:20 & 109:20,20 & 48:9 50:18,24 \\
\hline 78:3 81:7 & 101:16 103:12 & word 42:15 90:8 & 112:18,18 & 51:3,5 54:21 \\
\hline 86:20 87:19 & 105:3 216:16 & 90:8 & 172:24 208:3 & 71:15 \\
\hline 90:22 91:10 & weren't 84:5 & words 98:2 & worsening & 73:16 90:11 \\
\hline 92:19 94:10 & whack 130:10 & work 6:10 9:17 & 195:10 & \[
\begin{aligned}
& 91: 11,16 \\
& 106: 11 \quad 124: 3
\end{aligned}
\] \\
\hline 95:4,14,19,23 & whatsoever & 10:1,21 11:20 & worst 70:3 188:8 &  \\
\hline 96:3,6,8,12,14 & 10:18 & 37:10 64:24 & 195:4 & \begin{tabular}{l}
125:8 130:13 \\
\(137 \cdot 16\) 156:12
\end{tabular} \\
\hline 97:1,3 102:16 & WHEREOF & 69:15 73:8,22 & worth 22:8 & 137:16 156:12 \\
\hline 125:13 131:6 & 243:10 & 89:12 92:9 & 195:12 & 173:5,16 \\
\hline 131:20 140:3 & Whichever & 105:22,23 & wouldn't 41:10 & 197:10 198:16
204:6 213:10 \\
\hline 140:13,23 & 164:22 & 106:12,12,14 & 58:5,9 103:6,7 & 204:6 213:10 \\
\hline 141:8 142:19 & white 5:17 & 115:14 118:4 & 103:9 & 214:22 220 \\
\hline 165:11 168:23 & 177:11 218:12 & 121:17 153:2 & wound 61:16 & 226:20,22 \\
\hline 169:3,5 174:12 & 218:16 & 156:11 167:13 & 72:21 & 236:2 240:6 \\
\hline 198:11,16 & Whitehurst & 174:18,23 & wow 84:6 154:7 & 241:22 \\
\hline 205:18 234:22 & 194:21,22 & 175:20 180:14 & 172:14 & year 22:8 46:23 \\
\hline 235:14,17 & 196:8 & 187:18 198:24 & wrapper 106:18 & 58:4 98:24 \\
\hline 236:8 242:7 & wider 131:2 & 199:14 202:2 & Wright 3:16 & 102:23 144:22
\(145: 1147: 18\) \\
\hline Webb 216:1 & widespread & 217:23 218:1 & 177:2 235:21 & \(145: 1147: 18\)
\(148: 5 ~ 149: 4,7\) \\
\hline website 90:9,12 & 58:10 & 223:19 230:5 & 236:2,3,3 & 148:5 149:4,7 \\
\hline 94:5 122:4 & wife 9:21 & 237:18 238:17 & 237:4 &  \\
\hline 239:4 & wildly 96:9 & 238:23 & write 64:1 90:5 & 207:22 212:17 \\
\hline Wednesday & William 197:18 & worked 175:11 & 123:11 135:20 & 215:21 231:10 \\
\hline 102:10 104:24 & willing 120:7 & 176:4 & 156:7 205:4 & years 10:22 38.2 \\
\hline week 20:10 22:7 & 203:18 228:8 & worker 62:20 & writes 221:8 & years 10:22 38:2 \\
\hline 67:10 74:14 & 237:18 & working 33:1 & writing 105:3 & 43:5 45:6 56:1 \\
\hline 75:10 151:9 & willingness & 70:2 73:7 & 151:3 & 81:13,15 82:8 \\
\hline 215:24 & 236:11 & 114:21 125:20 & written 21:23 & 89:22 93:23 \\
\hline weekly 104:24 & Wilson 189:10 & 224:1 & 39:18 52:12,15 & \[
\begin{aligned}
& 103: 14 \text { 104:15 } \\
& 112: 7115: 5,6
\end{aligned}
\] \\
\hline weeks 36:15 & wine 191:5 & works 23:2 & 73:3 178:10 & 112:7 115:5,6 \\
\hline
\end{tabular}

HEARING 5/2/2016
\begin{tabular}{|c|c|c|c|c|}
\hline 118:13 130:4 & 1.1 201:10 204:4 & 165 2:21 & 2015 13:9 14:18 & \(35125: 22\) \\
\hline 163:15 167:3 & 204:5,6 & 169 2:22 & 15:12,12 126:8 & 166:10 \\
\hline 168:2 171:16 & 10 19:11 20:13 & 17 2:11 51:19 & 128:7 152:5 & 36 19:11 \\
\hline 186:13 187:12 & 20:16 45:3 & 178 3:2 148:9 & 171:3 230:21 & \(360225: 2\) \\
\hline 194:23 195:5 & 121:5 145:18 & 18 41:6 44:1,3 & 2016 1:11 4:5 & 39 59:22 178:17 \\
\hline 196:19 206:24 & 146:9 181:2 & 45:6 49:24 & 128:14 191:18 & 179:17 213:12 \\
\hline 211:19 227:7 & 188:9 193:4 & 50:6 56:1,6,8 & 202:20 224:4 & 215:3 217:21 \\
\hline Yep 48:14,14 & 201:12,15 & 87:12 88:24 & 2017 227:4 & 232:5,11 \\
\hline 102:7 200:4 & 207:23 208:5 & 210:16 & 228:16 & \\
\hline yesterday 105:4 & 223:18 & 18-year 36:23 & 2018 227:5 & 4 \\
\hline yoga 203:9 & 10.4 191:23 & 180 3:3 239:23 & \(2063: 10\) & \(4.6191: 24\) \\
\hline young 19:19 & 100 19:23 & 240:13 & 209 45:3 & 40 148:19,19,19 \\
\hline 36:24 39:12,15 & 195:13 201:15 & 1800's 197:24 & 2103:11 & 191:24 \\
\hline 41:9 & 207:18,23 & 183 3:4 & 2100 208:4 & 400 147:23 \\
\hline younger 111:10 & 208:1 214:21 & \(1863: 5\) & 213 3:12 & 405 148:9 \\
\hline 112:7 172:10 & 100\% 11:12 & 19 233:5 & 2153:13 & 420.00 225:10 \\
\hline youngest 116:14 & 100,000 119:1 & 19.00 224:22 & 2173:14 & 44 152:2 \\
\hline yucky 20:24 & 102 2:15 & 190 3:6 & 21st 43:1 & 440 225:3 \\
\hline Z & \(10323: 7\) & \(1923: 7\) & 22 103:3 212:17 & \(45117: 18181\) \\
\hline & 108 2:16 & 194 3:8 & 22.00 224:22 & 81:22 \\
\hline Z 18:16,18 & 11 208:4 & 1942 139:9 & \(2203: 15\) & \(49128: 8194: 23\) \\
\hline Zala 2:11 3:14 & 11:39 123:13 & 1988 11:14 & 225 36:14 & \\
\hline 17:14,15,19 & 11:57 141:20 & 1995 121:4 & 23 127:3 & 5 \\
\hline 18:1,8,9,10,15 & 110,000 201:16 & 1997 194:24 & \(2363: 16\) & 5\% 208:14 \\
\hline 18:16,18 21:13 & 111 41:23 & & 24 19:1 & 50 36:10 146:2 \\
\hline 21:16,20 22:2 & 1142:17 & 2 & 243 3:23 & 166:12 \\
\hline 22:6,13,18,22 & 115 20:12 & 2:30 234:21 & 25 181:1 & 50.00 225:19,21 \\
\hline 23:5,12,15,16 & 118 2:18 & 2:37 242:1,11 & 25,000 126:8 & 500 119:19 \\
\hline 23:20 24:13,16 & 12 19:11,19 44:6 & 20 10:22 20:13 & \(\mathbf{2 5 0} 215: 23\) & 55,000 202:24 \\
\hline 24:20,24 25:4 & 193:4,5 & 20:16 104:9 & 255 126:10 & 57 2:13 \\
\hline 25:6 31:8 33:6 & 12\% 208:8 & 146:5 153:15 & 28 58:4 163:15 & \[
\mathbf{5 9} 213: 24
\] \\
\hline 34:7 44:19 & 12,000 45:7 & 162:19 223:17 & 29th 51:15 & 5th 102:23 \\
\hline 51:15,19,21 & 12.8 208:13 & \(2003: 9\) & 2nd 1:11 & 6 \\
\hline \(179: 3,14\)
\(217 \cdot 13,15\) & 12:00 227:9 & 2000 117:18 & & 60 20:12 145:17 \\
\hline 217:13,15 & 12:45 141:21,22 & 215:22 & \[
3
\] & 154:5 \\
\hline 222:20 224:19 & 141:24 & 2004 117:19 & 3:00 193:15 & \\
\hline 225:7,11,16 & 121 191:22 & 144:19 182:22 & \(234: 21\)
3017.419 .10 & \[
60064: 24
\] \\
\hline 226:22
zebra 18:16,18 & \(192: 1\)
\(\mathbf{1 2 4} 2 \cdot 19\) & 2005 201:7
\(200629: 6\) & \(\begin{array}{rl}3017: 4 & 19: 10 \\ 98: 14 & 109: 10\end{array}\) & 616 19:2 \\
\hline zebra 18:16,18
zero 54:17,18,19 & 124 2:19 & \(2006729: 6\)
\(2007144: 21\) & 98:14 109:10
1115 112:7 & 62702 1:16 \\
\hline 70:11 82:14 & 144 2:20 & 2008 188:21 & 125:21 151:8 & \(65.00224: 21\) \\
\hline 94:9 117:21 & 15 4:9 20:9 45:6 & 2009 210:10 & 212:19 & 6630.507 119:10 \\
\hline 0 & 104:9 153:15 & 2010 30:9 & 300's 20:6 & 7 \\
\hline & 188:9 & 2013 119:18 & 31st 227:4,6 & 700 119:14 \\
\hline 1 & 15\% 208:9 & 02: & 239:21,24 & 721,575 208:11 \\
\hline \(1227: 5\) & \[
\begin{aligned}
& \mathbf{1 5 0 , 0 0 0} 201: 15 \\
& \mathbf{1 6} 102: 20
\end{aligned}
\] & 2014 19:1 & \[
\begin{array}{r}
240: 8 \\
\mathbf{3 4 2 : 1 2}
\end{array}
\] & \(75216: 17\) \\
\hline
\end{tabular}

HEARING 5/2/2016
```

